bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
catheter, therapy, coronary artery disease, techniques, patients, balloon angioplasty, tissue, stent, implantation, techniques, prevention, pharmacologic, radiotherapeutic, future	ZfuerKardiologie.8087s052.eng.abstr_task2	Sentence: The success of interventional catheter based therapy of coronary artery disease is still limited by a high rate of chronic restenosis . Using alternative mechanical techniques , there is increasing evidence that restenosis can be prevented in certain subsets of patients by optimized balloon angioplasty , DCA and stenting as well as by the combined approach of primary tissue removal with adjunctive stent implantation . This article summarizes the mechanical techniques of restenosis prevention or reduction that have been documented in controlled trials . Additional pharmacologic interventions and possibly genetic and/or radiotherapeutic approaches will be highly important for future reduction of restenosis . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	The success of interventional catheter based therapy of coronary artery disease is still limited by a high rate of chronic restenosis . Using alternative mechanical techniques , there is increasing evidence that restenosis can be prevented in certain subsets of patients by optimized balloon angioplasty , DCA and stenting as well as by the combined approach of primary tissue removal with adjunctive stent implantation . This article summarizes the mechanical techniques of restenosis prevention or reduction that have been documented in controlled trials . Additional pharmacologic interventions and possibly genetic and/or radiotherapeutic approaches will be highly important for future reduction of restenosis .	[ "The", "success", "of", "interventional", "catheter", "based", "therapy", "of", "coronary", "artery", "disease", "is", "still", "limited", "by", "a", "high", "rate", "of", "chronic", "restenosis", ".", "Using", "alternative", "mechanical", "techniques", ",", "there", "is", "increasing", "evidence", "that", "restenosis", "can", "be", "prevented", "in", "certain", "subsets", "of", "patients", "by", "optimized", "balloon", "angioplasty", ",", "DCA", "and", "stenting", "as", "well", "as", "by", "the", "combined", "approach", "of", "primary", "tissue", "removal", "with", "adjunctive", "stent", "implantation", ".", "This", "article", "summarizes", "the", "mechanical", "techniques", "of", "restenosis", "prevention", "or", "reduction", "that", "have", "been", "documented", "in", "controlled", "trials", ".", "Additional", "pharmacologic", "interventions", "and", "possibly", "genetic", "and", "/", "or", "radiotherapeutic", "approaches", "will", "be", "highly", "important", "for", "future", "reduction", "of", "restenosis", "." ]	[ "umlsterm" ]
lebensbedrohender is an umlsterm, Infektionskrankheiten is an umlsterm, Lungenpest is an umlsterm, Deutschland is an umlsterm, Zeit is an umlsterm, Diagnostik- is an umlsterm, Behandlungseinrichtungen is an umlsterm, Deutschlands is an umlsterm	Bundesgesundheitsblatt.90420389.ger.abstr_task0	Sentence: Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann .	[ "Ein", "Einschleppen", "lebensbedrohender", "und", "zugleich", "hochkontagioeser", "Infektionskrankheiten", "wie", "Lungenpest", "oder", "Ebola", "-", "Fieber", "nach", "Deutschland", "erscheint", "zur", "Zeit", "nicht", "sehr", "wahrscheinlich", ",", "ist", "aber", "grundsaetzlich", "nicht", "auszuschliessen", ".", "Gerade", "wegen", "der", "Seltenheit", "des", "Auftretens", "einer", "solchen", "Erkrankung", "sind", "jedoch", "auch", "hierzulande", "Handlungsrichtlinien", "notwendig", ",", "um", "gegebenenfalls", "einer", "Verbreitung", "entgegenzuwirken", ".", "Die", "Entwicklung", "konkreter", "Schutzvorkehrungen", "und", "Handlungsalgorithmen", "sowie", "das", "Vorhalten", "geeigneter", "Diagnostik-", "und", "Behandlungseinrichtungen", "ist", "in", "den", "einzelnen", "Regionen", "Deutschlands", "sehr", "unterschiedlich", "ausgepraegt", ".", "Ein", "bundesweiter", "Rahmenplan", "fehlt", ".", "Der", "vorliegende", "Konzeptentwurf", "zeigt", ",", "wie", "die", "Vorsorge", "mit", "vertretbarem", "finanziellen", "Mehraufwand", "durch", "eine", "gemeinsame", "ueberregionale", "Nutzung", "der", "z", ".", "T.", "vorhandenen", "Infrastruktur", "und", "durch", "eine", "Vereinbarung", "bundeseinheitlicher", "Vorgehensweisen", "wesentlich", "verbessert", "werden", "kann", "." ]	[ "umlsterm" ]
lebensbedrohender is an umlsterm, Infektionskrankheiten is an umlsterm, Lungenpest is an umlsterm, Deutschland is an umlsterm, Zeit is an umlsterm, Diagnostik- is an umlsterm, Behandlungseinrichtungen is an umlsterm, Deutschlands is an umlsterm	Bundesgesundheitsblatt.90420389.ger.abstr_task1	Sentence: Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann . Instructions: please typing these entity words according to sentence: lebensbedrohender, Infektionskrankheiten, Lungenpest, Deutschland, Zeit, Diagnostik-, Behandlungseinrichtungen, Deutschlands Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann .	[ "Ein", "Einschleppen", "lebensbedrohender", "und", "zugleich", "hochkontagioeser", "Infektionskrankheiten", "wie", "Lungenpest", "oder", "Ebola", "-", "Fieber", "nach", "Deutschland", "erscheint", "zur", "Zeit", "nicht", "sehr", "wahrscheinlich", ",", "ist", "aber", "grundsaetzlich", "nicht", "auszuschliessen", ".", "Gerade", "wegen", "der", "Seltenheit", "des", "Auftretens", "einer", "solchen", "Erkrankung", "sind", "jedoch", "auch", "hierzulande", "Handlungsrichtlinien", "notwendig", ",", "um", "gegebenenfalls", "einer", "Verbreitung", "entgegenzuwirken", ".", "Die", "Entwicklung", "konkreter", "Schutzvorkehrungen", "und", "Handlungsalgorithmen", "sowie", "das", "Vorhalten", "geeigneter", "Diagnostik-", "und", "Behandlungseinrichtungen", "ist", "in", "den", "einzelnen", "Regionen", "Deutschlands", "sehr", "unterschiedlich", "ausgepraegt", ".", "Ein", "bundesweiter", "Rahmenplan", "fehlt", ".", "Der", "vorliegende", "Konzeptentwurf", "zeigt", ",", "wie", "die", "Vorsorge", "mit", "vertretbarem", "finanziellen", "Mehraufwand", "durch", "eine", "gemeinsame", "ueberregionale", "Nutzung", "der", "z", ".", "T.", "vorhandenen", "Infrastruktur", "und", "durch", "eine", "Vereinbarung", "bundeseinheitlicher", "Vorgehensweisen", "wesentlich", "verbessert", "werden", "kann", "." ]	[ "umlsterm" ]
lebensbedrohender, Infektionskrankheiten, Lungenpest, Deutschland, Zeit, Diagnostik-, Behandlungseinrichtungen, Deutschlands	Bundesgesundheitsblatt.90420389.ger.abstr_task2	Sentence: Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann .	[ "Ein", "Einschleppen", "lebensbedrohender", "und", "zugleich", "hochkontagioeser", "Infektionskrankheiten", "wie", "Lungenpest", "oder", "Ebola", "-", "Fieber", "nach", "Deutschland", "erscheint", "zur", "Zeit", "nicht", "sehr", "wahrscheinlich", ",", "ist", "aber", "grundsaetzlich", "nicht", "auszuschliessen", ".", "Gerade", "wegen", "der", "Seltenheit", "des", "Auftretens", "einer", "solchen", "Erkrankung", "sind", "jedoch", "auch", "hierzulande", "Handlungsrichtlinien", "notwendig", ",", "um", "gegebenenfalls", "einer", "Verbreitung", "entgegenzuwirken", ".", "Die", "Entwicklung", "konkreter", "Schutzvorkehrungen", "und", "Handlungsalgorithmen", "sowie", "das", "Vorhalten", "geeigneter", "Diagnostik-", "und", "Behandlungseinrichtungen", "ist", "in", "den", "einzelnen", "Regionen", "Deutschlands", "sehr", "unterschiedlich", "ausgepraegt", ".", "Ein", "bundesweiter", "Rahmenplan", "fehlt", ".", "Der", "vorliegende", "Konzeptentwurf", "zeigt", ",", "wie", "die", "Vorsorge", "mit", "vertretbarem", "finanziellen", "Mehraufwand", "durch", "eine", "gemeinsame", "ueberregionale", "Nutzung", "der", "z", ".", "T.", "vorhandenen", "Infrastruktur", "und", "durch", "eine", "Vereinbarung", "bundeseinheitlicher", "Vorgehensweisen", "wesentlich", "verbessert", "werden", "kann", "." ]	[ "umlsterm" ]
Tumorinfiltration is an umlsterm, Pankreaskopfes is an umlsterm, Pfortaderresektion is an umlsterm, Morbiditaet is an umlsterm, Pfortaderinfiltration is an umlsterm, Tumoradhaerenz is an umlsterm, Patienten is an umlsterm, Pankreaskopfes is an umlsterm, Tumorinfiltration is an umlsterm, Tumoradhaerenz is an umlsterm, Diagnostik is an umlsterm, Portographie is an umlsterm, Pfortaderresektion is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Tumorinvasion is an umlsterm, Ultraschall is an umlsterm, Pfortaderinfiltration is an umlsterm, Standarddiagnostik is an umlsterm, Sensitivitaet und Spezifitaet is an umlsterm, Ultraschall is an umlsterm, Tumorinfiltration is an umlsterm, Patienten is an umlsterm, Tumoradhaerenz is an umlsterm, Pfortaderresektion is an umlsterm	DerChirurg.00710803.ger.abstr_task0	Sentence: Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren .	[ "Zusammenfassung", ".", "Die", "Tumorinfiltration", "der", "V.", "portae", "bei", "duktalen", "Adenocarcinomen", "des", "Pankreaskopfes", "gilt", "klassischerweise", "als", "Inoperabilitaetskriterium", ".", "Trotz", "operationstechnischer", "Fortschritte", "auf", "dem", "Gebiet", "der", "Pfortaderresektion", "im", "Rahmen", "von", "Whipple", "-", "Operationen", "mit", "akzeptaler", "Letalitaet", "und", "Morbiditaet", "kann", "eine", "Gefaessresektion", "bei", "Infiltration", "nicht", "prinzipiell", "empfohlen", "werden", ".", "Problematisch", "ist", "vor", "allem", "die", "praeoperative", "Sicherung", "einer", "eventuell", "vorliegenden", "Gefaessinfiltration", ",", "haeufig", "sieht", "sich", "der", "Chirurg", "erst", "intraoperativ", "mit", "der", "Situation", "einer", "makroskopischen", "Pfortaderinfiltration", "bzw", ".", "Tumoradhaerenz", "konfrontiert", ".", "Im", "Zeitraum", "von", "1986", "bis", "1995", "wurde", "an", "unserer", "Klinik", "bei", "105", "Patienten", "mit", "duktalem", "Adenocarcinom", "des", "Pankreaskopfes", "eine", "Whipple", "-", "Operation", "vorgenommen", ".", "In", "8", "Faellen", "erfolgte", "bei", "makroskopischer", "Tumorinfiltration", "bzw", ".", "Tumoradhaerenz", "und", "unauffaelliger", "praeoperativer", "Diagnostik", "mittels", "indirekter", "Portographie", "und", "CT", "eine", "partielle", "Pfortaderresektion", ".", "In", "4", "der", "8", "Faelle", "fand", "sich", "eine", "tatsaechliche", ",", "histologisch", "nachweisbare", "Infiltration", "der", "V.", "portae", "bis", "in", "die", "inneren", "Gefaesswandschichten", ",", "waehrend", "die", "uebrigen", "Faelle", "keine", "bzw", ".", "lediglich", "eine", "Adventitiainfiltration", "zeigten", ".", "Die", "Patienten", "ohne", "histologischen", "Nachweis", "einer", "tatsaechlichen", "Gefaessinfiltration", "wiesen", "eine", "deutlich", "laengere", "Ueberlebenszeit", "(", "27,75", "Monate", ")", "gegenueber", "den", "Patienten", "mit", "histologischer", "Tumorinvasion", "in", "die", "V.", "portae", "(", "6,67", "Monate", ")", "auf", ".", "Neuere", "Untersuchungen", "haben", "gezeigt", ",", "dass", "der", "endovasculaere", ",", "intraportale", "Ultraschall", "(", "IPEUS", ")", "einen", "deutlichen", "Informationsgewinn", "bezueglich", "der", "Frage", "einer", "vorliegenden", "Pfortaderinfiltration", "bieten", "kann", ".", "Auch", "wenn", "diese", "Untersuchung", "derzeit", "nicht", "als", "Standarddiagnostik", "gelten", "kann", ",", "so", "besteht", "die", "Moeglichkeit", ",", "bei", "entsprechender", "Indikation", "hierdurch", "mit", "hoher", "Sensitivitaet", "und", "Spezifitaet", "eine", "tatsaechliche", "Gefaessinfiltration", "zu", "erkennen", ".", "Kann", "mittels", "endovasculaerem", "Ultraschall", "eine", "Tumorinfiltration", "in", "die", "V.", "portae", "ausgeschlossen", "werden", ",", "so", "zeigen", "unsere", "Ergebnisse", ",", "dass", "Patienten", "mit", "makroskopischer", "Tumoradhaerenz", "tatsaechlich", "von", "einer", "partiellen", "Pfortaderresektion", "profitieren", "." ]	[ "umlsterm" ]
Tumorinfiltration is an umlsterm, Pankreaskopfes is an umlsterm, Pfortaderresektion is an umlsterm, Morbiditaet is an umlsterm, Pfortaderinfiltration is an umlsterm, Tumoradhaerenz is an umlsterm, Patienten is an umlsterm, Pankreaskopfes is an umlsterm, Tumorinfiltration is an umlsterm, Tumoradhaerenz is an umlsterm, Diagnostik is an umlsterm, Portographie is an umlsterm, Pfortaderresektion is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Tumorinvasion is an umlsterm, Ultraschall is an umlsterm, Pfortaderinfiltration is an umlsterm, Standarddiagnostik is an umlsterm, Sensitivitaet und Spezifitaet is an umlsterm, Ultraschall is an umlsterm, Tumorinfiltration is an umlsterm, Patienten is an umlsterm, Tumoradhaerenz is an umlsterm, Pfortaderresektion is an umlsterm	DerChirurg.00710803.ger.abstr_task1	Sentence: Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren . Instructions: please typing these entity words according to sentence: Tumorinfiltration, Pankreaskopfes, Pfortaderresektion, Morbiditaet, Pfortaderinfiltration, Tumoradhaerenz, Patienten, Pankreaskopfes, Tumorinfiltration, Tumoradhaerenz, Diagnostik, Portographie, Pfortaderresektion, Patienten, Patienten, Tumorinvasion, Ultraschall, Pfortaderinfiltration, Standarddiagnostik, Sensitivitaet und Spezifitaet, Ultraschall, Tumorinfiltration, Patienten, Tumoradhaerenz, Pfortaderresektion Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren .	[ "Zusammenfassung", ".", "Die", "Tumorinfiltration", "der", "V.", "portae", "bei", "duktalen", "Adenocarcinomen", "des", "Pankreaskopfes", "gilt", "klassischerweise", "als", "Inoperabilitaetskriterium", ".", "Trotz", "operationstechnischer", "Fortschritte", "auf", "dem", "Gebiet", "der", "Pfortaderresektion", "im", "Rahmen", "von", "Whipple", "-", "Operationen", "mit", "akzeptaler", "Letalitaet", "und", "Morbiditaet", "kann", "eine", "Gefaessresektion", "bei", "Infiltration", "nicht", "prinzipiell", "empfohlen", "werden", ".", "Problematisch", "ist", "vor", "allem", "die", "praeoperative", "Sicherung", "einer", "eventuell", "vorliegenden", "Gefaessinfiltration", ",", "haeufig", "sieht", "sich", "der", "Chirurg", "erst", "intraoperativ", "mit", "der", "Situation", "einer", "makroskopischen", "Pfortaderinfiltration", "bzw", ".", "Tumoradhaerenz", "konfrontiert", ".", "Im", "Zeitraum", "von", "1986", "bis", "1995", "wurde", "an", "unserer", "Klinik", "bei", "105", "Patienten", "mit", "duktalem", "Adenocarcinom", "des", "Pankreaskopfes", "eine", "Whipple", "-", "Operation", "vorgenommen", ".", "In", "8", "Faellen", "erfolgte", "bei", "makroskopischer", "Tumorinfiltration", "bzw", ".", "Tumoradhaerenz", "und", "unauffaelliger", "praeoperativer", "Diagnostik", "mittels", "indirekter", "Portographie", "und", "CT", "eine", "partielle", "Pfortaderresektion", ".", "In", "4", "der", "8", "Faelle", "fand", "sich", "eine", "tatsaechliche", ",", "histologisch", "nachweisbare", "Infiltration", "der", "V.", "portae", "bis", "in", "die", "inneren", "Gefaesswandschichten", ",", "waehrend", "die", "uebrigen", "Faelle", "keine", "bzw", ".", "lediglich", "eine", "Adventitiainfiltration", "zeigten", ".", "Die", "Patienten", "ohne", "histologischen", "Nachweis", "einer", "tatsaechlichen", "Gefaessinfiltration", "wiesen", "eine", "deutlich", "laengere", "Ueberlebenszeit", "(", "27,75", "Monate", ")", "gegenueber", "den", "Patienten", "mit", "histologischer", "Tumorinvasion", "in", "die", "V.", "portae", "(", "6,67", "Monate", ")", "auf", ".", "Neuere", "Untersuchungen", "haben", "gezeigt", ",", "dass", "der", "endovasculaere", ",", "intraportale", "Ultraschall", "(", "IPEUS", ")", "einen", "deutlichen", "Informationsgewinn", "bezueglich", "der", "Frage", "einer", "vorliegenden", "Pfortaderinfiltration", "bieten", "kann", ".", "Auch", "wenn", "diese", "Untersuchung", "derzeit", "nicht", "als", "Standarddiagnostik", "gelten", "kann", ",", "so", "besteht", "die", "Moeglichkeit", ",", "bei", "entsprechender", "Indikation", "hierdurch", "mit", "hoher", "Sensitivitaet", "und", "Spezifitaet", "eine", "tatsaechliche", "Gefaessinfiltration", "zu", "erkennen", ".", "Kann", "mittels", "endovasculaerem", "Ultraschall", "eine", "Tumorinfiltration", "in", "die", "V.", "portae", "ausgeschlossen", "werden", ",", "so", "zeigen", "unsere", "Ergebnisse", ",", "dass", "Patienten", "mit", "makroskopischer", "Tumoradhaerenz", "tatsaechlich", "von", "einer", "partiellen", "Pfortaderresektion", "profitieren", "." ]	[ "umlsterm" ]
Tumorinfiltration, Pankreaskopfes, Pfortaderresektion, Morbiditaet, Pfortaderinfiltration, Tumoradhaerenz, Patienten, Pankreaskopfes, Tumorinfiltration, Tumoradhaerenz, Diagnostik, Portographie, Pfortaderresektion, Patienten, Patienten, Tumorinvasion, Ultraschall, Pfortaderinfiltration, Standarddiagnostik, Sensitivitaet und Spezifitaet, Ultraschall, Tumorinfiltration, Patienten, Tumoradhaerenz, Pfortaderresektion	DerChirurg.00710803.ger.abstr_task2	Sentence: Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren .	[ "Zusammenfassung", ".", "Die", "Tumorinfiltration", "der", "V.", "portae", "bei", "duktalen", "Adenocarcinomen", "des", "Pankreaskopfes", "gilt", "klassischerweise", "als", "Inoperabilitaetskriterium", ".", "Trotz", "operationstechnischer", "Fortschritte", "auf", "dem", "Gebiet", "der", "Pfortaderresektion", "im", "Rahmen", "von", "Whipple", "-", "Operationen", "mit", "akzeptaler", "Letalitaet", "und", "Morbiditaet", "kann", "eine", "Gefaessresektion", "bei", "Infiltration", "nicht", "prinzipiell", "empfohlen", "werden", ".", "Problematisch", "ist", "vor", "allem", "die", "praeoperative", "Sicherung", "einer", "eventuell", "vorliegenden", "Gefaessinfiltration", ",", "haeufig", "sieht", "sich", "der", "Chirurg", "erst", "intraoperativ", "mit", "der", "Situation", "einer", "makroskopischen", "Pfortaderinfiltration", "bzw", ".", "Tumoradhaerenz", "konfrontiert", ".", "Im", "Zeitraum", "von", "1986", "bis", "1995", "wurde", "an", "unserer", "Klinik", "bei", "105", "Patienten", "mit", "duktalem", "Adenocarcinom", "des", "Pankreaskopfes", "eine", "Whipple", "-", "Operation", "vorgenommen", ".", "In", "8", "Faellen", "erfolgte", "bei", "makroskopischer", "Tumorinfiltration", "bzw", ".", "Tumoradhaerenz", "und", "unauffaelliger", "praeoperativer", "Diagnostik", "mittels", "indirekter", "Portographie", "und", "CT", "eine", "partielle", "Pfortaderresektion", ".", "In", "4", "der", "8", "Faelle", "fand", "sich", "eine", "tatsaechliche", ",", "histologisch", "nachweisbare", "Infiltration", "der", "V.", "portae", "bis", "in", "die", "inneren", "Gefaesswandschichten", ",", "waehrend", "die", "uebrigen", "Faelle", "keine", "bzw", ".", "lediglich", "eine", "Adventitiainfiltration", "zeigten", ".", "Die", "Patienten", "ohne", "histologischen", "Nachweis", "einer", "tatsaechlichen", "Gefaessinfiltration", "wiesen", "eine", "deutlich", "laengere", "Ueberlebenszeit", "(", "27,75", "Monate", ")", "gegenueber", "den", "Patienten", "mit", "histologischer", "Tumorinvasion", "in", "die", "V.", "portae", "(", "6,67", "Monate", ")", "auf", ".", "Neuere", "Untersuchungen", "haben", "gezeigt", ",", "dass", "der", "endovasculaere", ",", "intraportale", "Ultraschall", "(", "IPEUS", ")", "einen", "deutlichen", "Informationsgewinn", "bezueglich", "der", "Frage", "einer", "vorliegenden", "Pfortaderinfiltration", "bieten", "kann", ".", "Auch", "wenn", "diese", "Untersuchung", "derzeit", "nicht", "als", "Standarddiagnostik", "gelten", "kann", ",", "so", "besteht", "die", "Moeglichkeit", ",", "bei", "entsprechender", "Indikation", "hierdurch", "mit", "hoher", "Sensitivitaet", "und", "Spezifitaet", "eine", "tatsaechliche", "Gefaessinfiltration", "zu", "erkennen", ".", "Kann", "mittels", "endovasculaerem", "Ultraschall", "eine", "Tumorinfiltration", "in", "die", "V.", "portae", "ausgeschlossen", "werden", ",", "so", "zeigen", "unsere", "Ergebnisse", ",", "dass", "Patienten", "mit", "makroskopischer", "Tumoradhaerenz", "tatsaechlich", "von", "einer", "partiellen", "Pfortaderresektion", "profitieren", "." ]	[ "umlsterm" ]
Children is a Person, aging is a Person, between 3 and 6 years is a Value, good health conditions is a Condition, at least one is a Multiplier, occlusal or occlusal proximal is a Scope, caries lesion is a Condition, primary molars is a Qualifier, occlusal and / or occlusal - proximal surfaces is a Scope, caries lesions with dentin involvement is a Scope	NCT02562456_inc_task0	Sentence: Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Multiplier, Scope	[ "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]	Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement	[ "Children", "aging", "between", "3", "and", "6", "years", "\n", "presenting", "good", "health", "conditions", "\n", "whose", "parents", "or", "legal", "guardians", "accept", "and", "sign", "the", "consent", "form", "\n", "with", "at", "least", "one", "occlusal", "or", "occlusal", "proximal", "caries", "lesion", "in", "primary", "molars", "\n", "only", "occlusal", "and", "/", "or", "occlusal", "-", "proximal", "surfaces", "with", "caries", "lesions", "with", "dentin", "involvement", "\n" ]	[ "Scope", "Qualifier", "Condition", "Value", "Multiplier", "Person" ]
Children is a Person, aging is a Person, between 3 and 6 years is a Value, good health conditions is a Condition, at least one is a Multiplier, occlusal or occlusal proximal is a Scope, caries lesion is a Condition, primary molars is a Qualifier, occlusal and / or occlusal - proximal surfaces is a Scope, caries lesions with dentin involvement is a Scope	NCT02562456_inc_task1	Sentence: Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement Instructions: please typing these entity words according to sentence: Children, aging, between 3 and 6 years, good health conditions, at least one, occlusal or occlusal proximal, caries lesion, primary molars, occlusal and / or occlusal - proximal surfaces, caries lesions with dentin involvement Options: Condition, Qualifier, Value, Person, Multiplier, Scope	[ "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]	Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement	[ "Children", "aging", "between", "3", "and", "6", "years", "\n", "presenting", "good", "health", "conditions", "\n", "whose", "parents", "or", "legal", "guardians", "accept", "and", "sign", "the", "consent", "form", "\n", "with", "at", "least", "one", "occlusal", "or", "occlusal", "proximal", "caries", "lesion", "in", "primary", "molars", "\n", "only", "occlusal", "and", "/", "or", "occlusal", "-", "proximal", "surfaces", "with", "caries", "lesions", "with", "dentin", "involvement", "\n" ]	[ "Scope", "Qualifier", "Condition", "Value", "Multiplier", "Person" ]
Children, aging, between 3 and 6 years, good health conditions, at least one, occlusal or occlusal proximal, caries lesion, primary molars, occlusal and / or occlusal - proximal surfaces, caries lesions with dentin involvement	NCT02562456_inc_task2	Sentence: Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement Instructions: please extract entity words from the input sentence	[ "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]	Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement	[ "Children", "aging", "between", "3", "and", "6", "years", "\n", "presenting", "good", "health", "conditions", "\n", "whose", "parents", "or", "legal", "guardians", "accept", "and", "sign", "the", "consent", "form", "\n", "with", "at", "least", "one", "occlusal", "or", "occlusal", "proximal", "caries", "lesion", "in", "primary", "molars", "\n", "only", "occlusal", "and", "/", "or", "occlusal", "-", "proximal", "surfaces", "with", "caries", "lesions", "with", "dentin", "involvement", "\n" ]	[ "Scope", "Qualifier", "Condition", "Value", "Multiplier", "Person" ]
calcium channel blockers is a Intervention_Pharmacological, lipid - lowering therapy is a Intervention_Pharmacological, retarding progression of coronary atherosclerosis is a Participant_Condition, Lipid - lowering therapy is a Intervention_Pharmacological, progression of atherosclerosis is a Outcome_Physical, calcium channel blocker ( CCB ) is a Intervention_Pharmacological, CCBs is a Intervention_Pharmacological, lipid - lowering therapy . is a Intervention_Pharmacological, pravastatin is a Intervention_Pharmacological, placebo is a Intervention_Control, placebo ( no pravastatin ) is a Intervention_Control, angiographic new lesion formation is a Outcome_Physical, angiographic lesions is a Outcome_Physical, clinical events is a Outcome_Other, angiographic progression is a Outcome_Physical, progression of established coronary atherosclerosis is a Outcome_Physical	91933_task0	Sentence: Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway .	[ "Proposed", "synergistic", "effect", "of", "calcium", "channel", "blockers", "with", "lipid", "-", "lowering", "therapy", "in", "retarding", "progression", "of", "coronary", "atherosclerosis", ".", "Lipid", "-", "lowering", "therapy", "now", "has", "undoubtedly", "proven", "to", "be", "an", "effective", "therapeutic", "modality", "to", "retard", "the", "progression", "of", "coronary", "atherosclerosis", ".", "An", "additional", "approach", "for", "prevention", "of", "the", "progression", "of", "atherosclerosis", "is", "calcium", "channel", "blocker", "(", "CCB", ")", "treatment", ".", "Evidence", "indicating", "that", "CCBs", "inhibit", "atherosclerosis", "is", "less", "unequivocal", "than", "the", "clear", "evidence", "for", "lipid", "-", "lowering", "therapy", ".", "Many", "investigations", "support", "the", "view", "that", "a", "number", "of", "key", "processes", "in", "atherosclerosis", "may", "be", "influenced", "by", "CCBs", ".", "From", "the", "\"", "negative", "\"", "and", "\"", "positive", "\"", "studies", "with", "CCBs", "performed", "in", "animals", "and", "humans", "we", "must", "conclude", "that", "apparently", "some", ",", "but", "not", "all", ",", "types", "or", "stages", "of", "the", "atherosclerotic", "process", "are", "inhibited", "by", "CCBs", ".", "To", "assess", "whether", "lipid", "-", "lowering", "therapy", "and", "CCB", "treatment", "may", "have", "an", "additive", "or", "synergistic", "beneficial", "effect", "on", "human", "atherosclerosis", ",", "which", "is", "conceivable", "because", "their", "anti", "-", "atherosclerotic", "properties", "differ", ",", "data", "from", "the", "angiographic", "lipid", "-", "lowering", "trial", "REGRESS", "(", "pravastatin", "vs", ".", "placebo", ")", "were", "reviewed", ".", "In", "REGRESS", ",", "patients", "in", "the", "pravastatin", "group", "had", "significantly", "less", "progression", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "those", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", "no", "effect", "of", "CCB", "treatment", "was", "observed", ".", "With", "respect", "to", "angiographic", "new", "lesion", "formation", ",", "in", "the", "pravastatin", "group", "there", "were", "50", "%", "less", "patients", "with", "new", "angiographic", "lesions", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", ",", "again", ",", "no", "significant", "effect", "of", "CCB", "treatment", "was", "observed", ".", "No", "beneficial", "effects", "of", "CCB", "treatment", "on", "clinical", "events", "were", "observed", "during", "the", "2-year", "study", "follow", "-", "up", ".", "In", "view", "of", "the", "correlation", "between", "angiographic", "progression", "and", "subsequent", "clinical", "events", "as", "demonstrated", "in", "several", "large", "trials", ",", "it", "is", "not", "unrealistic", "to", "also", "anticipate", "in", "this", "population", ",", "a", "beneficial", "effect", "on", "clinical", "events", "with", "longer", "follow", "-", "up", ".", "Although", "the", "REGRESS", "trial", "was", "not", "designed", "to", "evaluate", "combination", "therapy", ",", "the", "results", "suggest", "that", "addition", "of", "CCBs", "to", "HMG", "-", "CoA", "reductase", "inhibitor", "therapy", "(", "pravastatin", ")", "acts", "synergistically", "in", "retarding", "the", "progression", "of", "established", "coronary", "atherosclerosis", ".", "These", "results", "appear", "to", "warrant", "prospective", "randomized", "trials", "to", "determine", "in", "a", "more", "definitive", "manner", "the", "merits", "of", "this", "combination", "in", "the", "prevention", "of", "progression", "of", "coronary", "atherosclerosis", ".", "Currently", "a", "number", "of", "studies", "in", "these", "fields", "are", "being", "designed", "or", "are", "already", "underway", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]
calcium channel blockers is a Intervention_Pharmacological, lipid - lowering therapy is a Intervention_Pharmacological, retarding progression of coronary atherosclerosis is a Participant_Condition, Lipid - lowering therapy is a Intervention_Pharmacological, progression of atherosclerosis is a Outcome_Physical, calcium channel blocker ( CCB ) is a Intervention_Pharmacological, CCBs is a Intervention_Pharmacological, lipid - lowering therapy . is a Intervention_Pharmacological, pravastatin is a Intervention_Pharmacological, placebo is a Intervention_Control, placebo ( no pravastatin ) is a Intervention_Control, angiographic new lesion formation is a Outcome_Physical, angiographic lesions is a Outcome_Physical, clinical events is a Outcome_Other, angiographic progression is a Outcome_Physical, progression of established coronary atherosclerosis is a Outcome_Physical	91933_task1	Sentence: Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway . Instructions: please typing these entity words according to sentence: calcium channel blockers, lipid - lowering therapy, retarding progression of coronary atherosclerosis, Lipid - lowering therapy, progression of atherosclerosis, calcium channel blocker ( CCB ), CCBs, lipid - lowering therapy ., pravastatin, placebo, placebo ( no pravastatin ), angiographic new lesion formation, angiographic lesions, clinical events, angiographic progression, progression of established coronary atherosclerosis Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway .	[ "Proposed", "synergistic", "effect", "of", "calcium", "channel", "blockers", "with", "lipid", "-", "lowering", "therapy", "in", "retarding", "progression", "of", "coronary", "atherosclerosis", ".", "Lipid", "-", "lowering", "therapy", "now", "has", "undoubtedly", "proven", "to", "be", "an", "effective", "therapeutic", "modality", "to", "retard", "the", "progression", "of", "coronary", "atherosclerosis", ".", "An", "additional", "approach", "for", "prevention", "of", "the", "progression", "of", "atherosclerosis", "is", "calcium", "channel", "blocker", "(", "CCB", ")", "treatment", ".", "Evidence", "indicating", "that", "CCBs", "inhibit", "atherosclerosis", "is", "less", "unequivocal", "than", "the", "clear", "evidence", "for", "lipid", "-", "lowering", "therapy", ".", "Many", "investigations", "support", "the", "view", "that", "a", "number", "of", "key", "processes", "in", "atherosclerosis", "may", "be", "influenced", "by", "CCBs", ".", "From", "the", "\"", "negative", "\"", "and", "\"", "positive", "\"", "studies", "with", "CCBs", "performed", "in", "animals", "and", "humans", "we", "must", "conclude", "that", "apparently", "some", ",", "but", "not", "all", ",", "types", "or", "stages", "of", "the", "atherosclerotic", "process", "are", "inhibited", "by", "CCBs", ".", "To", "assess", "whether", "lipid", "-", "lowering", "therapy", "and", "CCB", "treatment", "may", "have", "an", "additive", "or", "synergistic", "beneficial", "effect", "on", "human", "atherosclerosis", ",", "which", "is", "conceivable", "because", "their", "anti", "-", "atherosclerotic", "properties", "differ", ",", "data", "from", "the", "angiographic", "lipid", "-", "lowering", "trial", "REGRESS", "(", "pravastatin", "vs", ".", "placebo", ")", "were", "reviewed", ".", "In", "REGRESS", ",", "patients", "in", "the", "pravastatin", "group", "had", "significantly", "less", "progression", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "those", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", "no", "effect", "of", "CCB", "treatment", "was", "observed", ".", "With", "respect", "to", "angiographic", "new", "lesion", "formation", ",", "in", "the", "pravastatin", "group", "there", "were", "50", "%", "less", "patients", "with", "new", "angiographic", "lesions", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", ",", "again", ",", "no", "significant", "effect", "of", "CCB", "treatment", "was", "observed", ".", "No", "beneficial", "effects", "of", "CCB", "treatment", "on", "clinical", "events", "were", "observed", "during", "the", "2-year", "study", "follow", "-", "up", ".", "In", "view", "of", "the", "correlation", "between", "angiographic", "progression", "and", "subsequent", "clinical", "events", "as", "demonstrated", "in", "several", "large", "trials", ",", "it", "is", "not", "unrealistic", "to", "also", "anticipate", "in", "this", "population", ",", "a", "beneficial", "effect", "on", "clinical", "events", "with", "longer", "follow", "-", "up", ".", "Although", "the", "REGRESS", "trial", "was", "not", "designed", "to", "evaluate", "combination", "therapy", ",", "the", "results", "suggest", "that", "addition", "of", "CCBs", "to", "HMG", "-", "CoA", "reductase", "inhibitor", "therapy", "(", "pravastatin", ")", "acts", "synergistically", "in", "retarding", "the", "progression", "of", "established", "coronary", "atherosclerosis", ".", "These", "results", "appear", "to", "warrant", "prospective", "randomized", "trials", "to", "determine", "in", "a", "more", "definitive", "manner", "the", "merits", "of", "this", "combination", "in", "the", "prevention", "of", "progression", "of", "coronary", "atherosclerosis", ".", "Currently", "a", "number", "of", "studies", "in", "these", "fields", "are", "being", "designed", "or", "are", "already", "underway", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]
calcium channel blockers, lipid - lowering therapy, retarding progression of coronary atherosclerosis, Lipid - lowering therapy, progression of atherosclerosis, calcium channel blocker ( CCB ), CCBs, lipid - lowering therapy ., pravastatin, placebo, placebo ( no pravastatin ), angiographic new lesion formation, angiographic lesions, clinical events, angiographic progression, progression of established coronary atherosclerosis	91933_task2	Sentence: Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway .	[ "Proposed", "synergistic", "effect", "of", "calcium", "channel", "blockers", "with", "lipid", "-", "lowering", "therapy", "in", "retarding", "progression", "of", "coronary", "atherosclerosis", ".", "Lipid", "-", "lowering", "therapy", "now", "has", "undoubtedly", "proven", "to", "be", "an", "effective", "therapeutic", "modality", "to", "retard", "the", "progression", "of", "coronary", "atherosclerosis", ".", "An", "additional", "approach", "for", "prevention", "of", "the", "progression", "of", "atherosclerosis", "is", "calcium", "channel", "blocker", "(", "CCB", ")", "treatment", ".", "Evidence", "indicating", "that", "CCBs", "inhibit", "atherosclerosis", "is", "less", "unequivocal", "than", "the", "clear", "evidence", "for", "lipid", "-", "lowering", "therapy", ".", "Many", "investigations", "support", "the", "view", "that", "a", "number", "of", "key", "processes", "in", "atherosclerosis", "may", "be", "influenced", "by", "CCBs", ".", "From", "the", "\"", "negative", "\"", "and", "\"", "positive", "\"", "studies", "with", "CCBs", "performed", "in", "animals", "and", "humans", "we", "must", "conclude", "that", "apparently", "some", ",", "but", "not", "all", ",", "types", "or", "stages", "of", "the", "atherosclerotic", "process", "are", "inhibited", "by", "CCBs", ".", "To", "assess", "whether", "lipid", "-", "lowering", "therapy", "and", "CCB", "treatment", "may", "have", "an", "additive", "or", "synergistic", "beneficial", "effect", "on", "human", "atherosclerosis", ",", "which", "is", "conceivable", "because", "their", "anti", "-", "atherosclerotic", "properties", "differ", ",", "data", "from", "the", "angiographic", "lipid", "-", "lowering", "trial", "REGRESS", "(", "pravastatin", "vs", ".", "placebo", ")", "were", "reviewed", ".", "In", "REGRESS", ",", "patients", "in", "the", "pravastatin", "group", "had", "significantly", "less", "progression", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "those", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", "no", "effect", "of", "CCB", "treatment", "was", "observed", ".", "With", "respect", "to", "angiographic", "new", "lesion", "formation", ",", "in", "the", "pravastatin", "group", "there", "were", "50", "%", "less", "patients", "with", "new", "angiographic", "lesions", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", ",", "again", ",", "no", "significant", "effect", "of", "CCB", "treatment", "was", "observed", ".", "No", "beneficial", "effects", "of", "CCB", "treatment", "on", "clinical", "events", "were", "observed", "during", "the", "2-year", "study", "follow", "-", "up", ".", "In", "view", "of", "the", "correlation", "between", "angiographic", "progression", "and", "subsequent", "clinical", "events", "as", "demonstrated", "in", "several", "large", "trials", ",", "it", "is", "not", "unrealistic", "to", "also", "anticipate", "in", "this", "population", ",", "a", "beneficial", "effect", "on", "clinical", "events", "with", "longer", "follow", "-", "up", ".", "Although", "the", "REGRESS", "trial", "was", "not", "designed", "to", "evaluate", "combination", "therapy", ",", "the", "results", "suggest", "that", "addition", "of", "CCBs", "to", "HMG", "-", "CoA", "reductase", "inhibitor", "therapy", "(", "pravastatin", ")", "acts", "synergistically", "in", "retarding", "the", "progression", "of", "established", "coronary", "atherosclerosis", ".", "These", "results", "appear", "to", "warrant", "prospective", "randomized", "trials", "to", "determine", "in", "a", "more", "definitive", "manner", "the", "merits", "of", "this", "combination", "in", "the", "prevention", "of", "progression", "of", "coronary", "atherosclerosis", ".", "Currently", "a", "number", "of", "studies", "in", "these", "fields", "are", "being", "designed", "or", "are", "already", "underway", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]
Stress is an umlsterm, Fibromyalgie is an umlsterm, Patienten is an umlsterm, Uebergewicht is an umlsterm, Gewalt is an umlsterm, Depression is an umlsterm, Aengstlichkeit is an umlsterm, Fibromyalgie is an umlsterm	ZfuerRheumatologie.8057s088.ger.abstr_task0	Sentence: Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden .	[ "Psychosozialer", "Stress", "und", "psychische", "Auffaelligkeiten", "werden", "bei", "Fibromyalgie", "Patienten", "vermehrt", "beobachtet", ".", "In", "klinischen", "und", "epidemiologischen", "Studien", "findet", "sich", "gehaeuft", "ein", "Muster", "von", "niedrigem", "Bildungsgrad", ",", "erhoehter", "Scheidungsrate", ",", "Uebergewicht", "und", "Nikotinabusus", ".", "In", "gleicher", "Weise", "gehaeuft", "finden", "sich", "physische", "Gewalt", "und", "sexueller", "Missbrauch", "in", "der", "Anamnese", ".", "Manifeste", "Depression", "als", "auch", "erhoehte", "Raten", "auf", "Skalen", "fuer", "Depressivitaet", ",", "Aengstlichkeit", "und", "Somatisierungstendenz", "werden", "ueberlicherweise", "ebenso", "bei", "Fibromyalgie", "gefunden", "." ]	[ "umlsterm" ]
Stress is an umlsterm, Fibromyalgie is an umlsterm, Patienten is an umlsterm, Uebergewicht is an umlsterm, Gewalt is an umlsterm, Depression is an umlsterm, Aengstlichkeit is an umlsterm, Fibromyalgie is an umlsterm	ZfuerRheumatologie.8057s088.ger.abstr_task1	Sentence: Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden . Instructions: please typing these entity words according to sentence: Stress, Fibromyalgie, Patienten, Uebergewicht, Gewalt, Depression, Aengstlichkeit, Fibromyalgie Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden .	[ "Psychosozialer", "Stress", "und", "psychische", "Auffaelligkeiten", "werden", "bei", "Fibromyalgie", "Patienten", "vermehrt", "beobachtet", ".", "In", "klinischen", "und", "epidemiologischen", "Studien", "findet", "sich", "gehaeuft", "ein", "Muster", "von", "niedrigem", "Bildungsgrad", ",", "erhoehter", "Scheidungsrate", ",", "Uebergewicht", "und", "Nikotinabusus", ".", "In", "gleicher", "Weise", "gehaeuft", "finden", "sich", "physische", "Gewalt", "und", "sexueller", "Missbrauch", "in", "der", "Anamnese", ".", "Manifeste", "Depression", "als", "auch", "erhoehte", "Raten", "auf", "Skalen", "fuer", "Depressivitaet", ",", "Aengstlichkeit", "und", "Somatisierungstendenz", "werden", "ueberlicherweise", "ebenso", "bei", "Fibromyalgie", "gefunden", "." ]	[ "umlsterm" ]
Stress, Fibromyalgie, Patienten, Uebergewicht, Gewalt, Depression, Aengstlichkeit, Fibromyalgie	ZfuerRheumatologie.8057s088.ger.abstr_task2	Sentence: Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden .	[ "Psychosozialer", "Stress", "und", "psychische", "Auffaelligkeiten", "werden", "bei", "Fibromyalgie", "Patienten", "vermehrt", "beobachtet", ".", "In", "klinischen", "und", "epidemiologischen", "Studien", "findet", "sich", "gehaeuft", "ein", "Muster", "von", "niedrigem", "Bildungsgrad", ",", "erhoehter", "Scheidungsrate", ",", "Uebergewicht", "und", "Nikotinabusus", ".", "In", "gleicher", "Weise", "gehaeuft", "finden", "sich", "physische", "Gewalt", "und", "sexueller", "Missbrauch", "in", "der", "Anamnese", ".", "Manifeste", "Depression", "als", "auch", "erhoehte", "Raten", "auf", "Skalen", "fuer", "Depressivitaet", ",", "Aengstlichkeit", "und", "Somatisierungstendenz", "werden", "ueberlicherweise", "ebenso", "bei", "Fibromyalgie", "gefunden", "." ]	[ "umlsterm" ]
Maenner is an umlsterm, Frauen is an umlsterm, Bankautomaten is an umlsterm, Analysen is an umlsterm, Staedten is an umlsterm, Mannheim is an umlsterm, Ostdeutschland is an umlsterm, Italien is an umlsterm, Finnland is an umlsterm, Geschlecht is an umlsterm, Frauen is an umlsterm, Maennern is an umlsterm, Altersgruppen is an umlsterm, Gebrauch is an umlsterm, Automaten is an umlsterm, Staedten is an umlsterm, Automaten is an umlsterm, Bankautomaten is an umlsterm, Mannheim is an umlsterm, Regressionsanalysen is an umlsterm, Staedten is an umlsterm, Automaten is an umlsterm, Geraete is an umlsterm, Geschlecht is an umlsterm, Geraete is an umlsterm, Alltagsleben is an umlsterm, Automaten is an umlsterm, Geraete is an umlsterm, Staedten is an umlsterm, Mannheim is an umlsterm, Alltagsleben is an umlsterm, Staedten is an umlsterm, Technik is an umlsterm	ZfuerGerontologie+Geriatrie.00330169.ger.abstr_task0	Sentence: Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten .	[ "Die", "Autoren", "dieses", "Beitrags", "stellen", "Befunde", "ueber", "aeltere", "Maenner", "und", "Frauen", "als", "Nutzer", "von", "Fahrkartenautomaten", ",", "Bankautomaten", "und", "Kartentelefonen", "vor", ".", "Basis", "der", "Analysen", "bilden", "Daten", ",", "die", "im", "Rahmen", "des", "internationalen", "Kooperationsprojektes", "\"", "Keeping", "the", "Elderly", "Mobile", "\"", "in", "vier", "europaeischen", "Staedten", "erhoben", "wurden", ".", "Die", "Untersuchungen", "fanden", "1995", "in", "Mannheim", "(", "Westdeutschland", ")", "mit", "404", ",", "in", "Chemnitz", "(", "Ostdeutschland", ")", "mit", "400", ",", "in", "Ancona", "(", "Italien", ")", "mit", "600", "und", "in", "Jyvaeskylae", "(", "Finnland", ")", "mit", "618", "in", "Privathaushalten", "lebenden", "Befragten", "statt", ",", "die", "aus", "den", "jeweiligen", "Einwohnermeldedregistern", "zufaellig", "ausgewaehlt", "wurden", ".", "Die", "nach", "Geschlecht", "und", "Alter", "disproportional", "geschichtete", "Stichprobe", "setzte", "sich", "zu", "gleichen", "Teilen", "aus", "Frauen", "und", "Maennern", "zusammen", "und", "umfasste", "zwei", "Altersgruppen", "(", "55", "-", "74", "Jahre", "und", "75", "Jahre", "und", "aelter", ")", ".", "Der", "Gebrauch", "der", "Automaten", "ist", "in", "allen", "untersuchten", "Staedten", "allgemein", "gering", ":", "Die", "meisten", "Befragten", "benutzen", "sie", "nicht", ".", "Die", "gebraeuchlichsten", "Automaten", "sind", "Bankautomaten", "in", "Chemnitz", "und", "Kartentelefone", "in", "Mannheim", ".", "Logistische", "Regressionsanalysen", "ergaben", ",", "dass", "das", "Alter", "der", "Befragten", "in", "allen", "vier", "Staedten", "und", "bei", "allen", "drei", "Automaten", "den", "wichtigsten", "Erklaerungsfaktor", "bildet", ".", "Das", "bedeutet", ",", "dass", "die", "Geraete", "vor", "allem", "von", "Juengeren", "benutzt", "werden", ".", "Bildung", "erwies", "sich", "als", "weiterer", "wichtiger", "Faktor", ",", "noch", "vor", "Geschlecht", ".", "Fuer", "jedes", "der", "technischen", "Geraete", "wurde", "ausser", "nach", "der", "Nutzung", "auch", "gefragt", ",", "ob", "es", "das", "Alltagsleben", "erleichtert", ",", "schwieriger", "macht", ",", "oder", "ob", "kein", "Unterschied", "besteht", ".", "Die", "Mehrheit", "der", "Nutzer", "und", "Nutzerinnen", "fand", ",", "dass", "die", "Automaten", "-", "wiederum", "bezogen", "auf", "alle", "drei", "Geraete", "und", "in", "allen", "untersuchten", "Staedten", "-", "eine", "Erleichterung", "darstellen", ".", "Fast", "ein", "Drittel", "der", "Nutzer", "in", "Mannheim", "gab", "allerdings", "auch", "an", ",", "dass", "Fahrkartenautomaten", "ihr", "Alltagsleben", "erschweren", ".", "Weitere", "Unterschiede", "und", "Gemeinsamkeiten", "zwischen", "den", "Staedten", "werden", "im", "Beitrag", "vorgestellt", ".", "Die", "Ergebnisse", "verweisen", "auf", "Beziehungen", "zwischen", "Alter", "und", "Technik", ",", "die", "in", "vertiefenden", "Studien", "weiter", "untersucht", "werden", "sollten", "." ]	[ "umlsterm" ]
Maenner is an umlsterm, Frauen is an umlsterm, Bankautomaten is an umlsterm, Analysen is an umlsterm, Staedten is an umlsterm, Mannheim is an umlsterm, Ostdeutschland is an umlsterm, Italien is an umlsterm, Finnland is an umlsterm, Geschlecht is an umlsterm, Frauen is an umlsterm, Maennern is an umlsterm, Altersgruppen is an umlsterm, Gebrauch is an umlsterm, Automaten is an umlsterm, Staedten is an umlsterm, Automaten is an umlsterm, Bankautomaten is an umlsterm, Mannheim is an umlsterm, Regressionsanalysen is an umlsterm, Staedten is an umlsterm, Automaten is an umlsterm, Geraete is an umlsterm, Geschlecht is an umlsterm, Geraete is an umlsterm, Alltagsleben is an umlsterm, Automaten is an umlsterm, Geraete is an umlsterm, Staedten is an umlsterm, Mannheim is an umlsterm, Alltagsleben is an umlsterm, Staedten is an umlsterm, Technik is an umlsterm	ZfuerGerontologie+Geriatrie.00330169.ger.abstr_task1	Sentence: Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten . Instructions: please typing these entity words according to sentence: Maenner, Frauen, Bankautomaten, Analysen, Staedten, Mannheim, Ostdeutschland, Italien, Finnland, Geschlecht, Frauen, Maennern, Altersgruppen, Gebrauch, Automaten, Staedten, Automaten, Bankautomaten, Mannheim, Regressionsanalysen, Staedten, Automaten, Geraete, Geschlecht, Geraete, Alltagsleben, Automaten, Geraete, Staedten, Mannheim, Alltagsleben, Staedten, Technik Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten .	[ "Die", "Autoren", "dieses", "Beitrags", "stellen", "Befunde", "ueber", "aeltere", "Maenner", "und", "Frauen", "als", "Nutzer", "von", "Fahrkartenautomaten", ",", "Bankautomaten", "und", "Kartentelefonen", "vor", ".", "Basis", "der", "Analysen", "bilden", "Daten", ",", "die", "im", "Rahmen", "des", "internationalen", "Kooperationsprojektes", "\"", "Keeping", "the", "Elderly", "Mobile", "\"", "in", "vier", "europaeischen", "Staedten", "erhoben", "wurden", ".", "Die", "Untersuchungen", "fanden", "1995", "in", "Mannheim", "(", "Westdeutschland", ")", "mit", "404", ",", "in", "Chemnitz", "(", "Ostdeutschland", ")", "mit", "400", ",", "in", "Ancona", "(", "Italien", ")", "mit", "600", "und", "in", "Jyvaeskylae", "(", "Finnland", ")", "mit", "618", "in", "Privathaushalten", "lebenden", "Befragten", "statt", ",", "die", "aus", "den", "jeweiligen", "Einwohnermeldedregistern", "zufaellig", "ausgewaehlt", "wurden", ".", "Die", "nach", "Geschlecht", "und", "Alter", "disproportional", "geschichtete", "Stichprobe", "setzte", "sich", "zu", "gleichen", "Teilen", "aus", "Frauen", "und", "Maennern", "zusammen", "und", "umfasste", "zwei", "Altersgruppen", "(", "55", "-", "74", "Jahre", "und", "75", "Jahre", "und", "aelter", ")", ".", "Der", "Gebrauch", "der", "Automaten", "ist", "in", "allen", "untersuchten", "Staedten", "allgemein", "gering", ":", "Die", "meisten", "Befragten", "benutzen", "sie", "nicht", ".", "Die", "gebraeuchlichsten", "Automaten", "sind", "Bankautomaten", "in", "Chemnitz", "und", "Kartentelefone", "in", "Mannheim", ".", "Logistische", "Regressionsanalysen", "ergaben", ",", "dass", "das", "Alter", "der", "Befragten", "in", "allen", "vier", "Staedten", "und", "bei", "allen", "drei", "Automaten", "den", "wichtigsten", "Erklaerungsfaktor", "bildet", ".", "Das", "bedeutet", ",", "dass", "die", "Geraete", "vor", "allem", "von", "Juengeren", "benutzt", "werden", ".", "Bildung", "erwies", "sich", "als", "weiterer", "wichtiger", "Faktor", ",", "noch", "vor", "Geschlecht", ".", "Fuer", "jedes", "der", "technischen", "Geraete", "wurde", "ausser", "nach", "der", "Nutzung", "auch", "gefragt", ",", "ob", "es", "das", "Alltagsleben", "erleichtert", ",", "schwieriger", "macht", ",", "oder", "ob", "kein", "Unterschied", "besteht", ".", "Die", "Mehrheit", "der", "Nutzer", "und", "Nutzerinnen", "fand", ",", "dass", "die", "Automaten", "-", "wiederum", "bezogen", "auf", "alle", "drei", "Geraete", "und", "in", "allen", "untersuchten", "Staedten", "-", "eine", "Erleichterung", "darstellen", ".", "Fast", "ein", "Drittel", "der", "Nutzer", "in", "Mannheim", "gab", "allerdings", "auch", "an", ",", "dass", "Fahrkartenautomaten", "ihr", "Alltagsleben", "erschweren", ".", "Weitere", "Unterschiede", "und", "Gemeinsamkeiten", "zwischen", "den", "Staedten", "werden", "im", "Beitrag", "vorgestellt", ".", "Die", "Ergebnisse", "verweisen", "auf", "Beziehungen", "zwischen", "Alter", "und", "Technik", ",", "die", "in", "vertiefenden", "Studien", "weiter", "untersucht", "werden", "sollten", "." ]	[ "umlsterm" ]
Maenner, Frauen, Bankautomaten, Analysen, Staedten, Mannheim, Ostdeutschland, Italien, Finnland, Geschlecht, Frauen, Maennern, Altersgruppen, Gebrauch, Automaten, Staedten, Automaten, Bankautomaten, Mannheim, Regressionsanalysen, Staedten, Automaten, Geraete, Geschlecht, Geraete, Alltagsleben, Automaten, Geraete, Staedten, Mannheim, Alltagsleben, Staedten, Technik	ZfuerGerontologie+Geriatrie.00330169.ger.abstr_task2	Sentence: Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten .	[ "Die", "Autoren", "dieses", "Beitrags", "stellen", "Befunde", "ueber", "aeltere", "Maenner", "und", "Frauen", "als", "Nutzer", "von", "Fahrkartenautomaten", ",", "Bankautomaten", "und", "Kartentelefonen", "vor", ".", "Basis", "der", "Analysen", "bilden", "Daten", ",", "die", "im", "Rahmen", "des", "internationalen", "Kooperationsprojektes", "\"", "Keeping", "the", "Elderly", "Mobile", "\"", "in", "vier", "europaeischen", "Staedten", "erhoben", "wurden", ".", "Die", "Untersuchungen", "fanden", "1995", "in", "Mannheim", "(", "Westdeutschland", ")", "mit", "404", ",", "in", "Chemnitz", "(", "Ostdeutschland", ")", "mit", "400", ",", "in", "Ancona", "(", "Italien", ")", "mit", "600", "und", "in", "Jyvaeskylae", "(", "Finnland", ")", "mit", "618", "in", "Privathaushalten", "lebenden", "Befragten", "statt", ",", "die", "aus", "den", "jeweiligen", "Einwohnermeldedregistern", "zufaellig", "ausgewaehlt", "wurden", ".", "Die", "nach", "Geschlecht", "und", "Alter", "disproportional", "geschichtete", "Stichprobe", "setzte", "sich", "zu", "gleichen", "Teilen", "aus", "Frauen", "und", "Maennern", "zusammen", "und", "umfasste", "zwei", "Altersgruppen", "(", "55", "-", "74", "Jahre", "und", "75", "Jahre", "und", "aelter", ")", ".", "Der", "Gebrauch", "der", "Automaten", "ist", "in", "allen", "untersuchten", "Staedten", "allgemein", "gering", ":", "Die", "meisten", "Befragten", "benutzen", "sie", "nicht", ".", "Die", "gebraeuchlichsten", "Automaten", "sind", "Bankautomaten", "in", "Chemnitz", "und", "Kartentelefone", "in", "Mannheim", ".", "Logistische", "Regressionsanalysen", "ergaben", ",", "dass", "das", "Alter", "der", "Befragten", "in", "allen", "vier", "Staedten", "und", "bei", "allen", "drei", "Automaten", "den", "wichtigsten", "Erklaerungsfaktor", "bildet", ".", "Das", "bedeutet", ",", "dass", "die", "Geraete", "vor", "allem", "von", "Juengeren", "benutzt", "werden", ".", "Bildung", "erwies", "sich", "als", "weiterer", "wichtiger", "Faktor", ",", "noch", "vor", "Geschlecht", ".", "Fuer", "jedes", "der", "technischen", "Geraete", "wurde", "ausser", "nach", "der", "Nutzung", "auch", "gefragt", ",", "ob", "es", "das", "Alltagsleben", "erleichtert", ",", "schwieriger", "macht", ",", "oder", "ob", "kein", "Unterschied", "besteht", ".", "Die", "Mehrheit", "der", "Nutzer", "und", "Nutzerinnen", "fand", ",", "dass", "die", "Automaten", "-", "wiederum", "bezogen", "auf", "alle", "drei", "Geraete", "und", "in", "allen", "untersuchten", "Staedten", "-", "eine", "Erleichterung", "darstellen", ".", "Fast", "ein", "Drittel", "der", "Nutzer", "in", "Mannheim", "gab", "allerdings", "auch", "an", ",", "dass", "Fahrkartenautomaten", "ihr", "Alltagsleben", "erschweren", ".", "Weitere", "Unterschiede", "und", "Gemeinsamkeiten", "zwischen", "den", "Staedten", "werden", "im", "Beitrag", "vorgestellt", ".", "Die", "Ergebnisse", "verweisen", "auf", "Beziehungen", "zwischen", "Alter", "und", "Technik", ",", "die", "in", "vertiefenden", "Studien", "weiter", "untersucht", "werden", "sollten", "." ]	[ "umlsterm" ]
Adhaesion is an umlsterm, Zellen is an umlsterm, Endothelzellen is an umlsterm, Zelladhaesionsmolekuele is an umlsterm, Zelladhaesion is an umlsterm, Integrine is an umlsterm, LFA-1 is an umlsterm, ICAM-1 is an umlsterm, Transplantationsmedizin is an umlsterm, Entzuendungen is an umlsterm, Darmerkrankungen is an umlsterm, Tumormetastasierung is an umlsterm, tierexperimenteller is an umlsterm, Cytokine is an umlsterm, Spezifitaet is an umlsterm, Therapiekonzept is an umlsterm	DerChirurg.70680477.ger.abstr_task0	Sentence: Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann .	[ "Zusammenfassung", ".", "Die", "Adhaesion", "zirkulierender", "Zellen", "an", "Endothelzellen", "wird", "durch", "Zelladhaesionsmolekuele", "vermittelt", "und", "laeuft", "kaskadenfoermig", "ab", ".", "Die", "ersten", "Schritte", "dieser", "Zelladhaesionskaskade", "(", "rolling", ",", "tethering", ")", "werden", "vornehmlich", "durch", "Selektine", "(", "P-", ",", "E-", "und", "L", "-", "Selektin", ")", "reguliert", ",", "waehrend", "an", "der", "stabilen", "Zelladhaesion", "und", "der", "anschliessenden", "Migration", "hauptsaechlich", "Integrine", "(", "LFA-1", "u.", "a.", ")", "und", "Mitglieder", "der", "Immunglobulinsupergenfamilie", "(", "ICAM-1", "u.", "a.", ")", "beteiligt", "sind", ".", "Die", "Leukocytenendothelinteraktion", "laeuft", "unter", "physiologischen", "und", "pathophysiologischen", "Bedingungen", "sowie", "in", "verschiedenen", "Organen", "sehr", "aehnlich", "ab", ";", "moeglicherweise", "wird", "die", "Zellwanderung", "in", "individuelle", "Gewebe", "/", "Organe", "(", "z", ".", "B.", "beim", "homing", ")", "durch", "zusaetzliche", "organspezifische", ",", "topische", "Adhaesionsmolekuele", "(", "wie", "MAdCAM", ")", "ergaenzt", ".", "Die", "moegliche", "klinisch", "-", "chirurgische", "Bedeutung", "von", "Zelladhaesionsmolekuelen", "kommt", "insbesondere", "in", "der", "Transplantationsmedizin", "(", "Ischaemie", "/", "Reperfusion", "und", "Rejektion", ")", ",", "bei", "Entzuendungen", "(", "z", ".", "B.", "chronisch", "entzuendliche", "Darmerkrankungen", ")", "und", "in", "der", "Tumormetastasierung", "zum", "Tragen", ".", "Die", "Ergebnisse", "tierexperimenteller", "Untersuchungen", "zur", "Antiadhaesionstherapie", "zeigen", ",", "dass", "durch", "Blockade", "der", "Leukocytenendothelinteraktion", "die", "Entstehung", "von", "Entzuendungsinfiltraten", "und", "die", "Abstossungsreaktion", "verhindert", "werden", "koennen", "-", "Erfahrungen", "im", "Humansystem", "liegen", "bisher", "nur", "vereinzelt", "vor", ".", "Voraussetzung", "fuer", "die", "klinische", "Umsetzung", "ist", "u.", "a.", "ein", "besseres", "Verstaendnis", "der", "Regulation", "von", "Zelladhaesionsmolekuelen", "(", "Cytokine", ",", "chemotaktische", "Substanzen", "etc", ".", ")", "und", "der", "Spezifitaet", "dieser", "Prozesse", ".", "Schon", "heute", "legen", "die", "experimentellen", "Daten", "nahe", ",", "dass", "durch", "Interaktion", "mit", "dem", "Zelladhaesionssystem", "durch", "fruehe", "Beeinflussung", "eines", "grundlegenden", "pathophysiologischen", "Prinzips", "ein", "innovatives", "Therapiekonzept", "etabliert", "werden", "kann", "." ]	[ "umlsterm" ]
Adhaesion is an umlsterm, Zellen is an umlsterm, Endothelzellen is an umlsterm, Zelladhaesionsmolekuele is an umlsterm, Zelladhaesion is an umlsterm, Integrine is an umlsterm, LFA-1 is an umlsterm, ICAM-1 is an umlsterm, Transplantationsmedizin is an umlsterm, Entzuendungen is an umlsterm, Darmerkrankungen is an umlsterm, Tumormetastasierung is an umlsterm, tierexperimenteller is an umlsterm, Cytokine is an umlsterm, Spezifitaet is an umlsterm, Therapiekonzept is an umlsterm	DerChirurg.70680477.ger.abstr_task1	Sentence: Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann . Instructions: please typing these entity words according to sentence: Adhaesion, Zellen, Endothelzellen, Zelladhaesionsmolekuele, Zelladhaesion, Integrine, LFA-1, ICAM-1, Transplantationsmedizin, Entzuendungen, Darmerkrankungen, Tumormetastasierung, tierexperimenteller, Cytokine, Spezifitaet, Therapiekonzept Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann .	[ "Zusammenfassung", ".", "Die", "Adhaesion", "zirkulierender", "Zellen", "an", "Endothelzellen", "wird", "durch", "Zelladhaesionsmolekuele", "vermittelt", "und", "laeuft", "kaskadenfoermig", "ab", ".", "Die", "ersten", "Schritte", "dieser", "Zelladhaesionskaskade", "(", "rolling", ",", "tethering", ")", "werden", "vornehmlich", "durch", "Selektine", "(", "P-", ",", "E-", "und", "L", "-", "Selektin", ")", "reguliert", ",", "waehrend", "an", "der", "stabilen", "Zelladhaesion", "und", "der", "anschliessenden", "Migration", "hauptsaechlich", "Integrine", "(", "LFA-1", "u.", "a.", ")", "und", "Mitglieder", "der", "Immunglobulinsupergenfamilie", "(", "ICAM-1", "u.", "a.", ")", "beteiligt", "sind", ".", "Die", "Leukocytenendothelinteraktion", "laeuft", "unter", "physiologischen", "und", "pathophysiologischen", "Bedingungen", "sowie", "in", "verschiedenen", "Organen", "sehr", "aehnlich", "ab", ";", "moeglicherweise", "wird", "die", "Zellwanderung", "in", "individuelle", "Gewebe", "/", "Organe", "(", "z", ".", "B.", "beim", "homing", ")", "durch", "zusaetzliche", "organspezifische", ",", "topische", "Adhaesionsmolekuele", "(", "wie", "MAdCAM", ")", "ergaenzt", ".", "Die", "moegliche", "klinisch", "-", "chirurgische", "Bedeutung", "von", "Zelladhaesionsmolekuelen", "kommt", "insbesondere", "in", "der", "Transplantationsmedizin", "(", "Ischaemie", "/", "Reperfusion", "und", "Rejektion", ")", ",", "bei", "Entzuendungen", "(", "z", ".", "B.", "chronisch", "entzuendliche", "Darmerkrankungen", ")", "und", "in", "der", "Tumormetastasierung", "zum", "Tragen", ".", "Die", "Ergebnisse", "tierexperimenteller", "Untersuchungen", "zur", "Antiadhaesionstherapie", "zeigen", ",", "dass", "durch", "Blockade", "der", "Leukocytenendothelinteraktion", "die", "Entstehung", "von", "Entzuendungsinfiltraten", "und", "die", "Abstossungsreaktion", "verhindert", "werden", "koennen", "-", "Erfahrungen", "im", "Humansystem", "liegen", "bisher", "nur", "vereinzelt", "vor", ".", "Voraussetzung", "fuer", "die", "klinische", "Umsetzung", "ist", "u.", "a.", "ein", "besseres", "Verstaendnis", "der", "Regulation", "von", "Zelladhaesionsmolekuelen", "(", "Cytokine", ",", "chemotaktische", "Substanzen", "etc", ".", ")", "und", "der", "Spezifitaet", "dieser", "Prozesse", ".", "Schon", "heute", "legen", "die", "experimentellen", "Daten", "nahe", ",", "dass", "durch", "Interaktion", "mit", "dem", "Zelladhaesionssystem", "durch", "fruehe", "Beeinflussung", "eines", "grundlegenden", "pathophysiologischen", "Prinzips", "ein", "innovatives", "Therapiekonzept", "etabliert", "werden", "kann", "." ]	[ "umlsterm" ]
Adhaesion, Zellen, Endothelzellen, Zelladhaesionsmolekuele, Zelladhaesion, Integrine, LFA-1, ICAM-1, Transplantationsmedizin, Entzuendungen, Darmerkrankungen, Tumormetastasierung, tierexperimenteller, Cytokine, Spezifitaet, Therapiekonzept	DerChirurg.70680477.ger.abstr_task2	Sentence: Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann .	[ "Zusammenfassung", ".", "Die", "Adhaesion", "zirkulierender", "Zellen", "an", "Endothelzellen", "wird", "durch", "Zelladhaesionsmolekuele", "vermittelt", "und", "laeuft", "kaskadenfoermig", "ab", ".", "Die", "ersten", "Schritte", "dieser", "Zelladhaesionskaskade", "(", "rolling", ",", "tethering", ")", "werden", "vornehmlich", "durch", "Selektine", "(", "P-", ",", "E-", "und", "L", "-", "Selektin", ")", "reguliert", ",", "waehrend", "an", "der", "stabilen", "Zelladhaesion", "und", "der", "anschliessenden", "Migration", "hauptsaechlich", "Integrine", "(", "LFA-1", "u.", "a.", ")", "und", "Mitglieder", "der", "Immunglobulinsupergenfamilie", "(", "ICAM-1", "u.", "a.", ")", "beteiligt", "sind", ".", "Die", "Leukocytenendothelinteraktion", "laeuft", "unter", "physiologischen", "und", "pathophysiologischen", "Bedingungen", "sowie", "in", "verschiedenen", "Organen", "sehr", "aehnlich", "ab", ";", "moeglicherweise", "wird", "die", "Zellwanderung", "in", "individuelle", "Gewebe", "/", "Organe", "(", "z", ".", "B.", "beim", "homing", ")", "durch", "zusaetzliche", "organspezifische", ",", "topische", "Adhaesionsmolekuele", "(", "wie", "MAdCAM", ")", "ergaenzt", ".", "Die", "moegliche", "klinisch", "-", "chirurgische", "Bedeutung", "von", "Zelladhaesionsmolekuelen", "kommt", "insbesondere", "in", "der", "Transplantationsmedizin", "(", "Ischaemie", "/", "Reperfusion", "und", "Rejektion", ")", ",", "bei", "Entzuendungen", "(", "z", ".", "B.", "chronisch", "entzuendliche", "Darmerkrankungen", ")", "und", "in", "der", "Tumormetastasierung", "zum", "Tragen", ".", "Die", "Ergebnisse", "tierexperimenteller", "Untersuchungen", "zur", "Antiadhaesionstherapie", "zeigen", ",", "dass", "durch", "Blockade", "der", "Leukocytenendothelinteraktion", "die", "Entstehung", "von", "Entzuendungsinfiltraten", "und", "die", "Abstossungsreaktion", "verhindert", "werden", "koennen", "-", "Erfahrungen", "im", "Humansystem", "liegen", "bisher", "nur", "vereinzelt", "vor", ".", "Voraussetzung", "fuer", "die", "klinische", "Umsetzung", "ist", "u.", "a.", "ein", "besseres", "Verstaendnis", "der", "Regulation", "von", "Zelladhaesionsmolekuelen", "(", "Cytokine", ",", "chemotaktische", "Substanzen", "etc", ".", ")", "und", "der", "Spezifitaet", "dieser", "Prozesse", ".", "Schon", "heute", "legen", "die", "experimentellen", "Daten", "nahe", ",", "dass", "durch", "Interaktion", "mit", "dem", "Zelladhaesionssystem", "durch", "fruehe", "Beeinflussung", "eines", "grundlegenden", "pathophysiologischen", "Prinzips", "ein", "innovatives", "Therapiekonzept", "etabliert", "werden", "kann", "." ]	[ "umlsterm" ]
leukotriene receptor is a GENE-N, MUC2/5AC is a GENE-N, mucin is a GENE-N	17223000_task0	Sentence: The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N	[ "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]	The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells.	[ "The", "inhibitory", "effect", "of", "the", "leukotriene", "receptor", "antagonist", "on", "leukotriene", "D4-induced", "MUC2/5AC", "gene", "expression", "and", "mucin", "secretion", "in", "human", "airway", "epithelial", "cells", "." ]	[ "GENE-N", "CHEMICAL" ]
leukotriene receptor is a GENE-N, MUC2/5AC is a GENE-N, mucin is a GENE-N	17223000_task1	Sentence: The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells. Instructions: please typing these entity words according to sentence: leukotriene receptor, MUC2/5AC, mucin Options: GENE-N	[ "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]	The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells.	[ "The", "inhibitory", "effect", "of", "the", "leukotriene", "receptor", "antagonist", "on", "leukotriene", "D4-induced", "MUC2/5AC", "gene", "expression", "and", "mucin", "secretion", "in", "human", "airway", "epithelial", "cells", "." ]	[ "GENE-N", "CHEMICAL" ]
leukotriene receptor, MUC2/5AC, mucin	17223000_task2	Sentence: The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]	The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells.	[ "The", "inhibitory", "effect", "of", "the", "leukotriene", "receptor", "antagonist", "on", "leukotriene", "D4-induced", "MUC2/5AC", "gene", "expression", "and", "mucin", "secretion", "in", "human", "airway", "epithelial", "cells", "." ]	[ "GENE-N", "CHEMICAL" ]
IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, IFN - beta is a Protein, IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, P53 is a Protein, Rb is a Protein, Bcl - xL is a Protein, IL-2 is a Protein, tyrosine is a Entity, nucleus is a Entity, signal transducers and activators of transcription ( STAT ) 2 is a Protein, STAT2 is a Protein, IL-2 is a Protein	740_task0	Sentence: Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis.	[ "Rescue", "by", "cytokines", "of", "apoptotic", "cell", "death", "induced", "by", "IL-2", "deprivation", "of", "human", "antigen", "-", "specific", "T", "cell", "clones", ".", "\n", "The", "control", "of", "cell", "survival", "and", "cell", "death", "is", "of", "central", "importance", "in", "tissues", "with", "high", "cell", "turnover", "such", "as", "the", "lymphoid", "system", ".", "We", "have", "examined", "the", "effect", "of", "cytokines", "on", "IL-2", "deprivation", "-", "induced", "apoptosis", "of", "human", "antigen", "-", "specific", "T", "helper", "clones", "with", "different", "cytokine", "production", "profiles", ".", "We", "found", "that", "IL-2", ",", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", ",", "and", "IFN", "-", "beta", "inhibited", "IL-2", "deprivation", "apoptosis", "in", "Th0", ",", "Th1", ",", "and", "Th2", "clones", ".", "We", "also", "found", "that", "IL-2", "protects", "T", "cell", "clones", "from", "IL-2", "deprivation", "apoptosis", "accompanying", "active", "proliferation", "and", "enhanced", "expression", "of", "P53", ",", "Rb", "and", "Bcl", "-", "xL", "proteins", ".", "In", "contrast", ",", "IFN", "-", "alpha", "/", "beta", "rescued", "T", "cell", "clones", "from", "apoptosis", "without", "active", "proliferation", ",", "and", "expression", "of", "apoptosis", "-", "associated", "proteins", "tested", "so", "far", "was", "unaffected", ".", "This", "may", "be", "due", "to", "the", "fact", "that", "T", "cells", "treated", "with", "IL-2", "contained", "those", "located", "in", "S", "+", "G2", "/", "M", "phases", "of", "the", "cell", "cycle", ",", "whereas", "the", "vast", "majority", "of", "T", "cells", "treated", "with", "IFN", "-", "alpha", "/", "beta", "were", "located", "in", "G0", "/", "G1", "phase", ".", "IFN", "-", "alpha", "/", "beta", "specifically", "induced", "tyrosine", "phosphorylation", "and", "translocation", "into", "nucleus", "of", "signal", "transducers", "and", "activators", "of", "transcription", "(", "STAT", ")", "2", "protein", "in", "the", "T", "cell", "clones", ".", "In", "addition", ",", "over", "-", "expression", "of", "STAT2", "by", "transfection", "of", "the", "cDNA", "prevented", "apoptosis", "of", "the", "T", "cell", "clones", ".", "Our", "present", "study", "shows", "that", "IFN", "-", "alpha", "and", "-beta", "mediate", "anti", "-", "apoptotic", "effect", "through", "other", "pathways", "than", "that", "of", "IL-2", "in", "growth", "factor", "deprivation", "apoptosis", "." ]	[ "Protein", "Entity" ]
IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, IFN - beta is a Protein, IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, P53 is a Protein, Rb is a Protein, Bcl - xL is a Protein, IL-2 is a Protein, tyrosine is a Entity, nucleus is a Entity, signal transducers and activators of transcription ( STAT ) 2 is a Protein, STAT2 is a Protein, IL-2 is a Protein	740_task1	Sentence: Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis. Instructions: please typing these entity words according to sentence: IL-2, IL-2, IL-2, IFN - beta, IL-2, IL-2, IL-2, P53, Rb, Bcl - xL, IL-2, tyrosine, nucleus, signal transducers and activators of transcription ( STAT ) 2, STAT2, IL-2 Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis.	[ "Rescue", "by", "cytokines", "of", "apoptotic", "cell", "death", "induced", "by", "IL-2", "deprivation", "of", "human", "antigen", "-", "specific", "T", "cell", "clones", ".", "\n", "The", "control", "of", "cell", "survival", "and", "cell", "death", "is", "of", "central", "importance", "in", "tissues", "with", "high", "cell", "turnover", "such", "as", "the", "lymphoid", "system", ".", "We", "have", "examined", "the", "effect", "of", "cytokines", "on", "IL-2", "deprivation", "-", "induced", "apoptosis", "of", "human", "antigen", "-", "specific", "T", "helper", "clones", "with", "different", "cytokine", "production", "profiles", ".", "We", "found", "that", "IL-2", ",", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", ",", "and", "IFN", "-", "beta", "inhibited", "IL-2", "deprivation", "apoptosis", "in", "Th0", ",", "Th1", ",", "and", "Th2", "clones", ".", "We", "also", "found", "that", "IL-2", "protects", "T", "cell", "clones", "from", "IL-2", "deprivation", "apoptosis", "accompanying", "active", "proliferation", "and", "enhanced", "expression", "of", "P53", ",", "Rb", "and", "Bcl", "-", "xL", "proteins", ".", "In", "contrast", ",", "IFN", "-", "alpha", "/", "beta", "rescued", "T", "cell", "clones", "from", "apoptosis", "without", "active", "proliferation", ",", "and", "expression", "of", "apoptosis", "-", "associated", "proteins", "tested", "so", "far", "was", "unaffected", ".", "This", "may", "be", "due", "to", "the", "fact", "that", "T", "cells", "treated", "with", "IL-2", "contained", "those", "located", "in", "S", "+", "G2", "/", "M", "phases", "of", "the", "cell", "cycle", ",", "whereas", "the", "vast", "majority", "of", "T", "cells", "treated", "with", "IFN", "-", "alpha", "/", "beta", "were", "located", "in", "G0", "/", "G1", "phase", ".", "IFN", "-", "alpha", "/", "beta", "specifically", "induced", "tyrosine", "phosphorylation", "and", "translocation", "into", "nucleus", "of", "signal", "transducers", "and", "activators", "of", "transcription", "(", "STAT", ")", "2", "protein", "in", "the", "T", "cell", "clones", ".", "In", "addition", ",", "over", "-", "expression", "of", "STAT2", "by", "transfection", "of", "the", "cDNA", "prevented", "apoptosis", "of", "the", "T", "cell", "clones", ".", "Our", "present", "study", "shows", "that", "IFN", "-", "alpha", "and", "-beta", "mediate", "anti", "-", "apoptotic", "effect", "through", "other", "pathways", "than", "that", "of", "IL-2", "in", "growth", "factor", "deprivation", "apoptosis", "." ]	[ "Protein", "Entity" ]
IL-2, IL-2, IL-2, IFN - beta, IL-2, IL-2, IL-2, P53, Rb, Bcl - xL, IL-2, tyrosine, nucleus, signal transducers and activators of transcription ( STAT ) 2, STAT2, IL-2	740_task2	Sentence: Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis.	[ "Rescue", "by", "cytokines", "of", "apoptotic", "cell", "death", "induced", "by", "IL-2", "deprivation", "of", "human", "antigen", "-", "specific", "T", "cell", "clones", ".", "\n", "The", "control", "of", "cell", "survival", "and", "cell", "death", "is", "of", "central", "importance", "in", "tissues", "with", "high", "cell", "turnover", "such", "as", "the", "lymphoid", "system", ".", "We", "have", "examined", "the", "effect", "of", "cytokines", "on", "IL-2", "deprivation", "-", "induced", "apoptosis", "of", "human", "antigen", "-", "specific", "T", "helper", "clones", "with", "different", "cytokine", "production", "profiles", ".", "We", "found", "that", "IL-2", ",", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", ",", "and", "IFN", "-", "beta", "inhibited", "IL-2", "deprivation", "apoptosis", "in", "Th0", ",", "Th1", ",", "and", "Th2", "clones", ".", "We", "also", "found", "that", "IL-2", "protects", "T", "cell", "clones", "from", "IL-2", "deprivation", "apoptosis", "accompanying", "active", "proliferation", "and", "enhanced", "expression", "of", "P53", ",", "Rb", "and", "Bcl", "-", "xL", "proteins", ".", "In", "contrast", ",", "IFN", "-", "alpha", "/", "beta", "rescued", "T", "cell", "clones", "from", "apoptosis", "without", "active", "proliferation", ",", "and", "expression", "of", "apoptosis", "-", "associated", "proteins", "tested", "so", "far", "was", "unaffected", ".", "This", "may", "be", "due", "to", "the", "fact", "that", "T", "cells", "treated", "with", "IL-2", "contained", "those", "located", "in", "S", "+", "G2", "/", "M", "phases", "of", "the", "cell", "cycle", ",", "whereas", "the", "vast", "majority", "of", "T", "cells", "treated", "with", "IFN", "-", "alpha", "/", "beta", "were", "located", "in", "G0", "/", "G1", "phase", ".", "IFN", "-", "alpha", "/", "beta", "specifically", "induced", "tyrosine", "phosphorylation", "and", "translocation", "into", "nucleus", "of", "signal", "transducers", "and", "activators", "of", "transcription", "(", "STAT", ")", "2", "protein", "in", "the", "T", "cell", "clones", ".", "In", "addition", ",", "over", "-", "expression", "of", "STAT2", "by", "transfection", "of", "the", "cDNA", "prevented", "apoptosis", "of", "the", "T", "cell", "clones", ".", "Our", "present", "study", "shows", "that", "IFN", "-", "alpha", "and", "-beta", "mediate", "anti", "-", "apoptotic", "effect", "through", "other", "pathways", "than", "that", "of", "IL-2", "in", "growth", "factor", "deprivation", "apoptosis", "." ]	[ "Protein", "Entity" ]
intramedullary nail is an umlsterm, nature is an umlsterm, nail is an umlsterm, titanium is an umlsterm, nail is an umlsterm, bone formation is an umlsterm, bone formation is an umlsterm, nail is an umlsterm, cortex is an umlsterm, nail is an umlsterm, titanium is an umlsterm, nail is an umlsterm, therapeutic is an umlsterm	DerUnfallchirurg.81010950.eng.abstr_task0	Sentence: Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful .	[ "Impaction", "of", "an", "intramedullary", "nail", "during", "extraction", "is", "an", "unpredictable", "and", "delicate", "situation", ".", "Its", "problematic", "nature", "is", "unfolded", "on", "a", "report", "of", "two", "cases", ",", "one", "with", "a", "Kuentscher", "nail", "and", "one", "with", "a", "modern", "solid", "titanium", "nail", ".", "This", "event", "is", "caused", "by", "ingrowth", "of", "new", "bone", "formation", "into", "the", "slot", "or", "the", "dorsal", "flute", "respectively", ".", "The", "new", "bone", "formation", "is", "a", "mechanical", "barrier", "which", "effectively", "forces", "the", "distal", "part", "of", "the", "nail", "to", "jam", "against", "the", "cortex", ".", "Both", ",", "the", "slot", "of", "the", "unlocked", "reamed", "clover", "leaf", "nail", "and", "the", "wider", "dorsal", "flute", "of", "the", "solid", "titanium", "nail", ",", "realize", "certain", "therapeutic", "concepts", ".", "Their", "factual", "benefit", "within", "the", "concept", "of", "interlocking", "nailing", "is", "doubtful", "." ]	[ "umlsterm" ]
intramedullary nail is an umlsterm, nature is an umlsterm, nail is an umlsterm, titanium is an umlsterm, nail is an umlsterm, bone formation is an umlsterm, bone formation is an umlsterm, nail is an umlsterm, cortex is an umlsterm, nail is an umlsterm, titanium is an umlsterm, nail is an umlsterm, therapeutic is an umlsterm	DerUnfallchirurg.81010950.eng.abstr_task1	Sentence: Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful . Instructions: please typing these entity words according to sentence: intramedullary nail, nature, nail, titanium, nail, bone formation, bone formation, nail, cortex, nail, titanium, nail, therapeutic Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful .	[ "Impaction", "of", "an", "intramedullary", "nail", "during", "extraction", "is", "an", "unpredictable", "and", "delicate", "situation", ".", "Its", "problematic", "nature", "is", "unfolded", "on", "a", "report", "of", "two", "cases", ",", "one", "with", "a", "Kuentscher", "nail", "and", "one", "with", "a", "modern", "solid", "titanium", "nail", ".", "This", "event", "is", "caused", "by", "ingrowth", "of", "new", "bone", "formation", "into", "the", "slot", "or", "the", "dorsal", "flute", "respectively", ".", "The", "new", "bone", "formation", "is", "a", "mechanical", "barrier", "which", "effectively", "forces", "the", "distal", "part", "of", "the", "nail", "to", "jam", "against", "the", "cortex", ".", "Both", ",", "the", "slot", "of", "the", "unlocked", "reamed", "clover", "leaf", "nail", "and", "the", "wider", "dorsal", "flute", "of", "the", "solid", "titanium", "nail", ",", "realize", "certain", "therapeutic", "concepts", ".", "Their", "factual", "benefit", "within", "the", "concept", "of", "interlocking", "nailing", "is", "doubtful", "." ]	[ "umlsterm" ]
intramedullary nail, nature, nail, titanium, nail, bone formation, bone formation, nail, cortex, nail, titanium, nail, therapeutic	DerUnfallchirurg.81010950.eng.abstr_task2	Sentence: Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful .	[ "Impaction", "of", "an", "intramedullary", "nail", "during", "extraction", "is", "an", "unpredictable", "and", "delicate", "situation", ".", "Its", "problematic", "nature", "is", "unfolded", "on", "a", "report", "of", "two", "cases", ",", "one", "with", "a", "Kuentscher", "nail", "and", "one", "with", "a", "modern", "solid", "titanium", "nail", ".", "This", "event", "is", "caused", "by", "ingrowth", "of", "new", "bone", "formation", "into", "the", "slot", "or", "the", "dorsal", "flute", "respectively", ".", "The", "new", "bone", "formation", "is", "a", "mechanical", "barrier", "which", "effectively", "forces", "the", "distal", "part", "of", "the", "nail", "to", "jam", "against", "the", "cortex", ".", "Both", ",", "the", "slot", "of", "the", "unlocked", "reamed", "clover", "leaf", "nail", "and", "the", "wider", "dorsal", "flute", "of", "the", "solid", "titanium", "nail", ",", "realize", "certain", "therapeutic", "concepts", ".", "Their", "factual", "benefit", "within", "the", "concept", "of", "interlocking", "nailing", "is", "doubtful", "." ]	[ "umlsterm" ]
Chronic hepatitis B is a Condition, HBsAg is a Measurement, positive is a Value, > 6 months is a Temporal, HBeAg is a Measurement, negative is a Value, within six months prior to initiation of peginterferon alfa-2a is a Temporal, HBV DNA is a Measurement, < 200 IU / ml is a Value, during nucleos(t)ide analogue ( except Telbivudine ) treatment is a Temporal, within one month prior to initiation of peginterferon alfa-2a is a Temporal, Compensated is a Qualifier, liver disease is a Condition, Age is a Person, > 18 years is a Value	NCT01373684_inc_task0	Sentence: Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Measurement	[ "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O" ]	Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent	[ "Chronic", "hepatitis", "B", "(", "HBsAg", "positive", ">", "6", "months", ")", "\n", "HBeAg", "negative", "within", "six", "months", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "HBV", "DNA", "<", "200", "IU", "/", "ml", "during", "nucleos(t)ide", "analogue", "(", "except", "Telbivudine", ")", "treatment", "within", "one", "month", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "Compensated", "liver", "disease", "\n", "Age", ">", "18", "years", "\n", "Written", "informed", "consent", "\n" ]	[ "Temporal", "Reference_point", "Drug", "Condition", "Value", "Qualifier", "Measurement", "Negation", "Person" ]
Chronic hepatitis B is a Condition, HBsAg is a Measurement, positive is a Value, > 6 months is a Temporal, HBeAg is a Measurement, negative is a Value, within six months prior to initiation of peginterferon alfa-2a is a Temporal, HBV DNA is a Measurement, < 200 IU / ml is a Value, during nucleos(t)ide analogue ( except Telbivudine ) treatment is a Temporal, within one month prior to initiation of peginterferon alfa-2a is a Temporal, Compensated is a Qualifier, liver disease is a Condition, Age is a Person, > 18 years is a Value	NCT01373684_inc_task1	Sentence: Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent Instructions: please typing these entity words according to sentence: Chronic hepatitis B, HBsAg, positive, > 6 months, HBeAg, negative, within six months prior to initiation of peginterferon alfa-2a, HBV DNA, < 200 IU / ml, during nucleos(t)ide analogue ( except Telbivudine ) treatment, within one month prior to initiation of peginterferon alfa-2a, Compensated, liver disease, Age, > 18 years Options: Temporal, Condition, Qualifier, Value, Person, Measurement	[ "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O" ]	Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent	[ "Chronic", "hepatitis", "B", "(", "HBsAg", "positive", ">", "6", "months", ")", "\n", "HBeAg", "negative", "within", "six", "months", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "HBV", "DNA", "<", "200", "IU", "/", "ml", "during", "nucleos(t)ide", "analogue", "(", "except", "Telbivudine", ")", "treatment", "within", "one", "month", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "Compensated", "liver", "disease", "\n", "Age", ">", "18", "years", "\n", "Written", "informed", "consent", "\n" ]	[ "Temporal", "Reference_point", "Drug", "Condition", "Value", "Qualifier", "Measurement", "Negation", "Person" ]
Chronic hepatitis B, HBsAg, positive, > 6 months, HBeAg, negative, within six months prior to initiation of peginterferon alfa-2a, HBV DNA, < 200 IU / ml, during nucleos(t)ide analogue ( except Telbivudine ) treatment, within one month prior to initiation of peginterferon alfa-2a, Compensated, liver disease, Age, > 18 years	NCT01373684_inc_task2	Sentence: Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent Instructions: please extract entity words from the input sentence	[ "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O" ]	Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent	[ "Chronic", "hepatitis", "B", "(", "HBsAg", "positive", ">", "6", "months", ")", "\n", "HBeAg", "negative", "within", "six", "months", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "HBV", "DNA", "<", "200", "IU", "/", "ml", "during", "nucleos(t)ide", "analogue", "(", "except", "Telbivudine", ")", "treatment", "within", "one", "month", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "Compensated", "liver", "disease", "\n", "Age", ">", "18", "years", "\n", "Written", "informed", "consent", "\n" ]	[ "Temporal", "Reference_point", "Drug", "Condition", "Value", "Qualifier", "Measurement", "Negation", "Person" ]
moderate to severe is a Scope, Ankylosing Spondylitis ( AS ) is a Condition, prior is a Temporal, radiologic evidence is a Condition, fulfilling is a Value, Modified New York criteria for AS is a Measurement, Active is a Qualifier, AS is a Condition, total Bath Ankylosing Spondylitis Disease Activity index ( BASDAI ) is a Measurement, = 4 is a Value, at baseline is a Temporal, Spinal pain is a Condition, BASDAI question # 2 is a Measurement, = 4 cm is a Value, at baseline is a Temporal, Total back pain is a Condition, visual analog scale ( VAS ) is a Measurement, = 40 mm is a Value, at baseline is a Temporal, non - steroidal anti - inflammatory drugs ( NSAIDs ) is a Drug, maximum tolerated dose is a Multiplier, for at least 4 weeks prior to their Baseline Visit is a Temporal, inadequate response is a Condition, for less than 4 weeks is a Temporal, withdrawn for intolerance , toxicity or contraindications is a Scope, NSAIDs including Cyclooxygenase-1 ( COX-1 ) or Cyclooxygenase-2 ( COX-2 ) inhibitors is a Scope, for at least 2 weeks before their Baseline Visit is a Temporal, tumor necrosis factor alpha ( TNFa ) inhibitor ( not more than one ) is a Scope, inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti - TNFa agent is a Scope, Total ankylosis of the spine is a Condition, hypersensitivity is a Condition, study drugs or its excipients or to drugs of similar chemical classes is a Scope, Chest x - ray , computerized tomography ( CT ) scan , or chest magnetic resonance imaging ( MRI ) is a Scope, ongoing is a Temporal, infectious or malignant process is a Scope, within 3 months prior to screening is a Temporal, secukinumab or any other biologic drug is a Scope, targeting is a Condition, Interleukin-17 ( IL-17 ) , Interleukin-12/23 ( IL-12/23 ) , or the IL-17 receptor , or any other biologic immunomodulating agent is a Scope, except is a Negation, TNFa is a Drug, more than one is a Multiplier, anti - TNFa agent is a Drug, intramuscular or intravenous is a Scope, corticosteroid injection is a Procedure, within 2 weeks before baseline is a Temporal, intra - articular injections is a Procedure, corticosteroid is a Drug, within 4 weeks before baseline is a Temporal, Previous is a Temporal, cell - depleting therapies is a Procedure, high potency opioid analgesics is a Drug, methadone , hydromorphone , morphine is a Scope	NCT03350815_inc_task0	Sentence: Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Multiplier, Procedure, Negation, Scope, Measurement, Drug	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Temporal", "O", "B-Condition", "I-Condition", "B-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Qualifier", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine)	[ "Understand", "and", "communicate", "with", "the", "investigator", ",", "comply", "with", "the", "requirements", "of", "the", "study", "and", "give", "a", "written", ",", "signed", "and", "dated", "informed", "consent", "\n", "Male", "or", "non", "-", "pregnant", ",", "non", "-", "lactating", "female", "patients", "at", "least", "18", "years", "of", "age", "\n", "Diagnosis", "of", "moderate", "to", "severe", "Ankylosing", "Spondylitis", "(", "AS", ")", "with", "prior", "documented", "radiologic", "evidence", "fulfilling", "the", "Modified", "New", "York", "criteria", "for", "AS", "\n", "Active", "AS", "assessed", "by", "total", "Bath", "Ankylosing", "Spondylitis", "Disease", "Activity", "index", "(", "BASDAI", ")", "=", "4", "(", "0", "-", "10", ")", "at", "baseline", "\n", "Spinal", "pain", "as", "measured", "by", "BASDAI", "question", "#", "2", "=", "4", "cm", "(", "0", "-", "10", "cm", ")", "at", "baseline", "\n", "Total", "back", "pain", "as", "measured", "by", "visual", "analog", "scale", "(", "VAS", ")", "=", "40", "mm", "(", "0", "-", "100", "mm", ")", "at", "baseline", "\n", "Patients", "should", "have", "been", "on", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "at", "the", "maximum", "tolerated", "dose", "for", "at", "least", "4", "weeks", "prior", "to", "their", "Baseline", "Visit", ",", "with", "an", "inadequate", "response", "or", "for", "less", "than", "4", "weeks", "if", "withdrawn", "for", "intolerance", ",", "toxicity", "or", "contraindications", "\n", "Stable", "dose", "of", "NSAIDs", "including", "Cyclooxygenase-1", "(", "COX-1", ")", "or", "Cyclooxygenase-2", "(", "COX-2", ")", "inhibitors", "for", "at", "least", "2", "weeks", "before", "their", "Baseline", "Visit", "\n", "Patients", "who", "have", "been", "on", "a", "tumor", "necrosis", "factor", "alpha", "(", "TNFa", ")", "inhibitor", "(", "not", "more", "than", "one", ")", "must", "have", "experienced", "an", "inadequate", "response", "to", "previous", "or", "current", "treatment", "given", "at", "an", "approved", "dose", "for", "at", "least", "3", "months", "prior", "to", "baseline", "or", "had", "been", "intolerant", "upon", "administration", "of", "an", "anti", "-", "TNFa", "agent", "\n", "Total", "ankylosis", "of", "the", "spine", "\n", "Use", "of", "other", "investigational", "drugs", "within", "5", "half", "-", "lives", "of", "enrollment", ",", "or", "within", "4", "weeks", "before", "the", "Baseline", "Visit", ",", "whichever", "is", "longer", ".", "\n", "History", "of", "hypersensitivity", "to", "any", "of", "the", "study", "drugs", "or", "its", "excipients", "or", "to", "drugs", "of", "similar", "chemical", "classes", ".", "\n", "Chest", "x", "-", "ray", ",", "computerized", "tomography", "(", "CT", ")", "scan", ",", "or", "chest", "magnetic", "resonance", "imaging", "(", "MRI", ")", "with", "evidence", "of", "ongoing", "infectious", "or", "malignant", "process", ",", "obtained", "within", "3", "months", "prior", "to", "screening", "and", "evaluated", "by", "a", "qualified", "physician", ".", "\n", "Previous", "exposure", "to", "secukinumab", "or", "any", "other", "biologic", "drug", "directly", "targeting", "Interleukin-17", "(", "IL-17", ")", ",", "Interleukin-12/23", "(", "IL-12/23", ")", ",", "or", "the", "IL-17", "receptor", ",", "or", "any", "other", "biologic", "immunomodulating", "agent", ",", "except", "those", "targeting", "TNFa", "\n", "Patients", "who", "have", "taken", "more", "than", "one", "anti", "-", "TNFa", "agent", "\n", "Any", "intramuscular", "or", "intravenous", "corticosteroid", "injection", "within", "2", "weeks", "before", "baseline", "\n", "Any", "therapy", "by", "intra", "-", "articular", "injections", "(", "e.g", ".", "corticosteroid", ")", "within", "4", "weeks", "before", "baseline", "\n", "Previous", "treatment", "with", "any", "cell", "-", "depleting", "therapies", "\n", "Patients", "taking", "high", "potency", "opioid", "analgesics", "(", "e.g", ".", ",", "methadone", ",", "hydromorphone", ",", "morphine", ")", "\n" ]	[ "Scope", "Measurement", "Temporal", "Drug", "Procedure", "Condition", "Multiplier", "Reference_point", "Qualifier", "Value", "Negation" ]
moderate to severe is a Scope, Ankylosing Spondylitis ( AS ) is a Condition, prior is a Temporal, radiologic evidence is a Condition, fulfilling is a Value, Modified New York criteria for AS is a Measurement, Active is a Qualifier, AS is a Condition, total Bath Ankylosing Spondylitis Disease Activity index ( BASDAI ) is a Measurement, = 4 is a Value, at baseline is a Temporal, Spinal pain is a Condition, BASDAI question # 2 is a Measurement, = 4 cm is a Value, at baseline is a Temporal, Total back pain is a Condition, visual analog scale ( VAS ) is a Measurement, = 40 mm is a Value, at baseline is a Temporal, non - steroidal anti - inflammatory drugs ( NSAIDs ) is a Drug, maximum tolerated dose is a Multiplier, for at least 4 weeks prior to their Baseline Visit is a Temporal, inadequate response is a Condition, for less than 4 weeks is a Temporal, withdrawn for intolerance , toxicity or contraindications is a Scope, NSAIDs including Cyclooxygenase-1 ( COX-1 ) or Cyclooxygenase-2 ( COX-2 ) inhibitors is a Scope, for at least 2 weeks before their Baseline Visit is a Temporal, tumor necrosis factor alpha ( TNFa ) inhibitor ( not more than one ) is a Scope, inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti - TNFa agent is a Scope, Total ankylosis of the spine is a Condition, hypersensitivity is a Condition, study drugs or its excipients or to drugs of similar chemical classes is a Scope, Chest x - ray , computerized tomography ( CT ) scan , or chest magnetic resonance imaging ( MRI ) is a Scope, ongoing is a Temporal, infectious or malignant process is a Scope, within 3 months prior to screening is a Temporal, secukinumab or any other biologic drug is a Scope, targeting is a Condition, Interleukin-17 ( IL-17 ) , Interleukin-12/23 ( IL-12/23 ) , or the IL-17 receptor , or any other biologic immunomodulating agent is a Scope, except is a Negation, TNFa is a Drug, more than one is a Multiplier, anti - TNFa agent is a Drug, intramuscular or intravenous is a Scope, corticosteroid injection is a Procedure, within 2 weeks before baseline is a Temporal, intra - articular injections is a Procedure, corticosteroid is a Drug, within 4 weeks before baseline is a Temporal, Previous is a Temporal, cell - depleting therapies is a Procedure, high potency opioid analgesics is a Drug, methadone , hydromorphone , morphine is a Scope	NCT03350815_inc_task1	Sentence: Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine) Instructions: please typing these entity words according to sentence: moderate to severe, Ankylosing Spondylitis ( AS ), prior, radiologic evidence, fulfilling, Modified New York criteria for AS, Active, AS, total Bath Ankylosing Spondylitis Disease Activity index ( BASDAI ), = 4, at baseline, Spinal pain, BASDAI question # 2, = 4 cm, at baseline, Total back pain, visual analog scale ( VAS ), = 40 mm, at baseline, non - steroidal anti - inflammatory drugs ( NSAIDs ), maximum tolerated dose, for at least 4 weeks prior to their Baseline Visit, inadequate response, for less than 4 weeks, withdrawn for intolerance , toxicity or contraindications, NSAIDs including Cyclooxygenase-1 ( COX-1 ) or Cyclooxygenase-2 ( COX-2 ) inhibitors, for at least 2 weeks before their Baseline Visit, tumor necrosis factor alpha ( TNFa ) inhibitor ( not more than one ), inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti - TNFa agent, Total ankylosis of the spine, hypersensitivity, study drugs or its excipients or to drugs of similar chemical classes, Chest x - ray , computerized tomography ( CT ) scan , or chest magnetic resonance imaging ( MRI ), ongoing, infectious or malignant process, within 3 months prior to screening, secukinumab or any other biologic drug, targeting, Interleukin-17 ( IL-17 ) , Interleukin-12/23 ( IL-12/23 ) , or the IL-17 receptor , or any other biologic immunomodulating agent, except, TNFa, more than one, anti - TNFa agent, intramuscular or intravenous, corticosteroid injection, within 2 weeks before baseline, intra - articular injections, corticosteroid, within 4 weeks before baseline, Previous, cell - depleting therapies, high potency opioid analgesics, methadone , hydromorphone , morphine Options: Temporal, Condition, Qualifier, Value, Multiplier, Procedure, Negation, Scope, Measurement, Drug	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Temporal", "O", "B-Condition", "I-Condition", "B-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Qualifier", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine)	[ "Understand", "and", "communicate", "with", "the", "investigator", ",", "comply", "with", "the", "requirements", "of", "the", "study", "and", "give", "a", "written", ",", "signed", "and", "dated", "informed", "consent", "\n", "Male", "or", "non", "-", "pregnant", ",", "non", "-", "lactating", "female", "patients", "at", "least", "18", "years", "of", "age", "\n", "Diagnosis", "of", "moderate", "to", "severe", "Ankylosing", "Spondylitis", "(", "AS", ")", "with", "prior", "documented", "radiologic", "evidence", "fulfilling", "the", "Modified", "New", "York", "criteria", "for", "AS", "\n", "Active", "AS", "assessed", "by", "total", "Bath", "Ankylosing", "Spondylitis", "Disease", "Activity", "index", "(", "BASDAI", ")", "=", "4", "(", "0", "-", "10", ")", "at", "baseline", "\n", "Spinal", "pain", "as", "measured", "by", "BASDAI", "question", "#", "2", "=", "4", "cm", "(", "0", "-", "10", "cm", ")", "at", "baseline", "\n", "Total", "back", "pain", "as", "measured", "by", "visual", "analog", "scale", "(", "VAS", ")", "=", "40", "mm", "(", "0", "-", "100", "mm", ")", "at", "baseline", "\n", "Patients", "should", "have", "been", "on", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "at", "the", "maximum", "tolerated", "dose", "for", "at", "least", "4", "weeks", "prior", "to", "their", "Baseline", "Visit", ",", "with", "an", "inadequate", "response", "or", "for", "less", "than", "4", "weeks", "if", "withdrawn", "for", "intolerance", ",", "toxicity", "or", "contraindications", "\n", "Stable", "dose", "of", "NSAIDs", "including", "Cyclooxygenase-1", "(", "COX-1", ")", "or", "Cyclooxygenase-2", "(", "COX-2", ")", "inhibitors", "for", "at", "least", "2", "weeks", "before", "their", "Baseline", "Visit", "\n", "Patients", "who", "have", "been", "on", "a", "tumor", "necrosis", "factor", "alpha", "(", "TNFa", ")", "inhibitor", "(", "not", "more", "than", "one", ")", "must", "have", "experienced", "an", "inadequate", "response", "to", "previous", "or", "current", "treatment", "given", "at", "an", "approved", "dose", "for", "at", "least", "3", "months", "prior", "to", "baseline", "or", "had", "been", "intolerant", "upon", "administration", "of", "an", "anti", "-", "TNFa", "agent", "\n", "Total", "ankylosis", "of", "the", "spine", "\n", "Use", "of", "other", "investigational", "drugs", "within", "5", "half", "-", "lives", "of", "enrollment", ",", "or", "within", "4", "weeks", "before", "the", "Baseline", "Visit", ",", "whichever", "is", "longer", ".", "\n", "History", "of", "hypersensitivity", "to", "any", "of", "the", "study", "drugs", "or", "its", "excipients", "or", "to", "drugs", "of", "similar", "chemical", "classes", ".", "\n", "Chest", "x", "-", "ray", ",", "computerized", "tomography", "(", "CT", ")", "scan", ",", "or", "chest", "magnetic", "resonance", "imaging", "(", "MRI", ")", "with", "evidence", "of", "ongoing", "infectious", "or", "malignant", "process", ",", "obtained", "within", "3", "months", "prior", "to", "screening", "and", "evaluated", "by", "a", "qualified", "physician", ".", "\n", "Previous", "exposure", "to", "secukinumab", "or", "any", "other", "biologic", "drug", "directly", "targeting", "Interleukin-17", "(", "IL-17", ")", ",", "Interleukin-12/23", "(", "IL-12/23", ")", ",", "or", "the", "IL-17", "receptor", ",", "or", "any", "other", "biologic", "immunomodulating", "agent", ",", "except", "those", "targeting", "TNFa", "\n", "Patients", "who", "have", "taken", "more", "than", "one", "anti", "-", "TNFa", "agent", "\n", "Any", "intramuscular", "or", "intravenous", "corticosteroid", "injection", "within", "2", "weeks", "before", "baseline", "\n", "Any", "therapy", "by", "intra", "-", "articular", "injections", "(", "e.g", ".", "corticosteroid", ")", "within", "4", "weeks", "before", "baseline", "\n", "Previous", "treatment", "with", "any", "cell", "-", "depleting", "therapies", "\n", "Patients", "taking", "high", "potency", "opioid", "analgesics", "(", "e.g", ".", ",", "methadone", ",", "hydromorphone", ",", "morphine", ")", "\n" ]	[ "Scope", "Measurement", "Temporal", "Drug", "Procedure", "Condition", "Multiplier", "Reference_point", "Qualifier", "Value", "Negation" ]
moderate to severe, Ankylosing Spondylitis ( AS ), prior, radiologic evidence, fulfilling, Modified New York criteria for AS, Active, AS, total Bath Ankylosing Spondylitis Disease Activity index ( BASDAI ), = 4, at baseline, Spinal pain, BASDAI question # 2, = 4 cm, at baseline, Total back pain, visual analog scale ( VAS ), = 40 mm, at baseline, non - steroidal anti - inflammatory drugs ( NSAIDs ), maximum tolerated dose, for at least 4 weeks prior to their Baseline Visit, inadequate response, for less than 4 weeks, withdrawn for intolerance , toxicity or contraindications, NSAIDs including Cyclooxygenase-1 ( COX-1 ) or Cyclooxygenase-2 ( COX-2 ) inhibitors, for at least 2 weeks before their Baseline Visit, tumor necrosis factor alpha ( TNFa ) inhibitor ( not more than one ), inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti - TNFa agent, Total ankylosis of the spine, hypersensitivity, study drugs or its excipients or to drugs of similar chemical classes, Chest x - ray , computerized tomography ( CT ) scan , or chest magnetic resonance imaging ( MRI ), ongoing, infectious or malignant process, within 3 months prior to screening, secukinumab or any other biologic drug, targeting, Interleukin-17 ( IL-17 ) , Interleukin-12/23 ( IL-12/23 ) , or the IL-17 receptor , or any other biologic immunomodulating agent, except, TNFa, more than one, anti - TNFa agent, intramuscular or intravenous, corticosteroid injection, within 2 weeks before baseline, intra - articular injections, corticosteroid, within 4 weeks before baseline, Previous, cell - depleting therapies, high potency opioid analgesics, methadone , hydromorphone , morphine	NCT03350815_inc_task2	Sentence: Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine) Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Temporal", "O", "B-Condition", "I-Condition", "B-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Qualifier", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine)	[ "Understand", "and", "communicate", "with", "the", "investigator", ",", "comply", "with", "the", "requirements", "of", "the", "study", "and", "give", "a", "written", ",", "signed", "and", "dated", "informed", "consent", "\n", "Male", "or", "non", "-", "pregnant", ",", "non", "-", "lactating", "female", "patients", "at", "least", "18", "years", "of", "age", "\n", "Diagnosis", "of", "moderate", "to", "severe", "Ankylosing", "Spondylitis", "(", "AS", ")", "with", "prior", "documented", "radiologic", "evidence", "fulfilling", "the", "Modified", "New", "York", "criteria", "for", "AS", "\n", "Active", "AS", "assessed", "by", "total", "Bath", "Ankylosing", "Spondylitis", "Disease", "Activity", "index", "(", "BASDAI", ")", "=", "4", "(", "0", "-", "10", ")", "at", "baseline", "\n", "Spinal", "pain", "as", "measured", "by", "BASDAI", "question", "#", "2", "=", "4", "cm", "(", "0", "-", "10", "cm", ")", "at", "baseline", "\n", "Total", "back", "pain", "as", "measured", "by", "visual", "analog", "scale", "(", "VAS", ")", "=", "40", "mm", "(", "0", "-", "100", "mm", ")", "at", "baseline", "\n", "Patients", "should", "have", "been", "on", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "at", "the", "maximum", "tolerated", "dose", "for", "at", "least", "4", "weeks", "prior", "to", "their", "Baseline", "Visit", ",", "with", "an", "inadequate", "response", "or", "for", "less", "than", "4", "weeks", "if", "withdrawn", "for", "intolerance", ",", "toxicity", "or", "contraindications", "\n", "Stable", "dose", "of", "NSAIDs", "including", "Cyclooxygenase-1", "(", "COX-1", ")", "or", "Cyclooxygenase-2", "(", "COX-2", ")", "inhibitors", "for", "at", "least", "2", "weeks", "before", "their", "Baseline", "Visit", "\n", "Patients", "who", "have", "been", "on", "a", "tumor", "necrosis", "factor", "alpha", "(", "TNFa", ")", "inhibitor", "(", "not", "more", "than", "one", ")", "must", "have", "experienced", "an", "inadequate", "response", "to", "previous", "or", "current", "treatment", "given", "at", "an", "approved", "dose", "for", "at", "least", "3", "months", "prior", "to", "baseline", "or", "had", "been", "intolerant", "upon", "administration", "of", "an", "anti", "-", "TNFa", "agent", "\n", "Total", "ankylosis", "of", "the", "spine", "\n", "Use", "of", "other", "investigational", "drugs", "within", "5", "half", "-", "lives", "of", "enrollment", ",", "or", "within", "4", "weeks", "before", "the", "Baseline", "Visit", ",", "whichever", "is", "longer", ".", "\n", "History", "of", "hypersensitivity", "to", "any", "of", "the", "study", "drugs", "or", "its", "excipients", "or", "to", "drugs", "of", "similar", "chemical", "classes", ".", "\n", "Chest", "x", "-", "ray", ",", "computerized", "tomography", "(", "CT", ")", "scan", ",", "or", "chest", "magnetic", "resonance", "imaging", "(", "MRI", ")", "with", "evidence", "of", "ongoing", "infectious", "or", "malignant", "process", ",", "obtained", "within", "3", "months", "prior", "to", "screening", "and", "evaluated", "by", "a", "qualified", "physician", ".", "\n", "Previous", "exposure", "to", "secukinumab", "or", "any", "other", "biologic", "drug", "directly", "targeting", "Interleukin-17", "(", "IL-17", ")", ",", "Interleukin-12/23", "(", "IL-12/23", ")", ",", "or", "the", "IL-17", "receptor", ",", "or", "any", "other", "biologic", "immunomodulating", "agent", ",", "except", "those", "targeting", "TNFa", "\n", "Patients", "who", "have", "taken", "more", "than", "one", "anti", "-", "TNFa", "agent", "\n", "Any", "intramuscular", "or", "intravenous", "corticosteroid", "injection", "within", "2", "weeks", "before", "baseline", "\n", "Any", "therapy", "by", "intra", "-", "articular", "injections", "(", "e.g", ".", "corticosteroid", ")", "within", "4", "weeks", "before", "baseline", "\n", "Previous", "treatment", "with", "any", "cell", "-", "depleting", "therapies", "\n", "Patients", "taking", "high", "potency", "opioid", "analgesics", "(", "e.g", ".", ",", "methadone", ",", "hydromorphone", ",", "morphine", ")", "\n" ]	[ "Scope", "Measurement", "Temporal", "Drug", "Procedure", "Condition", "Multiplier", "Reference_point", "Qualifier", "Value", "Negation" ]
Bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]dopamine is a CHEMICAL, [ ( 3)H]norepinephrine is a CHEMICAL, Bupropion is a CHEMICAL, dopamine and norepinephrine transporters is a GENE-N, DAT is a GENE-Y, NET is a GENE-Y, bupropion is a CHEMICAL, alpha3beta2 , alpha3beta4 , and alpha4beta2 nicotinic acetylcholine receptors ( nAChRs ) is a GENE-N, bupropion is a CHEMICAL, alpha3beta2 * and alpha3beta4 * nAChRs is a GENE-N, nicotine is a CHEMICAL, [ ( 3)H]dopamine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]norepinephrine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, DAT is a GENE-Y, NET is a GENE-Y, nomifensine is a CHEMICAL, desipramine is a CHEMICAL, bupropion is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, alpha3beta2 * and alpha3beta4 * nAChRs is a GENE-N, DAT is a GENE-Y, NET is a GENE-Y, nAChR is a GENE-N, bupropion is a CHEMICAL	8740_task0	Sentence: Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL	[ "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent.	[ "Bupropion", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "and", "from", "rat", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", ".", "\n", "Bupropion", ",", "an", "efficacious", "antidepressant", "and", "smoking", "cessation", "agent", ",", "inhibits", "dopamine", "and", "norepinephrine", "transporters", "(", "DAT", "and", "NET", ",", "respectively", ")", ".", "Recently", ",", "bupropion", "has", "been", "reported", "to", "noncompetitively", "inhibit", "alpha3beta2", ",", "alpha3beta4", ",", "and", "alpha4beta2", "nicotinic", "acetylcholine", "receptors", "(", "nAChRs", ")", "expressed", "in", "Xenopus", "oocytes", "or", "established", "cell", "lines", ".", "The", "present", "study", "evaluated", "bupropion", "-", "induced", "inhibition", "of", "native", "alpha3beta2", "", "and", "alpha3beta4", "", "nAChRs", "using", "functional", "neurotransmitter", "release", "assays", ",", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "superfused", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "(", "[", "(", "3)H]DA", ")", ",", "and", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", "(", "[", "(", "3)H]NE", ")", ".", "The", "mechanism", "of", "inhibition", "was", "evaluated", "using", "Schild", "analysis", ".", "To", "eliminate", "the", "interaction", "of", "bupropion", "with", "DAT", "or", "NET", ",", "nomifensine", "or", "desipramine", ",", "respectively", ",", "was", "included", "in", "the", "superfusion", "buffer", ".", "A", "high", "bupropion", "concentration", "(", "100", "microM", ")", "elicited", "intrinsic", "activity", "in", "the", "[", "(", "3)H]DA", "release", "assay", ".", "However", ",", "none", "of", "the", "concentrations", "(", "1", "nM-100", "microM", ")", "examined", "evoked", "[", "(", "3)H]NE", "overflow", "and", ",", "thus", ",", "were", "without", "intrinsic", "activity", "in", "this", "assay", ".", "Moreover", ",", "bupropion", "inhibited", "both", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", "(", "IC(50", ")", "=", "1.27", "microM", ")", "and", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", "(", "IC(50", ")", "=", "323", "nM", ")", "at", "bupropion", "concentrations", "well", "below", "those", "eliciting", "intrinsic", "activity", ".", "Results", "from", "Schild", "analyses", "suggest", "that", "bupropion", "competitively", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", ",", "whereas", "evidence", "for", "receptor", "reserve", "was", "obtained", "upon", "assessment", "of", "bupropion", "inhibition", "of", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", ".", "Thus", ",", "bupropion", "acts", "as", "an", "antagonist", "at", "alpha3beta2", "", "and", "alpha3beta4", "", "nAChRs", "in", "rat", "striatum", "and", "hippocampus", ",", "respectively", ",", "across", "the", "same", "concentration", "range", "that", "inhibits", "DAT", "and", "NET", "function", ".", "The", "combination", "of", "nAChR", "and", "transporter", "inhibition", "produced", "by", "bupropion", "may", "contribute", "to", "its", "clinical", "efficacy", "as", "a", "smoking", "cessation", "agent", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]dopamine is a CHEMICAL, [ ( 3)H]norepinephrine is a CHEMICAL, Bupropion is a CHEMICAL, dopamine and norepinephrine transporters is a GENE-N, DAT is a GENE-Y, NET is a GENE-Y, bupropion is a CHEMICAL, alpha3beta2 , alpha3beta4 , and alpha4beta2 nicotinic acetylcholine receptors ( nAChRs ) is a GENE-N, bupropion is a CHEMICAL, alpha3beta2 * and alpha3beta4 * nAChRs is a GENE-N, nicotine is a CHEMICAL, [ ( 3)H]dopamine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]norepinephrine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, DAT is a GENE-Y, NET is a GENE-Y, nomifensine is a CHEMICAL, desipramine is a CHEMICAL, bupropion is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, alpha3beta2 * and alpha3beta4 * nAChRs is a GENE-N, DAT is a GENE-Y, NET is a GENE-Y, nAChR is a GENE-N, bupropion is a CHEMICAL	8740_task1	Sentence: Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent. Instructions: please typing these entity words according to sentence: Bupropion, nicotine, [ ( 3)H]dopamine, [ ( 3)H]norepinephrine, Bupropion, dopamine and norepinephrine transporters, DAT, NET, bupropion, alpha3beta2 , alpha3beta4 , and alpha4beta2 nicotinic acetylcholine receptors ( nAChRs ), bupropion, alpha3beta2 * and alpha3beta4 * nAChRs, nicotine, [ ( 3)H]dopamine, [ ( 3)H]DA, nicotine, [ ( 3)H]norepinephrine, [ ( 3)H]NE, bupropion, DAT, NET, nomifensine, desipramine, bupropion, [ ( 3)H]DA, [ ( 3)H]NE, bupropion, nicotine, [ ( 3)H]DA, nicotine, [ ( 3)H]NE, bupropion, bupropion, nicotine, [ ( 3)H]DA, bupropion, nicotine, [ ( 3)H]NE, bupropion, alpha3beta2 * and alpha3beta4 * nAChRs, DAT, NET, nAChR, bupropion Options: GENE-Y, GENE-N, CHEMICAL	[ "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent.	[ "Bupropion", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "and", "from", "rat", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", ".", "\n", "Bupropion", ",", "an", "efficacious", "antidepressant", "and", "smoking", "cessation", "agent", ",", "inhibits", "dopamine", "and", "norepinephrine", "transporters", "(", "DAT", "and", "NET", ",", "respectively", ")", ".", "Recently", ",", "bupropion", "has", "been", "reported", "to", "noncompetitively", "inhibit", "alpha3beta2", ",", "alpha3beta4", ",", "and", "alpha4beta2", "nicotinic", "acetylcholine", "receptors", "(", "nAChRs", ")", "expressed", "in", "Xenopus", "oocytes", "or", "established", "cell", "lines", ".", "The", "present", "study", "evaluated", "bupropion", "-", "induced", "inhibition", "of", "native", "alpha3beta2", "", "and", "alpha3beta4", "", "nAChRs", "using", "functional", "neurotransmitter", "release", "assays", ",", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "superfused", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "(", "[", "(", "3)H]DA", ")", ",", "and", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", "(", "[", "(", "3)H]NE", ")", ".", "The", "mechanism", "of", "inhibition", "was", "evaluated", "using", "Schild", "analysis", ".", "To", "eliminate", "the", "interaction", "of", "bupropion", "with", "DAT", "or", "NET", ",", "nomifensine", "or", "desipramine", ",", "respectively", ",", "was", "included", "in", "the", "superfusion", "buffer", ".", "A", "high", "bupropion", "concentration", "(", "100", "microM", ")", "elicited", "intrinsic", "activity", "in", "the", "[", "(", "3)H]DA", "release", "assay", ".", "However", ",", "none", "of", "the", "concentrations", "(", "1", "nM-100", "microM", ")", "examined", "evoked", "[", "(", "3)H]NE", "overflow", "and", ",", "thus", ",", "were", "without", "intrinsic", "activity", "in", "this", "assay", ".", "Moreover", ",", "bupropion", "inhibited", "both", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", "(", "IC(50", ")", "=", "1.27", "microM", ")", "and", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", "(", "IC(50", ")", "=", "323", "nM", ")", "at", "bupropion", "concentrations", "well", "below", "those", "eliciting", "intrinsic", "activity", ".", "Results", "from", "Schild", "analyses", "suggest", "that", "bupropion", "competitively", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", ",", "whereas", "evidence", "for", "receptor", "reserve", "was", "obtained", "upon", "assessment", "of", "bupropion", "inhibition", "of", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", ".", "Thus", ",", "bupropion", "acts", "as", "an", "antagonist", "at", "alpha3beta2", "", "and", "alpha3beta4", "", "nAChRs", "in", "rat", "striatum", "and", "hippocampus", ",", "respectively", ",", "across", "the", "same", "concentration", "range", "that", "inhibits", "DAT", "and", "NET", "function", ".", "The", "combination", "of", "nAChR", "and", "transporter", "inhibition", "produced", "by", "bupropion", "may", "contribute", "to", "its", "clinical", "efficacy", "as", "a", "smoking", "cessation", "agent", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Bupropion, nicotine, [ ( 3)H]dopamine, [ ( 3)H]norepinephrine, Bupropion, dopamine and norepinephrine transporters, DAT, NET, bupropion, alpha3beta2 , alpha3beta4 , and alpha4beta2 nicotinic acetylcholine receptors ( nAChRs ), bupropion, alpha3beta2 * and alpha3beta4 * nAChRs, nicotine, [ ( 3)H]dopamine, [ ( 3)H]DA, nicotine, [ ( 3)H]norepinephrine, [ ( 3)H]NE, bupropion, DAT, NET, nomifensine, desipramine, bupropion, [ ( 3)H]DA, [ ( 3)H]NE, bupropion, nicotine, [ ( 3)H]DA, nicotine, [ ( 3)H]NE, bupropion, bupropion, nicotine, [ ( 3)H]DA, bupropion, nicotine, [ ( 3)H]NE, bupropion, alpha3beta2 * and alpha3beta4 * nAChRs, DAT, NET, nAChR, bupropion	8740_task2	Sentence: Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent.	[ "Bupropion", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "and", "from", "rat", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", ".", "\n", "Bupropion", ",", "an", "efficacious", "antidepressant", "and", "smoking", "cessation", "agent", ",", "inhibits", "dopamine", "and", "norepinephrine", "transporters", "(", "DAT", "and", "NET", ",", "respectively", ")", ".", "Recently", ",", "bupropion", "has", "been", "reported", "to", "noncompetitively", "inhibit", "alpha3beta2", ",", "alpha3beta4", ",", "and", "alpha4beta2", "nicotinic", "acetylcholine", "receptors", "(", "nAChRs", ")", "expressed", "in", "Xenopus", "oocytes", "or", "established", "cell", "lines", ".", "The", "present", "study", "evaluated", "bupropion", "-", "induced", "inhibition", "of", "native", "alpha3beta2", "", "and", "alpha3beta4", "", "nAChRs", "using", "functional", "neurotransmitter", "release", "assays", ",", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "superfused", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "(", "[", "(", "3)H]DA", ")", ",", "and", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", "(", "[", "(", "3)H]NE", ")", ".", "The", "mechanism", "of", "inhibition", "was", "evaluated", "using", "Schild", "analysis", ".", "To", "eliminate", "the", "interaction", "of", "bupropion", "with", "DAT", "or", "NET", ",", "nomifensine", "or", "desipramine", ",", "respectively", ",", "was", "included", "in", "the", "superfusion", "buffer", ".", "A", "high", "bupropion", "concentration", "(", "100", "microM", ")", "elicited", "intrinsic", "activity", "in", "the", "[", "(", "3)H]DA", "release", "assay", ".", "However", ",", "none", "of", "the", "concentrations", "(", "1", "nM-100", "microM", ")", "examined", "evoked", "[", "(", "3)H]NE", "overflow", "and", ",", "thus", ",", "were", "without", "intrinsic", "activity", "in", "this", "assay", ".", "Moreover", ",", "bupropion", "inhibited", "both", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", "(", "IC(50", ")", "=", "1.27", "microM", ")", "and", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", "(", "IC(50", ")", "=", "323", "nM", ")", "at", "bupropion", "concentrations", "well", "below", "those", "eliciting", "intrinsic", "activity", ".", "Results", "from", "Schild", "analyses", "suggest", "that", "bupropion", "competitively", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", ",", "whereas", "evidence", "for", "receptor", "reserve", "was", "obtained", "upon", "assessment", "of", "bupropion", "inhibition", "of", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", ".", "Thus", ",", "bupropion", "acts", "as", "an", "antagonist", "at", "alpha3beta2", "", "and", "alpha3beta4", "", "nAChRs", "in", "rat", "striatum", "and", "hippocampus", ",", "respectively", ",", "across", "the", "same", "concentration", "range", "that", "inhibits", "DAT", "and", "NET", "function", ".", "The", "combination", "of", "nAChR", "and", "transporter", "inhibition", "produced", "by", "bupropion", "may", "contribute", "to", "its", "clinical", "efficacy", "as", "a", "smoking", "cessation", "agent", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
methimazole is a CHEMICAL, propylthiouracil is a CHEMICAL	23154533_task0	Sentence: The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant.	[ "The", "onset", "of", "antineutrophil", "cytoplasmic", "antibody", "-", "associated", "vasculitis", "immediately", "after", "methimazole", "was", "switched", "to", "propylthiouracil", "in", "a", "woman", "with", "Graves", "'", "disease", "who", "wished", "to", "become", "pregnant", "." ]	[ "CHEMICAL", "GENE-Y" ]
methimazole is a CHEMICAL, propylthiouracil is a CHEMICAL	23154533_task1	Sentence: The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. Instructions: please typing these entity words according to sentence: methimazole, propylthiouracil Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant.	[ "The", "onset", "of", "antineutrophil", "cytoplasmic", "antibody", "-", "associated", "vasculitis", "immediately", "after", "methimazole", "was", "switched", "to", "propylthiouracil", "in", "a", "woman", "with", "Graves", "'", "disease", "who", "wished", "to", "become", "pregnant", "." ]	[ "CHEMICAL", "GENE-Y" ]
methimazole, propylthiouracil	23154533_task2	Sentence: The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant.	[ "The", "onset", "of", "antineutrophil", "cytoplasmic", "antibody", "-", "associated", "vasculitis", "immediately", "after", "methimazole", "was", "switched", "to", "propylthiouracil", "in", "a", "woman", "with", "Graves", "'", "disease", "who", "wished", "to", "become", "pregnant", "." ]	[ "CHEMICAL", "GENE-Y" ]
RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, PCNA is a Protein, RAD18 is a Protein, 53BP1 is a Protein, NBS1 is a Protein, ATM is a Protein, BRCA1 is a Protein, H2AX is a Protein, RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, lysine 1268 is a Entity, 53BP1 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, 53BP1 is a Protein	375_task0	Sentence: RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O" ]	RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1.	[ "RAD18", "promotes", "DNA", "double", "-", "strand", "break", "repair", "during", "G1", "phase", "through", "chromatin", "retention", "of", "53BP1", ".", "\n", "Recruitment", "of", "RAD18", "to", "stalled", "replication", "forks", "facilitates", "monoubiquitination", "of", "PCNA", "during", "S", "-", "phase", ",", "promoting", "translesion", "synthesis", "at", "sites", "of", "UV", "irradiation", "-", "induced", "DNA", "damage", ".", "In", "this", "study", ",", "we", "show", "that", "RAD18", "is", "also", "recruited", "to", "ionizing", "radiation", "(", "IR)-induced", "sites", "of", "DNA", "double", "-", "strand", "breaks", "(", "DSBs", ")", "forming", "foci", "which", "are", "co", "-", "localized", "with", "53BP1", ",", "NBS1", ",", "phosphorylated", "ATM", ",", "BRCA1", "and", "gamma", "-", "H2AX", ".", "RAD18", "associates", "with", "53BP1", "and", "is", "recruited", "to", "DSB", "sites", "in", "a", "53BP1-dependent", "manner", "specifically", "during", "G1-phase", ",", "RAD18", "monoubiquitinates", "KBD", "domain", "of", "53BP1", "at", "lysine", "1268", "in", "vitro", ".", "A", "monoubiquitination", "-", "resistant", "53BP1", "mutant", "harboring", "a", "substitution", "at", "lysine", "1268", "is", "not", "retained", "efficiently", "at", "the", "chromatin", "in", "the", "vicinity", "of", "DSBs", ".", "In", "Rad18-null", "cells", ",", "retention", "of", "53BP1", "foci", ",", "efficiency", "of", "DSB", "repair", "and", "post", "-", "irradiation", "viability", "are", "impaired", "compared", "with", "wild", "-", "type", "cells", ".", "Taken", "together", ",", "these", "results", "suggest", "that", "RAD18", "promotes", "53BP1-directed", "DSB", "repair", "by", "enhancing", "retention", "of", "53BP1", ",", "possibly", "through", "an", "interaction", "between", "RAD18", "and", "53BP1", "and", "the", "modification", "of", "53BP1", ".", "\n" ]	[ "Entity", "Protein" ]
RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, PCNA is a Protein, RAD18 is a Protein, 53BP1 is a Protein, NBS1 is a Protein, ATM is a Protein, BRCA1 is a Protein, H2AX is a Protein, RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, lysine 1268 is a Entity, 53BP1 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, 53BP1 is a Protein	375_task1	Sentence: RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1. Instructions: please typing these entity words according to sentence: RAD18, 53BP1, RAD18, PCNA, RAD18, 53BP1, NBS1, ATM, BRCA1, H2AX, RAD18, 53BP1, RAD18, 53BP1, lysine 1268, 53BP1, 53BP1, RAD18, 53BP1, RAD18, 53BP1, 53BP1 Options: Entity, Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O" ]	RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1.	[ "RAD18", "promotes", "DNA", "double", "-", "strand", "break", "repair", "during", "G1", "phase", "through", "chromatin", "retention", "of", "53BP1", ".", "\n", "Recruitment", "of", "RAD18", "to", "stalled", "replication", "forks", "facilitates", "monoubiquitination", "of", "PCNA", "during", "S", "-", "phase", ",", "promoting", "translesion", "synthesis", "at", "sites", "of", "UV", "irradiation", "-", "induced", "DNA", "damage", ".", "In", "this", "study", ",", "we", "show", "that", "RAD18", "is", "also", "recruited", "to", "ionizing", "radiation", "(", "IR)-induced", "sites", "of", "DNA", "double", "-", "strand", "breaks", "(", "DSBs", ")", "forming", "foci", "which", "are", "co", "-", "localized", "with", "53BP1", ",", "NBS1", ",", "phosphorylated", "ATM", ",", "BRCA1", "and", "gamma", "-", "H2AX", ".", "RAD18", "associates", "with", "53BP1", "and", "is", "recruited", "to", "DSB", "sites", "in", "a", "53BP1-dependent", "manner", "specifically", "during", "G1-phase", ",", "RAD18", "monoubiquitinates", "KBD", "domain", "of", "53BP1", "at", "lysine", "1268", "in", "vitro", ".", "A", "monoubiquitination", "-", "resistant", "53BP1", "mutant", "harboring", "a", "substitution", "at", "lysine", "1268", "is", "not", "retained", "efficiently", "at", "the", "chromatin", "in", "the", "vicinity", "of", "DSBs", ".", "In", "Rad18-null", "cells", ",", "retention", "of", "53BP1", "foci", ",", "efficiency", "of", "DSB", "repair", "and", "post", "-", "irradiation", "viability", "are", "impaired", "compared", "with", "wild", "-", "type", "cells", ".", "Taken", "together", ",", "these", "results", "suggest", "that", "RAD18", "promotes", "53BP1-directed", "DSB", "repair", "by", "enhancing", "retention", "of", "53BP1", ",", "possibly", "through", "an", "interaction", "between", "RAD18", "and", "53BP1", "and", "the", "modification", "of", "53BP1", ".", "\n" ]	[ "Entity", "Protein" ]
RAD18, 53BP1, RAD18, PCNA, RAD18, 53BP1, NBS1, ATM, BRCA1, H2AX, RAD18, 53BP1, RAD18, 53BP1, lysine 1268, 53BP1, 53BP1, RAD18, 53BP1, RAD18, 53BP1, 53BP1	375_task2	Sentence: RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1. Instructions: please extract entity words from the input sentence	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O" ]	RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1.	[ "RAD18", "promotes", "DNA", "double", "-", "strand", "break", "repair", "during", "G1", "phase", "through", "chromatin", "retention", "of", "53BP1", ".", "\n", "Recruitment", "of", "RAD18", "to", "stalled", "replication", "forks", "facilitates", "monoubiquitination", "of", "PCNA", "during", "S", "-", "phase", ",", "promoting", "translesion", "synthesis", "at", "sites", "of", "UV", "irradiation", "-", "induced", "DNA", "damage", ".", "In", "this", "study", ",", "we", "show", "that", "RAD18", "is", "also", "recruited", "to", "ionizing", "radiation", "(", "IR)-induced", "sites", "of", "DNA", "double", "-", "strand", "breaks", "(", "DSBs", ")", "forming", "foci", "which", "are", "co", "-", "localized", "with", "53BP1", ",", "NBS1", ",", "phosphorylated", "ATM", ",", "BRCA1", "and", "gamma", "-", "H2AX", ".", "RAD18", "associates", "with", "53BP1", "and", "is", "recruited", "to", "DSB", "sites", "in", "a", "53BP1-dependent", "manner", "specifically", "during", "G1-phase", ",", "RAD18", "monoubiquitinates", "KBD", "domain", "of", "53BP1", "at", "lysine", "1268", "in", "vitro", ".", "A", "monoubiquitination", "-", "resistant", "53BP1", "mutant", "harboring", "a", "substitution", "at", "lysine", "1268", "is", "not", "retained", "efficiently", "at", "the", "chromatin", "in", "the", "vicinity", "of", "DSBs", ".", "In", "Rad18-null", "cells", ",", "retention", "of", "53BP1", "foci", ",", "efficiency", "of", "DSB", "repair", "and", "post", "-", "irradiation", "viability", "are", "impaired", "compared", "with", "wild", "-", "type", "cells", ".", "Taken", "together", ",", "these", "results", "suggest", "that", "RAD18", "promotes", "53BP1-directed", "DSB", "repair", "by", "enhancing", "retention", "of", "53BP1", ",", "possibly", "through", "an", "interaction", "between", "RAD18", "and", "53BP1", "and", "the", "modification", "of", "53BP1", ".", "\n" ]	[ "Entity", "Protein" ]
complication is an umlsterm, intramuscular injections is an umlsterm, necrosis is an umlsterm, skin is an umlsterm, para - arterial is an umlsterm, injections is an umlsterm, vessels is an umlsterm, occurrence is an umlsterm, intra - articular injections is an umlsterm, knee is an umlsterm	DerHautarzt.90500214.eng.abstr_task0	Sentence: Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]	Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee .	[ "Embolia", "cutis", "medicamentosa", "(", "Nicolau", "Syndrom", ")", "is", "a", "very", "rare", "complication", "of", "intramuscular", "injections", "which", "presents", "with", "extensive", "necrosis", "of", "the", "injected", "skin", "area", ".", "Intra", "-", "arterial", "and", "/", "or", "para", "-", "arterial", "injections", "after", "prior", "perforation", "of", "certain", "vessels", "are", "discussed", "as", "possible", "pathogenetic", "mechanisms", ".", "We", "describe", "the", "occurrence", "of", "embolia", "cutis", "medicamentosa", "after", "intra", "-", "articular", "injections", "into", "the", "knee", "." ]	[ "umlsterm" ]
complication is an umlsterm, intramuscular injections is an umlsterm, necrosis is an umlsterm, skin is an umlsterm, para - arterial is an umlsterm, injections is an umlsterm, vessels is an umlsterm, occurrence is an umlsterm, intra - articular injections is an umlsterm, knee is an umlsterm	DerHautarzt.90500214.eng.abstr_task1	Sentence: Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee . Instructions: please typing these entity words according to sentence: complication, intramuscular injections, necrosis, skin, para - arterial, injections, vessels, occurrence, intra - articular injections, knee Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]	Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee .	[ "Embolia", "cutis", "medicamentosa", "(", "Nicolau", "Syndrom", ")", "is", "a", "very", "rare", "complication", "of", "intramuscular", "injections", "which", "presents", "with", "extensive", "necrosis", "of", "the", "injected", "skin", "area", ".", "Intra", "-", "arterial", "and", "/", "or", "para", "-", "arterial", "injections", "after", "prior", "perforation", "of", "certain", "vessels", "are", "discussed", "as", "possible", "pathogenetic", "mechanisms", ".", "We", "describe", "the", "occurrence", "of", "embolia", "cutis", "medicamentosa", "after", "intra", "-", "articular", "injections", "into", "the", "knee", "." ]	[ "umlsterm" ]
complication, intramuscular injections, necrosis, skin, para - arterial, injections, vessels, occurrence, intra - articular injections, knee	DerHautarzt.90500214.eng.abstr_task2	Sentence: Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]	Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee .	[ "Embolia", "cutis", "medicamentosa", "(", "Nicolau", "Syndrom", ")", "is", "a", "very", "rare", "complication", "of", "intramuscular", "injections", "which", "presents", "with", "extensive", "necrosis", "of", "the", "injected", "skin", "area", ".", "Intra", "-", "arterial", "and", "/", "or", "para", "-", "arterial", "injections", "after", "prior", "perforation", "of", "certain", "vessels", "are", "discussed", "as", "possible", "pathogenetic", "mechanisms", ".", "We", "describe", "the", "occurrence", "of", "embolia", "cutis", "medicamentosa", "after", "intra", "-", "articular", "injections", "into", "the", "knee", "." ]	[ "umlsterm" ]
Esophageal is an umlsterm, disease is an umlsterm, etiology is an umlsterm, male is an umlsterm, patients is an umlsterm, disease is an umlsterm, dilatation is an umlsterm, esophageal is an umlsterm, Stenosis is an umlsterm, esophagitis is an umlsterm, patients is an umlsterm, All is an umlsterm, patients is an umlsterm, dysphagia is an umlsterm, esophageal is an umlsterm	DerChirurg.80690471.eng.abstr_task0	Sentence: Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth .	[ "Esophageal", "intramural", "pseudodiverticulosis", "is", "a", "very", "rare", "disease", "with", "unknown", "etiology", ",", "which", "especially", "affects", "male", "patients", "between", "45", "and", "65", "years", ".", "This", "disease", "is", "characterized", "by", "dilatation", "of", "the", "esophageal", "submucosal", "glands", "and", "their", "outlets", ".", "Stenosis", "caused", "by", "esophagitis", "due", "to", "intramural", "pseudodiverticulosis", "is", "found", "in", "most", "of", "the", "known", "patients", ".", "All", "patients", "presented", "with", "dysphagia", ",", "usually", "of", "long", "duration", ".", "The", "characteristic", "radiographic", "appearance", "is", "numerous", "intramural", "esophageal", "contrast", "-", "filled", "diverticulosis", "-", "like", "pouches", "-", "4", "mm", "in", "depth", "." ]	[ "umlsterm" ]
Esophageal is an umlsterm, disease is an umlsterm, etiology is an umlsterm, male is an umlsterm, patients is an umlsterm, disease is an umlsterm, dilatation is an umlsterm, esophageal is an umlsterm, Stenosis is an umlsterm, esophagitis is an umlsterm, patients is an umlsterm, All is an umlsterm, patients is an umlsterm, dysphagia is an umlsterm, esophageal is an umlsterm	DerChirurg.80690471.eng.abstr_task1	Sentence: Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth . Instructions: please typing these entity words according to sentence: Esophageal, disease, etiology, male, patients, disease, dilatation, esophageal, Stenosis, esophagitis, patients, All, patients, dysphagia, esophageal Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth .	[ "Esophageal", "intramural", "pseudodiverticulosis", "is", "a", "very", "rare", "disease", "with", "unknown", "etiology", ",", "which", "especially", "affects", "male", "patients", "between", "45", "and", "65", "years", ".", "This", "disease", "is", "characterized", "by", "dilatation", "of", "the", "esophageal", "submucosal", "glands", "and", "their", "outlets", ".", "Stenosis", "caused", "by", "esophagitis", "due", "to", "intramural", "pseudodiverticulosis", "is", "found", "in", "most", "of", "the", "known", "patients", ".", "All", "patients", "presented", "with", "dysphagia", ",", "usually", "of", "long", "duration", ".", "The", "characteristic", "radiographic", "appearance", "is", "numerous", "intramural", "esophageal", "contrast", "-", "filled", "diverticulosis", "-", "like", "pouches", "-", "4", "mm", "in", "depth", "." ]	[ "umlsterm" ]
Esophageal, disease, etiology, male, patients, disease, dilatation, esophageal, Stenosis, esophagitis, patients, All, patients, dysphagia, esophageal	DerChirurg.80690471.eng.abstr_task2	Sentence: Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth .	[ "Esophageal", "intramural", "pseudodiverticulosis", "is", "a", "very", "rare", "disease", "with", "unknown", "etiology", ",", "which", "especially", "affects", "male", "patients", "between", "45", "and", "65", "years", ".", "This", "disease", "is", "characterized", "by", "dilatation", "of", "the", "esophageal", "submucosal", "glands", "and", "their", "outlets", ".", "Stenosis", "caused", "by", "esophagitis", "due", "to", "intramural", "pseudodiverticulosis", "is", "found", "in", "most", "of", "the", "known", "patients", ".", "All", "patients", "presented", "with", "dysphagia", ",", "usually", "of", "long", "duration", ".", "The", "characteristic", "radiographic", "appearance", "is", "numerous", "intramural", "esophageal", "contrast", "-", "filled", "diverticulosis", "-", "like", "pouches", "-", "4", "mm", "in", "depth", "." ]	[ "umlsterm" ]
Web - based weight management programs is a Intervention_Educational, . is a Intervention_Other, efficacy is a Outcome_Other, Web - based tailored behavioral weight management program is a Intervention_Educational, 2862 is a Participant_Sample-size, overweight and obese ( BMI = 27 to 40 kg / m2 ) is a Participant_Condition, tailored expert system is a Intervention_Educational, information - only Web - based weight management materials is a Intervention_Educational, Weight change is a Outcome_Physical, program satisfaction is a Outcome_Other, weight loss is a Outcome_Physical, baseline weight is a Outcome_Physical, personally relevant , helpful , and easy to understand . is a Outcome_Other, Web - based tailored expert system for weight management is a Intervention_Educational, Web - based information - only weight management program is a Intervention_Educational	25784_task0	Sentence: Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O" ]	Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program .	[ "Web", "-", "based", "weight", "management", "programs", "in", "an", "integrated", "health", "care", "setting", ":", "a", "randomized", ",", "controlled", "trial", ".", "OBJECTIVE", "To", "assess", "the", "efficacy", "of", "a", "Web", "-", "based", "tailored", "behavioral", "weight", "management", "program", "compared", "with", "Web", "-", "based", "information", "-", "only", "weight", "management", "materials", ".", "RESEARCH", "METHODS", "AND", "PROCEDURES", "Participants", ",", "2862", "eligible", "overweight", "and", "obese", "(", "BMI", "=", "27", "to", "40", "kg", "/", "m2", ")", "members", "from", "four", "regions", "of", "Kaiser", "Permanente", "'", "s", "integrated", "health", "care", "delivery", "system", ",", "were", "randomized", "to", "receive", "either", "a", "tailored", "expert", "system", "or", "information", "-", "only", "Web", "-", "based", "weight", "management", "materials", ".", "Weight", "change", "and", "program", "satisfaction", "were", "assessed", "by", "self", "-", "report", "through", "an", "Internet", "-", "based", "survey", "at", "3-", "and", "6-month", "follow", "-", "up", "periods", ".", "RESULTS", "Significantly", "greater", "weight", "loss", "at", "follow", "-", "up", "was", "found", "among", "participants", "assigned", "to", "the", "tailored", "expert", "system", "than", "among", "those", "assigned", "to", "the", "information", "-", "only", "condition", ".", "Subjects", "in", "the", "tailored", "expert", "system", "lost", "a", "mean", "of", "3", "+", "/-", "0.3", "%", "of", "their", "baseline", "weight", ",", "whereas", "subjects", "in", "the", "information", "-", "only", "condition", "lost", "a", "mean", "of", "1.2", "+", "/-", "0.4", "%", "(", "p", "<", "0.0004", ")", ".", "Participants", "were", "also", "more", "likely", "to", "report", "that", "the", "tailored", "expert", "system", "was", "personally", "relevant", ",", "helpful", ",", "and", "easy", "to", "understand", ".", "Notably", ",", "36", "%", "of", "enrollees", "were", "African", "-", "American", ",", "with", "enrollment", "rates", "higher", "than", "the", "general", "proportion", "of", "African", "Americans", "in", "any", "of", "the", "study", "regions", ".", "DISCUSSION", "The", "results", "of", "this", "large", ",", "randomized", "control", "trial", "show", "the", "potential", "benefit", "of", "the", "Web", "-", "based", "tailored", "expert", "system", "for", "weight", "management", "compared", "with", "a", "Web", "-", "based", "information", "-", "only", "weight", "management", "program", "." ]	[ "Outcome_Other", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Sample-size", "Intervention_Other" ]
Web - based weight management programs is a Intervention_Educational, . is a Intervention_Other, efficacy is a Outcome_Other, Web - based tailored behavioral weight management program is a Intervention_Educational, 2862 is a Participant_Sample-size, overweight and obese ( BMI = 27 to 40 kg / m2 ) is a Participant_Condition, tailored expert system is a Intervention_Educational, information - only Web - based weight management materials is a Intervention_Educational, Weight change is a Outcome_Physical, program satisfaction is a Outcome_Other, weight loss is a Outcome_Physical, baseline weight is a Outcome_Physical, personally relevant , helpful , and easy to understand . is a Outcome_Other, Web - based tailored expert system for weight management is a Intervention_Educational, Web - based information - only weight management program is a Intervention_Educational	25784_task1	Sentence: Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program . Instructions: please typing these entity words according to sentence: Web - based weight management programs, ., efficacy, Web - based tailored behavioral weight management program, 2862, overweight and obese ( BMI = 27 to 40 kg / m2 ), tailored expert system, information - only Web - based weight management materials, Weight change, program satisfaction, weight loss, baseline weight, personally relevant , helpful , and easy to understand ., Web - based tailored expert system for weight management, Web - based information - only weight management program Options: Participant_Condition, Intervention_Educational, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O" ]	Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program .	[ "Web", "-", "based", "weight", "management", "programs", "in", "an", "integrated", "health", "care", "setting", ":", "a", "randomized", ",", "controlled", "trial", ".", "OBJECTIVE", "To", "assess", "the", "efficacy", "of", "a", "Web", "-", "based", "tailored", "behavioral", "weight", "management", "program", "compared", "with", "Web", "-", "based", "information", "-", "only", "weight", "management", "materials", ".", "RESEARCH", "METHODS", "AND", "PROCEDURES", "Participants", ",", "2862", "eligible", "overweight", "and", "obese", "(", "BMI", "=", "27", "to", "40", "kg", "/", "m2", ")", "members", "from", "four", "regions", "of", "Kaiser", "Permanente", "'", "s", "integrated", "health", "care", "delivery", "system", ",", "were", "randomized", "to", "receive", "either", "a", "tailored", "expert", "system", "or", "information", "-", "only", "Web", "-", "based", "weight", "management", "materials", ".", "Weight", "change", "and", "program", "satisfaction", "were", "assessed", "by", "self", "-", "report", "through", "an", "Internet", "-", "based", "survey", "at", "3-", "and", "6-month", "follow", "-", "up", "periods", ".", "RESULTS", "Significantly", "greater", "weight", "loss", "at", "follow", "-", "up", "was", "found", "among", "participants", "assigned", "to", "the", "tailored", "expert", "system", "than", "among", "those", "assigned", "to", "the", "information", "-", "only", "condition", ".", "Subjects", "in", "the", "tailored", "expert", "system", "lost", "a", "mean", "of", "3", "+", "/-", "0.3", "%", "of", "their", "baseline", "weight", ",", "whereas", "subjects", "in", "the", "information", "-", "only", "condition", "lost", "a", "mean", "of", "1.2", "+", "/-", "0.4", "%", "(", "p", "<", "0.0004", ")", ".", "Participants", "were", "also", "more", "likely", "to", "report", "that", "the", "tailored", "expert", "system", "was", "personally", "relevant", ",", "helpful", ",", "and", "easy", "to", "understand", ".", "Notably", ",", "36", "%", "of", "enrollees", "were", "African", "-", "American", ",", "with", "enrollment", "rates", "higher", "than", "the", "general", "proportion", "of", "African", "Americans", "in", "any", "of", "the", "study", "regions", ".", "DISCUSSION", "The", "results", "of", "this", "large", ",", "randomized", "control", "trial", "show", "the", "potential", "benefit", "of", "the", "Web", "-", "based", "tailored", "expert", "system", "for", "weight", "management", "compared", "with", "a", "Web", "-", "based", "information", "-", "only", "weight", "management", "program", "." ]	[ "Outcome_Other", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Sample-size", "Intervention_Other" ]
Web - based weight management programs, ., efficacy, Web - based tailored behavioral weight management program, 2862, overweight and obese ( BMI = 27 to 40 kg / m2 ), tailored expert system, information - only Web - based weight management materials, Weight change, program satisfaction, weight loss, baseline weight, personally relevant , helpful , and easy to understand ., Web - based tailored expert system for weight management, Web - based information - only weight management program	25784_task2	Sentence: Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O" ]	Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program .	[ "Web", "-", "based", "weight", "management", "programs", "in", "an", "integrated", "health", "care", "setting", ":", "a", "randomized", ",", "controlled", "trial", ".", "OBJECTIVE", "To", "assess", "the", "efficacy", "of", "a", "Web", "-", "based", "tailored", "behavioral", "weight", "management", "program", "compared", "with", "Web", "-", "based", "information", "-", "only", "weight", "management", "materials", ".", "RESEARCH", "METHODS", "AND", "PROCEDURES", "Participants", ",", "2862", "eligible", "overweight", "and", "obese", "(", "BMI", "=", "27", "to", "40", "kg", "/", "m2", ")", "members", "from", "four", "regions", "of", "Kaiser", "Permanente", "'", "s", "integrated", "health", "care", "delivery", "system", ",", "were", "randomized", "to", "receive", "either", "a", "tailored", "expert", "system", "or", "information", "-", "only", "Web", "-", "based", "weight", "management", "materials", ".", "Weight", "change", "and", "program", "satisfaction", "were", "assessed", "by", "self", "-", "report", "through", "an", "Internet", "-", "based", "survey", "at", "3-", "and", "6-month", "follow", "-", "up", "periods", ".", "RESULTS", "Significantly", "greater", "weight", "loss", "at", "follow", "-", "up", "was", "found", "among", "participants", "assigned", "to", "the", "tailored", "expert", "system", "than", "among", "those", "assigned", "to", "the", "information", "-", "only", "condition", ".", "Subjects", "in", "the", "tailored", "expert", "system", "lost", "a", "mean", "of", "3", "+", "/-", "0.3", "%", "of", "their", "baseline", "weight", ",", "whereas", "subjects", "in", "the", "information", "-", "only", "condition", "lost", "a", "mean", "of", "1.2", "+", "/-", "0.4", "%", "(", "p", "<", "0.0004", ")", ".", "Participants", "were", "also", "more", "likely", "to", "report", "that", "the", "tailored", "expert", "system", "was", "personally", "relevant", ",", "helpful", ",", "and", "easy", "to", "understand", ".", "Notably", ",", "36", "%", "of", "enrollees", "were", "African", "-", "American", ",", "with", "enrollment", "rates", "higher", "than", "the", "general", "proportion", "of", "African", "Americans", "in", "any", "of", "the", "study", "regions", ".", "DISCUSSION", "The", "results", "of", "this", "large", ",", "randomized", "control", "trial", "show", "the", "potential", "benefit", "of", "the", "Web", "-", "based", "tailored", "expert", "system", "for", "weight", "management", "compared", "with", "a", "Web", "-", "based", "information", "-", "only", "weight", "management", "program", "." ]	[ "Outcome_Other", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Sample-size", "Intervention_Other" ]
R124C is a ProteinMutation	842_task0	Sentence: Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ProteinMutation	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.	[ "Anticipation", "in", "familial", "lattice", "corneal", "dystrophy", "type", "I", "with", "R124C", "mutation", "in", "the", "TGFBI", "(", "BIGH3", ")", "gene", "." ]	[ "ProteinMutation", "DNAMutation" ]
R124C is a ProteinMutation	842_task1	Sentence: Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene. Instructions: please typing these entity words according to sentence: R124C Options: ProteinMutation	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.	[ "Anticipation", "in", "familial", "lattice", "corneal", "dystrophy", "type", "I", "with", "R124C", "mutation", "in", "the", "TGFBI", "(", "BIGH3", ")", "gene", "." ]	[ "ProteinMutation", "DNAMutation" ]
R124C	842_task2	Sentence: Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.	[ "Anticipation", "in", "familial", "lattice", "corneal", "dystrophy", "type", "I", "with", "R124C", "mutation", "in", "the", "TGFBI", "(", "BIGH3", ")", "gene", "." ]	[ "ProteinMutation", "DNAMutation" ]
Adenosine deaminase is a protein, ADA is a protein, adenosine is a compound, inosine is a compound, ammonia is a compound	DS.d469_task0	Sentence: Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "B-compound", "O" ]	Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia.	[ "Adenosine", "deaminase", "(", "ADA", ")", ",", "an", "enzyme", "involved", "in", "purine", "metabolism", ",", "catalyzes", "the", "hydrolytic", "breakdown", "of", "adenosine", "into", "inosine", "and", "free", "ammonia", "." ]	[ "protein", "compound" ]
Adenosine deaminase is a protein, ADA is a protein, adenosine is a compound, inosine is a compound, ammonia is a compound	DS.d469_task1	Sentence: Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia. Instructions: please typing these entity words according to sentence: Adenosine deaminase, ADA, adenosine, inosine, ammonia Options: compound, protein	[ "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "B-compound", "O" ]	Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia.	[ "Adenosine", "deaminase", "(", "ADA", ")", ",", "an", "enzyme", "involved", "in", "purine", "metabolism", ",", "catalyzes", "the", "hydrolytic", "breakdown", "of", "adenosine", "into", "inosine", "and", "free", "ammonia", "." ]	[ "protein", "compound" ]
Adenosine deaminase, ADA, adenosine, inosine, ammonia	DS.d469_task2	Sentence: Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia. Instructions: please extract entity words from the input sentence	[ "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "B-compound", "O" ]	Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia.	[ "Adenosine", "deaminase", "(", "ADA", ")", ",", "an", "enzyme", "involved", "in", "purine", "metabolism", ",", "catalyzes", "the", "hydrolytic", "breakdown", "of", "adenosine", "into", "inosine", "and", "free", "ammonia", "." ]	[ "protein", "compound" ]
protease is a GENE-Y	17635930_task0	Sentence: Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]	Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.	[ "Potent", "inhibition", "of", "HIV-1", "replication", "by", "novel", "non", "-", "peptidyl", "small", "molecule", "inhibitors", "of", "protease", "dimerization", "." ]	[ "GENE-Y" ]
protease is a GENE-Y	17635930_task1	Sentence: Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. Instructions: please typing these entity words according to sentence: protease Options: GENE-Y	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]	Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.	[ "Potent", "inhibition", "of", "HIV-1", "replication", "by", "novel", "non", "-", "peptidyl", "small", "molecule", "inhibitors", "of", "protease", "dimerization", "." ]	[ "GENE-Y" ]
protease	17635930_task2	Sentence: Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]	Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.	[ "Potent", "inhibition", "of", "HIV-1", "replication", "by", "novel", "non", "-", "peptidyl", "small", "molecule", "inhibitors", "of", "protease", "dimerization", "." ]	[ "GENE-Y" ]
Augenfolgebewegungen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Pathologie is an umlsterm, Augefolgebewegungen is an umlsterm, Augenfolgebewegungen is an umlsterm	HNO.70450385.ger.abstr_task0	Sentence: Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung .	[ "Die", "Pruefung", "der", "willkuerlichen", "langsamen", "Augenfolgebewegungen", "liefert", "wichtige", "Hinweise", "zur", "Aufdeckung", "zentral", "vestibulaerer", "Stoerungen", ".", "Ziel", "war", "es", "zu", "klaeren", ",", "ob", "neben", "der", "komplett", "gestoerten", "auch", "einer", "partiell", "gestoerten", "Blickfolgebewegung", "ein", "Krankheitswert", "zukommt", ".", "Retrospektiv", "wurde", "bei", "100", "Patienten", "die", "Blickfolgepruefung", "analysiert", ".", "Die", "einzelnen", "Kurvenverlaeufe", "wurden", "den", "3", "Gruppen", "der", "regelrechten", ",", "der", "partiell", "gestoerten", "und", "der", "komplett", "gestoerten", "Blickfolge", "zugeordnet", "und", "anschliessend", "der", "Uebereinstimmungsquotient", "errechnet", ";", "16", "Patienten", "zeigten", "qualitativ", "eine", "komplett", "gestoerte", "Blickfolge", ",", "und", "bei", "9", "von", "ihnen", "(", "56", "3", "%", ")", ",", "liess", "sich", "ein", "morphologisches", "Korrelat", "im", "Sinne", "einer", "zentralen", "Erkrankung", "finden", ".", "Bei", "29", "Patienten", "ergab", "sich", "eine", "partiell", "gestoerte", "Blickfolge", ",", "und", "nur", "bei", "2", "von", "ihnen", "(", "6,9", "%", ")", "fand", "sich", "eine", "zentrale", "Pathologie", ".", "Durchschnittlich", "fand", "sich", "der", "hoechste", "beidaeugig", "gemessene", "Uebereinstimmungsquotient", "mit", "1,44", "in", "der", "Gruppe", "mit", "komplett", "gestoerter", "Blickfolge", ".", "In", "der", "Gruppe", "mit", "partiell", "gestoerten", "Augefolgebewegungen", "lag", "er", "bei", "1,24", "und", "in", "der", "mit", "regelrechter", "Blickfolge", "bei", "1,17", ".", "Nur", "eine", "komplett", "gestoerte", "Blickfolge", "korreliert", "in", "den", "meisten", "Faellen", "mit", "einer", "zentralen", "Erkrankung", ".", "Partiell", "gestoerte", "Augenfolgebewegungen", "haben", "in", "der", "Regel", "keine", "pathologische", "Bedeutung", "." ]	[ "umlsterm" ]
Augenfolgebewegungen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Pathologie is an umlsterm, Augefolgebewegungen is an umlsterm, Augenfolgebewegungen is an umlsterm	HNO.70450385.ger.abstr_task1	Sentence: Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung . Instructions: please typing these entity words according to sentence: Augenfolgebewegungen, Patienten, Patienten, Patienten, Pathologie, Augefolgebewegungen, Augenfolgebewegungen Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung .	[ "Die", "Pruefung", "der", "willkuerlichen", "langsamen", "Augenfolgebewegungen", "liefert", "wichtige", "Hinweise", "zur", "Aufdeckung", "zentral", "vestibulaerer", "Stoerungen", ".", "Ziel", "war", "es", "zu", "klaeren", ",", "ob", "neben", "der", "komplett", "gestoerten", "auch", "einer", "partiell", "gestoerten", "Blickfolgebewegung", "ein", "Krankheitswert", "zukommt", ".", "Retrospektiv", "wurde", "bei", "100", "Patienten", "die", "Blickfolgepruefung", "analysiert", ".", "Die", "einzelnen", "Kurvenverlaeufe", "wurden", "den", "3", "Gruppen", "der", "regelrechten", ",", "der", "partiell", "gestoerten", "und", "der", "komplett", "gestoerten", "Blickfolge", "zugeordnet", "und", "anschliessend", "der", "Uebereinstimmungsquotient", "errechnet", ";", "16", "Patienten", "zeigten", "qualitativ", "eine", "komplett", "gestoerte", "Blickfolge", ",", "und", "bei", "9", "von", "ihnen", "(", "56", "3", "%", ")", ",", "liess", "sich", "ein", "morphologisches", "Korrelat", "im", "Sinne", "einer", "zentralen", "Erkrankung", "finden", ".", "Bei", "29", "Patienten", "ergab", "sich", "eine", "partiell", "gestoerte", "Blickfolge", ",", "und", "nur", "bei", "2", "von", "ihnen", "(", "6,9", "%", ")", "fand", "sich", "eine", "zentrale", "Pathologie", ".", "Durchschnittlich", "fand", "sich", "der", "hoechste", "beidaeugig", "gemessene", "Uebereinstimmungsquotient", "mit", "1,44", "in", "der", "Gruppe", "mit", "komplett", "gestoerter", "Blickfolge", ".", "In", "der", "Gruppe", "mit", "partiell", "gestoerten", "Augefolgebewegungen", "lag", "er", "bei", "1,24", "und", "in", "der", "mit", "regelrechter", "Blickfolge", "bei", "1,17", ".", "Nur", "eine", "komplett", "gestoerte", "Blickfolge", "korreliert", "in", "den", "meisten", "Faellen", "mit", "einer", "zentralen", "Erkrankung", ".", "Partiell", "gestoerte", "Augenfolgebewegungen", "haben", "in", "der", "Regel", "keine", "pathologische", "Bedeutung", "." ]	[ "umlsterm" ]
Augenfolgebewegungen, Patienten, Patienten, Patienten, Pathologie, Augefolgebewegungen, Augenfolgebewegungen	HNO.70450385.ger.abstr_task2	Sentence: Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung .	[ "Die", "Pruefung", "der", "willkuerlichen", "langsamen", "Augenfolgebewegungen", "liefert", "wichtige", "Hinweise", "zur", "Aufdeckung", "zentral", "vestibulaerer", "Stoerungen", ".", "Ziel", "war", "es", "zu", "klaeren", ",", "ob", "neben", "der", "komplett", "gestoerten", "auch", "einer", "partiell", "gestoerten", "Blickfolgebewegung", "ein", "Krankheitswert", "zukommt", ".", "Retrospektiv", "wurde", "bei", "100", "Patienten", "die", "Blickfolgepruefung", "analysiert", ".", "Die", "einzelnen", "Kurvenverlaeufe", "wurden", "den", "3", "Gruppen", "der", "regelrechten", ",", "der", "partiell", "gestoerten", "und", "der", "komplett", "gestoerten", "Blickfolge", "zugeordnet", "und", "anschliessend", "der", "Uebereinstimmungsquotient", "errechnet", ";", "16", "Patienten", "zeigten", "qualitativ", "eine", "komplett", "gestoerte", "Blickfolge", ",", "und", "bei", "9", "von", "ihnen", "(", "56", "3", "%", ")", ",", "liess", "sich", "ein", "morphologisches", "Korrelat", "im", "Sinne", "einer", "zentralen", "Erkrankung", "finden", ".", "Bei", "29", "Patienten", "ergab", "sich", "eine", "partiell", "gestoerte", "Blickfolge", ",", "und", "nur", "bei", "2", "von", "ihnen", "(", "6,9", "%", ")", "fand", "sich", "eine", "zentrale", "Pathologie", ".", "Durchschnittlich", "fand", "sich", "der", "hoechste", "beidaeugig", "gemessene", "Uebereinstimmungsquotient", "mit", "1,44", "in", "der", "Gruppe", "mit", "komplett", "gestoerter", "Blickfolge", ".", "In", "der", "Gruppe", "mit", "partiell", "gestoerten", "Augefolgebewegungen", "lag", "er", "bei", "1,24", "und", "in", "der", "mit", "regelrechter", "Blickfolge", "bei", "1,17", ".", "Nur", "eine", "komplett", "gestoerte", "Blickfolge", "korreliert", "in", "den", "meisten", "Faellen", "mit", "einer", "zentralen", "Erkrankung", ".", "Partiell", "gestoerte", "Augenfolgebewegungen", "haben", "in", "der", "Regel", "keine", "pathologische", "Bedeutung", "." ]	[ "umlsterm" ]
DNA polymerase kappa is a Protein, DNA polymerase kappa is a Protein, polkappa is a Protein, POLK is a Protein, stimulating protein-1 is a Protein, SP1 is a Protein, SP1 is a Protein, SP1 is a Protein, SP1 is a Protein, POLK is a Protein, SP1 is a Protein	217_task0	Sentence: Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours.	[ "Characterization", "of", "promoter", "regulatory", "elements", "involved", "in", "downexpression", "of", "the", "DNA", "polymerase", "kappa", "in", "colorectal", "cancer", ".", "\n", "The", "low", "-", "fidelity", "DNA", "polymerases", "thought", "to", "be", "specialized", "in", "DNA", "damage", "processing", "are", "frequently", "misregulated", "in", "cancers", ".", "We", "show", "here", "that", "DNA", "polymerase", "kappa", "(", "polkappa", ")", ",", "prone", "to", "replicate", "across", "oxidative", "and", "aromatic", "adducts", "and", "known", "to", "function", "in", "nucleotide", "excision", "repair", "(", "NER", ")", ",", "is", "downregulated", "in", "colorectal", "tumour", "biopsies", ".", "Contrary", "to", "the", "replicative", "poldelta", "and", "polalpha", ",", "for", "which", "only", "activating", "domains", "were", "described", ",", "we", "identified", "an", "upstream", "465-bp", "-", "long", "repressor", "region", "in", "the", "promoter", "of", "POLK", ".", "We", "also", "found", "an", "activating", "237-bp", "region", "that", "includes", "stimulating", "protein-1", "(", "SP1", ")", "and", "cyclic", "AMP", "-", "responsive", "element", "(", "CRE)-binding", "sites", ".", "Mutations", "at", "one", "CRE", "-", "binding", "site", "led", "to", "a", "dramatic", "80", "%", "decrease", "in", "promoter", "activity", ".", "Alterations", "of", "the", "SP1-binding", "site", "also", "affected", ",", "to", "a", "lesser", "extent", ",", "the", "transcription", ".", "Gel", "shift", "assays", "confirmed", "the", "role", "played", "by", "CRE", "/", "SP1", "recognition", "sequences", ".", "Moreover", ",", "ectopic", "expression", "of", "SP1", "or", "CRE", "-", "binding", "protein", "(", "CREB", ")", "protein", "favoured", "polkappa", "transcription", ".", "Finally", ",", "we", "found", "that", "polkappa", "downexpression", "in", "colorectal", "biopsies", "correlated", "with", "a", "decreased", "level", "of", "CREB", "and", "SP1", "transcripts", ".", "This", "work", "shows", "that", "the", "promoter", "of", "POLK", "is", "cis", "-", "controlled", "and", "suggests", "that", "silencing", "of", "CREB", "and", "SP1", "proteins", "could", "contribute", "to", "downregulation", "of", "this", "repair", "polymerase", "in", "colorectal", "tumours", ".", "\n" ]	[ "Protein" ]
DNA polymerase kappa is a Protein, DNA polymerase kappa is a Protein, polkappa is a Protein, POLK is a Protein, stimulating protein-1 is a Protein, SP1 is a Protein, SP1 is a Protein, SP1 is a Protein, SP1 is a Protein, POLK is a Protein, SP1 is a Protein	217_task1	Sentence: Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours. Instructions: please typing these entity words according to sentence: DNA polymerase kappa, DNA polymerase kappa, polkappa, POLK, stimulating protein-1, SP1, SP1, SP1, SP1, POLK, SP1 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours.	[ "Characterization", "of", "promoter", "regulatory", "elements", "involved", "in", "downexpression", "of", "the", "DNA", "polymerase", "kappa", "in", "colorectal", "cancer", ".", "\n", "The", "low", "-", "fidelity", "DNA", "polymerases", "thought", "to", "be", "specialized", "in", "DNA", "damage", "processing", "are", "frequently", "misregulated", "in", "cancers", ".", "We", "show", "here", "that", "DNA", "polymerase", "kappa", "(", "polkappa", ")", ",", "prone", "to", "replicate", "across", "oxidative", "and", "aromatic", "adducts", "and", "known", "to", "function", "in", "nucleotide", "excision", "repair", "(", "NER", ")", ",", "is", "downregulated", "in", "colorectal", "tumour", "biopsies", ".", "Contrary", "to", "the", "replicative", "poldelta", "and", "polalpha", ",", "for", "which", "only", "activating", "domains", "were", "described", ",", "we", "identified", "an", "upstream", "465-bp", "-", "long", "repressor", "region", "in", "the", "promoter", "of", "POLK", ".", "We", "also", "found", "an", "activating", "237-bp", "region", "that", "includes", "stimulating", "protein-1", "(", "SP1", ")", "and", "cyclic", "AMP", "-", "responsive", "element", "(", "CRE)-binding", "sites", ".", "Mutations", "at", "one", "CRE", "-", "binding", "site", "led", "to", "a", "dramatic", "80", "%", "decrease", "in", "promoter", "activity", ".", "Alterations", "of", "the", "SP1-binding", "site", "also", "affected", ",", "to", "a", "lesser", "extent", ",", "the", "transcription", ".", "Gel", "shift", "assays", "confirmed", "the", "role", "played", "by", "CRE", "/", "SP1", "recognition", "sequences", ".", "Moreover", ",", "ectopic", "expression", "of", "SP1", "or", "CRE", "-", "binding", "protein", "(", "CREB", ")", "protein", "favoured", "polkappa", "transcription", ".", "Finally", ",", "we", "found", "that", "polkappa", "downexpression", "in", "colorectal", "biopsies", "correlated", "with", "a", "decreased", "level", "of", "CREB", "and", "SP1", "transcripts", ".", "This", "work", "shows", "that", "the", "promoter", "of", "POLK", "is", "cis", "-", "controlled", "and", "suggests", "that", "silencing", "of", "CREB", "and", "SP1", "proteins", "could", "contribute", "to", "downregulation", "of", "this", "repair", "polymerase", "in", "colorectal", "tumours", ".", "\n" ]	[ "Protein" ]
DNA polymerase kappa, DNA polymerase kappa, polkappa, POLK, stimulating protein-1, SP1, SP1, SP1, SP1, POLK, SP1	217_task2	Sentence: Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours.	[ "Characterization", "of", "promoter", "regulatory", "elements", "involved", "in", "downexpression", "of", "the", "DNA", "polymerase", "kappa", "in", "colorectal", "cancer", ".", "\n", "The", "low", "-", "fidelity", "DNA", "polymerases", "thought", "to", "be", "specialized", "in", "DNA", "damage", "processing", "are", "frequently", "misregulated", "in", "cancers", ".", "We", "show", "here", "that", "DNA", "polymerase", "kappa", "(", "polkappa", ")", ",", "prone", "to", "replicate", "across", "oxidative", "and", "aromatic", "adducts", "and", "known", "to", "function", "in", "nucleotide", "excision", "repair", "(", "NER", ")", ",", "is", "downregulated", "in", "colorectal", "tumour", "biopsies", ".", "Contrary", "to", "the", "replicative", "poldelta", "and", "polalpha", ",", "for", "which", "only", "activating", "domains", "were", "described", ",", "we", "identified", "an", "upstream", "465-bp", "-", "long", "repressor", "region", "in", "the", "promoter", "of", "POLK", ".", "We", "also", "found", "an", "activating", "237-bp", "region", "that", "includes", "stimulating", "protein-1", "(", "SP1", ")", "and", "cyclic", "AMP", "-", "responsive", "element", "(", "CRE)-binding", "sites", ".", "Mutations", "at", "one", "CRE", "-", "binding", "site", "led", "to", "a", "dramatic", "80", "%", "decrease", "in", "promoter", "activity", ".", "Alterations", "of", "the", "SP1-binding", "site", "also", "affected", ",", "to", "a", "lesser", "extent", ",", "the", "transcription", ".", "Gel", "shift", "assays", "confirmed", "the", "role", "played", "by", "CRE", "/", "SP1", "recognition", "sequences", ".", "Moreover", ",", "ectopic", "expression", "of", "SP1", "or", "CRE", "-", "binding", "protein", "(", "CREB", ")", "protein", "favoured", "polkappa", "transcription", ".", "Finally", ",", "we", "found", "that", "polkappa", "downexpression", "in", "colorectal", "biopsies", "correlated", "with", "a", "decreased", "level", "of", "CREB", "and", "SP1", "transcripts", ".", "This", "work", "shows", "that", "the", "promoter", "of", "POLK", "is", "cis", "-", "controlled", "and", "suggests", "that", "silencing", "of", "CREB", "and", "SP1", "proteins", "could", "contribute", "to", "downregulation", "of", "this", "repair", "polymerase", "in", "colorectal", "tumours", ".", "\n" ]	[ "Protein" ]
Krebsfrueherkennung is an umlsterm, Mammae is an umlsterm, Haut is an umlsterm, Rektum is an umlsterm, Kolon is an umlsterm, Methoden is an umlsterm, gezielte is an umlsterm, koerperliche Untersuchung is an umlsterm, Selbstuntersuchung is an umlsterm, Mammae is an umlsterm, Zervixabstrich is an umlsterm, Blut is an umlsterm, Stuhl is an umlsterm, Mammographie is an umlsterm, Brustveraenderungen is an umlsterm	DerGynaekologe.00330474.ger.abstr_task0	Sentence: Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen .	[ "Die", "Durchfuehrung", "der", "Krebsfrueherkennung", "orientiert", "sich", "an", "den", "1971", "festgelegten", "Richtlinien", "des", "gesetzlichen", "Krebsfrueherkennungsprogramms", "(", "GKFP", ")", ".", "Untersuchte", "Organe", "sind", "das", "aeussere", "und", "innere", "Genitale", ",", "die", "Mammae", ",", "die", "Haut", "sowie", "das", "Rektum", "und", "das", "Kolon", ".", "Die", "Methoden", "umfassen", "die", "gezielte", "Anamnese", ",", "die", "koerperliche", "Untersuchung", ",", "die", "Anleitung", "zur", "Selbstuntersuchung", "der", "Mammae", ",", "den", "zytologischen", "Zervixabstrich", "und", "die", "Testung", "auf", "Blut", "im", "Stuhl", ".", "Die", "Durchfuehrung", "der", "Mammographie", "ist", "beschraenkt", "auf", "Indikationen", "wie", "Zugehoerigkeit", "zu", "anamnestischen", "Risikogruppen", "und", "manifesten", "Brustveraenderungen", "." ]	[ "umlsterm" ]
Krebsfrueherkennung is an umlsterm, Mammae is an umlsterm, Haut is an umlsterm, Rektum is an umlsterm, Kolon is an umlsterm, Methoden is an umlsterm, gezielte is an umlsterm, koerperliche Untersuchung is an umlsterm, Selbstuntersuchung is an umlsterm, Mammae is an umlsterm, Zervixabstrich is an umlsterm, Blut is an umlsterm, Stuhl is an umlsterm, Mammographie is an umlsterm, Brustveraenderungen is an umlsterm	DerGynaekologe.00330474.ger.abstr_task1	Sentence: Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen . Instructions: please typing these entity words according to sentence: Krebsfrueherkennung, Mammae, Haut, Rektum, Kolon, Methoden, gezielte, koerperliche Untersuchung, Selbstuntersuchung, Mammae, Zervixabstrich, Blut, Stuhl, Mammographie, Brustveraenderungen Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen .	[ "Die", "Durchfuehrung", "der", "Krebsfrueherkennung", "orientiert", "sich", "an", "den", "1971", "festgelegten", "Richtlinien", "des", "gesetzlichen", "Krebsfrueherkennungsprogramms", "(", "GKFP", ")", ".", "Untersuchte", "Organe", "sind", "das", "aeussere", "und", "innere", "Genitale", ",", "die", "Mammae", ",", "die", "Haut", "sowie", "das", "Rektum", "und", "das", "Kolon", ".", "Die", "Methoden", "umfassen", "die", "gezielte", "Anamnese", ",", "die", "koerperliche", "Untersuchung", ",", "die", "Anleitung", "zur", "Selbstuntersuchung", "der", "Mammae", ",", "den", "zytologischen", "Zervixabstrich", "und", "die", "Testung", "auf", "Blut", "im", "Stuhl", ".", "Die", "Durchfuehrung", "der", "Mammographie", "ist", "beschraenkt", "auf", "Indikationen", "wie", "Zugehoerigkeit", "zu", "anamnestischen", "Risikogruppen", "und", "manifesten", "Brustveraenderungen", "." ]	[ "umlsterm" ]
Krebsfrueherkennung, Mammae, Haut, Rektum, Kolon, Methoden, gezielte, koerperliche Untersuchung, Selbstuntersuchung, Mammae, Zervixabstrich, Blut, Stuhl, Mammographie, Brustveraenderungen	DerGynaekologe.00330474.ger.abstr_task2	Sentence: Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen .	[ "Die", "Durchfuehrung", "der", "Krebsfrueherkennung", "orientiert", "sich", "an", "den", "1971", "festgelegten", "Richtlinien", "des", "gesetzlichen", "Krebsfrueherkennungsprogramms", "(", "GKFP", ")", ".", "Untersuchte", "Organe", "sind", "das", "aeussere", "und", "innere", "Genitale", ",", "die", "Mammae", ",", "die", "Haut", "sowie", "das", "Rektum", "und", "das", "Kolon", ".", "Die", "Methoden", "umfassen", "die", "gezielte", "Anamnese", ",", "die", "koerperliche", "Untersuchung", ",", "die", "Anleitung", "zur", "Selbstuntersuchung", "der", "Mammae", ",", "den", "zytologischen", "Zervixabstrich", "und", "die", "Testung", "auf", "Blut", "im", "Stuhl", ".", "Die", "Durchfuehrung", "der", "Mammographie", "ist", "beschraenkt", "auf", "Indikationen", "wie", "Zugehoerigkeit", "zu", "anamnestischen", "Risikogruppen", "und", "manifesten", "Brustveraenderungen", "." ]	[ "umlsterm" ]
Adhaesionen is an umlsterm, Ischaemie is an umlsterm, Fremdkoerper is an umlsterm, weiblicher Infertilitaet is an umlsterm, Lebenserwartung is an umlsterm, Komplikationen is an umlsterm, Adhaesionen is an umlsterm, Belastungen is an umlsterm, Forschung is an umlsterm, Blutgerinnung is an umlsterm, Wundheilung is an umlsterm	DerChirurg.00710510.ger.abstr_task0	Sentence: Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert .	[ "Zusammenfassung", ".", "Seit", "ueber", "einhundert", "Jahren", "sind", "peritoneale", "Adhaesionen", "als", "haeufige", "Folge", "abdomineller", "Eingriffe", "bekannt", ".", "Intraoperative", "Laesionen", "des", "Mesothels", "durch", "Abrasion", ",", "Ischaemie", ",", "Austrocknung", "und", "Fremdkoerper", "fuehren", "zu", "Beschwerden", ",", "Passagestoerungen", ",", "weiblicher", "Infertilitaet", "und", "Problemen", "bei", "Reeingriffen", ".", "Weltweit", "fuehren", "eine", "Steigerung", "von", "Lebenserwartung", "und", "Operationszahlen", "zu", "einer", "Zunahme", "der", "Komplikationen", "durch", "Adhaesionen", "und", "den", "damit", "verbundenen", ",", "sozio", "-", "oekonomischen", "Belastungen", ".", "Bis", "heute", "steht", "keine", "sichere", "und", "zuverlaessige", "Prophylaxe", "zur", "Verfuegung", ".", "Zielsetzung", "der", "Forschung", "sollte", "eine", "fluessige", "Substanz", "sein", ",", "die", "nach", "einmaliger", ",", "intraabdomineller", "Applikation", "ohne", "negativen", "Einfluss", "auf", "Blutgerinnung", "und", "Wundheilung", "das", "Auftreten", "postoperativer", "Verwachsungen", "mit", "vertretbaren", "Kosten", "signifikant", "reduziert", "." ]	[ "umlsterm" ]
Adhaesionen is an umlsterm, Ischaemie is an umlsterm, Fremdkoerper is an umlsterm, weiblicher Infertilitaet is an umlsterm, Lebenserwartung is an umlsterm, Komplikationen is an umlsterm, Adhaesionen is an umlsterm, Belastungen is an umlsterm, Forschung is an umlsterm, Blutgerinnung is an umlsterm, Wundheilung is an umlsterm	DerChirurg.00710510.ger.abstr_task1	Sentence: Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert . Instructions: please typing these entity words according to sentence: Adhaesionen, Ischaemie, Fremdkoerper, weiblicher Infertilitaet, Lebenserwartung, Komplikationen, Adhaesionen, Belastungen, Forschung, Blutgerinnung, Wundheilung Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert .	[ "Zusammenfassung", ".", "Seit", "ueber", "einhundert", "Jahren", "sind", "peritoneale", "Adhaesionen", "als", "haeufige", "Folge", "abdomineller", "Eingriffe", "bekannt", ".", "Intraoperative", "Laesionen", "des", "Mesothels", "durch", "Abrasion", ",", "Ischaemie", ",", "Austrocknung", "und", "Fremdkoerper", "fuehren", "zu", "Beschwerden", ",", "Passagestoerungen", ",", "weiblicher", "Infertilitaet", "und", "Problemen", "bei", "Reeingriffen", ".", "Weltweit", "fuehren", "eine", "Steigerung", "von", "Lebenserwartung", "und", "Operationszahlen", "zu", "einer", "Zunahme", "der", "Komplikationen", "durch", "Adhaesionen", "und", "den", "damit", "verbundenen", ",", "sozio", "-", "oekonomischen", "Belastungen", ".", "Bis", "heute", "steht", "keine", "sichere", "und", "zuverlaessige", "Prophylaxe", "zur", "Verfuegung", ".", "Zielsetzung", "der", "Forschung", "sollte", "eine", "fluessige", "Substanz", "sein", ",", "die", "nach", "einmaliger", ",", "intraabdomineller", "Applikation", "ohne", "negativen", "Einfluss", "auf", "Blutgerinnung", "und", "Wundheilung", "das", "Auftreten", "postoperativer", "Verwachsungen", "mit", "vertretbaren", "Kosten", "signifikant", "reduziert", "." ]	[ "umlsterm" ]
Adhaesionen, Ischaemie, Fremdkoerper, weiblicher Infertilitaet, Lebenserwartung, Komplikationen, Adhaesionen, Belastungen, Forschung, Blutgerinnung, Wundheilung	DerChirurg.00710510.ger.abstr_task2	Sentence: Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert .	[ "Zusammenfassung", ".", "Seit", "ueber", "einhundert", "Jahren", "sind", "peritoneale", "Adhaesionen", "als", "haeufige", "Folge", "abdomineller", "Eingriffe", "bekannt", ".", "Intraoperative", "Laesionen", "des", "Mesothels", "durch", "Abrasion", ",", "Ischaemie", ",", "Austrocknung", "und", "Fremdkoerper", "fuehren", "zu", "Beschwerden", ",", "Passagestoerungen", ",", "weiblicher", "Infertilitaet", "und", "Problemen", "bei", "Reeingriffen", ".", "Weltweit", "fuehren", "eine", "Steigerung", "von", "Lebenserwartung", "und", "Operationszahlen", "zu", "einer", "Zunahme", "der", "Komplikationen", "durch", "Adhaesionen", "und", "den", "damit", "verbundenen", ",", "sozio", "-", "oekonomischen", "Belastungen", ".", "Bis", "heute", "steht", "keine", "sichere", "und", "zuverlaessige", "Prophylaxe", "zur", "Verfuegung", ".", "Zielsetzung", "der", "Forschung", "sollte", "eine", "fluessige", "Substanz", "sein", ",", "die", "nach", "einmaliger", ",", "intraabdomineller", "Applikation", "ohne", "negativen", "Einfluss", "auf", "Blutgerinnung", "und", "Wundheilung", "das", "Auftreten", "postoperativer", "Verwachsungen", "mit", "vertretbaren", "Kosten", "signifikant", "reduziert", "." ]	[ "umlsterm" ]
use is an umlsterm, epidural analgesia is an umlsterm, obstetrics is an umlsterm, use is an umlsterm, side effects is an umlsterm, labor is an umlsterm, stress is an umlsterm, release is an umlsterm, epinephrine is an umlsterm, norepinephrine is an umlsterm, vasoconstriction is an umlsterm, arteries is an umlsterm, fetal asphyxia is an umlsterm, fetus is an umlsterm, asphyxia is an umlsterm, epidural analgesia is an umlsterm, stress is an umlsterm, hypotension is an umlsterm, Ringer 's is an umlsterm, solution is an umlsterm, colloids is an umlsterm, concentration is an umlsterm, local anaesthetics is an umlsterm, opioids is an umlsterm, deliveries is an umlsterm, use is an umlsterm, epidural analgesia is an umlsterm, local anaesthetics is an umlsterm	DerAnaesthesist.7046s159.eng.abstr_task0	Sentence: Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]	Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced .	[ "Until", "today", ",", "the", "use", "of", "epidural", "analgesia", "in", "obstetrics", "still", "remains", "controversial", ".", "In", "the", "opinion", "of", "many", "obstetricians", "the", "use", "of", "an", "epidural", "for", "a", "healthy", "laboring", "parturient", "is", "not", "necessary", "and", "can", "lead", "to", "potentially", "harmful", "side", "effects", ".", "However", ",", "painful", "labor", "leads", "to", "a", "maternal", "stress", "reaction", "with", "the", "release", "of", "epinephrine", "and", "norepinephrine", ".", "The", "resulting", "vasoconstriction", "of", "uterine", "arteries", "can", "induce", "fetal", "asphyxia", "in", "an", "otherwise", "healthy", "fetus", "or", "can", "aggravate", "asphyxia", "in", "already", "compromised", "fetusses", ".", "Several", "studies", "show", "that", "epidural", "analgesia", "can", "attenuate", "the", "maternal", "stress", "reaction", "and", "thereby", "improve", "maternal", "and", "fetal", "well", "-", "being", ",", "as", "long", "as", "precautions", "are", "taken", ".", "The", "avoidance", "of", "maternal", "hypotension", "with", "sufficient", "volume", "preload", "with", "lactated", "Ringer", "'s", "solution", "or", "colloids", ",", "and", "decreasing", "the", "concentration", "of", "local", "anaesthetics", "by", "adding", "opioids", "will", "prevent", "an", "increase", "in", "instrumental", "deliveries", ".", "With", "the", "use", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", "the", "amount", "of", "local", "anaesthetics", "can", "even", "further", "be", "reduced", "." ]	[ "umlsterm" ]
use is an umlsterm, epidural analgesia is an umlsterm, obstetrics is an umlsterm, use is an umlsterm, side effects is an umlsterm, labor is an umlsterm, stress is an umlsterm, release is an umlsterm, epinephrine is an umlsterm, norepinephrine is an umlsterm, vasoconstriction is an umlsterm, arteries is an umlsterm, fetal asphyxia is an umlsterm, fetus is an umlsterm, asphyxia is an umlsterm, epidural analgesia is an umlsterm, stress is an umlsterm, hypotension is an umlsterm, Ringer 's is an umlsterm, solution is an umlsterm, colloids is an umlsterm, concentration is an umlsterm, local anaesthetics is an umlsterm, opioids is an umlsterm, deliveries is an umlsterm, use is an umlsterm, epidural analgesia is an umlsterm, local anaesthetics is an umlsterm	DerAnaesthesist.7046s159.eng.abstr_task1	Sentence: Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced . Instructions: please typing these entity words according to sentence: use, epidural analgesia, obstetrics, use, side effects, labor, stress, release, epinephrine, norepinephrine, vasoconstriction, arteries, fetal asphyxia, fetus, asphyxia, epidural analgesia, stress, hypotension, Ringer 's, solution, colloids, concentration, local anaesthetics, opioids, deliveries, use, epidural analgesia, local anaesthetics Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]	Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced .	[ "Until", "today", ",", "the", "use", "of", "epidural", "analgesia", "in", "obstetrics", "still", "remains", "controversial", ".", "In", "the", "opinion", "of", "many", "obstetricians", "the", "use", "of", "an", "epidural", "for", "a", "healthy", "laboring", "parturient", "is", "not", "necessary", "and", "can", "lead", "to", "potentially", "harmful", "side", "effects", ".", "However", ",", "painful", "labor", "leads", "to", "a", "maternal", "stress", "reaction", "with", "the", "release", "of", "epinephrine", "and", "norepinephrine", ".", "The", "resulting", "vasoconstriction", "of", "uterine", "arteries", "can", "induce", "fetal", "asphyxia", "in", "an", "otherwise", "healthy", "fetus", "or", "can", "aggravate", "asphyxia", "in", "already", "compromised", "fetusses", ".", "Several", "studies", "show", "that", "epidural", "analgesia", "can", "attenuate", "the", "maternal", "stress", "reaction", "and", "thereby", "improve", "maternal", "and", "fetal", "well", "-", "being", ",", "as", "long", "as", "precautions", "are", "taken", ".", "The", "avoidance", "of", "maternal", "hypotension", "with", "sufficient", "volume", "preload", "with", "lactated", "Ringer", "'s", "solution", "or", "colloids", ",", "and", "decreasing", "the", "concentration", "of", "local", "anaesthetics", "by", "adding", "opioids", "will", "prevent", "an", "increase", "in", "instrumental", "deliveries", ".", "With", "the", "use", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", "the", "amount", "of", "local", "anaesthetics", "can", "even", "further", "be", "reduced", "." ]	[ "umlsterm" ]
use, epidural analgesia, obstetrics, use, side effects, labor, stress, release, epinephrine, norepinephrine, vasoconstriction, arteries, fetal asphyxia, fetus, asphyxia, epidural analgesia, stress, hypotension, Ringer 's, solution, colloids, concentration, local anaesthetics, opioids, deliveries, use, epidural analgesia, local anaesthetics	DerAnaesthesist.7046s159.eng.abstr_task2	Sentence: Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]	Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced .	[ "Until", "today", ",", "the", "use", "of", "epidural", "analgesia", "in", "obstetrics", "still", "remains", "controversial", ".", "In", "the", "opinion", "of", "many", "obstetricians", "the", "use", "of", "an", "epidural", "for", "a", "healthy", "laboring", "parturient", "is", "not", "necessary", "and", "can", "lead", "to", "potentially", "harmful", "side", "effects", ".", "However", ",", "painful", "labor", "leads", "to", "a", "maternal", "stress", "reaction", "with", "the", "release", "of", "epinephrine", "and", "norepinephrine", ".", "The", "resulting", "vasoconstriction", "of", "uterine", "arteries", "can", "induce", "fetal", "asphyxia", "in", "an", "otherwise", "healthy", "fetus", "or", "can", "aggravate", "asphyxia", "in", "already", "compromised", "fetusses", ".", "Several", "studies", "show", "that", "epidural", "analgesia", "can", "attenuate", "the", "maternal", "stress", "reaction", "and", "thereby", "improve", "maternal", "and", "fetal", "well", "-", "being", ",", "as", "long", "as", "precautions", "are", "taken", ".", "The", "avoidance", "of", "maternal", "hypotension", "with", "sufficient", "volume", "preload", "with", "lactated", "Ringer", "'s", "solution", "or", "colloids", ",", "and", "decreasing", "the", "concentration", "of", "local", "anaesthetics", "by", "adding", "opioids", "will", "prevent", "an", "increase", "in", "instrumental", "deliveries", ".", "With", "the", "use", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", "the", "amount", "of", "local", "anaesthetics", "can", "even", "further", "be", "reduced", "." ]	[ "umlsterm" ]
subdural hematomas is an umlsterm, acceleration is an umlsterm, injuries is an umlsterm, traffic accidents is an umlsterm, vein is an umlsterm, ruptures is an umlsterm, causes is an umlsterm, Ruptures is an umlsterm, vessels is an umlsterm, literature is an umlsterm, institute is an umlsterm, systematic is an umlsterm, analysis is an umlsterm, veins is an umlsterm, blunt head injury is an umlsterm, morphological is an umlsterm, vessels is an umlsterm, imaging is an umlsterm, contrast is an umlsterm, car is an umlsterm, age is an umlsterm, head injury is an umlsterm, fractures is an umlsterm, injuries is an umlsterm, skull is an umlsterm, skull fracture is an umlsterm, focal brain injury is an umlsterm, signs is an umlsterm, diffuse brain injury is an umlsterm, direct is an umlsterm, head is an umlsterm, car is an umlsterm, ruptures is an umlsterm, veins is an umlsterm, survival is an umlsterm, minor is an umlsterm, ruptures is an umlsterm, thrombosis is an umlsterm, ruptures is an umlsterm, thrombosis is an umlsterm, knowledge is an umlsterm, vein is an umlsterm, ruptures is an umlsterm, frequency is an umlsterm, vein is an umlsterm, head injuries is an umlsterm, literature is an umlsterm, intracranial pressure is an umlsterm, accident is an umlsterm, cerebral circulation is an umlsterm	DerUnfallchirurg.01030552.eng.abstr_task0	Sentence: Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases .	[ "Experimental", "data", "and", "clinical", "as", "well", "as", "postmortem", "experiences", "have", "indicated", "that", "subdural", "hematomas", "are", "less", "frequent", "in", "acceleration", "injuries", "in", "traffic", "accidents", "compared", "to", "falls", "or", "assaults", ".", "The", "present", "report", "demonstrates", "that", "this", "does", "not", "hold", "true", "in", "the", "same", "way", "for", "bridging", "vein", "ruptures", "(", "one", "of", "the", "predominant", "causes", "for", "subdural", "bleedings", ")", ".", "Ruptures", "of", "these", "vessels", "without", "subdural", "bleeding", "(", "SDB", ")", "are", "only", "seldom", "mentioned", "in", "the", "literature", ".", "However", ",", "if", "no", "SDB", "is", "present", ",", "no", "one", "will", "look", "for", "these", "structures", ".", "In", "our", "institute", "a", "systematic", "analysis", "of", "the", "bridging", "veins", "in", "all", "cases", "of", "lethal", "blunt", "head", "injury", "is", "made", ":", "prior", "to", "the", "careful", "morphological", "preparation", "we", "investigate", "these", "vessels", "by", "radiographic", "imaging", "after", "filling", "with", "contrast", "medium", ".", "6", "car", "passengers", "(", "age", "between", "4", "and", "31", "years", ")", "which", "suffered", "a", "lethal", "head", "injury", "were", "examined", "in", "the", "last", "year", ".", "2", "victims", "had", "impressed", "fractures", "with", "cerebral", "compression", "injuries", ".", "In", "1", "case", "the", "base", "of", "the", "skull", "was", "broken", "and", "in", "3", "cases", "no", "skull", "fracture", "was", "present", ";", "no", "serious", "focal", "brain", "injury", "had", "occured", "in", "these", "4", "cases", ",", "but", "3", "victims", "had", "signs", "of", "diffuse", "brain", "injury", ".", "In", "5", "cases", "a", "direct", "impact", "of", "the", "head", "against", "the", "interior", "of", "the", "car", "was", "obvious", ".", "In", "5", "cases", "ruptures", "of", "serveral", "bridging", "veins", "could", "be", "demonstrated", ".", "In", "one", "case", "(", "survival", "for", "3", "days", ")", "a", "minor", "SDB", "(", "20", "ml", ")", "was", "present", "and", "the", "ruptures", "had", "been", "closed", "by", "thrombosis", ";", "another", "victim", "died", "at", "the", "scene", ".", "The", "other", "3", "victims", "survived", "between", "4", "and", "15", "hours", "without", "developing", "SDB", "and", "without", "closing", "of", "the", "ruptures", "by", "thrombosis", ".", "This", "combination", "is", "surprising", "and", "shows", "that", "our", "knowledge", "concerning", "the", "relationship", "between", "bridging", "vein", "ruptures", "and", "SDB", "is", "restrictred", ".", "The", "frequency", "of", "bridging", "vein", "lesions", "in", "severe", "head", "injuries", "is", "likely", "underestimated", "in", "the", "clinical", "as", "well", "as", "in", "the", "postmortem", "literature", ".", "A", "rapid", "increase", "of", "intracranial", "pressure", "after", "the", "accident", "resulting", "in", "a", "collapse", "of", "the", "cerebral", "circulation", "is", "probably", "responsible", "for", "the", "absence", "of", "the", "SDB", "in", "the", "presented", "cases", "." ]	[ "umlsterm" ]
subdural hematomas is an umlsterm, acceleration is an umlsterm, injuries is an umlsterm, traffic accidents is an umlsterm, vein is an umlsterm, ruptures is an umlsterm, causes is an umlsterm, Ruptures is an umlsterm, vessels is an umlsterm, literature is an umlsterm, institute is an umlsterm, systematic is an umlsterm, analysis is an umlsterm, veins is an umlsterm, blunt head injury is an umlsterm, morphological is an umlsterm, vessels is an umlsterm, imaging is an umlsterm, contrast is an umlsterm, car is an umlsterm, age is an umlsterm, head injury is an umlsterm, fractures is an umlsterm, injuries is an umlsterm, skull is an umlsterm, skull fracture is an umlsterm, focal brain injury is an umlsterm, signs is an umlsterm, diffuse brain injury is an umlsterm, direct is an umlsterm, head is an umlsterm, car is an umlsterm, ruptures is an umlsterm, veins is an umlsterm, survival is an umlsterm, minor is an umlsterm, ruptures is an umlsterm, thrombosis is an umlsterm, ruptures is an umlsterm, thrombosis is an umlsterm, knowledge is an umlsterm, vein is an umlsterm, ruptures is an umlsterm, frequency is an umlsterm, vein is an umlsterm, head injuries is an umlsterm, literature is an umlsterm, intracranial pressure is an umlsterm, accident is an umlsterm, cerebral circulation is an umlsterm	DerUnfallchirurg.01030552.eng.abstr_task1	Sentence: Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases . Instructions: please typing these entity words according to sentence: subdural hematomas, acceleration, injuries, traffic accidents, vein, ruptures, causes, Ruptures, vessels, literature, institute, systematic, analysis, veins, blunt head injury, morphological, vessels, imaging, contrast, car, age, head injury, fractures, injuries, skull, skull fracture, focal brain injury, signs, diffuse brain injury, direct, head, car, ruptures, veins, survival, minor, ruptures, thrombosis, ruptures, thrombosis, knowledge, vein, ruptures, frequency, vein, head injuries, literature, intracranial pressure, accident, cerebral circulation Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases .	[ "Experimental", "data", "and", "clinical", "as", "well", "as", "postmortem", "experiences", "have", "indicated", "that", "subdural", "hematomas", "are", "less", "frequent", "in", "acceleration", "injuries", "in", "traffic", "accidents", "compared", "to", "falls", "or", "assaults", ".", "The", "present", "report", "demonstrates", "that", "this", "does", "not", "hold", "true", "in", "the", "same", "way", "for", "bridging", "vein", "ruptures", "(", "one", "of", "the", "predominant", "causes", "for", "subdural", "bleedings", ")", ".", "Ruptures", "of", "these", "vessels", "without", "subdural", "bleeding", "(", "SDB", ")", "are", "only", "seldom", "mentioned", "in", "the", "literature", ".", "However", ",", "if", "no", "SDB", "is", "present", ",", "no", "one", "will", "look", "for", "these", "structures", ".", "In", "our", "institute", "a", "systematic", "analysis", "of", "the", "bridging", "veins", "in", "all", "cases", "of", "lethal", "blunt", "head", "injury", "is", "made", ":", "prior", "to", "the", "careful", "morphological", "preparation", "we", "investigate", "these", "vessels", "by", "radiographic", "imaging", "after", "filling", "with", "contrast", "medium", ".", "6", "car", "passengers", "(", "age", "between", "4", "and", "31", "years", ")", "which", "suffered", "a", "lethal", "head", "injury", "were", "examined", "in", "the", "last", "year", ".", "2", "victims", "had", "impressed", "fractures", "with", "cerebral", "compression", "injuries", ".", "In", "1", "case", "the", "base", "of", "the", "skull", "was", "broken", "and", "in", "3", "cases", "no", "skull", "fracture", "was", "present", ";", "no", "serious", "focal", "brain", "injury", "had", "occured", "in", "these", "4", "cases", ",", "but", "3", "victims", "had", "signs", "of", "diffuse", "brain", "injury", ".", "In", "5", "cases", "a", "direct", "impact", "of", "the", "head", "against", "the", "interior", "of", "the", "car", "was", "obvious", ".", "In", "5", "cases", "ruptures", "of", "serveral", "bridging", "veins", "could", "be", "demonstrated", ".", "In", "one", "case", "(", "survival", "for", "3", "days", ")", "a", "minor", "SDB", "(", "20", "ml", ")", "was", "present", "and", "the", "ruptures", "had", "been", "closed", "by", "thrombosis", ";", "another", "victim", "died", "at", "the", "scene", ".", "The", "other", "3", "victims", "survived", "between", "4", "and", "15", "hours", "without", "developing", "SDB", "and", "without", "closing", "of", "the", "ruptures", "by", "thrombosis", ".", "This", "combination", "is", "surprising", "and", "shows", "that", "our", "knowledge", "concerning", "the", "relationship", "between", "bridging", "vein", "ruptures", "and", "SDB", "is", "restrictred", ".", "The", "frequency", "of", "bridging", "vein", "lesions", "in", "severe", "head", "injuries", "is", "likely", "underestimated", "in", "the", "clinical", "as", "well", "as", "in", "the", "postmortem", "literature", ".", "A", "rapid", "increase", "of", "intracranial", "pressure", "after", "the", "accident", "resulting", "in", "a", "collapse", "of", "the", "cerebral", "circulation", "is", "probably", "responsible", "for", "the", "absence", "of", "the", "SDB", "in", "the", "presented", "cases", "." ]	[ "umlsterm" ]
subdural hematomas, acceleration, injuries, traffic accidents, vein, ruptures, causes, Ruptures, vessels, literature, institute, systematic, analysis, veins, blunt head injury, morphological, vessels, imaging, contrast, car, age, head injury, fractures, injuries, skull, skull fracture, focal brain injury, signs, diffuse brain injury, direct, head, car, ruptures, veins, survival, minor, ruptures, thrombosis, ruptures, thrombosis, knowledge, vein, ruptures, frequency, vein, head injuries, literature, intracranial pressure, accident, cerebral circulation	DerUnfallchirurg.01030552.eng.abstr_task2	Sentence: Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases .	[ "Experimental", "data", "and", "clinical", "as", "well", "as", "postmortem", "experiences", "have", "indicated", "that", "subdural", "hematomas", "are", "less", "frequent", "in", "acceleration", "injuries", "in", "traffic", "accidents", "compared", "to", "falls", "or", "assaults", ".", "The", "present", "report", "demonstrates", "that", "this", "does", "not", "hold", "true", "in", "the", "same", "way", "for", "bridging", "vein", "ruptures", "(", "one", "of", "the", "predominant", "causes", "for", "subdural", "bleedings", ")", ".", "Ruptures", "of", "these", "vessels", "without", "subdural", "bleeding", "(", "SDB", ")", "are", "only", "seldom", "mentioned", "in", "the", "literature", ".", "However", ",", "if", "no", "SDB", "is", "present", ",", "no", "one", "will", "look", "for", "these", "structures", ".", "In", "our", "institute", "a", "systematic", "analysis", "of", "the", "bridging", "veins", "in", "all", "cases", "of", "lethal", "blunt", "head", "injury", "is", "made", ":", "prior", "to", "the", "careful", "morphological", "preparation", "we", "investigate", "these", "vessels", "by", "radiographic", "imaging", "after", "filling", "with", "contrast", "medium", ".", "6", "car", "passengers", "(", "age", "between", "4", "and", "31", "years", ")", "which", "suffered", "a", "lethal", "head", "injury", "were", "examined", "in", "the", "last", "year", ".", "2", "victims", "had", "impressed", "fractures", "with", "cerebral", "compression", "injuries", ".", "In", "1", "case", "the", "base", "of", "the", "skull", "was", "broken", "and", "in", "3", "cases", "no", "skull", "fracture", "was", "present", ";", "no", "serious", "focal", "brain", "injury", "had", "occured", "in", "these", "4", "cases", ",", "but", "3", "victims", "had", "signs", "of", "diffuse", "brain", "injury", ".", "In", "5", "cases", "a", "direct", "impact", "of", "the", "head", "against", "the", "interior", "of", "the", "car", "was", "obvious", ".", "In", "5", "cases", "ruptures", "of", "serveral", "bridging", "veins", "could", "be", "demonstrated", ".", "In", "one", "case", "(", "survival", "for", "3", "days", ")", "a", "minor", "SDB", "(", "20", "ml", ")", "was", "present", "and", "the", "ruptures", "had", "been", "closed", "by", "thrombosis", ";", "another", "victim", "died", "at", "the", "scene", ".", "The", "other", "3", "victims", "survived", "between", "4", "and", "15", "hours", "without", "developing", "SDB", "and", "without", "closing", "of", "the", "ruptures", "by", "thrombosis", ".", "This", "combination", "is", "surprising", "and", "shows", "that", "our", "knowledge", "concerning", "the", "relationship", "between", "bridging", "vein", "ruptures", "and", "SDB", "is", "restrictred", ".", "The", "frequency", "of", "bridging", "vein", "lesions", "in", "severe", "head", "injuries", "is", "likely", "underestimated", "in", "the", "clinical", "as", "well", "as", "in", "the", "postmortem", "literature", ".", "A", "rapid", "increase", "of", "intracranial", "pressure", "after", "the", "accident", "resulting", "in", "a", "collapse", "of", "the", "cerebral", "circulation", "is", "probably", "responsible", "for", "the", "absence", "of", "the", "SDB", "in", "the", "presented", "cases", "." ]	[ "umlsterm" ]
Biobrane is a NO_NORMALIZABLES, clorhexidina is a NORMALIZABLES, Imipenem is a NORMALIZABLES, Cilastatina is a NORMALIZABLES	261_task0	Sentence: Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, NO_NORMALIZABLES	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio.	[ "Varón", "de", "75", "años", "de", "edad", "con", "antecedentes", "de", "hipertensión", "arterial", ",", "diabetes", "mellitus", "tipo", "2", ",", "accidente", "isquémico", "transitorio", ",", "hipotiroidismo", "autoinmune", "y", "deterioro", "cognitivo", "leve", ".", "Sufrió", "una", "quemadura", "por", "contacto", "con", "llama", "por", "inflamación", "de", "la", "ropa", "al", "avivar", "una", "llama", "con", "gasóleo", ",", "a", "consecuencia", "de", "la", "cual", "presentaba", "lesiones", "dérmicas", "profundas", "y", "subdérmicas", "en", "ambas", "extremidades", "inferiores", ",", "con", "una", "superficie", "corporal", "total", "quemada", "del", "20", "%", ".", "Las", "quemaduras", "eran", "dérmicas", "profundas", "en", "la", "superficie", "posterior", "de", "ambos", "muslos", "y", "circunferenciales", "en", "ambas", "piernas", ",", "con", "una", "placa", "de", "afectación", "subdérmica", "en", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ",", "así", "como", "quemaduras", "dérmicas", "superficiales", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "la", "cara", ".", "\n", "La", "reanimación", "en", "las", "primeras", "horas", "tras", "el", "accidente", "se", "realizó", "en", "un", "hospital", "de", "otra", "región", ",", "desde", "el", "que", "se", "derivó", "a", "la", "Unidad", "de", "Cuidados", "Intensivos", "de", "nuestro", "hospital", "para", "continuar", "con", "el", "tratamiento", "de", "las", "lesiones", ".", "\n", "El", "día", "del", "ingreso", "hospitalario", "realizamos", "escarotomías", "de", "urgencia", "en", "ambas", "piernas", "y", "completamos", "la", "reanimación", "inicial", ".", "Durante", "las", "primeras", "3", "semanas", "de", "ingreso", "realizamos", "4", "sesiones", "de", "desbridamiento", "seriado", "de", "las", "zonas", "quemadas", "y", "cobertura", "con", "autoinjerto", "de", "piel", "parcial", "mallado", "de", "la", "superficie", "anterior", "de", "los", "muslos", "en", "los", "defectos", "provocados", "por", "la", "exéresis", "de", "las", "quemaduras", "más", "profundas", ",", "piernas", "y", "muslos", "posteriores", ",", "y", "con", "sustitutivos", "dérmicos", "(", "Biobrane", "®", ")", "en", "las", "zonas", "desbridadas", "de", "quemaduras", "superficiales", ",", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "áreas", "parcheadas", "de", "las", "piernas", "A", "la", "semana", "de", "postoperatorio", "objetivamos", "la", "pérdida", "del", "injerto", "de", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ".", "\n\n", "En", "una", "nueva", "sesión", "quirúrgica", "realizamos", "desbridamiento", "de", "la", "zona", "pretibial", "izquierda", ",", "con", "persistencia", "bajo", "el", "injerto", "de", "quemadura", "que", "no", "había", "sido", "eliminada", "durante", "las", "cirugías", "previas", ".", "Tras", "la", "adecuada", "eliminación", "de", "esta", "escara", "objetivamos", "un", "defecto", "pretibial", "de", "20", "cm", "de", "longitud", ",", "con", "exposición", "de", "la", "tibia", ".", "Realizamos", "escoplado", "de", "la", "totalidad", "del", "periostio", "expuesto", "e", "inicio", "de", "terapia", "de", "vacío", "sobre", "el", "defecto", "resultante", ".", "Aplicamos", "la", "terapia", "de", "vacío", "mediante", "dispositivo", "VAC", "®", "(", "KCI", "Clinic", "Spain", "SL", ")", ",", "en", "modo", "continuo", ",", "a", "125", "mmHg", ".", "Las", "curas", "se", "realizaron", "cada", "72", "horas", "con", "jabón", "de", "clorhexidina", ".", "No", "fueron", "necesarios", "nuevos", "procesos", "de", "desbridamiento", "en", "quirófano", ".", "Tras", "45", "días", "de", "terapia", "de", "vacío", "comprobamos", "la", "cobertura", "completa", "del", "hueso", "por", "tejido", "de", "granulación", "y", "realizamos", "tratamiento", "definitivo", "con", "autoinjertos", "de", "piel", "parcial", "tomados", "de", "los", "glúteos", ",", "tras", "lo", "cual", "conseguimos", "el", "cierre", "completo", "de", "las", "heridas", ".", "\n\n", "Durante", "el", "periodo", "de", "aplicación", "de", "la", "terapia", "los", "cultivos", "microbiológicos", "del", "tejido", "de", "granulación", "subyacente", "fueron", "positivos", "para", "Pseudomonas", "aeruginosa", "multirresistente", ",", "que", "previamente", "el", "paciente", "había", "presentado", "también", "en", "orina", ".", "Instauramos", "tratamiento", "sistémico", "con", "Imipenem", "y", "Cilastatina", ",", "y", "practicamos", "desbridamiento", "parcial", "del", "tejido", "de", "granulación", "más", "superficial", "e", "hipertrófico", "durante", "los", "cambios", "de", "cura", "en", "la", "habitación", ".", "Una", "vez", "completada", "la", "terapia", "de", "vacío", "e", "injertado", "el", "defecto", ",", "el", "paciente", "no", "volvió", "a", "presentar", "signos", "de", "infección", "de", "los", "injertos", ".", "A", "los", "100", "días", "de", "ingreso", "fue", "dado", "de", "alta", "hospitalaria", ",", "con", "dificultad", "para", "la", "deambulación", "y", "con", "tratamiento", "rehabilitador", "en", "régimen", "ambulatorio", ".", "\n" ]	[ "NORMALIZABLES", "NO_NORMALIZABLES" ]
Biobrane is a NO_NORMALIZABLES, clorhexidina is a NORMALIZABLES, Imipenem is a NORMALIZABLES, Cilastatina is a NORMALIZABLES	261_task1	Sentence: Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio. Instructions: please typing these entity words according to sentence: Biobrane, clorhexidina, Imipenem, Cilastatina Options: NORMALIZABLES, NO_NORMALIZABLES	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio.	[ "Varón", "de", "75", "años", "de", "edad", "con", "antecedentes", "de", "hipertensión", "arterial", ",", "diabetes", "mellitus", "tipo", "2", ",", "accidente", "isquémico", "transitorio", ",", "hipotiroidismo", "autoinmune", "y", "deterioro", "cognitivo", "leve", ".", "Sufrió", "una", "quemadura", "por", "contacto", "con", "llama", "por", "inflamación", "de", "la", "ropa", "al", "avivar", "una", "llama", "con", "gasóleo", ",", "a", "consecuencia", "de", "la", "cual", "presentaba", "lesiones", "dérmicas", "profundas", "y", "subdérmicas", "en", "ambas", "extremidades", "inferiores", ",", "con", "una", "superficie", "corporal", "total", "quemada", "del", "20", "%", ".", "Las", "quemaduras", "eran", "dérmicas", "profundas", "en", "la", "superficie", "posterior", "de", "ambos", "muslos", "y", "circunferenciales", "en", "ambas", "piernas", ",", "con", "una", "placa", "de", "afectación", "subdérmica", "en", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ",", "así", "como", "quemaduras", "dérmicas", "superficiales", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "la", "cara", ".", "\n", "La", "reanimación", "en", "las", "primeras", "horas", "tras", "el", "accidente", "se", "realizó", "en", "un", "hospital", "de", "otra", "región", ",", "desde", "el", "que", "se", "derivó", "a", "la", "Unidad", "de", "Cuidados", "Intensivos", "de", "nuestro", "hospital", "para", "continuar", "con", "el", "tratamiento", "de", "las", "lesiones", ".", "\n", "El", "día", "del", "ingreso", "hospitalario", "realizamos", "escarotomías", "de", "urgencia", "en", "ambas", "piernas", "y", "completamos", "la", "reanimación", "inicial", ".", "Durante", "las", "primeras", "3", "semanas", "de", "ingreso", "realizamos", "4", "sesiones", "de", "desbridamiento", "seriado", "de", "las", "zonas", "quemadas", "y", "cobertura", "con", "autoinjerto", "de", "piel", "parcial", "mallado", "de", "la", "superficie", "anterior", "de", "los", "muslos", "en", "los", "defectos", "provocados", "por", "la", "exéresis", "de", "las", "quemaduras", "más", "profundas", ",", "piernas", "y", "muslos", "posteriores", ",", "y", "con", "sustitutivos", "dérmicos", "(", "Biobrane", "®", ")", "en", "las", "zonas", "desbridadas", "de", "quemaduras", "superficiales", ",", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "áreas", "parcheadas", "de", "las", "piernas", "A", "la", "semana", "de", "postoperatorio", "objetivamos", "la", "pérdida", "del", "injerto", "de", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ".", "\n\n", "En", "una", "nueva", "sesión", "quirúrgica", "realizamos", "desbridamiento", "de", "la", "zona", "pretibial", "izquierda", ",", "con", "persistencia", "bajo", "el", "injerto", "de", "quemadura", "que", "no", "había", "sido", "eliminada", "durante", "las", "cirugías", "previas", ".", "Tras", "la", "adecuada", "eliminación", "de", "esta", "escara", "objetivamos", "un", "defecto", "pretibial", "de", "20", "cm", "de", "longitud", ",", "con", "exposición", "de", "la", "tibia", ".", "Realizamos", "escoplado", "de", "la", "totalidad", "del", "periostio", "expuesto", "e", "inicio", "de", "terapia", "de", "vacío", "sobre", "el", "defecto", "resultante", ".", "Aplicamos", "la", "terapia", "de", "vacío", "mediante", "dispositivo", "VAC", "®", "(", "KCI", "Clinic", "Spain", "SL", ")", ",", "en", "modo", "continuo", ",", "a", "125", "mmHg", ".", "Las", "curas", "se", "realizaron", "cada", "72", "horas", "con", "jabón", "de", "clorhexidina", ".", "No", "fueron", "necesarios", "nuevos", "procesos", "de", "desbridamiento", "en", "quirófano", ".", "Tras", "45", "días", "de", "terapia", "de", "vacío", "comprobamos", "la", "cobertura", "completa", "del", "hueso", "por", "tejido", "de", "granulación", "y", "realizamos", "tratamiento", "definitivo", "con", "autoinjertos", "de", "piel", "parcial", "tomados", "de", "los", "glúteos", ",", "tras", "lo", "cual", "conseguimos", "el", "cierre", "completo", "de", "las", "heridas", ".", "\n\n", "Durante", "el", "periodo", "de", "aplicación", "de", "la", "terapia", "los", "cultivos", "microbiológicos", "del", "tejido", "de", "granulación", "subyacente", "fueron", "positivos", "para", "Pseudomonas", "aeruginosa", "multirresistente", ",", "que", "previamente", "el", "paciente", "había", "presentado", "también", "en", "orina", ".", "Instauramos", "tratamiento", "sistémico", "con", "Imipenem", "y", "Cilastatina", ",", "y", "practicamos", "desbridamiento", "parcial", "del", "tejido", "de", "granulación", "más", "superficial", "e", "hipertrófico", "durante", "los", "cambios", "de", "cura", "en", "la", "habitación", ".", "Una", "vez", "completada", "la", "terapia", "de", "vacío", "e", "injertado", "el", "defecto", ",", "el", "paciente", "no", "volvió", "a", "presentar", "signos", "de", "infección", "de", "los", "injertos", ".", "A", "los", "100", "días", "de", "ingreso", "fue", "dado", "de", "alta", "hospitalaria", ",", "con", "dificultad", "para", "la", "deambulación", "y", "con", "tratamiento", "rehabilitador", "en", "régimen", "ambulatorio", ".", "\n" ]	[ "NORMALIZABLES", "NO_NORMALIZABLES" ]
Biobrane, clorhexidina, Imipenem, Cilastatina	261_task2	Sentence: Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio.	[ "Varón", "de", "75", "años", "de", "edad", "con", "antecedentes", "de", "hipertensión", "arterial", ",", "diabetes", "mellitus", "tipo", "2", ",", "accidente", "isquémico", "transitorio", ",", "hipotiroidismo", "autoinmune", "y", "deterioro", "cognitivo", "leve", ".", "Sufrió", "una", "quemadura", "por", "contacto", "con", "llama", "por", "inflamación", "de", "la", "ropa", "al", "avivar", "una", "llama", "con", "gasóleo", ",", "a", "consecuencia", "de", "la", "cual", "presentaba", "lesiones", "dérmicas", "profundas", "y", "subdérmicas", "en", "ambas", "extremidades", "inferiores", ",", "con", "una", "superficie", "corporal", "total", "quemada", "del", "20", "%", ".", "Las", "quemaduras", "eran", "dérmicas", "profundas", "en", "la", "superficie", "posterior", "de", "ambos", "muslos", "y", "circunferenciales", "en", "ambas", "piernas", ",", "con", "una", "placa", "de", "afectación", "subdérmica", "en", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ",", "así", "como", "quemaduras", "dérmicas", "superficiales", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "la", "cara", ".", "\n", "La", "reanimación", "en", "las", "primeras", "horas", "tras", "el", "accidente", "se", "realizó", "en", "un", "hospital", "de", "otra", "región", ",", "desde", "el", "que", "se", "derivó", "a", "la", "Unidad", "de", "Cuidados", "Intensivos", "de", "nuestro", "hospital", "para", "continuar", "con", "el", "tratamiento", "de", "las", "lesiones", ".", "\n", "El", "día", "del", "ingreso", "hospitalario", "realizamos", "escarotomías", "de", "urgencia", "en", "ambas", "piernas", "y", "completamos", "la", "reanimación", "inicial", ".", "Durante", "las", "primeras", "3", "semanas", "de", "ingreso", "realizamos", "4", "sesiones", "de", "desbridamiento", "seriado", "de", "las", "zonas", "quemadas", "y", "cobertura", "con", "autoinjerto", "de", "piel", "parcial", "mallado", "de", "la", "superficie", "anterior", "de", "los", "muslos", "en", "los", "defectos", "provocados", "por", "la", "exéresis", "de", "las", "quemaduras", "más", "profundas", ",", "piernas", "y", "muslos", "posteriores", ",", "y", "con", "sustitutivos", "dérmicos", "(", "Biobrane", "®", ")", "en", "las", "zonas", "desbridadas", "de", "quemaduras", "superficiales", ",", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "áreas", "parcheadas", "de", "las", "piernas", "A", "la", "semana", "de", "postoperatorio", "objetivamos", "la", "pérdida", "del", "injerto", "de", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ".", "\n\n", "En", "una", "nueva", "sesión", "quirúrgica", "realizamos", "desbridamiento", "de", "la", "zona", "pretibial", "izquierda", ",", "con", "persistencia", "bajo", "el", "injerto", "de", "quemadura", "que", "no", "había", "sido", "eliminada", "durante", "las", "cirugías", "previas", ".", "Tras", "la", "adecuada", "eliminación", "de", "esta", "escara", "objetivamos", "un", "defecto", "pretibial", "de", "20", "cm", "de", "longitud", ",", "con", "exposición", "de", "la", "tibia", ".", "Realizamos", "escoplado", "de", "la", "totalidad", "del", "periostio", "expuesto", "e", "inicio", "de", "terapia", "de", "vacío", "sobre", "el", "defecto", "resultante", ".", "Aplicamos", "la", "terapia", "de", "vacío", "mediante", "dispositivo", "VAC", "®", "(", "KCI", "Clinic", "Spain", "SL", ")", ",", "en", "modo", "continuo", ",", "a", "125", "mmHg", ".", "Las", "curas", "se", "realizaron", "cada", "72", "horas", "con", "jabón", "de", "clorhexidina", ".", "No", "fueron", "necesarios", "nuevos", "procesos", "de", "desbridamiento", "en", "quirófano", ".", "Tras", "45", "días", "de", "terapia", "de", "vacío", "comprobamos", "la", "cobertura", "completa", "del", "hueso", "por", "tejido", "de", "granulación", "y", "realizamos", "tratamiento", "definitivo", "con", "autoinjertos", "de", "piel", "parcial", "tomados", "de", "los", "glúteos", ",", "tras", "lo", "cual", "conseguimos", "el", "cierre", "completo", "de", "las", "heridas", ".", "\n\n", "Durante", "el", "periodo", "de", "aplicación", "de", "la", "terapia", "los", "cultivos", "microbiológicos", "del", "tejido", "de", "granulación", "subyacente", "fueron", "positivos", "para", "Pseudomonas", "aeruginosa", "multirresistente", ",", "que", "previamente", "el", "paciente", "había", "presentado", "también", "en", "orina", ".", "Instauramos", "tratamiento", "sistémico", "con", "Imipenem", "y", "Cilastatina", ",", "y", "practicamos", "desbridamiento", "parcial", "del", "tejido", "de", "granulación", "más", "superficial", "e", "hipertrófico", "durante", "los", "cambios", "de", "cura", "en", "la", "habitación", ".", "Una", "vez", "completada", "la", "terapia", "de", "vacío", "e", "injertado", "el", "defecto", ",", "el", "paciente", "no", "volvió", "a", "presentar", "signos", "de", "infección", "de", "los", "injertos", ".", "A", "los", "100", "días", "de", "ingreso", "fue", "dado", "de", "alta", "hospitalaria", ",", "con", "dificultad", "para", "la", "deambulación", "y", "con", "tratamiento", "rehabilitador", "en", "régimen", "ambulatorio", ".", "\n" ]	[ "NORMALIZABLES", "NO_NORMALIZABLES" ]
Pediatric is a Person, under 18 years is a Value, Pregnancy is a Condition, unresponsive is a Observation, at baseline is a Temporal, neurologic deficits is a Condition, at baseline is a Temporal, allergic is a Condition, dexmedetomidine is a Drug	NCT02245256_exc_task0	Sentence: Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Value, Person, Observation, Drug	[ "B-Person", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "B-Observation", "B-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "O", "B-Drug", "O" ]	Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine	[ "Pediatric", "patients", "(", "under", "18", "years", ")", "Pregnancy", "Patients", "who", "are", "unresponsive", "at", "baseline", ",", "who", "have", "neurologic", "deficits", "at", "baseline", ",", "or", "who", "are", "allergic", "to", "dexmedetomidine", "\n" ]	[ "Condition", "Drug", "Value", "Scope", "Observation", "Temporal", "Person" ]
Pediatric is a Person, under 18 years is a Value, Pregnancy is a Condition, unresponsive is a Observation, at baseline is a Temporal, neurologic deficits is a Condition, at baseline is a Temporal, allergic is a Condition, dexmedetomidine is a Drug	NCT02245256_exc_task1	Sentence: Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine Instructions: please typing these entity words according to sentence: Pediatric, under 18 years, Pregnancy, unresponsive, at baseline, neurologic deficits, at baseline, allergic, dexmedetomidine Options: Temporal, Condition, Value, Person, Observation, Drug	[ "B-Person", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "B-Observation", "B-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "O", "B-Drug", "O" ]	Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine	[ "Pediatric", "patients", "(", "under", "18", "years", ")", "Pregnancy", "Patients", "who", "are", "unresponsive", "at", "baseline", ",", "who", "have", "neurologic", "deficits", "at", "baseline", ",", "or", "who", "are", "allergic", "to", "dexmedetomidine", "\n" ]	[ "Condition", "Drug", "Value", "Scope", "Observation", "Temporal", "Person" ]
Pediatric, under 18 years, Pregnancy, unresponsive, at baseline, neurologic deficits, at baseline, allergic, dexmedetomidine	NCT02245256_exc_task2	Sentence: Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine Instructions: please extract entity words from the input sentence	[ "B-Person", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "B-Observation", "B-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "O", "B-Drug", "O" ]	Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine	[ "Pediatric", "patients", "(", "under", "18", "years", ")", "Pregnancy", "Patients", "who", "are", "unresponsive", "at", "baseline", ",", "who", "have", "neurologic", "deficits", "at", "baseline", ",", "or", "who", "are", "allergic", "to", "dexmedetomidine", "\n" ]	[ "Condition", "Drug", "Value", "Scope", "Observation", "Temporal", "Person" ]
cellular is a Cell, CRP is a Gene_or_gene_product, breast cancer is a Cancer, patients is a Organism, endocrine is a Anatomical_system, patients is a Organism, endocrine is a Anatomical_system, breast cancer is a Cancer, breast cancer is a Cancer, patients is a Organism, endocrine is a Anatomical_system, beta - interferon is a Gene_or_gene_product, interleukin-2 is a Gene_or_gene_product, cellular is a Cell, CRP is a Gene_or_gene_product, Interleukin-2 is a Gene_or_gene_product, lymphocytes is a Cell, CD4 + , CD8 + , CD16 + 56 + ( NK ) cells is a Cell, IL-6 is a Gene_or_gene_product, IL-12 is a Gene_or_gene_product, CRP is a Gene_or_gene_product, IL-10 is a Gene_or_gene_product, TGFbeta1 is a Gene_or_gene_product, IL-10 is a Gene_or_gene_product, TGFbeta1 is a Gene_or_gene_product, cellular is a Cell, IL-2 is a Gene_or_gene_product, CRP is a Gene_or_gene_product	137_task0	Sentence: Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Anatomical_system, Organism, Cancer, Gene_or_gene_product, Cell	[ "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Anatomical_system", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively.	[ "Relationship", "of", "cellular", "immunity", ",", "cytokines", "and", "CRP", "with", "clinical", "course", "in", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "immunotherapy", ".", "\n", "We", "have", "reported", "important", "benefits", "and", "survival", "with", "an", "immunotherapy", "schedule", "in", "patients", "with", "endocrine", "-", "dependent", "breast", "cancer", "and", "distant", "metastases", ".", "Here", "clinical", "outcome", "is", "updated", "and", "its", "correlation", "with", "new", "immunological", "data", "is", "shown", ".", "In", "32", "evaluated", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "a", "new", "immunotherapy", "schedule", "(", "cyclic", "administration", "of", "beta", "-", "interferon", "and", "interleukin-2", ")", ",", "cellular", "immunity", ",", "cytokines", "and", "CRP", "were", "related", "to", "the", "clinical", "course", ".", "Estimated", "and", "true", "5", "-", "10", "year", "overall", "survival", "rates", "from", "first", "line", "antiestrogen", "and", "distant", "metastases", "were", "higher", "than", "previously", "reported", "in", "a", "similar", "population", ".", "Interleukin-2", "administration", "was", "followed", "by", "a", "significant", "increase", "in", "total", "lymphocytes", ",", "CD4", "+", ",", "CD8", "+", ",", "CD16", "+", "56", "+", "(", "NK", ")", "cells", ",", "IL-6", ",", "IL-12", ",", "and", "CRP", "(", "from", "P<0.04", "to", "P<0.000", ")", "but", "no", "change", "in", "IL-10", "and", "TGFbeta1", "during", "clinical", "benefit", ".", "During", "progressive", "disease", "no", "change", "was", "observed", "in", "the", "former", "parameters", ",", "concomitant", "with", "a", "significant", "increase", "in", "IL-10", "(", "P=0.020", ")", "and", "a", "significant", "decrease", "in", "TGFbeta1", "(", "P=0.023", ")", ".", "These", "findings", "confirm", "that", "cellular", "immunity", "is", "significantly", "stimulated", "by", "IL-2", "only", "during", "clinical", "benefit", ".", "Furthermore", ",", "these", "results", "demonstrate", "that", "different", "changes", "of", "proinflammatory", "cytokines", ",", "CRP", "and", "inhibiting", "factors", "are", "consistent", "with", "associated", "clinical", "benefit", "or", "with", "disease", "progression", ",", "respectively", ".", "\n" ]	[ "Cell", "Gene_or_gene_product", "Cancer", "Anatomical_system", "Organism" ]
cellular is a Cell, CRP is a Gene_or_gene_product, breast cancer is a Cancer, patients is a Organism, endocrine is a Anatomical_system, patients is a Organism, endocrine is a Anatomical_system, breast cancer is a Cancer, breast cancer is a Cancer, patients is a Organism, endocrine is a Anatomical_system, beta - interferon is a Gene_or_gene_product, interleukin-2 is a Gene_or_gene_product, cellular is a Cell, CRP is a Gene_or_gene_product, Interleukin-2 is a Gene_or_gene_product, lymphocytes is a Cell, CD4 + , CD8 + , CD16 + 56 + ( NK ) cells is a Cell, IL-6 is a Gene_or_gene_product, IL-12 is a Gene_or_gene_product, CRP is a Gene_or_gene_product, IL-10 is a Gene_or_gene_product, TGFbeta1 is a Gene_or_gene_product, IL-10 is a Gene_or_gene_product, TGFbeta1 is a Gene_or_gene_product, cellular is a Cell, IL-2 is a Gene_or_gene_product, CRP is a Gene_or_gene_product	137_task1	Sentence: Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively. Instructions: please typing these entity words according to sentence: cellular, CRP, breast cancer, patients, endocrine, patients, endocrine, breast cancer, breast cancer, patients, endocrine, beta - interferon, interleukin-2, cellular, CRP, Interleukin-2, lymphocytes, CD4 + , CD8 + , CD16 + 56 + ( NK ) cells, IL-6, IL-12, CRP, IL-10, TGFbeta1, IL-10, TGFbeta1, cellular, IL-2, CRP Options: Anatomical_system, Organism, Cancer, Gene_or_gene_product, Cell	[ "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Anatomical_system", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively.	[ "Relationship", "of", "cellular", "immunity", ",", "cytokines", "and", "CRP", "with", "clinical", "course", "in", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "immunotherapy", ".", "\n", "We", "have", "reported", "important", "benefits", "and", "survival", "with", "an", "immunotherapy", "schedule", "in", "patients", "with", "endocrine", "-", "dependent", "breast", "cancer", "and", "distant", "metastases", ".", "Here", "clinical", "outcome", "is", "updated", "and", "its", "correlation", "with", "new", "immunological", "data", "is", "shown", ".", "In", "32", "evaluated", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "a", "new", "immunotherapy", "schedule", "(", "cyclic", "administration", "of", "beta", "-", "interferon", "and", "interleukin-2", ")", ",", "cellular", "immunity", ",", "cytokines", "and", "CRP", "were", "related", "to", "the", "clinical", "course", ".", "Estimated", "and", "true", "5", "-", "10", "year", "overall", "survival", "rates", "from", "first", "line", "antiestrogen", "and", "distant", "metastases", "were", "higher", "than", "previously", "reported", "in", "a", "similar", "population", ".", "Interleukin-2", "administration", "was", "followed", "by", "a", "significant", "increase", "in", "total", "lymphocytes", ",", "CD4", "+", ",", "CD8", "+", ",", "CD16", "+", "56", "+", "(", "NK", ")", "cells", ",", "IL-6", ",", "IL-12", ",", "and", "CRP", "(", "from", "P<0.04", "to", "P<0.000", ")", "but", "no", "change", "in", "IL-10", "and", "TGFbeta1", "during", "clinical", "benefit", ".", "During", "progressive", "disease", "no", "change", "was", "observed", "in", "the", "former", "parameters", ",", "concomitant", "with", "a", "significant", "increase", "in", "IL-10", "(", "P=0.020", ")", "and", "a", "significant", "decrease", "in", "TGFbeta1", "(", "P=0.023", ")", ".", "These", "findings", "confirm", "that", "cellular", "immunity", "is", "significantly", "stimulated", "by", "IL-2", "only", "during", "clinical", "benefit", ".", "Furthermore", ",", "these", "results", "demonstrate", "that", "different", "changes", "of", "proinflammatory", "cytokines", ",", "CRP", "and", "inhibiting", "factors", "are", "consistent", "with", "associated", "clinical", "benefit", "or", "with", "disease", "progression", ",", "respectively", ".", "\n" ]	[ "Cell", "Gene_or_gene_product", "Cancer", "Anatomical_system", "Organism" ]
cellular, CRP, breast cancer, patients, endocrine, patients, endocrine, breast cancer, breast cancer, patients, endocrine, beta - interferon, interleukin-2, cellular, CRP, Interleukin-2, lymphocytes, CD4 + , CD8 + , CD16 + 56 + ( NK ) cells, IL-6, IL-12, CRP, IL-10, TGFbeta1, IL-10, TGFbeta1, cellular, IL-2, CRP	137_task2	Sentence: Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Anatomical_system", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively.	[ "Relationship", "of", "cellular", "immunity", ",", "cytokines", "and", "CRP", "with", "clinical", "course", "in", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "immunotherapy", ".", "\n", "We", "have", "reported", "important", "benefits", "and", "survival", "with", "an", "immunotherapy", "schedule", "in", "patients", "with", "endocrine", "-", "dependent", "breast", "cancer", "and", "distant", "metastases", ".", "Here", "clinical", "outcome", "is", "updated", "and", "its", "correlation", "with", "new", "immunological", "data", "is", "shown", ".", "In", "32", "evaluated", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "a", "new", "immunotherapy", "schedule", "(", "cyclic", "administration", "of", "beta", "-", "interferon", "and", "interleukin-2", ")", ",", "cellular", "immunity", ",", "cytokines", "and", "CRP", "were", "related", "to", "the", "clinical", "course", ".", "Estimated", "and", "true", "5", "-", "10", "year", "overall", "survival", "rates", "from", "first", "line", "antiestrogen", "and", "distant", "metastases", "were", "higher", "than", "previously", "reported", "in", "a", "similar", "population", ".", "Interleukin-2", "administration", "was", "followed", "by", "a", "significant", "increase", "in", "total", "lymphocytes", ",", "CD4", "+", ",", "CD8", "+", ",", "CD16", "+", "56", "+", "(", "NK", ")", "cells", ",", "IL-6", ",", "IL-12", ",", "and", "CRP", "(", "from", "P<0.04", "to", "P<0.000", ")", "but", "no", "change", "in", "IL-10", "and", "TGFbeta1", "during", "clinical", "benefit", ".", "During", "progressive", "disease", "no", "change", "was", "observed", "in", "the", "former", "parameters", ",", "concomitant", "with", "a", "significant", "increase", "in", "IL-10", "(", "P=0.020", ")", "and", "a", "significant", "decrease", "in", "TGFbeta1", "(", "P=0.023", ")", ".", "These", "findings", "confirm", "that", "cellular", "immunity", "is", "significantly", "stimulated", "by", "IL-2", "only", "during", "clinical", "benefit", ".", "Furthermore", ",", "these", "results", "demonstrate", "that", "different", "changes", "of", "proinflammatory", "cytokines", ",", "CRP", "and", "inhibiting", "factors", "are", "consistent", "with", "associated", "clinical", "benefit", "or", "with", "disease", "progression", ",", "respectively", ".", "\n" ]	[ "Cell", "Gene_or_gene_product", "Cancer", "Anatomical_system", "Organism" ]
TNF - alpha is a Protein, TNF - alpha is a Protein, IkappaB alpha is a Protein, TNF - alpha is a Protein, IkappaB alpha is a Protein	842_task0	Sentence: Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly.	[ "Nuclear", "factor", "-", "kappaB", "induction", "in", "CD45RO+", "and", "CD45RA+", "T", "cell", "subsets", "during", "aging", ".", "\n", "An", "increase", "in", "the", "ratio", "of", "memory", "to", "naive", "T", "cells", "has", "been", "postulated", "to", "underlie", "immune", "hyporesponsiveness", "accompanying", "aging", ".", "Our", "analyses", "of", "the", "induction", "of", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "in", "activated", "memory", "(", "CD45RO+", ")", "and", "naive", "(", "CD45RA+", ")", "T", "cell", "subsets", "from", "young", "and", "elderly", "donors", "has", "demonstrated", "that", ",", "regardless", "of", "donor", "age", ",", "memory", "T", "cells", "are", "not", "significantly", "altered", "in", "their", "responsiveness", "to", "TNF", "-", "alpha", "-", "mediated", "induction", "of", "NFkappaB.", "Although", "treatment", "with", "TNF", "-", "alpha", "induced", "nuclear", "localization", "of", "NFkappaB", "in", "both", "memory", "and", "naive", "T", "cell", "subsets", ",", "irrespective", "of", "the", "age", "of", "the", "donor", ",", "the", "levels", "of", "induced", "NFkappaB", "were", "significantly", "lower", "in", "both", "subsets", "of", "T", "cells", "obtained", "from", "the", "elderly", ",", "when", "compared", "to", "those", "in", "young", ".", "Examination", "of", "IkappaB", "alpha", "regulation", "revealed", "that", "TNF", "-", "alpha", "-", "mediated", "degradation", "of", "IkappaB", "alpha", "in", "both", "memory", "and", "naive", "T", "cells", "from", "the", "elderly", "was", "severely", "impaired", ",", "thus", "contributing", "to", "the", "lowered", "induction", "of", "the", "observed", "NFkappaB.", "In", "addition", ",", "this", "age", "-", "related", "decrease", "in", "induction", "of", "nuclear", "NFkappaB", "correlated", "with", "decrease", "in", "intracellular", "IL-2", "receptor", "expression", "and", "anti", "-", "CD3-induced", "proliferation", "of", "both", "memory", "and", "naive", "T", "cells", "subsets", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "the", "age", "-", "related", "hyporesponsiveness", "cannot", "be", "attributed", "to", "a", "skewing", "of", "the", "T", "cell", "population", "towards", "a", "memory", "phenotype", "in", "the", "elderly", "." ]	[ "Protein" ]
TNF - alpha is a Protein, TNF - alpha is a Protein, IkappaB alpha is a Protein, TNF - alpha is a Protein, IkappaB alpha is a Protein	842_task1	Sentence: Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly. Instructions: please typing these entity words according to sentence: TNF - alpha, TNF - alpha, IkappaB alpha, TNF - alpha, IkappaB alpha Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly.	[ "Nuclear", "factor", "-", "kappaB", "induction", "in", "CD45RO+", "and", "CD45RA+", "T", "cell", "subsets", "during", "aging", ".", "\n", "An", "increase", "in", "the", "ratio", "of", "memory", "to", "naive", "T", "cells", "has", "been", "postulated", "to", "underlie", "immune", "hyporesponsiveness", "accompanying", "aging", ".", "Our", "analyses", "of", "the", "induction", "of", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "in", "activated", "memory", "(", "CD45RO+", ")", "and", "naive", "(", "CD45RA+", ")", "T", "cell", "subsets", "from", "young", "and", "elderly", "donors", "has", "demonstrated", "that", ",", "regardless", "of", "donor", "age", ",", "memory", "T", "cells", "are", "not", "significantly", "altered", "in", "their", "responsiveness", "to", "TNF", "-", "alpha", "-", "mediated", "induction", "of", "NFkappaB.", "Although", "treatment", "with", "TNF", "-", "alpha", "induced", "nuclear", "localization", "of", "NFkappaB", "in", "both", "memory", "and", "naive", "T", "cell", "subsets", ",", "irrespective", "of", "the", "age", "of", "the", "donor", ",", "the", "levels", "of", "induced", "NFkappaB", "were", "significantly", "lower", "in", "both", "subsets", "of", "T", "cells", "obtained", "from", "the", "elderly", ",", "when", "compared", "to", "those", "in", "young", ".", "Examination", "of", "IkappaB", "alpha", "regulation", "revealed", "that", "TNF", "-", "alpha", "-", "mediated", "degradation", "of", "IkappaB", "alpha", "in", "both", "memory", "and", "naive", "T", "cells", "from", "the", "elderly", "was", "severely", "impaired", ",", "thus", "contributing", "to", "the", "lowered", "induction", "of", "the", "observed", "NFkappaB.", "In", "addition", ",", "this", "age", "-", "related", "decrease", "in", "induction", "of", "nuclear", "NFkappaB", "correlated", "with", "decrease", "in", "intracellular", "IL-2", "receptor", "expression", "and", "anti", "-", "CD3-induced", "proliferation", "of", "both", "memory", "and", "naive", "T", "cells", "subsets", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "the", "age", "-", "related", "hyporesponsiveness", "cannot", "be", "attributed", "to", "a", "skewing", "of", "the", "T", "cell", "population", "towards", "a", "memory", "phenotype", "in", "the", "elderly", "." ]	[ "Protein" ]
TNF - alpha, TNF - alpha, IkappaB alpha, TNF - alpha, IkappaB alpha	842_task2	Sentence: Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly.	[ "Nuclear", "factor", "-", "kappaB", "induction", "in", "CD45RO+", "and", "CD45RA+", "T", "cell", "subsets", "during", "aging", ".", "\n", "An", "increase", "in", "the", "ratio", "of", "memory", "to", "naive", "T", "cells", "has", "been", "postulated", "to", "underlie", "immune", "hyporesponsiveness", "accompanying", "aging", ".", "Our", "analyses", "of", "the", "induction", "of", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "in", "activated", "memory", "(", "CD45RO+", ")", "and", "naive", "(", "CD45RA+", ")", "T", "cell", "subsets", "from", "young", "and", "elderly", "donors", "has", "demonstrated", "that", ",", "regardless", "of", "donor", "age", ",", "memory", "T", "cells", "are", "not", "significantly", "altered", "in", "their", "responsiveness", "to", "TNF", "-", "alpha", "-", "mediated", "induction", "of", "NFkappaB.", "Although", "treatment", "with", "TNF", "-", "alpha", "induced", "nuclear", "localization", "of", "NFkappaB", "in", "both", "memory", "and", "naive", "T", "cell", "subsets", ",", "irrespective", "of", "the", "age", "of", "the", "donor", ",", "the", "levels", "of", "induced", "NFkappaB", "were", "significantly", "lower", "in", "both", "subsets", "of", "T", "cells", "obtained", "from", "the", "elderly", ",", "when", "compared", "to", "those", "in", "young", ".", "Examination", "of", "IkappaB", "alpha", "regulation", "revealed", "that", "TNF", "-", "alpha", "-", "mediated", "degradation", "of", "IkappaB", "alpha", "in", "both", "memory", "and", "naive", "T", "cells", "from", "the", "elderly", "was", "severely", "impaired", ",", "thus", "contributing", "to", "the", "lowered", "induction", "of", "the", "observed", "NFkappaB.", "In", "addition", ",", "this", "age", "-", "related", "decrease", "in", "induction", "of", "nuclear", "NFkappaB", "correlated", "with", "decrease", "in", "intracellular", "IL-2", "receptor", "expression", "and", "anti", "-", "CD3-induced", "proliferation", "of", "both", "memory", "and", "naive", "T", "cells", "subsets", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "the", "age", "-", "related", "hyporesponsiveness", "cannot", "be", "attributed", "to", "a", "skewing", "of", "the", "T", "cell", "population", "towards", "a", "memory", "phenotype", "in", "the", "elderly", "." ]	[ "Protein" ]
ATM is a Genes & Molecular Sequences, ATR is a Genes & Molecular Sequences	1635_task0	Sentence: ATM and ATR: components of an integrated circuit. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Genes & Molecular Sequences	[ "B-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O" ]	ATM and ATR: components of an integrated circuit.	[ "ATM", "and", "ATR", ":", "components", "of", "an", "integrated", "circuit", "." ]	[ "Genes & Molecular Sequences", "Diseases & Disorders", "" ]
ATM is a Genes & Molecular Sequences, ATR is a Genes & Molecular Sequences	1635_task1	Sentence: ATM and ATR: components of an integrated circuit. Instructions: please typing these entity words according to sentence: ATM, ATR Options: Genes & Molecular Sequences	[ "B-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O" ]	ATM and ATR: components of an integrated circuit.	[ "ATM", "and", "ATR", ":", "components", "of", "an", "integrated", "circuit", "." ]	[ "Genes & Molecular Sequences", "Diseases & Disorders", "" ]
ATM, ATR	1635_task2	Sentence: ATM and ATR: components of an integrated circuit. Instructions: please extract entity words from the input sentence	[ "B-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O" ]	ATM and ATR: components of an integrated circuit.	[ "ATM", "and", "ATR", ":", "components", "of", "an", "integrated", "circuit", "." ]	[ "Genes & Molecular Sequences", "Diseases & Disorders", "" ]
radiologische is an umlsterm, Haende is an umlsterm, Kniegelenke is an umlsterm, Haende is an umlsterm, Haende is an umlsterm, Arthrosemuster is an umlsterm, Arthrosen is an umlsterm, Gelenke is an umlsterm, radiologischen is an umlsterm, Arthrose is an umlsterm, Haenden is an umlsterm, Hypertrophie is an umlsterm, Belastung is an umlsterm, Kraftgriff is an umlsterm, Coxarthrose is an umlsterm	ZfuerRheumatologie.90580345.ger.abstr_task0	Sentence: Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf .	[ "Bei", "25", "pensionierten", "landwirtschaftlichen", "Arbeitern", ",", "welche", "durchschnittlich", "51", "Jahre", "eine", "Schwerarbeit", "als", "Knechte", "\"", "\"", "verrichtet", "hatten", ",", "erfolgte", "eine", "eingehende", "klinische", "und", "radiologische", "Untersuchung", "der", "Haende", ",", "Hueft-", "und", "Kniegelenke", ",", "wobei", "das", "Schwergewicht", "im", "Bereich", "der", "Haende", "lag", ".", "Das", "im", "Bereich", "der", "Haende", "gefundene", "Arthrosemuster", "zeigte", "eine", "auffaellige", "Verteilung", "mit", "einem", "ueberproportionalen", "Befall", "der", "Metacarpophalangealgelenke", "und", "weniger", "ausgepraegt", "der", "Intercarpalgelenke", ".", "Die", "Arthrosen", "der", "Metacarpophalangealgelenke", "betrafen", "gehaeuft", "Strahl", "I", "-", "III", ",", "diejenigen", "der", "Intercarpalgelenke", "gehaeuft", "die", "peritrapezialen", "Gelenke", ".", "Insbesondere", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", "bestaetigte", "sich", "eine", "Diskrepanz", "zwischen", "den", "klinisch", "z.", "T.", "eindruecklichen", "hypertrophen", "Veraenderungen", "(", "welche", "durchaus", "den", "Eindruck", "von", "Bouchardarthrosen", "erwecken", "konnten", ")", "und", "den", "selten", "vorkommenden", ",", "leichten", "radiologischen", "Zeichen", "der", "Arthrose", ".", "Die", "Ergebnisse", "betonen", "die", "Bedeutung", "des", "Belastungsmusters", "fuer", "die", "Entwicklung", "arthrotischer", "Veraenderungen", "an", "den", "Haenden", ".", "Die", "Untersuchung", "zeigt", "zudem", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", ",", "dass", "eine", "Hypertrophie", "der", "periartikulaeren", "Strukturen", "als", "Anpassung", "an", "die", "jahrzehntelange", "manuelle", "Belastung", "im", "Kraftgriff", "auftreten", "kann", ".", "Mit", "einer", "Ausnahme", "wiesen", "zudem", "saemtliche", "Teilnehmer", "mindestens", "eine", "unilaterale", "Coxarthrose", "auf", "." ]	[ "umlsterm" ]
radiologische is an umlsterm, Haende is an umlsterm, Kniegelenke is an umlsterm, Haende is an umlsterm, Haende is an umlsterm, Arthrosemuster is an umlsterm, Arthrosen is an umlsterm, Gelenke is an umlsterm, radiologischen is an umlsterm, Arthrose is an umlsterm, Haenden is an umlsterm, Hypertrophie is an umlsterm, Belastung is an umlsterm, Kraftgriff is an umlsterm, Coxarthrose is an umlsterm	ZfuerRheumatologie.90580345.ger.abstr_task1	Sentence: Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf . Instructions: please typing these entity words according to sentence: radiologische, Haende, Kniegelenke, Haende, Haende, Arthrosemuster, Arthrosen, Gelenke, radiologischen, Arthrose, Haenden, Hypertrophie, Belastung, Kraftgriff, Coxarthrose Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf .	[ "Bei", "25", "pensionierten", "landwirtschaftlichen", "Arbeitern", ",", "welche", "durchschnittlich", "51", "Jahre", "eine", "Schwerarbeit", "als", "Knechte", "\"", "\"", "verrichtet", "hatten", ",", "erfolgte", "eine", "eingehende", "klinische", "und", "radiologische", "Untersuchung", "der", "Haende", ",", "Hueft-", "und", "Kniegelenke", ",", "wobei", "das", "Schwergewicht", "im", "Bereich", "der", "Haende", "lag", ".", "Das", "im", "Bereich", "der", "Haende", "gefundene", "Arthrosemuster", "zeigte", "eine", "auffaellige", "Verteilung", "mit", "einem", "ueberproportionalen", "Befall", "der", "Metacarpophalangealgelenke", "und", "weniger", "ausgepraegt", "der", "Intercarpalgelenke", ".", "Die", "Arthrosen", "der", "Metacarpophalangealgelenke", "betrafen", "gehaeuft", "Strahl", "I", "-", "III", ",", "diejenigen", "der", "Intercarpalgelenke", "gehaeuft", "die", "peritrapezialen", "Gelenke", ".", "Insbesondere", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", "bestaetigte", "sich", "eine", "Diskrepanz", "zwischen", "den", "klinisch", "z.", "T.", "eindruecklichen", "hypertrophen", "Veraenderungen", "(", "welche", "durchaus", "den", "Eindruck", "von", "Bouchardarthrosen", "erwecken", "konnten", ")", "und", "den", "selten", "vorkommenden", ",", "leichten", "radiologischen", "Zeichen", "der", "Arthrose", ".", "Die", "Ergebnisse", "betonen", "die", "Bedeutung", "des", "Belastungsmusters", "fuer", "die", "Entwicklung", "arthrotischer", "Veraenderungen", "an", "den", "Haenden", ".", "Die", "Untersuchung", "zeigt", "zudem", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", ",", "dass", "eine", "Hypertrophie", "der", "periartikulaeren", "Strukturen", "als", "Anpassung", "an", "die", "jahrzehntelange", "manuelle", "Belastung", "im", "Kraftgriff", "auftreten", "kann", ".", "Mit", "einer", "Ausnahme", "wiesen", "zudem", "saemtliche", "Teilnehmer", "mindestens", "eine", "unilaterale", "Coxarthrose", "auf", "." ]	[ "umlsterm" ]
radiologische, Haende, Kniegelenke, Haende, Haende, Arthrosemuster, Arthrosen, Gelenke, radiologischen, Arthrose, Haenden, Hypertrophie, Belastung, Kraftgriff, Coxarthrose	ZfuerRheumatologie.90580345.ger.abstr_task2	Sentence: Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf .	[ "Bei", "25", "pensionierten", "landwirtschaftlichen", "Arbeitern", ",", "welche", "durchschnittlich", "51", "Jahre", "eine", "Schwerarbeit", "als", "Knechte", "\"", "\"", "verrichtet", "hatten", ",", "erfolgte", "eine", "eingehende", "klinische", "und", "radiologische", "Untersuchung", "der", "Haende", ",", "Hueft-", "und", "Kniegelenke", ",", "wobei", "das", "Schwergewicht", "im", "Bereich", "der", "Haende", "lag", ".", "Das", "im", "Bereich", "der", "Haende", "gefundene", "Arthrosemuster", "zeigte", "eine", "auffaellige", "Verteilung", "mit", "einem", "ueberproportionalen", "Befall", "der", "Metacarpophalangealgelenke", "und", "weniger", "ausgepraegt", "der", "Intercarpalgelenke", ".", "Die", "Arthrosen", "der", "Metacarpophalangealgelenke", "betrafen", "gehaeuft", "Strahl", "I", "-", "III", ",", "diejenigen", "der", "Intercarpalgelenke", "gehaeuft", "die", "peritrapezialen", "Gelenke", ".", "Insbesondere", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", "bestaetigte", "sich", "eine", "Diskrepanz", "zwischen", "den", "klinisch", "z.", "T.", "eindruecklichen", "hypertrophen", "Veraenderungen", "(", "welche", "durchaus", "den", "Eindruck", "von", "Bouchardarthrosen", "erwecken", "konnten", ")", "und", "den", "selten", "vorkommenden", ",", "leichten", "radiologischen", "Zeichen", "der", "Arthrose", ".", "Die", "Ergebnisse", "betonen", "die", "Bedeutung", "des", "Belastungsmusters", "fuer", "die", "Entwicklung", "arthrotischer", "Veraenderungen", "an", "den", "Haenden", ".", "Die", "Untersuchung", "zeigt", "zudem", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", ",", "dass", "eine", "Hypertrophie", "der", "periartikulaeren", "Strukturen", "als", "Anpassung", "an", "die", "jahrzehntelange", "manuelle", "Belastung", "im", "Kraftgriff", "auftreten", "kann", ".", "Mit", "einer", "Ausnahme", "wiesen", "zudem", "saemtliche", "Teilnehmer", "mindestens", "eine", "unilaterale", "Coxarthrose", "auf", "." ]	[ "umlsterm" ]

catheter, therapy, coronary artery disease, techniques, patients, balloon angioplasty, tissue, stent, implantation, techniques, prevention, pharmacologic, radiotherapeutic, future

ZfuerKardiologie.8087s052.eng.abstr_task2

Sentence: The success of interventional catheter based therapy of coronary artery disease is still limited by a high rate of chronic restenosis . Using alternative mechanical techniques , there is increasing evidence that restenosis can be prevented in certain subsets of patients by optimized balloon angioplasty , DCA and stenting as well as by the combined approach of primary tissue removal with adjunctive stent implantation . This article summarizes the mechanical techniques of restenosis prevention or reduction that have been documented in controlled trials . Additional pharmacologic interventions and possibly genetic and/or radiotherapeutic approaches will be highly important for future reduction of restenosis . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

The success of interventional catheter based therapy of coronary artery disease is still limited by a high rate of chronic restenosis . Using alternative mechanical techniques , there is increasing evidence that restenosis can be prevented in certain subsets of patients by optimized balloon angioplasty , DCA and stenting as well as by the combined approach of primary tissue removal with adjunctive stent implantation . This article summarizes the mechanical techniques of restenosis prevention or reduction that have been documented in controlled trials . Additional pharmacologic interventions and possibly genetic and/or radiotherapeutic approaches will be highly important for future reduction of restenosis .

[ "The", "success", "of", "interventional", "catheter", "based", "therapy", "of", "coronary", "artery", "disease", "is", "still", "limited", "by", "a", "high", "rate", "of", "chronic", "restenosis", ".", "Using", "alternative", "mechanical", "techniques", ",", "there", "is", "increasing", "evidence", "that", "restenosis", "can", "be", "prevented", "in", "certain", "subsets", "of", "patients", "by", "optimized", "balloon", "angioplasty", ",", "DCA", "and", "stenting", "as", "well", "as", "by", "the", "combined", "approach", "of", "primary", "tissue", "removal", "with", "adjunctive", "stent", "implantation", ".", "This", "article", "summarizes", "the", "mechanical", "techniques", "of", "restenosis", "prevention", "or", "reduction", "that", "have", "been", "documented", "in", "controlled", "trials", ".", "Additional", "pharmacologic", "interventions", "and", "possibly", "genetic", "and", "/", "or", "radiotherapeutic", "approaches", "will", "be", "highly", "important", "for", "future", "reduction", "of", "restenosis", "." ]

[ "umlsterm" ]

lebensbedrohender is an umlsterm, Infektionskrankheiten is an umlsterm, Lungenpest is an umlsterm, Deutschland is an umlsterm, Zeit is an umlsterm, Diagnostik- is an umlsterm, Behandlungseinrichtungen is an umlsterm, Deutschlands is an umlsterm

Bundesgesundheitsblatt.90420389.ger.abstr_task0

Sentence: Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann .

[ "Ein", "Einschleppen", "lebensbedrohender", "und", "zugleich", "hochkontagioeser", "Infektionskrankheiten", "wie", "Lungenpest", "oder", "Ebola", "-", "Fieber", "nach", "Deutschland", "erscheint", "zur", "Zeit", "nicht", "sehr", "wahrscheinlich", ",", "ist", "aber", "grundsaetzlich", "nicht", "auszuschliessen", ".", "Gerade", "wegen", "der", "Seltenheit", "des", "Auftretens", "einer", "solchen", "Erkrankung", "sind", "jedoch", "auch", "hierzulande", "Handlungsrichtlinien", "notwendig", ",", "um", "gegebenenfalls", "einer", "Verbreitung", "entgegenzuwirken", ".", "Die", "Entwicklung", "konkreter", "Schutzvorkehrungen", "und", "Handlungsalgorithmen", "sowie", "das", "Vorhalten", "geeigneter", "Diagnostik-", "und", "Behandlungseinrichtungen", "ist", "in", "den", "einzelnen", "Regionen", "Deutschlands", "sehr", "unterschiedlich", "ausgepraegt", ".", "Ein", "bundesweiter", "Rahmenplan", "fehlt", ".", "Der", "vorliegende", "Konzeptentwurf", "zeigt", ",", "wie", "die", "Vorsorge", "mit", "vertretbarem", "finanziellen", "Mehraufwand", "durch", "eine", "gemeinsame", "ueberregionale", "Nutzung", "der", "z", ".", "T.", "vorhandenen", "Infrastruktur", "und", "durch", "eine", "Vereinbarung", "bundeseinheitlicher", "Vorgehensweisen", "wesentlich", "verbessert", "werden", "kann", "." ]

[ "umlsterm" ]

lebensbedrohender is an umlsterm, Infektionskrankheiten is an umlsterm, Lungenpest is an umlsterm, Deutschland is an umlsterm, Zeit is an umlsterm, Diagnostik- is an umlsterm, Behandlungseinrichtungen is an umlsterm, Deutschlands is an umlsterm

Bundesgesundheitsblatt.90420389.ger.abstr_task1

Sentence: Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann . Instructions: please typing these entity words according to sentence: lebensbedrohender, Infektionskrankheiten, Lungenpest, Deutschland, Zeit, Diagnostik-, Behandlungseinrichtungen, Deutschlands Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann .

[ "Ein", "Einschleppen", "lebensbedrohender", "und", "zugleich", "hochkontagioeser", "Infektionskrankheiten", "wie", "Lungenpest", "oder", "Ebola", "-", "Fieber", "nach", "Deutschland", "erscheint", "zur", "Zeit", "nicht", "sehr", "wahrscheinlich", ",", "ist", "aber", "grundsaetzlich", "nicht", "auszuschliessen", ".", "Gerade", "wegen", "der", "Seltenheit", "des", "Auftretens", "einer", "solchen", "Erkrankung", "sind", "jedoch", "auch", "hierzulande", "Handlungsrichtlinien", "notwendig", ",", "um", "gegebenenfalls", "einer", "Verbreitung", "entgegenzuwirken", ".", "Die", "Entwicklung", "konkreter", "Schutzvorkehrungen", "und", "Handlungsalgorithmen", "sowie", "das", "Vorhalten", "geeigneter", "Diagnostik-", "und", "Behandlungseinrichtungen", "ist", "in", "den", "einzelnen", "Regionen", "Deutschlands", "sehr", "unterschiedlich", "ausgepraegt", ".", "Ein", "bundesweiter", "Rahmenplan", "fehlt", ".", "Der", "vorliegende", "Konzeptentwurf", "zeigt", ",", "wie", "die", "Vorsorge", "mit", "vertretbarem", "finanziellen", "Mehraufwand", "durch", "eine", "gemeinsame", "ueberregionale", "Nutzung", "der", "z", ".", "T.", "vorhandenen", "Infrastruktur", "und", "durch", "eine", "Vereinbarung", "bundeseinheitlicher", "Vorgehensweisen", "wesentlich", "verbessert", "werden", "kann", "." ]

[ "umlsterm" ]

lebensbedrohender, Infektionskrankheiten, Lungenpest, Deutschland, Zeit, Diagnostik-, Behandlungseinrichtungen, Deutschlands

Bundesgesundheitsblatt.90420389.ger.abstr_task2

Sentence: Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ein Einschleppen lebensbedrohender und zugleich hochkontagioeser Infektionskrankheiten wie Lungenpest oder Ebola-Fieber nach Deutschland erscheint zur Zeit nicht sehr wahrscheinlich , ist aber grundsaetzlich nicht auszuschliessen . Gerade wegen der Seltenheit des Auftretens einer solchen Erkrankung sind jedoch auch hierzulande Handlungsrichtlinien notwendig , um gegebenenfalls einer Verbreitung entgegenzuwirken . Die Entwicklung konkreter Schutzvorkehrungen und Handlungsalgorithmen sowie das Vorhalten geeigneter Diagnostik- und Behandlungseinrichtungen ist in den einzelnen Regionen Deutschlands sehr unterschiedlich ausgepraegt . Ein bundesweiter Rahmenplan fehlt . Der vorliegende Konzeptentwurf zeigt , wie die Vorsorge mit vertretbarem finanziellen Mehraufwand durch eine gemeinsame ueberregionale Nutzung der z . T. vorhandenen Infrastruktur und durch eine Vereinbarung bundeseinheitlicher Vorgehensweisen wesentlich verbessert werden kann .

[ "Ein", "Einschleppen", "lebensbedrohender", "und", "zugleich", "hochkontagioeser", "Infektionskrankheiten", "wie", "Lungenpest", "oder", "Ebola", "-", "Fieber", "nach", "Deutschland", "erscheint", "zur", "Zeit", "nicht", "sehr", "wahrscheinlich", ",", "ist", "aber", "grundsaetzlich", "nicht", "auszuschliessen", ".", "Gerade", "wegen", "der", "Seltenheit", "des", "Auftretens", "einer", "solchen", "Erkrankung", "sind", "jedoch", "auch", "hierzulande", "Handlungsrichtlinien", "notwendig", ",", "um", "gegebenenfalls", "einer", "Verbreitung", "entgegenzuwirken", ".", "Die", "Entwicklung", "konkreter", "Schutzvorkehrungen", "und", "Handlungsalgorithmen", "sowie", "das", "Vorhalten", "geeigneter", "Diagnostik-", "und", "Behandlungseinrichtungen", "ist", "in", "den", "einzelnen", "Regionen", "Deutschlands", "sehr", "unterschiedlich", "ausgepraegt", ".", "Ein", "bundesweiter", "Rahmenplan", "fehlt", ".", "Der", "vorliegende", "Konzeptentwurf", "zeigt", ",", "wie", "die", "Vorsorge", "mit", "vertretbarem", "finanziellen", "Mehraufwand", "durch", "eine", "gemeinsame", "ueberregionale", "Nutzung", "der", "z", ".", "T.", "vorhandenen", "Infrastruktur", "und", "durch", "eine", "Vereinbarung", "bundeseinheitlicher", "Vorgehensweisen", "wesentlich", "verbessert", "werden", "kann", "." ]

[ "umlsterm" ]

Tumorinfiltration is an umlsterm, Pankreaskopfes is an umlsterm, Pfortaderresektion is an umlsterm, Morbiditaet is an umlsterm, Pfortaderinfiltration is an umlsterm, Tumoradhaerenz is an umlsterm, Patienten is an umlsterm, Pankreaskopfes is an umlsterm, Tumorinfiltration is an umlsterm, Tumoradhaerenz is an umlsterm, Diagnostik is an umlsterm, Portographie is an umlsterm, Pfortaderresektion is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Tumorinvasion is an umlsterm, Ultraschall is an umlsterm, Pfortaderinfiltration is an umlsterm, Standarddiagnostik is an umlsterm, Sensitivitaet und Spezifitaet is an umlsterm, Ultraschall is an umlsterm, Tumorinfiltration is an umlsterm, Patienten is an umlsterm, Tumoradhaerenz is an umlsterm, Pfortaderresektion is an umlsterm

DerChirurg.00710803.ger.abstr_task0

Sentence: Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren .

[ "Zusammenfassung", ".", "Die", "Tumorinfiltration", "der", "V.", "portae", "bei", "duktalen", "Adenocarcinomen", "des", "Pankreaskopfes", "gilt", "klassischerweise", "als", "Inoperabilitaetskriterium", ".", "Trotz", "operationstechnischer", "Fortschritte", "auf", "dem", "Gebiet", "der", "Pfortaderresektion", "im", "Rahmen", "von", "Whipple", "-", "Operationen", "mit", "akzeptaler", "Letalitaet", "und", "Morbiditaet", "kann", "eine", "Gefaessresektion", "bei", "Infiltration", "nicht", "prinzipiell", "empfohlen", "werden", ".", "Problematisch", "ist", "vor", "allem", "die", "praeoperative", "Sicherung", "einer", "eventuell", "vorliegenden", "Gefaessinfiltration", ",", "haeufig", "sieht", "sich", "der", "Chirurg", "erst", "intraoperativ", "mit", "der", "Situation", "einer", "makroskopischen", "Pfortaderinfiltration", "bzw", ".", "Tumoradhaerenz", "konfrontiert", ".", "Im", "Zeitraum", "von", "1986", "bis", "1995", "wurde", "an", "unserer", "Klinik", "bei", "105", "Patienten", "mit", "duktalem", "Adenocarcinom", "des", "Pankreaskopfes", "eine", "Whipple", "-", "Operation", "vorgenommen", ".", "In", "8", "Faellen", "erfolgte", "bei", "makroskopischer", "Tumorinfiltration", "bzw", ".", "Tumoradhaerenz", "und", "unauffaelliger", "praeoperativer", "Diagnostik", "mittels", "indirekter", "Portographie", "und", "CT", "eine", "partielle", "Pfortaderresektion", ".", "In", "4", "der", "8", "Faelle", "fand", "sich", "eine", "tatsaechliche", ",", "histologisch", "nachweisbare", "Infiltration", "der", "V.", "portae", "bis", "in", "die", "inneren", "Gefaesswandschichten", ",", "waehrend", "die", "uebrigen", "Faelle", "keine", "bzw", ".", "lediglich", "eine", "Adventitiainfiltration", "zeigten", ".", "Die", "Patienten", "ohne", "histologischen", "Nachweis", "einer", "tatsaechlichen", "Gefaessinfiltration", "wiesen", "eine", "deutlich", "laengere", "Ueberlebenszeit", "(", "27,75", "Monate", ")", "gegenueber", "den", "Patienten", "mit", "histologischer", "Tumorinvasion", "in", "die", "V.", "portae", "(", "6,67", "Monate", ")", "auf", ".", "Neuere", "Untersuchungen", "haben", "gezeigt", ",", "dass", "der", "endovasculaere", ",", "intraportale", "Ultraschall", "(", "IPEUS", ")", "einen", "deutlichen", "Informationsgewinn", "bezueglich", "der", "Frage", "einer", "vorliegenden", "Pfortaderinfiltration", "bieten", "kann", ".", "Auch", "wenn", "diese", "Untersuchung", "derzeit", "nicht", "als", "Standarddiagnostik", "gelten", "kann", ",", "so", "besteht", "die", "Moeglichkeit", ",", "bei", "entsprechender", "Indikation", "hierdurch", "mit", "hoher", "Sensitivitaet", "und", "Spezifitaet", "eine", "tatsaechliche", "Gefaessinfiltration", "zu", "erkennen", ".", "Kann", "mittels", "endovasculaerem", "Ultraschall", "eine", "Tumorinfiltration", "in", "die", "V.", "portae", "ausgeschlossen", "werden", ",", "so", "zeigen", "unsere", "Ergebnisse", ",", "dass", "Patienten", "mit", "makroskopischer", "Tumoradhaerenz", "tatsaechlich", "von", "einer", "partiellen", "Pfortaderresektion", "profitieren", "." ]

[ "umlsterm" ]

Tumorinfiltration is an umlsterm, Pankreaskopfes is an umlsterm, Pfortaderresektion is an umlsterm, Morbiditaet is an umlsterm, Pfortaderinfiltration is an umlsterm, Tumoradhaerenz is an umlsterm, Patienten is an umlsterm, Pankreaskopfes is an umlsterm, Tumorinfiltration is an umlsterm, Tumoradhaerenz is an umlsterm, Diagnostik is an umlsterm, Portographie is an umlsterm, Pfortaderresektion is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Tumorinvasion is an umlsterm, Ultraschall is an umlsterm, Pfortaderinfiltration is an umlsterm, Standarddiagnostik is an umlsterm, Sensitivitaet und Spezifitaet is an umlsterm, Ultraschall is an umlsterm, Tumorinfiltration is an umlsterm, Patienten is an umlsterm, Tumoradhaerenz is an umlsterm, Pfortaderresektion is an umlsterm

DerChirurg.00710803.ger.abstr_task1

Sentence: Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren . Instructions: please typing these entity words according to sentence: Tumorinfiltration, Pankreaskopfes, Pfortaderresektion, Morbiditaet, Pfortaderinfiltration, Tumoradhaerenz, Patienten, Pankreaskopfes, Tumorinfiltration, Tumoradhaerenz, Diagnostik, Portographie, Pfortaderresektion, Patienten, Patienten, Tumorinvasion, Ultraschall, Pfortaderinfiltration, Standarddiagnostik, Sensitivitaet und Spezifitaet, Ultraschall, Tumorinfiltration, Patienten, Tumoradhaerenz, Pfortaderresektion Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren .

[ "Zusammenfassung", ".", "Die", "Tumorinfiltration", "der", "V.", "portae", "bei", "duktalen", "Adenocarcinomen", "des", "Pankreaskopfes", "gilt", "klassischerweise", "als", "Inoperabilitaetskriterium", ".", "Trotz", "operationstechnischer", "Fortschritte", "auf", "dem", "Gebiet", "der", "Pfortaderresektion", "im", "Rahmen", "von", "Whipple", "-", "Operationen", "mit", "akzeptaler", "Letalitaet", "und", "Morbiditaet", "kann", "eine", "Gefaessresektion", "bei", "Infiltration", "nicht", "prinzipiell", "empfohlen", "werden", ".", "Problematisch", "ist", "vor", "allem", "die", "praeoperative", "Sicherung", "einer", "eventuell", "vorliegenden", "Gefaessinfiltration", ",", "haeufig", "sieht", "sich", "der", "Chirurg", "erst", "intraoperativ", "mit", "der", "Situation", "einer", "makroskopischen", "Pfortaderinfiltration", "bzw", ".", "Tumoradhaerenz", "konfrontiert", ".", "Im", "Zeitraum", "von", "1986", "bis", "1995", "wurde", "an", "unserer", "Klinik", "bei", "105", "Patienten", "mit", "duktalem", "Adenocarcinom", "des", "Pankreaskopfes", "eine", "Whipple", "-", "Operation", "vorgenommen", ".", "In", "8", "Faellen", "erfolgte", "bei", "makroskopischer", "Tumorinfiltration", "bzw", ".", "Tumoradhaerenz", "und", "unauffaelliger", "praeoperativer", "Diagnostik", "mittels", "indirekter", "Portographie", "und", "CT", "eine", "partielle", "Pfortaderresektion", ".", "In", "4", "der", "8", "Faelle", "fand", "sich", "eine", "tatsaechliche", ",", "histologisch", "nachweisbare", "Infiltration", "der", "V.", "portae", "bis", "in", "die", "inneren", "Gefaesswandschichten", ",", "waehrend", "die", "uebrigen", "Faelle", "keine", "bzw", ".", "lediglich", "eine", "Adventitiainfiltration", "zeigten", ".", "Die", "Patienten", "ohne", "histologischen", "Nachweis", "einer", "tatsaechlichen", "Gefaessinfiltration", "wiesen", "eine", "deutlich", "laengere", "Ueberlebenszeit", "(", "27,75", "Monate", ")", "gegenueber", "den", "Patienten", "mit", "histologischer", "Tumorinvasion", "in", "die", "V.", "portae", "(", "6,67", "Monate", ")", "auf", ".", "Neuere", "Untersuchungen", "haben", "gezeigt", ",", "dass", "der", "endovasculaere", ",", "intraportale", "Ultraschall", "(", "IPEUS", ")", "einen", "deutlichen", "Informationsgewinn", "bezueglich", "der", "Frage", "einer", "vorliegenden", "Pfortaderinfiltration", "bieten", "kann", ".", "Auch", "wenn", "diese", "Untersuchung", "derzeit", "nicht", "als", "Standarddiagnostik", "gelten", "kann", ",", "so", "besteht", "die", "Moeglichkeit", ",", "bei", "entsprechender", "Indikation", "hierdurch", "mit", "hoher", "Sensitivitaet", "und", "Spezifitaet", "eine", "tatsaechliche", "Gefaessinfiltration", "zu", "erkennen", ".", "Kann", "mittels", "endovasculaerem", "Ultraschall", "eine", "Tumorinfiltration", "in", "die", "V.", "portae", "ausgeschlossen", "werden", ",", "so", "zeigen", "unsere", "Ergebnisse", ",", "dass", "Patienten", "mit", "makroskopischer", "Tumoradhaerenz", "tatsaechlich", "von", "einer", "partiellen", "Pfortaderresektion", "profitieren", "." ]

[ "umlsterm" ]

Tumorinfiltration, Pankreaskopfes, Pfortaderresektion, Morbiditaet, Pfortaderinfiltration, Tumoradhaerenz, Patienten, Pankreaskopfes, Tumorinfiltration, Tumoradhaerenz, Diagnostik, Portographie, Pfortaderresektion, Patienten, Patienten, Tumorinvasion, Ultraschall, Pfortaderinfiltration, Standarddiagnostik, Sensitivitaet und Spezifitaet, Ultraschall, Tumorinfiltration, Patienten, Tumoradhaerenz, Pfortaderresektion

DerChirurg.00710803.ger.abstr_task2

Sentence: Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Die Tumorinfiltration der V. portae bei duktalen Adenocarcinomen des Pankreaskopfes gilt klassischerweise als Inoperabilitaetskriterium . Trotz operationstechnischer Fortschritte auf dem Gebiet der Pfortaderresektion im Rahmen von Whipple-Operationen mit akzeptaler Letalitaet und Morbiditaet kann eine Gefaessresektion bei Infiltration nicht prinzipiell empfohlen werden . Problematisch ist vor allem die praeoperative Sicherung einer eventuell vorliegenden Gefaessinfiltration , haeufig sieht sich der Chirurg erst intraoperativ mit der Situation einer makroskopischen Pfortaderinfiltration bzw. Tumoradhaerenz konfrontiert . Im Zeitraum von 1986 bis 1995 wurde an unserer Klinik bei 105 Patienten mit duktalem Adenocarcinom des Pankreaskopfes eine Whipple-Operation vorgenommen . In 8 Faellen erfolgte bei makroskopischer Tumorinfiltration bzw. Tumoradhaerenz und unauffaelliger praeoperativer Diagnostik mittels indirekter Portographie und CT eine partielle Pfortaderresektion . In 4 der 8 Faelle fand sich eine tatsaechliche , histologisch nachweisbare Infiltration der V. portae bis in die inneren Gefaesswandschichten , waehrend die uebrigen Faelle keine bzw. lediglich eine Adventitiainfiltration zeigten . Die Patienten ohne histologischen Nachweis einer tatsaechlichen Gefaessinfiltration wiesen eine deutlich laengere Ueberlebenszeit ( 27,75 Monate ) gegenueber den Patienten mit histologischer Tumorinvasion in die V. portae ( 6,67 Monate ) auf . Neuere Untersuchungen haben gezeigt , dass der endovasculaere , intraportale Ultraschall ( IPEUS ) einen deutlichen Informationsgewinn bezueglich der Frage einer vorliegenden Pfortaderinfiltration bieten kann . Auch wenn diese Untersuchung derzeit nicht als Standarddiagnostik gelten kann , so besteht die Moeglichkeit , bei entsprechender Indikation hierdurch mit hoher Sensitivitaet und Spezifitaet eine tatsaechliche Gefaessinfiltration zu erkennen . Kann mittels endovasculaerem Ultraschall eine Tumorinfiltration in die V. portae ausgeschlossen werden , so zeigen unsere Ergebnisse , dass Patienten mit makroskopischer Tumoradhaerenz tatsaechlich von einer partiellen Pfortaderresektion profitieren .

[ "Zusammenfassung", ".", "Die", "Tumorinfiltration", "der", "V.", "portae", "bei", "duktalen", "Adenocarcinomen", "des", "Pankreaskopfes", "gilt", "klassischerweise", "als", "Inoperabilitaetskriterium", ".", "Trotz", "operationstechnischer", "Fortschritte", "auf", "dem", "Gebiet", "der", "Pfortaderresektion", "im", "Rahmen", "von", "Whipple", "-", "Operationen", "mit", "akzeptaler", "Letalitaet", "und", "Morbiditaet", "kann", "eine", "Gefaessresektion", "bei", "Infiltration", "nicht", "prinzipiell", "empfohlen", "werden", ".", "Problematisch", "ist", "vor", "allem", "die", "praeoperative", "Sicherung", "einer", "eventuell", "vorliegenden", "Gefaessinfiltration", ",", "haeufig", "sieht", "sich", "der", "Chirurg", "erst", "intraoperativ", "mit", "der", "Situation", "einer", "makroskopischen", "Pfortaderinfiltration", "bzw", ".", "Tumoradhaerenz", "konfrontiert", ".", "Im", "Zeitraum", "von", "1986", "bis", "1995", "wurde", "an", "unserer", "Klinik", "bei", "105", "Patienten", "mit", "duktalem", "Adenocarcinom", "des", "Pankreaskopfes", "eine", "Whipple", "-", "Operation", "vorgenommen", ".", "In", "8", "Faellen", "erfolgte", "bei", "makroskopischer", "Tumorinfiltration", "bzw", ".", "Tumoradhaerenz", "und", "unauffaelliger", "praeoperativer", "Diagnostik", "mittels", "indirekter", "Portographie", "und", "CT", "eine", "partielle", "Pfortaderresektion", ".", "In", "4", "der", "8", "Faelle", "fand", "sich", "eine", "tatsaechliche", ",", "histologisch", "nachweisbare", "Infiltration", "der", "V.", "portae", "bis", "in", "die", "inneren", "Gefaesswandschichten", ",", "waehrend", "die", "uebrigen", "Faelle", "keine", "bzw", ".", "lediglich", "eine", "Adventitiainfiltration", "zeigten", ".", "Die", "Patienten", "ohne", "histologischen", "Nachweis", "einer", "tatsaechlichen", "Gefaessinfiltration", "wiesen", "eine", "deutlich", "laengere", "Ueberlebenszeit", "(", "27,75", "Monate", ")", "gegenueber", "den", "Patienten", "mit", "histologischer", "Tumorinvasion", "in", "die", "V.", "portae", "(", "6,67", "Monate", ")", "auf", ".", "Neuere", "Untersuchungen", "haben", "gezeigt", ",", "dass", "der", "endovasculaere", ",", "intraportale", "Ultraschall", "(", "IPEUS", ")", "einen", "deutlichen", "Informationsgewinn", "bezueglich", "der", "Frage", "einer", "vorliegenden", "Pfortaderinfiltration", "bieten", "kann", ".", "Auch", "wenn", "diese", "Untersuchung", "derzeit", "nicht", "als", "Standarddiagnostik", "gelten", "kann", ",", "so", "besteht", "die", "Moeglichkeit", ",", "bei", "entsprechender", "Indikation", "hierdurch", "mit", "hoher", "Sensitivitaet", "und", "Spezifitaet", "eine", "tatsaechliche", "Gefaessinfiltration", "zu", "erkennen", ".", "Kann", "mittels", "endovasculaerem", "Ultraschall", "eine", "Tumorinfiltration", "in", "die", "V.", "portae", "ausgeschlossen", "werden", ",", "so", "zeigen", "unsere", "Ergebnisse", ",", "dass", "Patienten", "mit", "makroskopischer", "Tumoradhaerenz", "tatsaechlich", "von", "einer", "partiellen", "Pfortaderresektion", "profitieren", "." ]

[ "umlsterm" ]

Children is a Person, aging is a Person, between 3 and 6 years is a Value, good health conditions is a Condition, at least one is a Multiplier, occlusal or occlusal proximal is a Scope, caries lesion is a Condition, primary molars is a Qualifier, occlusal and / or occlusal - proximal surfaces is a Scope, caries lesions with dentin involvement is a Scope

NCT02562456_inc_task0

Sentence: Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Multiplier, Scope

[ "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]

Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement

[ "Children", "aging", "between", "3", "and", "6", "years", "\n", "presenting", "good", "health", "conditions", "\n", "whose", "parents", "or", "legal", "guardians", "accept", "and", "sign", "the", "consent", "form", "\n", "with", "at", "least", "one", "occlusal", "or", "occlusal", "proximal", "caries", "lesion", "in", "primary", "molars", "\n", "only", "occlusal", "and", "/", "or", "occlusal", "-", "proximal", "surfaces", "with", "caries", "lesions", "with", "dentin", "involvement", "\n" ]

[ "Scope", "Qualifier", "Condition", "Value", "Multiplier", "Person" ]

Children is a Person, aging is a Person, between 3 and 6 years is a Value, good health conditions is a Condition, at least one is a Multiplier, occlusal or occlusal proximal is a Scope, caries lesion is a Condition, primary molars is a Qualifier, occlusal and / or occlusal - proximal surfaces is a Scope, caries lesions with dentin involvement is a Scope

NCT02562456_inc_task1

Sentence: Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement Instructions: please typing these entity words according to sentence: Children, aging, between 3 and 6 years, good health conditions, at least one, occlusal or occlusal proximal, caries lesion, primary molars, occlusal and / or occlusal - proximal surfaces, caries lesions with dentin involvement Options: Condition, Qualifier, Value, Person, Multiplier, Scope

[ "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]

Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement

[ "Children", "aging", "between", "3", "and", "6", "years", "\n", "presenting", "good", "health", "conditions", "\n", "whose", "parents", "or", "legal", "guardians", "accept", "and", "sign", "the", "consent", "form", "\n", "with", "at", "least", "one", "occlusal", "or", "occlusal", "proximal", "caries", "lesion", "in", "primary", "molars", "\n", "only", "occlusal", "and", "/", "or", "occlusal", "-", "proximal", "surfaces", "with", "caries", "lesions", "with", "dentin", "involvement", "\n" ]

[ "Scope", "Qualifier", "Condition", "Value", "Multiplier", "Person" ]

Children, aging, between 3 and 6 years, good health conditions, at least one, occlusal or occlusal proximal, caries lesion, primary molars, occlusal and / or occlusal - proximal surfaces, caries lesions with dentin involvement

NCT02562456_inc_task2

Sentence: Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement Instructions: please extract entity words from the input sentence

[ "B-Person", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Qualifier", "I-Qualifier", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]

Children aging between 3 and 6 years presenting good health conditions whose parents or legal guardians accept and sign the consent form with at least one occlusal or occlusal proximal caries lesion in primary molars only occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement

[ "Children", "aging", "between", "3", "and", "6", "years", "\n", "presenting", "good", "health", "conditions", "\n", "whose", "parents", "or", "legal", "guardians", "accept", "and", "sign", "the", "consent", "form", "\n", "with", "at", "least", "one", "occlusal", "or", "occlusal", "proximal", "caries", "lesion", "in", "primary", "molars", "\n", "only", "occlusal", "and", "/", "or", "occlusal", "-", "proximal", "surfaces", "with", "caries", "lesions", "with", "dentin", "involvement", "\n" ]

[ "Scope", "Qualifier", "Condition", "Value", "Multiplier", "Person" ]

calcium channel blockers is a Intervention_Pharmacological, lipid - lowering therapy is a Intervention_Pharmacological, retarding progression of coronary atherosclerosis is a Participant_Condition, Lipid - lowering therapy is a Intervention_Pharmacological, progression of atherosclerosis is a Outcome_Physical, calcium channel blocker ( CCB ) is a Intervention_Pharmacological, CCBs is a Intervention_Pharmacological, lipid - lowering therapy . is a Intervention_Pharmacological, pravastatin is a Intervention_Pharmacological, placebo is a Intervention_Control, placebo ( no pravastatin ) is a Intervention_Control, angiographic new lesion formation is a Outcome_Physical, angiographic lesions is a Outcome_Physical, clinical events is a Outcome_Other, angiographic progression is a Outcome_Physical, progression of established coronary atherosclerosis is a Outcome_Physical

91933_task0

Sentence: Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway .

[ "Proposed", "synergistic", "effect", "of", "calcium", "channel", "blockers", "with", "lipid", "-", "lowering", "therapy", "in", "retarding", "progression", "of", "coronary", "atherosclerosis", ".", "Lipid", "-", "lowering", "therapy", "now", "has", "undoubtedly", "proven", "to", "be", "an", "effective", "therapeutic", "modality", "to", "retard", "the", "progression", "of", "coronary", "atherosclerosis", ".", "An", "additional", "approach", "for", "prevention", "of", "the", "progression", "of", "atherosclerosis", "is", "calcium", "channel", "blocker", "(", "CCB", ")", "treatment", ".", "Evidence", "indicating", "that", "CCBs", "inhibit", "atherosclerosis", "is", "less", "unequivocal", "than", "the", "clear", "evidence", "for", "lipid", "-", "lowering", "therapy", ".", "Many", "investigations", "support", "the", "view", "that", "a", "number", "of", "key", "processes", "in", "atherosclerosis", "may", "be", "influenced", "by", "CCBs", ".", "From", "the", "\"", "negative", "\"", "and", "\"", "positive", "\"", "studies", "with", "CCBs", "performed", "in", "animals", "and", "humans", "we", "must", "conclude", "that", "apparently", "some", ",", "but", "not", "all", ",", "types", "or", "stages", "of", "the", "atherosclerotic", "process", "are", "inhibited", "by", "CCBs", ".", "To", "assess", "whether", "lipid", "-", "lowering", "therapy", "and", "CCB", "treatment", "may", "have", "an", "additive", "or", "synergistic", "beneficial", "effect", "on", "human", "atherosclerosis", ",", "which", "is", "conceivable", "because", "their", "anti", "-", "atherosclerotic", "properties", "differ", ",", "data", "from", "the", "angiographic", "lipid", "-", "lowering", "trial", "REGRESS", "(", "pravastatin", "vs", ".", "placebo", ")", "were", "reviewed", ".", "In", "REGRESS", ",", "patients", "in", "the", "pravastatin", "group", "had", "significantly", "less", "progression", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "those", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", "no", "effect", "of", "CCB", "treatment", "was", "observed", ".", "With", "respect", "to", "angiographic", "new", "lesion", "formation", ",", "in", "the", "pravastatin", "group", "there", "were", "50", "%", "less", "patients", "with", "new", "angiographic", "lesions", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", ",", "again", ",", "no", "significant", "effect", "of", "CCB", "treatment", "was", "observed", ".", "No", "beneficial", "effects", "of", "CCB", "treatment", "on", "clinical", "events", "were", "observed", "during", "the", "2-year", "study", "follow", "-", "up", ".", "In", "view", "of", "the", "correlation", "between", "angiographic", "progression", "and", "subsequent", "clinical", "events", "as", "demonstrated", "in", "several", "large", "trials", ",", "it", "is", "not", "unrealistic", "to", "also", "anticipate", "in", "this", "population", ",", "a", "beneficial", "effect", "on", "clinical", "events", "with", "longer", "follow", "-", "up", ".", "Although", "the", "REGRESS", "trial", "was", "not", "designed", "to", "evaluate", "combination", "therapy", ",", "the", "results", "suggest", "that", "addition", "of", "CCBs", "to", "HMG", "-", "CoA", "reductase", "inhibitor", "therapy", "(", "pravastatin", ")", "acts", "synergistically", "in", "retarding", "the", "progression", "of", "established", "coronary", "atherosclerosis", ".", "These", "results", "appear", "to", "warrant", "prospective", "randomized", "trials", "to", "determine", "in", "a", "more", "definitive", "manner", "the", "merits", "of", "this", "combination", "in", "the", "prevention", "of", "progression", "of", "coronary", "atherosclerosis", ".", "Currently", "a", "number", "of", "studies", "in", "these", "fields", "are", "being", "designed", "or", "are", "already", "underway", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]

calcium channel blockers is a Intervention_Pharmacological, lipid - lowering therapy is a Intervention_Pharmacological, retarding progression of coronary atherosclerosis is a Participant_Condition, Lipid - lowering therapy is a Intervention_Pharmacological, progression of atherosclerosis is a Outcome_Physical, calcium channel blocker ( CCB ) is a Intervention_Pharmacological, CCBs is a Intervention_Pharmacological, lipid - lowering therapy . is a Intervention_Pharmacological, pravastatin is a Intervention_Pharmacological, placebo is a Intervention_Control, placebo ( no pravastatin ) is a Intervention_Control, angiographic new lesion formation is a Outcome_Physical, angiographic lesions is a Outcome_Physical, clinical events is a Outcome_Other, angiographic progression is a Outcome_Physical, progression of established coronary atherosclerosis is a Outcome_Physical

91933_task1

Sentence: Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway . Instructions: please typing these entity words according to sentence: calcium channel blockers, lipid - lowering therapy, retarding progression of coronary atherosclerosis, Lipid - lowering therapy, progression of atherosclerosis, calcium channel blocker ( CCB ), CCBs, lipid - lowering therapy ., pravastatin, placebo, placebo ( no pravastatin ), angiographic new lesion formation, angiographic lesions, clinical events, angiographic progression, progression of established coronary atherosclerosis Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway .

[ "Proposed", "synergistic", "effect", "of", "calcium", "channel", "blockers", "with", "lipid", "-", "lowering", "therapy", "in", "retarding", "progression", "of", "coronary", "atherosclerosis", ".", "Lipid", "-", "lowering", "therapy", "now", "has", "undoubtedly", "proven", "to", "be", "an", "effective", "therapeutic", "modality", "to", "retard", "the", "progression", "of", "coronary", "atherosclerosis", ".", "An", "additional", "approach", "for", "prevention", "of", "the", "progression", "of", "atherosclerosis", "is", "calcium", "channel", "blocker", "(", "CCB", ")", "treatment", ".", "Evidence", "indicating", "that", "CCBs", "inhibit", "atherosclerosis", "is", "less", "unequivocal", "than", "the", "clear", "evidence", "for", "lipid", "-", "lowering", "therapy", ".", "Many", "investigations", "support", "the", "view", "that", "a", "number", "of", "key", "processes", "in", "atherosclerosis", "may", "be", "influenced", "by", "CCBs", ".", "From", "the", "\"", "negative", "\"", "and", "\"", "positive", "\"", "studies", "with", "CCBs", "performed", "in", "animals", "and", "humans", "we", "must", "conclude", "that", "apparently", "some", ",", "but", "not", "all", ",", "types", "or", "stages", "of", "the", "atherosclerotic", "process", "are", "inhibited", "by", "CCBs", ".", "To", "assess", "whether", "lipid", "-", "lowering", "therapy", "and", "CCB", "treatment", "may", "have", "an", "additive", "or", "synergistic", "beneficial", "effect", "on", "human", "atherosclerosis", ",", "which", "is", "conceivable", "because", "their", "anti", "-", "atherosclerotic", "properties", "differ", ",", "data", "from", "the", "angiographic", "lipid", "-", "lowering", "trial", "REGRESS", "(", "pravastatin", "vs", ".", "placebo", ")", "were", "reviewed", ".", "In", "REGRESS", ",", "patients", "in", "the", "pravastatin", "group", "had", "significantly", "less", "progression", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "those", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", "no", "effect", "of", "CCB", "treatment", "was", "observed", ".", "With", "respect", "to", "angiographic", "new", "lesion", "formation", ",", "in", "the", "pravastatin", "group", "there", "were", "50", "%", "less", "patients", "with", "new", "angiographic", "lesions", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", ",", "again", ",", "no", "significant", "effect", "of", "CCB", "treatment", "was", "observed", ".", "No", "beneficial", "effects", "of", "CCB", "treatment", "on", "clinical", "events", "were", "observed", "during", "the", "2-year", "study", "follow", "-", "up", ".", "In", "view", "of", "the", "correlation", "between", "angiographic", "progression", "and", "subsequent", "clinical", "events", "as", "demonstrated", "in", "several", "large", "trials", ",", "it", "is", "not", "unrealistic", "to", "also", "anticipate", "in", "this", "population", ",", "a", "beneficial", "effect", "on", "clinical", "events", "with", "longer", "follow", "-", "up", ".", "Although", "the", "REGRESS", "trial", "was", "not", "designed", "to", "evaluate", "combination", "therapy", ",", "the", "results", "suggest", "that", "addition", "of", "CCBs", "to", "HMG", "-", "CoA", "reductase", "inhibitor", "therapy", "(", "pravastatin", ")", "acts", "synergistically", "in", "retarding", "the", "progression", "of", "established", "coronary", "atherosclerosis", ".", "These", "results", "appear", "to", "warrant", "prospective", "randomized", "trials", "to", "determine", "in", "a", "more", "definitive", "manner", "the", "merits", "of", "this", "combination", "in", "the", "prevention", "of", "progression", "of", "coronary", "atherosclerosis", ".", "Currently", "a", "number", "of", "studies", "in", "these", "fields", "are", "being", "designed", "or", "are", "already", "underway", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]

calcium channel blockers, lipid - lowering therapy, retarding progression of coronary atherosclerosis, Lipid - lowering therapy, progression of atherosclerosis, calcium channel blocker ( CCB ), CCBs, lipid - lowering therapy ., pravastatin, placebo, placebo ( no pravastatin ), angiographic new lesion formation, angiographic lesions, clinical events, angiographic progression, progression of established coronary atherosclerosis

91933_task2

Sentence: Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis . Lipid-lowering therapy now has undoubtedly proven to be an effective therapeutic modality to retard the progression of coronary atherosclerosis . An additional approach for prevention of the progression of atherosclerosis is calcium channel blocker ( CCB ) treatment . Evidence indicating that CCBs inhibit atherosclerosis is less unequivocal than the clear evidence for lipid-lowering therapy . Many investigations support the view that a number of key processes in atherosclerosis may be influenced by CCBs . From the " negative " and " positive " studies with CCBs performed in animals and humans we must conclude that apparently some , but not all , types or stages of the atherosclerotic process are inhibited by CCBs . To assess whether lipid-lowering therapy and CCB treatment may have an additive or synergistic beneficial effect on human atherosclerosis , which is conceivable because their anti-atherosclerotic properties differ , data from the angiographic lipid-lowering trial REGRESS ( pravastatin vs. placebo ) were reviewed . In REGRESS , patients in the pravastatin group had significantly less progression if cotreated with CCBs as compared with those with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group no effect of CCB treatment was observed . With respect to angiographic new lesion formation , in the pravastatin group there were 50 % less patients with new angiographic lesions if cotreated with CCBs as compared with no CCB cotreatment , whereas in the placebo ( no pravastatin ) group , again , no significant effect of CCB treatment was observed . No beneficial effects of CCB treatment on clinical events were observed during the 2-year study follow-up . In view of the correlation between angiographic progression and subsequent clinical events as demonstrated in several large trials , it is not unrealistic to also anticipate in this population , a beneficial effect on clinical events with longer follow-up . Although the REGRESS trial was not designed to evaluate combination therapy , the results suggest that addition of CCBs to HMG-CoA reductase inhibitor therapy ( pravastatin ) acts synergistically in retarding the progression of established coronary atherosclerosis . These results appear to warrant prospective randomized trials to determine in a more definitive manner the merits of this combination in the prevention of progression of coronary atherosclerosis . Currently a number of studies in these fields are being designed or are already underway .

[ "Proposed", "synergistic", "effect", "of", "calcium", "channel", "blockers", "with", "lipid", "-", "lowering", "therapy", "in", "retarding", "progression", "of", "coronary", "atherosclerosis", ".", "Lipid", "-", "lowering", "therapy", "now", "has", "undoubtedly", "proven", "to", "be", "an", "effective", "therapeutic", "modality", "to", "retard", "the", "progression", "of", "coronary", "atherosclerosis", ".", "An", "additional", "approach", "for", "prevention", "of", "the", "progression", "of", "atherosclerosis", "is", "calcium", "channel", "blocker", "(", "CCB", ")", "treatment", ".", "Evidence", "indicating", "that", "CCBs", "inhibit", "atherosclerosis", "is", "less", "unequivocal", "than", "the", "clear", "evidence", "for", "lipid", "-", "lowering", "therapy", ".", "Many", "investigations", "support", "the", "view", "that", "a", "number", "of", "key", "processes", "in", "atherosclerosis", "may", "be", "influenced", "by", "CCBs", ".", "From", "the", "\"", "negative", "\"", "and", "\"", "positive", "\"", "studies", "with", "CCBs", "performed", "in", "animals", "and", "humans", "we", "must", "conclude", "that", "apparently", "some", ",", "but", "not", "all", ",", "types", "or", "stages", "of", "the", "atherosclerotic", "process", "are", "inhibited", "by", "CCBs", ".", "To", "assess", "whether", "lipid", "-", "lowering", "therapy", "and", "CCB", "treatment", "may", "have", "an", "additive", "or", "synergistic", "beneficial", "effect", "on", "human", "atherosclerosis", ",", "which", "is", "conceivable", "because", "their", "anti", "-", "atherosclerotic", "properties", "differ", ",", "data", "from", "the", "angiographic", "lipid", "-", "lowering", "trial", "REGRESS", "(", "pravastatin", "vs", ".", "placebo", ")", "were", "reviewed", ".", "In", "REGRESS", ",", "patients", "in", "the", "pravastatin", "group", "had", "significantly", "less", "progression", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "those", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", "no", "effect", "of", "CCB", "treatment", "was", "observed", ".", "With", "respect", "to", "angiographic", "new", "lesion", "formation", ",", "in", "the", "pravastatin", "group", "there", "were", "50", "%", "less", "patients", "with", "new", "angiographic", "lesions", "if", "cotreated", "with", "CCBs", "as", "compared", "with", "no", "CCB", "cotreatment", ",", "whereas", "in", "the", "placebo", "(", "no", "pravastatin", ")", "group", ",", "again", ",", "no", "significant", "effect", "of", "CCB", "treatment", "was", "observed", ".", "No", "beneficial", "effects", "of", "CCB", "treatment", "on", "clinical", "events", "were", "observed", "during", "the", "2-year", "study", "follow", "-", "up", ".", "In", "view", "of", "the", "correlation", "between", "angiographic", "progression", "and", "subsequent", "clinical", "events", "as", "demonstrated", "in", "several", "large", "trials", ",", "it", "is", "not", "unrealistic", "to", "also", "anticipate", "in", "this", "population", ",", "a", "beneficial", "effect", "on", "clinical", "events", "with", "longer", "follow", "-", "up", ".", "Although", "the", "REGRESS", "trial", "was", "not", "designed", "to", "evaluate", "combination", "therapy", ",", "the", "results", "suggest", "that", "addition", "of", "CCBs", "to", "HMG", "-", "CoA", "reductase", "inhibitor", "therapy", "(", "pravastatin", ")", "acts", "synergistically", "in", "retarding", "the", "progression", "of", "established", "coronary", "atherosclerosis", ".", "These", "results", "appear", "to", "warrant", "prospective", "randomized", "trials", "to", "determine", "in", "a", "more", "definitive", "manner", "the", "merits", "of", "this", "combination", "in", "the", "prevention", "of", "progression", "of", "coronary", "atherosclerosis", ".", "Currently", "a", "number", "of", "studies", "in", "these", "fields", "are", "being", "designed", "or", "are", "already", "underway", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]

Stress is an umlsterm, Fibromyalgie is an umlsterm, Patienten is an umlsterm, Uebergewicht is an umlsterm, Gewalt is an umlsterm, Depression is an umlsterm, Aengstlichkeit is an umlsterm, Fibromyalgie is an umlsterm

ZfuerRheumatologie.8057s088.ger.abstr_task0

Sentence: Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden .

[ "Psychosozialer", "Stress", "und", "psychische", "Auffaelligkeiten", "werden", "bei", "Fibromyalgie", "Patienten", "vermehrt", "beobachtet", ".", "In", "klinischen", "und", "epidemiologischen", "Studien", "findet", "sich", "gehaeuft", "ein", "Muster", "von", "niedrigem", "Bildungsgrad", ",", "erhoehter", "Scheidungsrate", ",", "Uebergewicht", "und", "Nikotinabusus", ".", "In", "gleicher", "Weise", "gehaeuft", "finden", "sich", "physische", "Gewalt", "und", "sexueller", "Missbrauch", "in", "der", "Anamnese", ".", "Manifeste", "Depression", "als", "auch", "erhoehte", "Raten", "auf", "Skalen", "fuer", "Depressivitaet", ",", "Aengstlichkeit", "und", "Somatisierungstendenz", "werden", "ueberlicherweise", "ebenso", "bei", "Fibromyalgie", "gefunden", "." ]

[ "umlsterm" ]

Stress is an umlsterm, Fibromyalgie is an umlsterm, Patienten is an umlsterm, Uebergewicht is an umlsterm, Gewalt is an umlsterm, Depression is an umlsterm, Aengstlichkeit is an umlsterm, Fibromyalgie is an umlsterm

ZfuerRheumatologie.8057s088.ger.abstr_task1

Sentence: Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden . Instructions: please typing these entity words according to sentence: Stress, Fibromyalgie, Patienten, Uebergewicht, Gewalt, Depression, Aengstlichkeit, Fibromyalgie Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden .

[ "Psychosozialer", "Stress", "und", "psychische", "Auffaelligkeiten", "werden", "bei", "Fibromyalgie", "Patienten", "vermehrt", "beobachtet", ".", "In", "klinischen", "und", "epidemiologischen", "Studien", "findet", "sich", "gehaeuft", "ein", "Muster", "von", "niedrigem", "Bildungsgrad", ",", "erhoehter", "Scheidungsrate", ",", "Uebergewicht", "und", "Nikotinabusus", ".", "In", "gleicher", "Weise", "gehaeuft", "finden", "sich", "physische", "Gewalt", "und", "sexueller", "Missbrauch", "in", "der", "Anamnese", ".", "Manifeste", "Depression", "als", "auch", "erhoehte", "Raten", "auf", "Skalen", "fuer", "Depressivitaet", ",", "Aengstlichkeit", "und", "Somatisierungstendenz", "werden", "ueberlicherweise", "ebenso", "bei", "Fibromyalgie", "gefunden", "." ]

[ "umlsterm" ]

Stress, Fibromyalgie, Patienten, Uebergewicht, Gewalt, Depression, Aengstlichkeit, Fibromyalgie

ZfuerRheumatologie.8057s088.ger.abstr_task2

Sentence: Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Psychosozialer Stress und psychische Auffaelligkeiten werden bei Fibromyalgie Patienten vermehrt beobachtet . In klinischen und epidemiologischen Studien findet sich gehaeuft ein Muster von niedrigem Bildungsgrad , erhoehter Scheidungsrate , Uebergewicht und Nikotinabusus . In gleicher Weise gehaeuft finden sich physische Gewalt und sexueller Missbrauch in der Anamnese . Manifeste Depression als auch erhoehte Raten auf Skalen fuer Depressivitaet , Aengstlichkeit und Somatisierungstendenz werden ueberlicherweise ebenso bei Fibromyalgie gefunden .

[ "Psychosozialer", "Stress", "und", "psychische", "Auffaelligkeiten", "werden", "bei", "Fibromyalgie", "Patienten", "vermehrt", "beobachtet", ".", "In", "klinischen", "und", "epidemiologischen", "Studien", "findet", "sich", "gehaeuft", "ein", "Muster", "von", "niedrigem", "Bildungsgrad", ",", "erhoehter", "Scheidungsrate", ",", "Uebergewicht", "und", "Nikotinabusus", ".", "In", "gleicher", "Weise", "gehaeuft", "finden", "sich", "physische", "Gewalt", "und", "sexueller", "Missbrauch", "in", "der", "Anamnese", ".", "Manifeste", "Depression", "als", "auch", "erhoehte", "Raten", "auf", "Skalen", "fuer", "Depressivitaet", ",", "Aengstlichkeit", "und", "Somatisierungstendenz", "werden", "ueberlicherweise", "ebenso", "bei", "Fibromyalgie", "gefunden", "." ]

[ "umlsterm" ]

Maenner is an umlsterm, Frauen is an umlsterm, Bankautomaten is an umlsterm, Analysen is an umlsterm, Staedten is an umlsterm, Mannheim is an umlsterm, Ostdeutschland is an umlsterm, Italien is an umlsterm, Finnland is an umlsterm, Geschlecht is an umlsterm, Frauen is an umlsterm, Maennern is an umlsterm, Altersgruppen is an umlsterm, Gebrauch is an umlsterm, Automaten is an umlsterm, Staedten is an umlsterm, Automaten is an umlsterm, Bankautomaten is an umlsterm, Mannheim is an umlsterm, Regressionsanalysen is an umlsterm, Staedten is an umlsterm, Automaten is an umlsterm, Geraete is an umlsterm, Geschlecht is an umlsterm, Geraete is an umlsterm, Alltagsleben is an umlsterm, Automaten is an umlsterm, Geraete is an umlsterm, Staedten is an umlsterm, Mannheim is an umlsterm, Alltagsleben is an umlsterm, Staedten is an umlsterm, Technik is an umlsterm

ZfuerGerontologie+Geriatrie.00330169.ger.abstr_task0

Sentence: Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten .

[ "Die", "Autoren", "dieses", "Beitrags", "stellen", "Befunde", "ueber", "aeltere", "Maenner", "und", "Frauen", "als", "Nutzer", "von", "Fahrkartenautomaten", ",", "Bankautomaten", "und", "Kartentelefonen", "vor", ".", "Basis", "der", "Analysen", "bilden", "Daten", ",", "die", "im", "Rahmen", "des", "internationalen", "Kooperationsprojektes", "\"", "Keeping", "the", "Elderly", "Mobile", "\"", "in", "vier", "europaeischen", "Staedten", "erhoben", "wurden", ".", "Die", "Untersuchungen", "fanden", "1995", "in", "Mannheim", "(", "Westdeutschland", ")", "mit", "404", ",", "in", "Chemnitz", "(", "Ostdeutschland", ")", "mit", "400", ",", "in", "Ancona", "(", "Italien", ")", "mit", "600", "und", "in", "Jyvaeskylae", "(", "Finnland", ")", "mit", "618", "in", "Privathaushalten", "lebenden", "Befragten", "statt", ",", "die", "aus", "den", "jeweiligen", "Einwohnermeldedregistern", "zufaellig", "ausgewaehlt", "wurden", ".", "Die", "nach", "Geschlecht", "und", "Alter", "disproportional", "geschichtete", "Stichprobe", "setzte", "sich", "zu", "gleichen", "Teilen", "aus", "Frauen", "und", "Maennern", "zusammen", "und", "umfasste", "zwei", "Altersgruppen", "(", "55", "-", "74", "Jahre", "und", "75", "Jahre", "und", "aelter", ")", ".", "Der", "Gebrauch", "der", "Automaten", "ist", "in", "allen", "untersuchten", "Staedten", "allgemein", "gering", ":", "Die", "meisten", "Befragten", "benutzen", "sie", "nicht", ".", "Die", "gebraeuchlichsten", "Automaten", "sind", "Bankautomaten", "in", "Chemnitz", "und", "Kartentelefone", "in", "Mannheim", ".", "Logistische", "Regressionsanalysen", "ergaben", ",", "dass", "das", "Alter", "der", "Befragten", "in", "allen", "vier", "Staedten", "und", "bei", "allen", "drei", "Automaten", "den", "wichtigsten", "Erklaerungsfaktor", "bildet", ".", "Das", "bedeutet", ",", "dass", "die", "Geraete", "vor", "allem", "von", "Juengeren", "benutzt", "werden", ".", "Bildung", "erwies", "sich", "als", "weiterer", "wichtiger", "Faktor", ",", "noch", "vor", "Geschlecht", ".", "Fuer", "jedes", "der", "technischen", "Geraete", "wurde", "ausser", "nach", "der", "Nutzung", "auch", "gefragt", ",", "ob", "es", "das", "Alltagsleben", "erleichtert", ",", "schwieriger", "macht", ",", "oder", "ob", "kein", "Unterschied", "besteht", ".", "Die", "Mehrheit", "der", "Nutzer", "und", "Nutzerinnen", "fand", ",", "dass", "die", "Automaten", "-", "wiederum", "bezogen", "auf", "alle", "drei", "Geraete", "und", "in", "allen", "untersuchten", "Staedten", "-", "eine", "Erleichterung", "darstellen", ".", "Fast", "ein", "Drittel", "der", "Nutzer", "in", "Mannheim", "gab", "allerdings", "auch", "an", ",", "dass", "Fahrkartenautomaten", "ihr", "Alltagsleben", "erschweren", ".", "Weitere", "Unterschiede", "und", "Gemeinsamkeiten", "zwischen", "den", "Staedten", "werden", "im", "Beitrag", "vorgestellt", ".", "Die", "Ergebnisse", "verweisen", "auf", "Beziehungen", "zwischen", "Alter", "und", "Technik", ",", "die", "in", "vertiefenden", "Studien", "weiter", "untersucht", "werden", "sollten", "." ]

[ "umlsterm" ]

Maenner is an umlsterm, Frauen is an umlsterm, Bankautomaten is an umlsterm, Analysen is an umlsterm, Staedten is an umlsterm, Mannheim is an umlsterm, Ostdeutschland is an umlsterm, Italien is an umlsterm, Finnland is an umlsterm, Geschlecht is an umlsterm, Frauen is an umlsterm, Maennern is an umlsterm, Altersgruppen is an umlsterm, Gebrauch is an umlsterm, Automaten is an umlsterm, Staedten is an umlsterm, Automaten is an umlsterm, Bankautomaten is an umlsterm, Mannheim is an umlsterm, Regressionsanalysen is an umlsterm, Staedten is an umlsterm, Automaten is an umlsterm, Geraete is an umlsterm, Geschlecht is an umlsterm, Geraete is an umlsterm, Alltagsleben is an umlsterm, Automaten is an umlsterm, Geraete is an umlsterm, Staedten is an umlsterm, Mannheim is an umlsterm, Alltagsleben is an umlsterm, Staedten is an umlsterm, Technik is an umlsterm

ZfuerGerontologie+Geriatrie.00330169.ger.abstr_task1

Sentence: Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten . Instructions: please typing these entity words according to sentence: Maenner, Frauen, Bankautomaten, Analysen, Staedten, Mannheim, Ostdeutschland, Italien, Finnland, Geschlecht, Frauen, Maennern, Altersgruppen, Gebrauch, Automaten, Staedten, Automaten, Bankautomaten, Mannheim, Regressionsanalysen, Staedten, Automaten, Geraete, Geschlecht, Geraete, Alltagsleben, Automaten, Geraete, Staedten, Mannheim, Alltagsleben, Staedten, Technik Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten .

[ "Die", "Autoren", "dieses", "Beitrags", "stellen", "Befunde", "ueber", "aeltere", "Maenner", "und", "Frauen", "als", "Nutzer", "von", "Fahrkartenautomaten", ",", "Bankautomaten", "und", "Kartentelefonen", "vor", ".", "Basis", "der", "Analysen", "bilden", "Daten", ",", "die", "im", "Rahmen", "des", "internationalen", "Kooperationsprojektes", "\"", "Keeping", "the", "Elderly", "Mobile", "\"", "in", "vier", "europaeischen", "Staedten", "erhoben", "wurden", ".", "Die", "Untersuchungen", "fanden", "1995", "in", "Mannheim", "(", "Westdeutschland", ")", "mit", "404", ",", "in", "Chemnitz", "(", "Ostdeutschland", ")", "mit", "400", ",", "in", "Ancona", "(", "Italien", ")", "mit", "600", "und", "in", "Jyvaeskylae", "(", "Finnland", ")", "mit", "618", "in", "Privathaushalten", "lebenden", "Befragten", "statt", ",", "die", "aus", "den", "jeweiligen", "Einwohnermeldedregistern", "zufaellig", "ausgewaehlt", "wurden", ".", "Die", "nach", "Geschlecht", "und", "Alter", "disproportional", "geschichtete", "Stichprobe", "setzte", "sich", "zu", "gleichen", "Teilen", "aus", "Frauen", "und", "Maennern", "zusammen", "und", "umfasste", "zwei", "Altersgruppen", "(", "55", "-", "74", "Jahre", "und", "75", "Jahre", "und", "aelter", ")", ".", "Der", "Gebrauch", "der", "Automaten", "ist", "in", "allen", "untersuchten", "Staedten", "allgemein", "gering", ":", "Die", "meisten", "Befragten", "benutzen", "sie", "nicht", ".", "Die", "gebraeuchlichsten", "Automaten", "sind", "Bankautomaten", "in", "Chemnitz", "und", "Kartentelefone", "in", "Mannheim", ".", "Logistische", "Regressionsanalysen", "ergaben", ",", "dass", "das", "Alter", "der", "Befragten", "in", "allen", "vier", "Staedten", "und", "bei", "allen", "drei", "Automaten", "den", "wichtigsten", "Erklaerungsfaktor", "bildet", ".", "Das", "bedeutet", ",", "dass", "die", "Geraete", "vor", "allem", "von", "Juengeren", "benutzt", "werden", ".", "Bildung", "erwies", "sich", "als", "weiterer", "wichtiger", "Faktor", ",", "noch", "vor", "Geschlecht", ".", "Fuer", "jedes", "der", "technischen", "Geraete", "wurde", "ausser", "nach", "der", "Nutzung", "auch", "gefragt", ",", "ob", "es", "das", "Alltagsleben", "erleichtert", ",", "schwieriger", "macht", ",", "oder", "ob", "kein", "Unterschied", "besteht", ".", "Die", "Mehrheit", "der", "Nutzer", "und", "Nutzerinnen", "fand", ",", "dass", "die", "Automaten", "-", "wiederum", "bezogen", "auf", "alle", "drei", "Geraete", "und", "in", "allen", "untersuchten", "Staedten", "-", "eine", "Erleichterung", "darstellen", ".", "Fast", "ein", "Drittel", "der", "Nutzer", "in", "Mannheim", "gab", "allerdings", "auch", "an", ",", "dass", "Fahrkartenautomaten", "ihr", "Alltagsleben", "erschweren", ".", "Weitere", "Unterschiede", "und", "Gemeinsamkeiten", "zwischen", "den", "Staedten", "werden", "im", "Beitrag", "vorgestellt", ".", "Die", "Ergebnisse", "verweisen", "auf", "Beziehungen", "zwischen", "Alter", "und", "Technik", ",", "die", "in", "vertiefenden", "Studien", "weiter", "untersucht", "werden", "sollten", "." ]

[ "umlsterm" ]

Maenner, Frauen, Bankautomaten, Analysen, Staedten, Mannheim, Ostdeutschland, Italien, Finnland, Geschlecht, Frauen, Maennern, Altersgruppen, Gebrauch, Automaten, Staedten, Automaten, Bankautomaten, Mannheim, Regressionsanalysen, Staedten, Automaten, Geraete, Geschlecht, Geraete, Alltagsleben, Automaten, Geraete, Staedten, Mannheim, Alltagsleben, Staedten, Technik

ZfuerGerontologie+Geriatrie.00330169.ger.abstr_task2

Sentence: Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Autoren dieses Beitrags stellen Befunde ueber aeltere Maenner und Frauen als Nutzer von Fahrkartenautomaten , Bankautomaten und Kartentelefonen vor . Basis der Analysen bilden Daten , die im Rahmen des internationalen Kooperationsprojektes " Keeping the Elderly Mobile " in vier europaeischen Staedten erhoben wurden . Die Untersuchungen fanden 1995 in Mannheim ( Westdeutschland ) mit 404 , in Chemnitz ( Ostdeutschland ) mit 400 , in Ancona ( Italien ) mit 600 und in Jyvaeskylae ( Finnland ) mit 618 in Privathaushalten lebenden Befragten statt , die aus den jeweiligen Einwohnermeldedregistern zufaellig ausgewaehlt wurden . Die nach Geschlecht und Alter disproportional geschichtete Stichprobe setzte sich zu gleichen Teilen aus Frauen und Maennern zusammen und umfasste zwei Altersgruppen ( 55-74 Jahre und 75 Jahre und aelter ) . Der Gebrauch der Automaten ist in allen untersuchten Staedten allgemein gering : Die meisten Befragten benutzen sie nicht . Die gebraeuchlichsten Automaten sind Bankautomaten in Chemnitz und Kartentelefone in Mannheim . Logistische Regressionsanalysen ergaben , dass das Alter der Befragten in allen vier Staedten und bei allen drei Automaten den wichtigsten Erklaerungsfaktor bildet . Das bedeutet , dass die Geraete vor allem von Juengeren benutzt werden . Bildung erwies sich als weiterer wichtiger Faktor , noch vor Geschlecht . Fuer jedes der technischen Geraete wurde ausser nach der Nutzung auch gefragt , ob es das Alltagsleben erleichtert , schwieriger macht , oder ob kein Unterschied besteht . Die Mehrheit der Nutzer und Nutzerinnen fand , dass die Automaten - wiederum bezogen auf alle drei Geraete und in allen untersuchten Staedten - eine Erleichterung darstellen . Fast ein Drittel der Nutzer in Mannheim gab allerdings auch an , dass Fahrkartenautomaten ihr Alltagsleben erschweren . Weitere Unterschiede und Gemeinsamkeiten zwischen den Staedten werden im Beitrag vorgestellt . Die Ergebnisse verweisen auf Beziehungen zwischen Alter und Technik , die in vertiefenden Studien weiter untersucht werden sollten .

[ "Die", "Autoren", "dieses", "Beitrags", "stellen", "Befunde", "ueber", "aeltere", "Maenner", "und", "Frauen", "als", "Nutzer", "von", "Fahrkartenautomaten", ",", "Bankautomaten", "und", "Kartentelefonen", "vor", ".", "Basis", "der", "Analysen", "bilden", "Daten", ",", "die", "im", "Rahmen", "des", "internationalen", "Kooperationsprojektes", "\"", "Keeping", "the", "Elderly", "Mobile", "\"", "in", "vier", "europaeischen", "Staedten", "erhoben", "wurden", ".", "Die", "Untersuchungen", "fanden", "1995", "in", "Mannheim", "(", "Westdeutschland", ")", "mit", "404", ",", "in", "Chemnitz", "(", "Ostdeutschland", ")", "mit", "400", ",", "in", "Ancona", "(", "Italien", ")", "mit", "600", "und", "in", "Jyvaeskylae", "(", "Finnland", ")", "mit", "618", "in", "Privathaushalten", "lebenden", "Befragten", "statt", ",", "die", "aus", "den", "jeweiligen", "Einwohnermeldedregistern", "zufaellig", "ausgewaehlt", "wurden", ".", "Die", "nach", "Geschlecht", "und", "Alter", "disproportional", "geschichtete", "Stichprobe", "setzte", "sich", "zu", "gleichen", "Teilen", "aus", "Frauen", "und", "Maennern", "zusammen", "und", "umfasste", "zwei", "Altersgruppen", "(", "55", "-", "74", "Jahre", "und", "75", "Jahre", "und", "aelter", ")", ".", "Der", "Gebrauch", "der", "Automaten", "ist", "in", "allen", "untersuchten", "Staedten", "allgemein", "gering", ":", "Die", "meisten", "Befragten", "benutzen", "sie", "nicht", ".", "Die", "gebraeuchlichsten", "Automaten", "sind", "Bankautomaten", "in", "Chemnitz", "und", "Kartentelefone", "in", "Mannheim", ".", "Logistische", "Regressionsanalysen", "ergaben", ",", "dass", "das", "Alter", "der", "Befragten", "in", "allen", "vier", "Staedten", "und", "bei", "allen", "drei", "Automaten", "den", "wichtigsten", "Erklaerungsfaktor", "bildet", ".", "Das", "bedeutet", ",", "dass", "die", "Geraete", "vor", "allem", "von", "Juengeren", "benutzt", "werden", ".", "Bildung", "erwies", "sich", "als", "weiterer", "wichtiger", "Faktor", ",", "noch", "vor", "Geschlecht", ".", "Fuer", "jedes", "der", "technischen", "Geraete", "wurde", "ausser", "nach", "der", "Nutzung", "auch", "gefragt", ",", "ob", "es", "das", "Alltagsleben", "erleichtert", ",", "schwieriger", "macht", ",", "oder", "ob", "kein", "Unterschied", "besteht", ".", "Die", "Mehrheit", "der", "Nutzer", "und", "Nutzerinnen", "fand", ",", "dass", "die", "Automaten", "-", "wiederum", "bezogen", "auf", "alle", "drei", "Geraete", "und", "in", "allen", "untersuchten", "Staedten", "-", "eine", "Erleichterung", "darstellen", ".", "Fast", "ein", "Drittel", "der", "Nutzer", "in", "Mannheim", "gab", "allerdings", "auch", "an", ",", "dass", "Fahrkartenautomaten", "ihr", "Alltagsleben", "erschweren", ".", "Weitere", "Unterschiede", "und", "Gemeinsamkeiten", "zwischen", "den", "Staedten", "werden", "im", "Beitrag", "vorgestellt", ".", "Die", "Ergebnisse", "verweisen", "auf", "Beziehungen", "zwischen", "Alter", "und", "Technik", ",", "die", "in", "vertiefenden", "Studien", "weiter", "untersucht", "werden", "sollten", "." ]

[ "umlsterm" ]

Adhaesion is an umlsterm, Zellen is an umlsterm, Endothelzellen is an umlsterm, Zelladhaesionsmolekuele is an umlsterm, Zelladhaesion is an umlsterm, Integrine is an umlsterm, LFA-1 is an umlsterm, ICAM-1 is an umlsterm, Transplantationsmedizin is an umlsterm, Entzuendungen is an umlsterm, Darmerkrankungen is an umlsterm, Tumormetastasierung is an umlsterm, tierexperimenteller is an umlsterm, Cytokine is an umlsterm, Spezifitaet is an umlsterm, Therapiekonzept is an umlsterm

DerChirurg.70680477.ger.abstr_task0

Sentence: Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann .

[ "Zusammenfassung", ".", "Die", "Adhaesion", "zirkulierender", "Zellen", "an", "Endothelzellen", "wird", "durch", "Zelladhaesionsmolekuele", "vermittelt", "und", "laeuft", "kaskadenfoermig", "ab", ".", "Die", "ersten", "Schritte", "dieser", "Zelladhaesionskaskade", "(", "rolling", ",", "tethering", ")", "werden", "vornehmlich", "durch", "Selektine", "(", "P-", ",", "E-", "und", "L", "-", "Selektin", ")", "reguliert", ",", "waehrend", "an", "der", "stabilen", "Zelladhaesion", "und", "der", "anschliessenden", "Migration", "hauptsaechlich", "Integrine", "(", "LFA-1", "u.", "a.", ")", "und", "Mitglieder", "der", "Immunglobulinsupergenfamilie", "(", "ICAM-1", "u.", "a.", ")", "beteiligt", "sind", ".", "Die", "Leukocytenendothelinteraktion", "laeuft", "unter", "physiologischen", "und", "pathophysiologischen", "Bedingungen", "sowie", "in", "verschiedenen", "Organen", "sehr", "aehnlich", "ab", ";", "moeglicherweise", "wird", "die", "Zellwanderung", "in", "individuelle", "Gewebe", "/", "Organe", "(", "z", ".", "B.", "beim", "homing", ")", "durch", "zusaetzliche", "organspezifische", ",", "topische", "Adhaesionsmolekuele", "(", "wie", "MAdCAM", ")", "ergaenzt", ".", "Die", "moegliche", "klinisch", "-", "chirurgische", "Bedeutung", "von", "Zelladhaesionsmolekuelen", "kommt", "insbesondere", "in", "der", "Transplantationsmedizin", "(", "Ischaemie", "/", "Reperfusion", "und", "Rejektion", ")", ",", "bei", "Entzuendungen", "(", "z", ".", "B.", "chronisch", "entzuendliche", "Darmerkrankungen", ")", "und", "in", "der", "Tumormetastasierung", "zum", "Tragen", ".", "Die", "Ergebnisse", "tierexperimenteller", "Untersuchungen", "zur", "Antiadhaesionstherapie", "zeigen", ",", "dass", "durch", "Blockade", "der", "Leukocytenendothelinteraktion", "die", "Entstehung", "von", "Entzuendungsinfiltraten", "und", "die", "Abstossungsreaktion", "verhindert", "werden", "koennen", "-", "Erfahrungen", "im", "Humansystem", "liegen", "bisher", "nur", "vereinzelt", "vor", ".", "Voraussetzung", "fuer", "die", "klinische", "Umsetzung", "ist", "u.", "a.", "ein", "besseres", "Verstaendnis", "der", "Regulation", "von", "Zelladhaesionsmolekuelen", "(", "Cytokine", ",", "chemotaktische", "Substanzen", "etc", ".", ")", "und", "der", "Spezifitaet", "dieser", "Prozesse", ".", "Schon", "heute", "legen", "die", "experimentellen", "Daten", "nahe", ",", "dass", "durch", "Interaktion", "mit", "dem", "Zelladhaesionssystem", "durch", "fruehe", "Beeinflussung", "eines", "grundlegenden", "pathophysiologischen", "Prinzips", "ein", "innovatives", "Therapiekonzept", "etabliert", "werden", "kann", "." ]

[ "umlsterm" ]

Adhaesion is an umlsterm, Zellen is an umlsterm, Endothelzellen is an umlsterm, Zelladhaesionsmolekuele is an umlsterm, Zelladhaesion is an umlsterm, Integrine is an umlsterm, LFA-1 is an umlsterm, ICAM-1 is an umlsterm, Transplantationsmedizin is an umlsterm, Entzuendungen is an umlsterm, Darmerkrankungen is an umlsterm, Tumormetastasierung is an umlsterm, tierexperimenteller is an umlsterm, Cytokine is an umlsterm, Spezifitaet is an umlsterm, Therapiekonzept is an umlsterm

DerChirurg.70680477.ger.abstr_task1

Sentence: Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann . Instructions: please typing these entity words according to sentence: Adhaesion, Zellen, Endothelzellen, Zelladhaesionsmolekuele, Zelladhaesion, Integrine, LFA-1, ICAM-1, Transplantationsmedizin, Entzuendungen, Darmerkrankungen, Tumormetastasierung, tierexperimenteller, Cytokine, Spezifitaet, Therapiekonzept Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann .

[ "Zusammenfassung", ".", "Die", "Adhaesion", "zirkulierender", "Zellen", "an", "Endothelzellen", "wird", "durch", "Zelladhaesionsmolekuele", "vermittelt", "und", "laeuft", "kaskadenfoermig", "ab", ".", "Die", "ersten", "Schritte", "dieser", "Zelladhaesionskaskade", "(", "rolling", ",", "tethering", ")", "werden", "vornehmlich", "durch", "Selektine", "(", "P-", ",", "E-", "und", "L", "-", "Selektin", ")", "reguliert", ",", "waehrend", "an", "der", "stabilen", "Zelladhaesion", "und", "der", "anschliessenden", "Migration", "hauptsaechlich", "Integrine", "(", "LFA-1", "u.", "a.", ")", "und", "Mitglieder", "der", "Immunglobulinsupergenfamilie", "(", "ICAM-1", "u.", "a.", ")", "beteiligt", "sind", ".", "Die", "Leukocytenendothelinteraktion", "laeuft", "unter", "physiologischen", "und", "pathophysiologischen", "Bedingungen", "sowie", "in", "verschiedenen", "Organen", "sehr", "aehnlich", "ab", ";", "moeglicherweise", "wird", "die", "Zellwanderung", "in", "individuelle", "Gewebe", "/", "Organe", "(", "z", ".", "B.", "beim", "homing", ")", "durch", "zusaetzliche", "organspezifische", ",", "topische", "Adhaesionsmolekuele", "(", "wie", "MAdCAM", ")", "ergaenzt", ".", "Die", "moegliche", "klinisch", "-", "chirurgische", "Bedeutung", "von", "Zelladhaesionsmolekuelen", "kommt", "insbesondere", "in", "der", "Transplantationsmedizin", "(", "Ischaemie", "/", "Reperfusion", "und", "Rejektion", ")", ",", "bei", "Entzuendungen", "(", "z", ".", "B.", "chronisch", "entzuendliche", "Darmerkrankungen", ")", "und", "in", "der", "Tumormetastasierung", "zum", "Tragen", ".", "Die", "Ergebnisse", "tierexperimenteller", "Untersuchungen", "zur", "Antiadhaesionstherapie", "zeigen", ",", "dass", "durch", "Blockade", "der", "Leukocytenendothelinteraktion", "die", "Entstehung", "von", "Entzuendungsinfiltraten", "und", "die", "Abstossungsreaktion", "verhindert", "werden", "koennen", "-", "Erfahrungen", "im", "Humansystem", "liegen", "bisher", "nur", "vereinzelt", "vor", ".", "Voraussetzung", "fuer", "die", "klinische", "Umsetzung", "ist", "u.", "a.", "ein", "besseres", "Verstaendnis", "der", "Regulation", "von", "Zelladhaesionsmolekuelen", "(", "Cytokine", ",", "chemotaktische", "Substanzen", "etc", ".", ")", "und", "der", "Spezifitaet", "dieser", "Prozesse", ".", "Schon", "heute", "legen", "die", "experimentellen", "Daten", "nahe", ",", "dass", "durch", "Interaktion", "mit", "dem", "Zelladhaesionssystem", "durch", "fruehe", "Beeinflussung", "eines", "grundlegenden", "pathophysiologischen", "Prinzips", "ein", "innovatives", "Therapiekonzept", "etabliert", "werden", "kann", "." ]

[ "umlsterm" ]

Adhaesion, Zellen, Endothelzellen, Zelladhaesionsmolekuele, Zelladhaesion, Integrine, LFA-1, ICAM-1, Transplantationsmedizin, Entzuendungen, Darmerkrankungen, Tumormetastasierung, tierexperimenteller, Cytokine, Spezifitaet, Therapiekonzept

DerChirurg.70680477.ger.abstr_task2

Sentence: Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Die Adhaesion zirkulierender Zellen an Endothelzellen wird durch Zelladhaesionsmolekuele vermittelt und laeuft kaskadenfoermig ab . Die ersten Schritte dieser Zelladhaesionskaskade ( rolling , tethering ) werden vornehmlich durch Selektine ( P- , E- und L-Selektin ) reguliert , waehrend an der stabilen Zelladhaesion und der anschliessenden Migration hauptsaechlich Integrine ( LFA-1 u. a. ) und Mitglieder der Immunglobulinsupergenfamilie ( ICAM-1 u. a. ) beteiligt sind . Die Leukocytenendothelinteraktion laeuft unter physiologischen und pathophysiologischen Bedingungen sowie in verschiedenen Organen sehr aehnlich ab ; moeglicherweise wird die Zellwanderung in individuelle Gewebe/Organe ( z . B. beim homing ) durch zusaetzliche organspezifische , topische Adhaesionsmolekuele ( wie MAdCAM ) ergaenzt . Die moegliche klinisch-chirurgische Bedeutung von Zelladhaesionsmolekuelen kommt insbesondere in der Transplantationsmedizin ( Ischaemie/Reperfusion und Rejektion ) , bei Entzuendungen ( z . B. chronisch entzuendliche Darmerkrankungen ) und in der Tumormetastasierung zum Tragen . Die Ergebnisse tierexperimenteller Untersuchungen zur Antiadhaesionstherapie zeigen , dass durch Blockade der Leukocytenendothelinteraktion die Entstehung von Entzuendungsinfiltraten und die Abstossungsreaktion verhindert werden koennen - Erfahrungen im Humansystem liegen bisher nur vereinzelt vor . Voraussetzung fuer die klinische Umsetzung ist u. a. ein besseres Verstaendnis der Regulation von Zelladhaesionsmolekuelen ( Cytokine , chemotaktische Substanzen etc. ) und der Spezifitaet dieser Prozesse . Schon heute legen die experimentellen Daten nahe , dass durch Interaktion mit dem Zelladhaesionssystem durch fruehe Beeinflussung eines grundlegenden pathophysiologischen Prinzips ein innovatives Therapiekonzept etabliert werden kann .

[ "Zusammenfassung", ".", "Die", "Adhaesion", "zirkulierender", "Zellen", "an", "Endothelzellen", "wird", "durch", "Zelladhaesionsmolekuele", "vermittelt", "und", "laeuft", "kaskadenfoermig", "ab", ".", "Die", "ersten", "Schritte", "dieser", "Zelladhaesionskaskade", "(", "rolling", ",", "tethering", ")", "werden", "vornehmlich", "durch", "Selektine", "(", "P-", ",", "E-", "und", "L", "-", "Selektin", ")", "reguliert", ",", "waehrend", "an", "der", "stabilen", "Zelladhaesion", "und", "der", "anschliessenden", "Migration", "hauptsaechlich", "Integrine", "(", "LFA-1", "u.", "a.", ")", "und", "Mitglieder", "der", "Immunglobulinsupergenfamilie", "(", "ICAM-1", "u.", "a.", ")", "beteiligt", "sind", ".", "Die", "Leukocytenendothelinteraktion", "laeuft", "unter", "physiologischen", "und", "pathophysiologischen", "Bedingungen", "sowie", "in", "verschiedenen", "Organen", "sehr", "aehnlich", "ab", ";", "moeglicherweise", "wird", "die", "Zellwanderung", "in", "individuelle", "Gewebe", "/", "Organe", "(", "z", ".", "B.", "beim", "homing", ")", "durch", "zusaetzliche", "organspezifische", ",", "topische", "Adhaesionsmolekuele", "(", "wie", "MAdCAM", ")", "ergaenzt", ".", "Die", "moegliche", "klinisch", "-", "chirurgische", "Bedeutung", "von", "Zelladhaesionsmolekuelen", "kommt", "insbesondere", "in", "der", "Transplantationsmedizin", "(", "Ischaemie", "/", "Reperfusion", "und", "Rejektion", ")", ",", "bei", "Entzuendungen", "(", "z", ".", "B.", "chronisch", "entzuendliche", "Darmerkrankungen", ")", "und", "in", "der", "Tumormetastasierung", "zum", "Tragen", ".", "Die", "Ergebnisse", "tierexperimenteller", "Untersuchungen", "zur", "Antiadhaesionstherapie", "zeigen", ",", "dass", "durch", "Blockade", "der", "Leukocytenendothelinteraktion", "die", "Entstehung", "von", "Entzuendungsinfiltraten", "und", "die", "Abstossungsreaktion", "verhindert", "werden", "koennen", "-", "Erfahrungen", "im", "Humansystem", "liegen", "bisher", "nur", "vereinzelt", "vor", ".", "Voraussetzung", "fuer", "die", "klinische", "Umsetzung", "ist", "u.", "a.", "ein", "besseres", "Verstaendnis", "der", "Regulation", "von", "Zelladhaesionsmolekuelen", "(", "Cytokine", ",", "chemotaktische", "Substanzen", "etc", ".", ")", "und", "der", "Spezifitaet", "dieser", "Prozesse", ".", "Schon", "heute", "legen", "die", "experimentellen", "Daten", "nahe", ",", "dass", "durch", "Interaktion", "mit", "dem", "Zelladhaesionssystem", "durch", "fruehe", "Beeinflussung", "eines", "grundlegenden", "pathophysiologischen", "Prinzips", "ein", "innovatives", "Therapiekonzept", "etabliert", "werden", "kann", "." ]

[ "umlsterm" ]

leukotriene receptor is a GENE-N, MUC2/5AC is a GENE-N, mucin is a GENE-N

17223000_task0

Sentence: The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N

[ "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]

The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells.

[ "The", "inhibitory", "effect", "of", "the", "leukotriene", "receptor", "antagonist", "on", "leukotriene", "D4-induced", "MUC2/5AC", "gene", "expression", "and", "mucin", "secretion", "in", "human", "airway", "epithelial", "cells", "." ]

[ "GENE-N", "CHEMICAL" ]

leukotriene receptor is a GENE-N, MUC2/5AC is a GENE-N, mucin is a GENE-N

17223000_task1

Sentence: The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells. Instructions: please typing these entity words according to sentence: leukotriene receptor, MUC2/5AC, mucin Options: GENE-N

[ "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]

The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells.

[ "The", "inhibitory", "effect", "of", "the", "leukotriene", "receptor", "antagonist", "on", "leukotriene", "D4-induced", "MUC2/5AC", "gene", "expression", "and", "mucin", "secretion", "in", "human", "airway", "epithelial", "cells", "." ]

[ "GENE-N", "CHEMICAL" ]

leukotriene receptor, MUC2/5AC, mucin

17223000_task2

Sentence: The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]

The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells.

[ "The", "inhibitory", "effect", "of", "the", "leukotriene", "receptor", "antagonist", "on", "leukotriene", "D4-induced", "MUC2/5AC", "gene", "expression", "and", "mucin", "secretion", "in", "human", "airway", "epithelial", "cells", "." ]

[ "GENE-N", "CHEMICAL" ]

IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, IFN - beta is a Protein, IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, P53 is a Protein, Rb is a Protein, Bcl - xL is a Protein, IL-2 is a Protein, tyrosine is a Entity, nucleus is a Entity, signal transducers and activators of transcription ( STAT ) 2 is a Protein, STAT2 is a Protein, IL-2 is a Protein

740_task0

Sentence: Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis.

[ "Rescue", "by", "cytokines", "of", "apoptotic", "cell", "death", "induced", "by", "IL-2", "deprivation", "of", "human", "antigen", "-", "specific", "T", "cell", "clones", ".", "\n", "The", "control", "of", "cell", "survival", "and", "cell", "death", "is", "of", "central", "importance", "in", "tissues", "with", "high", "cell", "turnover", "such", "as", "the", "lymphoid", "system", ".", "We", "have", "examined", "the", "effect", "of", "cytokines", "on", "IL-2", "deprivation", "-", "induced", "apoptosis", "of", "human", "antigen", "-", "specific", "T", "helper", "clones", "with", "different", "cytokine", "production", "profiles", ".", "We", "found", "that", "IL-2", ",", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", ",", "and", "IFN", "-", "beta", "inhibited", "IL-2", "deprivation", "apoptosis", "in", "Th0", ",", "Th1", ",", "and", "Th2", "clones", ".", "We", "also", "found", "that", "IL-2", "protects", "T", "cell", "clones", "from", "IL-2", "deprivation", "apoptosis", "accompanying", "active", "proliferation", "and", "enhanced", "expression", "of", "P53", ",", "Rb", "and", "Bcl", "-", "xL", "proteins", ".", "In", "contrast", ",", "IFN", "-", "alpha", "/", "beta", "rescued", "T", "cell", "clones", "from", "apoptosis", "without", "active", "proliferation", ",", "and", "expression", "of", "apoptosis", "-", "associated", "proteins", "tested", "so", "far", "was", "unaffected", ".", "This", "may", "be", "due", "to", "the", "fact", "that", "T", "cells", "treated", "with", "IL-2", "contained", "those", "located", "in", "S", "+", "G2", "/", "M", "phases", "of", "the", "cell", "cycle", ",", "whereas", "the", "vast", "majority", "of", "T", "cells", "treated", "with", "IFN", "-", "alpha", "/", "beta", "were", "located", "in", "G0", "/", "G1", "phase", ".", "IFN", "-", "alpha", "/", "beta", "specifically", "induced", "tyrosine", "phosphorylation", "and", "translocation", "into", "nucleus", "of", "signal", "transducers", "and", "activators", "of", "transcription", "(", "STAT", ")", "2", "protein", "in", "the", "T", "cell", "clones", ".", "In", "addition", ",", "over", "-", "expression", "of", "STAT2", "by", "transfection", "of", "the", "cDNA", "prevented", "apoptosis", "of", "the", "T", "cell", "clones", ".", "Our", "present", "study", "shows", "that", "IFN", "-", "alpha", "and", "-beta", "mediate", "anti", "-", "apoptotic", "effect", "through", "other", "pathways", "than", "that", "of", "IL-2", "in", "growth", "factor", "deprivation", "apoptosis", "." ]

[ "Protein", "Entity" ]

IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, IFN - beta is a Protein, IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, P53 is a Protein, Rb is a Protein, Bcl - xL is a Protein, IL-2 is a Protein, tyrosine is a Entity, nucleus is a Entity, signal transducers and activators of transcription ( STAT ) 2 is a Protein, STAT2 is a Protein, IL-2 is a Protein

740_task1

Sentence: Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis. Instructions: please typing these entity words according to sentence: IL-2, IL-2, IL-2, IFN - beta, IL-2, IL-2, IL-2, P53, Rb, Bcl - xL, IL-2, tyrosine, nucleus, signal transducers and activators of transcription ( STAT ) 2, STAT2, IL-2 Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis.

[ "Rescue", "by", "cytokines", "of", "apoptotic", "cell", "death", "induced", "by", "IL-2", "deprivation", "of", "human", "antigen", "-", "specific", "T", "cell", "clones", ".", "\n", "The", "control", "of", "cell", "survival", "and", "cell", "death", "is", "of", "central", "importance", "in", "tissues", "with", "high", "cell", "turnover", "such", "as", "the", "lymphoid", "system", ".", "We", "have", "examined", "the", "effect", "of", "cytokines", "on", "IL-2", "deprivation", "-", "induced", "apoptosis", "of", "human", "antigen", "-", "specific", "T", "helper", "clones", "with", "different", "cytokine", "production", "profiles", ".", "We", "found", "that", "IL-2", ",", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", ",", "and", "IFN", "-", "beta", "inhibited", "IL-2", "deprivation", "apoptosis", "in", "Th0", ",", "Th1", ",", "and", "Th2", "clones", ".", "We", "also", "found", "that", "IL-2", "protects", "T", "cell", "clones", "from", "IL-2", "deprivation", "apoptosis", "accompanying", "active", "proliferation", "and", "enhanced", "expression", "of", "P53", ",", "Rb", "and", "Bcl", "-", "xL", "proteins", ".", "In", "contrast", ",", "IFN", "-", "alpha", "/", "beta", "rescued", "T", "cell", "clones", "from", "apoptosis", "without", "active", "proliferation", ",", "and", "expression", "of", "apoptosis", "-", "associated", "proteins", "tested", "so", "far", "was", "unaffected", ".", "This", "may", "be", "due", "to", "the", "fact", "that", "T", "cells", "treated", "with", "IL-2", "contained", "those", "located", "in", "S", "+", "G2", "/", "M", "phases", "of", "the", "cell", "cycle", ",", "whereas", "the", "vast", "majority", "of", "T", "cells", "treated", "with", "IFN", "-", "alpha", "/", "beta", "were", "located", "in", "G0", "/", "G1", "phase", ".", "IFN", "-", "alpha", "/", "beta", "specifically", "induced", "tyrosine", "phosphorylation", "and", "translocation", "into", "nucleus", "of", "signal", "transducers", "and", "activators", "of", "transcription", "(", "STAT", ")", "2", "protein", "in", "the", "T", "cell", "clones", ".", "In", "addition", ",", "over", "-", "expression", "of", "STAT2", "by", "transfection", "of", "the", "cDNA", "prevented", "apoptosis", "of", "the", "T", "cell", "clones", ".", "Our", "present", "study", "shows", "that", "IFN", "-", "alpha", "and", "-beta", "mediate", "anti", "-", "apoptotic", "effect", "through", "other", "pathways", "than", "that", "of", "IL-2", "in", "growth", "factor", "deprivation", "apoptosis", "." ]

[ "Protein", "Entity" ]

IL-2, IL-2, IL-2, IFN - beta, IL-2, IL-2, IL-2, P53, Rb, Bcl - xL, IL-2, tyrosine, nucleus, signal transducers and activators of transcription ( STAT ) 2, STAT2, IL-2

740_task2

Sentence: Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. The control of cell survival and cell death is of central importance in tissues with high cell turnover such as the lymphoid system. We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles. We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones. We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins. In contrast, IFN-alpha/beta rescued T cell clones from apoptosis without active proliferation, and expression of apoptosis-associated proteins tested so far was unaffected. This may be due to the fact that T cells treated with IL-2 contained those located in S + G2/M phases of the cell cycle, whereas the vast majority of T cells treated with IFN-alpha/beta were located in G0/G1 phase. IFN-alpha/beta specifically induced tyrosine phosphorylation and translocation into nucleus of signal transducers and activators of transcription (STAT) 2 protein in the T cell clones. In addition, over-expression of STAT2 by transfection of the cDNA prevented apoptosis of the T cell clones. Our present study shows that IFN-alpha and -beta mediate anti-apoptotic effect through other pathways than that of IL-2 in growth factor deprivation apoptosis.

[ "Rescue", "by", "cytokines", "of", "apoptotic", "cell", "death", "induced", "by", "IL-2", "deprivation", "of", "human", "antigen", "-", "specific", "T", "cell", "clones", ".", "\n", "The", "control", "of", "cell", "survival", "and", "cell", "death", "is", "of", "central", "importance", "in", "tissues", "with", "high", "cell", "turnover", "such", "as", "the", "lymphoid", "system", ".", "We", "have", "examined", "the", "effect", "of", "cytokines", "on", "IL-2", "deprivation", "-", "induced", "apoptosis", "of", "human", "antigen", "-", "specific", "T", "helper", "clones", "with", "different", "cytokine", "production", "profiles", ".", "We", "found", "that", "IL-2", ",", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", ",", "and", "IFN", "-", "beta", "inhibited", "IL-2", "deprivation", "apoptosis", "in", "Th0", ",", "Th1", ",", "and", "Th2", "clones", ".", "We", "also", "found", "that", "IL-2", "protects", "T", "cell", "clones", "from", "IL-2", "deprivation", "apoptosis", "accompanying", "active", "proliferation", "and", "enhanced", "expression", "of", "P53", ",", "Rb", "and", "Bcl", "-", "xL", "proteins", ".", "In", "contrast", ",", "IFN", "-", "alpha", "/", "beta", "rescued", "T", "cell", "clones", "from", "apoptosis", "without", "active", "proliferation", ",", "and", "expression", "of", "apoptosis", "-", "associated", "proteins", "tested", "so", "far", "was", "unaffected", ".", "This", "may", "be", "due", "to", "the", "fact", "that", "T", "cells", "treated", "with", "IL-2", "contained", "those", "located", "in", "S", "+", "G2", "/", "M", "phases", "of", "the", "cell", "cycle", ",", "whereas", "the", "vast", "majority", "of", "T", "cells", "treated", "with", "IFN", "-", "alpha", "/", "beta", "were", "located", "in", "G0", "/", "G1", "phase", ".", "IFN", "-", "alpha", "/", "beta", "specifically", "induced", "tyrosine", "phosphorylation", "and", "translocation", "into", "nucleus", "of", "signal", "transducers", "and", "activators", "of", "transcription", "(", "STAT", ")", "2", "protein", "in", "the", "T", "cell", "clones", ".", "In", "addition", ",", "over", "-", "expression", "of", "STAT2", "by", "transfection", "of", "the", "cDNA", "prevented", "apoptosis", "of", "the", "T", "cell", "clones", ".", "Our", "present", "study", "shows", "that", "IFN", "-", "alpha", "and", "-beta", "mediate", "anti", "-", "apoptotic", "effect", "through", "other", "pathways", "than", "that", "of", "IL-2", "in", "growth", "factor", "deprivation", "apoptosis", "." ]

[ "Protein", "Entity" ]

intramedullary nail is an umlsterm, nature is an umlsterm, nail is an umlsterm, titanium is an umlsterm, nail is an umlsterm, bone formation is an umlsterm, bone formation is an umlsterm, nail is an umlsterm, cortex is an umlsterm, nail is an umlsterm, titanium is an umlsterm, nail is an umlsterm, therapeutic is an umlsterm

DerUnfallchirurg.81010950.eng.abstr_task0

Sentence: Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful .

[ "Impaction", "of", "an", "intramedullary", "nail", "during", "extraction", "is", "an", "unpredictable", "and", "delicate", "situation", ".", "Its", "problematic", "nature", "is", "unfolded", "on", "a", "report", "of", "two", "cases", ",", "one", "with", "a", "Kuentscher", "nail", "and", "one", "with", "a", "modern", "solid", "titanium", "nail", ".", "This", "event", "is", "caused", "by", "ingrowth", "of", "new", "bone", "formation", "into", "the", "slot", "or", "the", "dorsal", "flute", "respectively", ".", "The", "new", "bone", "formation", "is", "a", "mechanical", "barrier", "which", "effectively", "forces", "the", "distal", "part", "of", "the", "nail", "to", "jam", "against", "the", "cortex", ".", "Both", ",", "the", "slot", "of", "the", "unlocked", "reamed", "clover", "leaf", "nail", "and", "the", "wider", "dorsal", "flute", "of", "the", "solid", "titanium", "nail", ",", "realize", "certain", "therapeutic", "concepts", ".", "Their", "factual", "benefit", "within", "the", "concept", "of", "interlocking", "nailing", "is", "doubtful", "." ]

[ "umlsterm" ]

intramedullary nail is an umlsterm, nature is an umlsterm, nail is an umlsterm, titanium is an umlsterm, nail is an umlsterm, bone formation is an umlsterm, bone formation is an umlsterm, nail is an umlsterm, cortex is an umlsterm, nail is an umlsterm, titanium is an umlsterm, nail is an umlsterm, therapeutic is an umlsterm

DerUnfallchirurg.81010950.eng.abstr_task1

Sentence: Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful . Instructions: please typing these entity words according to sentence: intramedullary nail, nature, nail, titanium, nail, bone formation, bone formation, nail, cortex, nail, titanium, nail, therapeutic Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful .

[ "Impaction", "of", "an", "intramedullary", "nail", "during", "extraction", "is", "an", "unpredictable", "and", "delicate", "situation", ".", "Its", "problematic", "nature", "is", "unfolded", "on", "a", "report", "of", "two", "cases", ",", "one", "with", "a", "Kuentscher", "nail", "and", "one", "with", "a", "modern", "solid", "titanium", "nail", ".", "This", "event", "is", "caused", "by", "ingrowth", "of", "new", "bone", "formation", "into", "the", "slot", "or", "the", "dorsal", "flute", "respectively", ".", "The", "new", "bone", "formation", "is", "a", "mechanical", "barrier", "which", "effectively", "forces", "the", "distal", "part", "of", "the", "nail", "to", "jam", "against", "the", "cortex", ".", "Both", ",", "the", "slot", "of", "the", "unlocked", "reamed", "clover", "leaf", "nail", "and", "the", "wider", "dorsal", "flute", "of", "the", "solid", "titanium", "nail", ",", "realize", "certain", "therapeutic", "concepts", ".", "Their", "factual", "benefit", "within", "the", "concept", "of", "interlocking", "nailing", "is", "doubtful", "." ]

[ "umlsterm" ]

intramedullary nail, nature, nail, titanium, nail, bone formation, bone formation, nail, cortex, nail, titanium, nail, therapeutic

DerUnfallchirurg.81010950.eng.abstr_task2

Sentence: Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Impaction of an intramedullary nail during extraction is an unpredictable and delicate situation . Its problematic nature is unfolded on a report of two cases , one with a Kuentscher nail and one with a modern solid titanium nail . This event is caused by ingrowth of new bone formation into the slot or the dorsal flute respectively . The new bone formation is a mechanical barrier which effectively forces the distal part of the nail to jam against the cortex . Both , the slot of the unlocked reamed clover leaf nail and the wider dorsal flute of the solid titanium nail , realize certain therapeutic concepts . Their factual benefit within the concept of interlocking nailing is doubtful .

[ "Impaction", "of", "an", "intramedullary", "nail", "during", "extraction", "is", "an", "unpredictable", "and", "delicate", "situation", ".", "Its", "problematic", "nature", "is", "unfolded", "on", "a", "report", "of", "two", "cases", ",", "one", "with", "a", "Kuentscher", "nail", "and", "one", "with", "a", "modern", "solid", "titanium", "nail", ".", "This", "event", "is", "caused", "by", "ingrowth", "of", "new", "bone", "formation", "into", "the", "slot", "or", "the", "dorsal", "flute", "respectively", ".", "The", "new", "bone", "formation", "is", "a", "mechanical", "barrier", "which", "effectively", "forces", "the", "distal", "part", "of", "the", "nail", "to", "jam", "against", "the", "cortex", ".", "Both", ",", "the", "slot", "of", "the", "unlocked", "reamed", "clover", "leaf", "nail", "and", "the", "wider", "dorsal", "flute", "of", "the", "solid", "titanium", "nail", ",", "realize", "certain", "therapeutic", "concepts", ".", "Their", "factual", "benefit", "within", "the", "concept", "of", "interlocking", "nailing", "is", "doubtful", "." ]

[ "umlsterm" ]

Chronic hepatitis B is a Condition, HBsAg is a Measurement, positive is a Value, > 6 months is a Temporal, HBeAg is a Measurement, negative is a Value, within six months prior to initiation of peginterferon alfa-2a is a Temporal, HBV DNA is a Measurement, < 200 IU / ml is a Value, during nucleos(t)ide analogue ( except Telbivudine ) treatment is a Temporal, within one month prior to initiation of peginterferon alfa-2a is a Temporal, Compensated is a Qualifier, liver disease is a Condition, Age is a Person, > 18 years is a Value

NCT01373684_inc_task0

Sentence: Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Measurement

[ "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O" ]

Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent

[ "Chronic", "hepatitis", "B", "(", "HBsAg", "positive", ">", "6", "months", ")", "\n", "HBeAg", "negative", "within", "six", "months", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "HBV", "DNA", "<", "200", "IU", "/", "ml", "during", "nucleos(t)ide", "analogue", "(", "except", "Telbivudine", ")", "treatment", "within", "one", "month", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "Compensated", "liver", "disease", "\n", "Age", ">", "18", "years", "\n", "Written", "informed", "consent", "\n" ]

[ "Temporal", "Reference_point", "Drug", "Condition", "Value", "Qualifier", "Measurement", "Negation", "Person" ]

Chronic hepatitis B is a Condition, HBsAg is a Measurement, positive is a Value, > 6 months is a Temporal, HBeAg is a Measurement, negative is a Value, within six months prior to initiation of peginterferon alfa-2a is a Temporal, HBV DNA is a Measurement, < 200 IU / ml is a Value, during nucleos(t)ide analogue ( except Telbivudine ) treatment is a Temporal, within one month prior to initiation of peginterferon alfa-2a is a Temporal, Compensated is a Qualifier, liver disease is a Condition, Age is a Person, > 18 years is a Value

NCT01373684_inc_task1

Sentence: Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent Instructions: please typing these entity words according to sentence: Chronic hepatitis B, HBsAg, positive, > 6 months, HBeAg, negative, within six months prior to initiation of peginterferon alfa-2a, HBV DNA, < 200 IU / ml, during nucleos(t)ide analogue ( except Telbivudine ) treatment, within one month prior to initiation of peginterferon alfa-2a, Compensated, liver disease, Age, > 18 years Options: Temporal, Condition, Qualifier, Value, Person, Measurement

[ "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O" ]

Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent

[ "Chronic", "hepatitis", "B", "(", "HBsAg", "positive", ">", "6", "months", ")", "\n", "HBeAg", "negative", "within", "six", "months", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "HBV", "DNA", "<", "200", "IU", "/", "ml", "during", "nucleos(t)ide", "analogue", "(", "except", "Telbivudine", ")", "treatment", "within", "one", "month", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "Compensated", "liver", "disease", "\n", "Age", ">", "18", "years", "\n", "Written", "informed", "consent", "\n" ]

[ "Temporal", "Reference_point", "Drug", "Condition", "Value", "Qualifier", "Measurement", "Negation", "Person" ]

Chronic hepatitis B, HBsAg, positive, > 6 months, HBeAg, negative, within six months prior to initiation of peginterferon alfa-2a, HBV DNA, < 200 IU / ml, during nucleos(t)ide analogue ( except Telbivudine ) treatment, within one month prior to initiation of peginterferon alfa-2a, Compensated, liver disease, Age, > 18 years

NCT01373684_inc_task2

Sentence: Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent Instructions: please extract entity words from the input sentence

[ "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Measurement", "B-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O" ]

Chronic hepatitis B (HBsAg positive > 6 months) HBeAg negative within six months prior to initiation of peginterferon alfa-2a HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a Compensated liver disease Age > 18 years Written informed consent

[ "Chronic", "hepatitis", "B", "(", "HBsAg", "positive", ">", "6", "months", ")", "\n", "HBeAg", "negative", "within", "six", "months", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "HBV", "DNA", "<", "200", "IU", "/", "ml", "during", "nucleos(t)ide", "analogue", "(", "except", "Telbivudine", ")", "treatment", "within", "one", "month", "prior", "to", "initiation", "of", "peginterferon", "alfa-2a", "\n", "Compensated", "liver", "disease", "\n", "Age", ">", "18", "years", "\n", "Written", "informed", "consent", "\n" ]

[ "Temporal", "Reference_point", "Drug", "Condition", "Value", "Qualifier", "Measurement", "Negation", "Person" ]

moderate to severe is a Scope, Ankylosing Spondylitis ( AS ) is a Condition, prior is a Temporal, radiologic evidence is a Condition, fulfilling is a Value, Modified New York criteria for AS is a Measurement, Active is a Qualifier, AS is a Condition, total Bath Ankylosing Spondylitis Disease Activity index ( BASDAI ) is a Measurement, = 4 is a Value, at baseline is a Temporal, Spinal pain is a Condition, BASDAI question # 2 is a Measurement, = 4 cm is a Value, at baseline is a Temporal, Total back pain is a Condition, visual analog scale ( VAS ) is a Measurement, = 40 mm is a Value, at baseline is a Temporal, non - steroidal anti - inflammatory drugs ( NSAIDs ) is a Drug, maximum tolerated dose is a Multiplier, for at least 4 weeks prior to their Baseline Visit is a Temporal, inadequate response is a Condition, for less than 4 weeks is a Temporal, withdrawn for intolerance , toxicity or contraindications is a Scope, NSAIDs including Cyclooxygenase-1 ( COX-1 ) or Cyclooxygenase-2 ( COX-2 ) inhibitors is a Scope, for at least 2 weeks before their Baseline Visit is a Temporal, tumor necrosis factor alpha ( TNFa ) inhibitor ( not more than one ) is a Scope, inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti - TNFa agent is a Scope, Total ankylosis of the spine is a Condition, hypersensitivity is a Condition, study drugs or its excipients or to drugs of similar chemical classes is a Scope, Chest x - ray , computerized tomography ( CT ) scan , or chest magnetic resonance imaging ( MRI ) is a Scope, ongoing is a Temporal, infectious or malignant process is a Scope, within 3 months prior to screening is a Temporal, secukinumab or any other biologic drug is a Scope, targeting is a Condition, Interleukin-17 ( IL-17 ) , Interleukin-12/23 ( IL-12/23 ) , or the IL-17 receptor , or any other biologic immunomodulating agent is a Scope, except is a Negation, TNFa is a Drug, more than one is a Multiplier, anti - TNFa agent is a Drug, intramuscular or intravenous is a Scope, corticosteroid injection is a Procedure, within 2 weeks before baseline is a Temporal, intra - articular injections is a Procedure, corticosteroid is a Drug, within 4 weeks before baseline is a Temporal, Previous is a Temporal, cell - depleting therapies is a Procedure, high potency opioid analgesics is a Drug, methadone , hydromorphone , morphine is a Scope

NCT03350815_inc_task0

Sentence: Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Multiplier, Procedure, Negation, Scope, Measurement, Drug

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Temporal", "O", "B-Condition", "I-Condition", "B-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Qualifier", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine)

[ "Understand", "and", "communicate", "with", "the", "investigator", ",", "comply", "with", "the", "requirements", "of", "the", "study", "and", "give", "a", "written", ",", "signed", "and", "dated", "informed", "consent", "\n", "Male", "or", "non", "-", "pregnant", ",", "non", "-", "lactating", "female", "patients", "at", "least", "18", "years", "of", "age", "\n", "Diagnosis", "of", "moderate", "to", "severe", "Ankylosing", "Spondylitis", "(", "AS", ")", "with", "prior", "documented", "radiologic", "evidence", "fulfilling", "the", "Modified", "New", "York", "criteria", "for", "AS", "\n", "Active", "AS", "assessed", "by", "total", "Bath", "Ankylosing", "Spondylitis", "Disease", "Activity", "index", "(", "BASDAI", ")", "=", "4", "(", "0", "-", "10", ")", "at", "baseline", "\n", "Spinal", "pain", "as", "measured", "by", "BASDAI", "question", "#", "2", "=", "4", "cm", "(", "0", "-", "10", "cm", ")", "at", "baseline", "\n", "Total", "back", "pain", "as", "measured", "by", "visual", "analog", "scale", "(", "VAS", ")", "=", "40", "mm", "(", "0", "-", "100", "mm", ")", "at", "baseline", "\n", "Patients", "should", "have", "been", "on", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "at", "the", "maximum", "tolerated", "dose", "for", "at", "least", "4", "weeks", "prior", "to", "their", "Baseline", "Visit", ",", "with", "an", "inadequate", "response", "or", "for", "less", "than", "4", "weeks", "if", "withdrawn", "for", "intolerance", ",", "toxicity", "or", "contraindications", "\n", "Stable", "dose", "of", "NSAIDs", "including", "Cyclooxygenase-1", "(", "COX-1", ")", "or", "Cyclooxygenase-2", "(", "COX-2", ")", "inhibitors", "for", "at", "least", "2", "weeks", "before", "their", "Baseline", "Visit", "\n", "Patients", "who", "have", "been", "on", "a", "tumor", "necrosis", "factor", "alpha", "(", "TNFa", ")", "inhibitor", "(", "not", "more", "than", "one", ")", "must", "have", "experienced", "an", "inadequate", "response", "to", "previous", "or", "current", "treatment", "given", "at", "an", "approved", "dose", "for", "at", "least", "3", "months", "prior", "to", "baseline", "or", "had", "been", "intolerant", "upon", "administration", "of", "an", "anti", "-", "TNFa", "agent", "\n", "Total", "ankylosis", "of", "the", "spine", "\n", "Use", "of", "other", "investigational", "drugs", "within", "5", "half", "-", "lives", "of", "enrollment", ",", "or", "within", "4", "weeks", "before", "the", "Baseline", "Visit", ",", "whichever", "is", "longer", ".", "\n", "History", "of", "hypersensitivity", "to", "any", "of", "the", "study", "drugs", "or", "its", "excipients", "or", "to", "drugs", "of", "similar", "chemical", "classes", ".", "\n", "Chest", "x", "-", "ray", ",", "computerized", "tomography", "(", "CT", ")", "scan", ",", "or", "chest", "magnetic", "resonance", "imaging", "(", "MRI", ")", "with", "evidence", "of", "ongoing", "infectious", "or", "malignant", "process", ",", "obtained", "within", "3", "months", "prior", "to", "screening", "and", "evaluated", "by", "a", "qualified", "physician", ".", "\n", "Previous", "exposure", "to", "secukinumab", "or", "any", "other", "biologic", "drug", "directly", "targeting", "Interleukin-17", "(", "IL-17", ")", ",", "Interleukin-12/23", "(", "IL-12/23", ")", ",", "or", "the", "IL-17", "receptor", ",", "or", "any", "other", "biologic", "immunomodulating", "agent", ",", "except", "those", "targeting", "TNFa", "\n", "Patients", "who", "have", "taken", "more", "than", "one", "anti", "-", "TNFa", "agent", "\n", "Any", "intramuscular", "or", "intravenous", "corticosteroid", "injection", "within", "2", "weeks", "before", "baseline", "\n", "Any", "therapy", "by", "intra", "-", "articular", "injections", "(", "e.g", ".", "corticosteroid", ")", "within", "4", "weeks", "before", "baseline", "\n", "Previous", "treatment", "with", "any", "cell", "-", "depleting", "therapies", "\n", "Patients", "taking", "high", "potency", "opioid", "analgesics", "(", "e.g", ".", ",", "methadone", ",", "hydromorphone", ",", "morphine", ")", "\n" ]

[ "Scope", "Measurement", "Temporal", "Drug", "Procedure", "Condition", "Multiplier", "Reference_point", "Qualifier", "Value", "Negation" ]

moderate to severe is a Scope, Ankylosing Spondylitis ( AS ) is a Condition, prior is a Temporal, radiologic evidence is a Condition, fulfilling is a Value, Modified New York criteria for AS is a Measurement, Active is a Qualifier, AS is a Condition, total Bath Ankylosing Spondylitis Disease Activity index ( BASDAI ) is a Measurement, = 4 is a Value, at baseline is a Temporal, Spinal pain is a Condition, BASDAI question # 2 is a Measurement, = 4 cm is a Value, at baseline is a Temporal, Total back pain is a Condition, visual analog scale ( VAS ) is a Measurement, = 40 mm is a Value, at baseline is a Temporal, non - steroidal anti - inflammatory drugs ( NSAIDs ) is a Drug, maximum tolerated dose is a Multiplier, for at least 4 weeks prior to their Baseline Visit is a Temporal, inadequate response is a Condition, for less than 4 weeks is a Temporal, withdrawn for intolerance , toxicity or contraindications is a Scope, NSAIDs including Cyclooxygenase-1 ( COX-1 ) or Cyclooxygenase-2 ( COX-2 ) inhibitors is a Scope, for at least 2 weeks before their Baseline Visit is a Temporal, tumor necrosis factor alpha ( TNFa ) inhibitor ( not more than one ) is a Scope, inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti - TNFa agent is a Scope, Total ankylosis of the spine is a Condition, hypersensitivity is a Condition, study drugs or its excipients or to drugs of similar chemical classes is a Scope, Chest x - ray , computerized tomography ( CT ) scan , or chest magnetic resonance imaging ( MRI ) is a Scope, ongoing is a Temporal, infectious or malignant process is a Scope, within 3 months prior to screening is a Temporal, secukinumab or any other biologic drug is a Scope, targeting is a Condition, Interleukin-17 ( IL-17 ) , Interleukin-12/23 ( IL-12/23 ) , or the IL-17 receptor , or any other biologic immunomodulating agent is a Scope, except is a Negation, TNFa is a Drug, more than one is a Multiplier, anti - TNFa agent is a Drug, intramuscular or intravenous is a Scope, corticosteroid injection is a Procedure, within 2 weeks before baseline is a Temporal, intra - articular injections is a Procedure, corticosteroid is a Drug, within 4 weeks before baseline is a Temporal, Previous is a Temporal, cell - depleting therapies is a Procedure, high potency opioid analgesics is a Drug, methadone , hydromorphone , morphine is a Scope

NCT03350815_inc_task1

Sentence: Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine) Instructions: please typing these entity words according to sentence: moderate to severe, Ankylosing Spondylitis ( AS ), prior, radiologic evidence, fulfilling, Modified New York criteria for AS, Active, AS, total Bath Ankylosing Spondylitis Disease Activity index ( BASDAI ), = 4, at baseline, Spinal pain, BASDAI question # 2, = 4 cm, at baseline, Total back pain, visual analog scale ( VAS ), = 40 mm, at baseline, non - steroidal anti - inflammatory drugs ( NSAIDs ), maximum tolerated dose, for at least 4 weeks prior to their Baseline Visit, inadequate response, for less than 4 weeks, withdrawn for intolerance , toxicity or contraindications, NSAIDs including Cyclooxygenase-1 ( COX-1 ) or Cyclooxygenase-2 ( COX-2 ) inhibitors, for at least 2 weeks before their Baseline Visit, tumor necrosis factor alpha ( TNFa ) inhibitor ( not more than one ), inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti - TNFa agent, Total ankylosis of the spine, hypersensitivity, study drugs or its excipients or to drugs of similar chemical classes, Chest x - ray , computerized tomography ( CT ) scan , or chest magnetic resonance imaging ( MRI ), ongoing, infectious or malignant process, within 3 months prior to screening, secukinumab or any other biologic drug, targeting, Interleukin-17 ( IL-17 ) , Interleukin-12/23 ( IL-12/23 ) , or the IL-17 receptor , or any other biologic immunomodulating agent, except, TNFa, more than one, anti - TNFa agent, intramuscular or intravenous, corticosteroid injection, within 2 weeks before baseline, intra - articular injections, corticosteroid, within 4 weeks before baseline, Previous, cell - depleting therapies, high potency opioid analgesics, methadone , hydromorphone , morphine Options: Temporal, Condition, Qualifier, Value, Multiplier, Procedure, Negation, Scope, Measurement, Drug

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Temporal", "O", "B-Condition", "I-Condition", "B-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Qualifier", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine)

[ "Understand", "and", "communicate", "with", "the", "investigator", ",", "comply", "with", "the", "requirements", "of", "the", "study", "and", "give", "a", "written", ",", "signed", "and", "dated", "informed", "consent", "\n", "Male", "or", "non", "-", "pregnant", ",", "non", "-", "lactating", "female", "patients", "at", "least", "18", "years", "of", "age", "\n", "Diagnosis", "of", "moderate", "to", "severe", "Ankylosing", "Spondylitis", "(", "AS", ")", "with", "prior", "documented", "radiologic", "evidence", "fulfilling", "the", "Modified", "New", "York", "criteria", "for", "AS", "\n", "Active", "AS", "assessed", "by", "total", "Bath", "Ankylosing", "Spondylitis", "Disease", "Activity", "index", "(", "BASDAI", ")", "=", "4", "(", "0", "-", "10", ")", "at", "baseline", "\n", "Spinal", "pain", "as", "measured", "by", "BASDAI", "question", "#", "2", "=", "4", "cm", "(", "0", "-", "10", "cm", ")", "at", "baseline", "\n", "Total", "back", "pain", "as", "measured", "by", "visual", "analog", "scale", "(", "VAS", ")", "=", "40", "mm", "(", "0", "-", "100", "mm", ")", "at", "baseline", "\n", "Patients", "should", "have", "been", "on", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "at", "the", "maximum", "tolerated", "dose", "for", "at", "least", "4", "weeks", "prior", "to", "their", "Baseline", "Visit", ",", "with", "an", "inadequate", "response", "or", "for", "less", "than", "4", "weeks", "if", "withdrawn", "for", "intolerance", ",", "toxicity", "or", "contraindications", "\n", "Stable", "dose", "of", "NSAIDs", "including", "Cyclooxygenase-1", "(", "COX-1", ")", "or", "Cyclooxygenase-2", "(", "COX-2", ")", "inhibitors", "for", "at", "least", "2", "weeks", "before", "their", "Baseline", "Visit", "\n", "Patients", "who", "have", "been", "on", "a", "tumor", "necrosis", "factor", "alpha", "(", "TNFa", ")", "inhibitor", "(", "not", "more", "than", "one", ")", "must", "have", "experienced", "an", "inadequate", "response", "to", "previous", "or", "current", "treatment", "given", "at", "an", "approved", "dose", "for", "at", "least", "3", "months", "prior", "to", "baseline", "or", "had", "been", "intolerant", "upon", "administration", "of", "an", "anti", "-", "TNFa", "agent", "\n", "Total", "ankylosis", "of", "the", "spine", "\n", "Use", "of", "other", "investigational", "drugs", "within", "5", "half", "-", "lives", "of", "enrollment", ",", "or", "within", "4", "weeks", "before", "the", "Baseline", "Visit", ",", "whichever", "is", "longer", ".", "\n", "History", "of", "hypersensitivity", "to", "any", "of", "the", "study", "drugs", "or", "its", "excipients", "or", "to", "drugs", "of", "similar", "chemical", "classes", ".", "\n", "Chest", "x", "-", "ray", ",", "computerized", "tomography", "(", "CT", ")", "scan", ",", "or", "chest", "magnetic", "resonance", "imaging", "(", "MRI", ")", "with", "evidence", "of", "ongoing", "infectious", "or", "malignant", "process", ",", "obtained", "within", "3", "months", "prior", "to", "screening", "and", "evaluated", "by", "a", "qualified", "physician", ".", "\n", "Previous", "exposure", "to", "secukinumab", "or", "any", "other", "biologic", "drug", "directly", "targeting", "Interleukin-17", "(", "IL-17", ")", ",", "Interleukin-12/23", "(", "IL-12/23", ")", ",", "or", "the", "IL-17", "receptor", ",", "or", "any", "other", "biologic", "immunomodulating", "agent", ",", "except", "those", "targeting", "TNFa", "\n", "Patients", "who", "have", "taken", "more", "than", "one", "anti", "-", "TNFa", "agent", "\n", "Any", "intramuscular", "or", "intravenous", "corticosteroid", "injection", "within", "2", "weeks", "before", "baseline", "\n", "Any", "therapy", "by", "intra", "-", "articular", "injections", "(", "e.g", ".", "corticosteroid", ")", "within", "4", "weeks", "before", "baseline", "\n", "Previous", "treatment", "with", "any", "cell", "-", "depleting", "therapies", "\n", "Patients", "taking", "high", "potency", "opioid", "analgesics", "(", "e.g", ".", ",", "methadone", ",", "hydromorphone", ",", "morphine", ")", "\n" ]

[ "Scope", "Measurement", "Temporal", "Drug", "Procedure", "Condition", "Multiplier", "Reference_point", "Qualifier", "Value", "Negation" ]

moderate to severe, Ankylosing Spondylitis ( AS ), prior, radiologic evidence, fulfilling, Modified New York criteria for AS, Active, AS, total Bath Ankylosing Spondylitis Disease Activity index ( BASDAI ), = 4, at baseline, Spinal pain, BASDAI question # 2, = 4 cm, at baseline, Total back pain, visual analog scale ( VAS ), = 40 mm, at baseline, non - steroidal anti - inflammatory drugs ( NSAIDs ), maximum tolerated dose, for at least 4 weeks prior to their Baseline Visit, inadequate response, for less than 4 weeks, withdrawn for intolerance , toxicity or contraindications, NSAIDs including Cyclooxygenase-1 ( COX-1 ) or Cyclooxygenase-2 ( COX-2 ) inhibitors, for at least 2 weeks before their Baseline Visit, tumor necrosis factor alpha ( TNFa ) inhibitor ( not more than one ), inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti - TNFa agent, Total ankylosis of the spine, hypersensitivity, study drugs or its excipients or to drugs of similar chemical classes, Chest x - ray , computerized tomography ( CT ) scan , or chest magnetic resonance imaging ( MRI ), ongoing, infectious or malignant process, within 3 months prior to screening, secukinumab or any other biologic drug, targeting, Interleukin-17 ( IL-17 ) , Interleukin-12/23 ( IL-12/23 ) , or the IL-17 receptor , or any other biologic immunomodulating agent, except, TNFa, more than one, anti - TNFa agent, intramuscular or intravenous, corticosteroid injection, within 2 weeks before baseline, intra - articular injections, corticosteroid, within 4 weeks before baseline, Previous, cell - depleting therapies, high potency opioid analgesics, methadone , hydromorphone , morphine

NCT03350815_inc_task2

Sentence: Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine) Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Temporal", "O", "B-Condition", "I-Condition", "B-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Qualifier", "B-Condition", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "O", "O", "B-Drug", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent Male or non-pregnant, non-lactating female patients at least 18 years of age Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent Total ankylosis of the spine Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes. Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician. Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa Patients who have taken more than one anti-TNFa agent Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline Previous treatment with any cell-depleting therapies Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine)

[ "Understand", "and", "communicate", "with", "the", "investigator", ",", "comply", "with", "the", "requirements", "of", "the", "study", "and", "give", "a", "written", ",", "signed", "and", "dated", "informed", "consent", "\n", "Male", "or", "non", "-", "pregnant", ",", "non", "-", "lactating", "female", "patients", "at", "least", "18", "years", "of", "age", "\n", "Diagnosis", "of", "moderate", "to", "severe", "Ankylosing", "Spondylitis", "(", "AS", ")", "with", "prior", "documented", "radiologic", "evidence", "fulfilling", "the", "Modified", "New", "York", "criteria", "for", "AS", "\n", "Active", "AS", "assessed", "by", "total", "Bath", "Ankylosing", "Spondylitis", "Disease", "Activity", "index", "(", "BASDAI", ")", "=", "4", "(", "0", "-", "10", ")", "at", "baseline", "\n", "Spinal", "pain", "as", "measured", "by", "BASDAI", "question", "#", "2", "=", "4", "cm", "(", "0", "-", "10", "cm", ")", "at", "baseline", "\n", "Total", "back", "pain", "as", "measured", "by", "visual", "analog", "scale", "(", "VAS", ")", "=", "40", "mm", "(", "0", "-", "100", "mm", ")", "at", "baseline", "\n", "Patients", "should", "have", "been", "on", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "at", "the", "maximum", "tolerated", "dose", "for", "at", "least", "4", "weeks", "prior", "to", "their", "Baseline", "Visit", ",", "with", "an", "inadequate", "response", "or", "for", "less", "than", "4", "weeks", "if", "withdrawn", "for", "intolerance", ",", "toxicity", "or", "contraindications", "\n", "Stable", "dose", "of", "NSAIDs", "including", "Cyclooxygenase-1", "(", "COX-1", ")", "or", "Cyclooxygenase-2", "(", "COX-2", ")", "inhibitors", "for", "at", "least", "2", "weeks", "before", "their", "Baseline", "Visit", "\n", "Patients", "who", "have", "been", "on", "a", "tumor", "necrosis", "factor", "alpha", "(", "TNFa", ")", "inhibitor", "(", "not", "more", "than", "one", ")", "must", "have", "experienced", "an", "inadequate", "response", "to", "previous", "or", "current", "treatment", "given", "at", "an", "approved", "dose", "for", "at", "least", "3", "months", "prior", "to", "baseline", "or", "had", "been", "intolerant", "upon", "administration", "of", "an", "anti", "-", "TNFa", "agent", "\n", "Total", "ankylosis", "of", "the", "spine", "\n", "Use", "of", "other", "investigational", "drugs", "within", "5", "half", "-", "lives", "of", "enrollment", ",", "or", "within", "4", "weeks", "before", "the", "Baseline", "Visit", ",", "whichever", "is", "longer", ".", "\n", "History", "of", "hypersensitivity", "to", "any", "of", "the", "study", "drugs", "or", "its", "excipients", "or", "to", "drugs", "of", "similar", "chemical", "classes", ".", "\n", "Chest", "x", "-", "ray", ",", "computerized", "tomography", "(", "CT", ")", "scan", ",", "or", "chest", "magnetic", "resonance", "imaging", "(", "MRI", ")", "with", "evidence", "of", "ongoing", "infectious", "or", "malignant", "process", ",", "obtained", "within", "3", "months", "prior", "to", "screening", "and", "evaluated", "by", "a", "qualified", "physician", ".", "\n", "Previous", "exposure", "to", "secukinumab", "or", "any", "other", "biologic", "drug", "directly", "targeting", "Interleukin-17", "(", "IL-17", ")", ",", "Interleukin-12/23", "(", "IL-12/23", ")", ",", "or", "the", "IL-17", "receptor", ",", "or", "any", "other", "biologic", "immunomodulating", "agent", ",", "except", "those", "targeting", "TNFa", "\n", "Patients", "who", "have", "taken", "more", "than", "one", "anti", "-", "TNFa", "agent", "\n", "Any", "intramuscular", "or", "intravenous", "corticosteroid", "injection", "within", "2", "weeks", "before", "baseline", "\n", "Any", "therapy", "by", "intra", "-", "articular", "injections", "(", "e.g", ".", "corticosteroid", ")", "within", "4", "weeks", "before", "baseline", "\n", "Previous", "treatment", "with", "any", "cell", "-", "depleting", "therapies", "\n", "Patients", "taking", "high", "potency", "opioid", "analgesics", "(", "e.g", ".", ",", "methadone", ",", "hydromorphone", ",", "morphine", ")", "\n" ]

[ "Scope", "Measurement", "Temporal", "Drug", "Procedure", "Condition", "Multiplier", "Reference_point", "Qualifier", "Value", "Negation" ]

Bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]dopamine is a CHEMICAL, [ ( 3)H]norepinephrine is a CHEMICAL, Bupropion is a CHEMICAL, dopamine and norepinephrine transporters is a GENE-N, DAT is a GENE-Y, NET is a GENE-Y, bupropion is a CHEMICAL, alpha3beta2 , alpha3beta4 , and alpha4beta2 nicotinic acetylcholine receptors ( nAChRs ) is a GENE-N, bupropion is a CHEMICAL, alpha3beta2 * and alpha3beta4 * nAChRs is a GENE-N, nicotine is a CHEMICAL, [ ( 3)H]dopamine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]norepinephrine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, DAT is a GENE-Y, NET is a GENE-Y, nomifensine is a CHEMICAL, desipramine is a CHEMICAL, bupropion is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, alpha3beta2 * and alpha3beta4 * nAChRs is a GENE-N, DAT is a GENE-Y, NET is a GENE-Y, nAChR is a GENE-N, bupropion is a CHEMICAL

8740_task0

Sentence: Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL

[ "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent.

[ "Bupropion", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "and", "from", "rat", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", ".", "\n", "Bupropion", ",", "an", "efficacious", "antidepressant", "and", "smoking", "cessation", "agent", ",", "inhibits", "dopamine", "and", "norepinephrine", "transporters", "(", "DAT", "and", "NET", ",", "respectively", ")", ".", "Recently", ",", "bupropion", "has", "been", "reported", "to", "noncompetitively", "inhibit", "alpha3beta2", ",", "alpha3beta4", ",", "and", "alpha4beta2", "nicotinic", "acetylcholine", "receptors", "(", "nAChRs", ")", "expressed", "in", "Xenopus", "oocytes", "or", "established", "cell", "lines", ".", "The", "present", "study", "evaluated", "bupropion", "-", "induced", "inhibition", "of", "native", "alpha3beta2", "*", "and", "alpha3beta4", "*", "nAChRs", "using", "functional", "neurotransmitter", "release", "assays", ",", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "superfused", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "(", "[", "(", "3)H]DA", ")", ",", "and", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", "(", "[", "(", "3)H]NE", ")", ".", "The", "mechanism", "of", "inhibition", "was", "evaluated", "using", "Schild", "analysis", ".", "To", "eliminate", "the", "interaction", "of", "bupropion", "with", "DAT", "or", "NET", ",", "nomifensine", "or", "desipramine", ",", "respectively", ",", "was", "included", "in", "the", "superfusion", "buffer", ".", "A", "high", "bupropion", "concentration", "(", "100", "microM", ")", "elicited", "intrinsic", "activity", "in", "the", "[", "(", "3)H]DA", "release", "assay", ".", "However", ",", "none", "of", "the", "concentrations", "(", "1", "nM-100", "microM", ")", "examined", "evoked", "[", "(", "3)H]NE", "overflow", "and", ",", "thus", ",", "were", "without", "intrinsic", "activity", "in", "this", "assay", ".", "Moreover", ",", "bupropion", "inhibited", "both", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", "(", "IC(50", ")", "=", "1.27", "microM", ")", "and", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", "(", "IC(50", ")", "=", "323", "nM", ")", "at", "bupropion", "concentrations", "well", "below", "those", "eliciting", "intrinsic", "activity", ".", "Results", "from", "Schild", "analyses", "suggest", "that", "bupropion", "competitively", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", ",", "whereas", "evidence", "for", "receptor", "reserve", "was", "obtained", "upon", "assessment", "of", "bupropion", "inhibition", "of", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", ".", "Thus", ",", "bupropion", "acts", "as", "an", "antagonist", "at", "alpha3beta2", "*", "and", "alpha3beta4", "*", "nAChRs", "in", "rat", "striatum", "and", "hippocampus", ",", "respectively", ",", "across", "the", "same", "concentration", "range", "that", "inhibits", "DAT", "and", "NET", "function", ".", "The", "combination", "of", "nAChR", "and", "transporter", "inhibition", "produced", "by", "bupropion", "may", "contribute", "to", "its", "clinical", "efficacy", "as", "a", "smoking", "cessation", "agent", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]dopamine is a CHEMICAL, [ ( 3)H]norepinephrine is a CHEMICAL, Bupropion is a CHEMICAL, dopamine and norepinephrine transporters is a GENE-N, DAT is a GENE-Y, NET is a GENE-Y, bupropion is a CHEMICAL, alpha3beta2 , alpha3beta4 , and alpha4beta2 nicotinic acetylcholine receptors ( nAChRs ) is a GENE-N, bupropion is a CHEMICAL, alpha3beta2 * and alpha3beta4 * nAChRs is a GENE-N, nicotine is a CHEMICAL, [ ( 3)H]dopamine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]norepinephrine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, DAT is a GENE-Y, NET is a GENE-Y, nomifensine is a CHEMICAL, desipramine is a CHEMICAL, bupropion is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]DA is a CHEMICAL, bupropion is a CHEMICAL, nicotine is a CHEMICAL, [ ( 3)H]NE is a CHEMICAL, bupropion is a CHEMICAL, alpha3beta2 * and alpha3beta4 * nAChRs is a GENE-N, DAT is a GENE-Y, NET is a GENE-Y, nAChR is a GENE-N, bupropion is a CHEMICAL

8740_task1

Sentence: Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent. Instructions: please typing these entity words according to sentence: Bupropion, nicotine, [ ( 3)H]dopamine, [ ( 3)H]norepinephrine, Bupropion, dopamine and norepinephrine transporters, DAT, NET, bupropion, alpha3beta2 , alpha3beta4 , and alpha4beta2 nicotinic acetylcholine receptors ( nAChRs ), bupropion, alpha3beta2 * and alpha3beta4 * nAChRs, nicotine, [ ( 3)H]dopamine, [ ( 3)H]DA, nicotine, [ ( 3)H]norepinephrine, [ ( 3)H]NE, bupropion, DAT, NET, nomifensine, desipramine, bupropion, [ ( 3)H]DA, [ ( 3)H]NE, bupropion, nicotine, [ ( 3)H]DA, nicotine, [ ( 3)H]NE, bupropion, bupropion, nicotine, [ ( 3)H]DA, bupropion, nicotine, [ ( 3)H]NE, bupropion, alpha3beta2 * and alpha3beta4 * nAChRs, DAT, NET, nAChR, bupropion Options: GENE-Y, GENE-N, CHEMICAL

[ "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent.

[ "Bupropion", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "and", "from", "rat", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", ".", "\n", "Bupropion", ",", "an", "efficacious", "antidepressant", "and", "smoking", "cessation", "agent", ",", "inhibits", "dopamine", "and", "norepinephrine", "transporters", "(", "DAT", "and", "NET", ",", "respectively", ")", ".", "Recently", ",", "bupropion", "has", "been", "reported", "to", "noncompetitively", "inhibit", "alpha3beta2", ",", "alpha3beta4", ",", "and", "alpha4beta2", "nicotinic", "acetylcholine", "receptors", "(", "nAChRs", ")", "expressed", "in", "Xenopus", "oocytes", "or", "established", "cell", "lines", ".", "The", "present", "study", "evaluated", "bupropion", "-", "induced", "inhibition", "of", "native", "alpha3beta2", "*", "and", "alpha3beta4", "*", "nAChRs", "using", "functional", "neurotransmitter", "release", "assays", ",", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "superfused", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "(", "[", "(", "3)H]DA", ")", ",", "and", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", "(", "[", "(", "3)H]NE", ")", ".", "The", "mechanism", "of", "inhibition", "was", "evaluated", "using", "Schild", "analysis", ".", "To", "eliminate", "the", "interaction", "of", "bupropion", "with", "DAT", "or", "NET", ",", "nomifensine", "or", "desipramine", ",", "respectively", ",", "was", "included", "in", "the", "superfusion", "buffer", ".", "A", "high", "bupropion", "concentration", "(", "100", "microM", ")", "elicited", "intrinsic", "activity", "in", "the", "[", "(", "3)H]DA", "release", "assay", ".", "However", ",", "none", "of", "the", "concentrations", "(", "1", "nM-100", "microM", ")", "examined", "evoked", "[", "(", "3)H]NE", "overflow", "and", ",", "thus", ",", "were", "without", "intrinsic", "activity", "in", "this", "assay", ".", "Moreover", ",", "bupropion", "inhibited", "both", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", "(", "IC(50", ")", "=", "1.27", "microM", ")", "and", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", "(", "IC(50", ")", "=", "323", "nM", ")", "at", "bupropion", "concentrations", "well", "below", "those", "eliciting", "intrinsic", "activity", ".", "Results", "from", "Schild", "analyses", "suggest", "that", "bupropion", "competitively", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", ",", "whereas", "evidence", "for", "receptor", "reserve", "was", "obtained", "upon", "assessment", "of", "bupropion", "inhibition", "of", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", ".", "Thus", ",", "bupropion", "acts", "as", "an", "antagonist", "at", "alpha3beta2", "*", "and", "alpha3beta4", "*", "nAChRs", "in", "rat", "striatum", "and", "hippocampus", ",", "respectively", ",", "across", "the", "same", "concentration", "range", "that", "inhibits", "DAT", "and", "NET", "function", ".", "The", "combination", "of", "nAChR", "and", "transporter", "inhibition", "produced", "by", "bupropion", "may", "contribute", "to", "its", "clinical", "efficacy", "as", "a", "smoking", "cessation", "agent", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Bupropion, nicotine, [ ( 3)H]dopamine, [ ( 3)H]norepinephrine, Bupropion, dopamine and norepinephrine transporters, DAT, NET, bupropion, alpha3beta2 , alpha3beta4 , and alpha4beta2 nicotinic acetylcholine receptors ( nAChRs ), bupropion, alpha3beta2 * and alpha3beta4 * nAChRs, nicotine, [ ( 3)H]dopamine, [ ( 3)H]DA, nicotine, [ ( 3)H]norepinephrine, [ ( 3)H]NE, bupropion, DAT, NET, nomifensine, desipramine, bupropion, [ ( 3)H]DA, [ ( 3)H]NE, bupropion, nicotine, [ ( 3)H]DA, nicotine, [ ( 3)H]NE, bupropion, bupropion, nicotine, [ ( 3)H]DA, bupropion, nicotine, [ ( 3)H]NE, bupropion, alpha3beta2 * and alpha3beta4 * nAChRs, DAT, NET, nAChR, bupropion

8740_task2

Sentence: Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 microM) elicited intrinsic activity in the [(3)H]DA release assay. However, none of the concentrations (1 nM-100 microM) examined evoked [(3)H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [(3)H]DA overflow (IC(50) = 1.27 microM) and nicotine-evoked [(3)H]NE overflow (IC(50) = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [(3)H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [(3)H]NE overflow. Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent.

[ "Bupropion", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "and", "from", "rat", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", ".", "\n", "Bupropion", ",", "an", "efficacious", "antidepressant", "and", "smoking", "cessation", "agent", ",", "inhibits", "dopamine", "and", "norepinephrine", "transporters", "(", "DAT", "and", "NET", ",", "respectively", ")", ".", "Recently", ",", "bupropion", "has", "been", "reported", "to", "noncompetitively", "inhibit", "alpha3beta2", ",", "alpha3beta4", ",", "and", "alpha4beta2", "nicotinic", "acetylcholine", "receptors", "(", "nAChRs", ")", "expressed", "in", "Xenopus", "oocytes", "or", "established", "cell", "lines", ".", "The", "present", "study", "evaluated", "bupropion", "-", "induced", "inhibition", "of", "native", "alpha3beta2", "*", "and", "alpha3beta4", "*", "nAChRs", "using", "functional", "neurotransmitter", "release", "assays", ",", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "superfused", "rat", "striatal", "slices", "preloaded", "with", "[", "(", "3)H]dopamine", "(", "[", "(", "3)H]DA", ")", ",", "and", "nicotine", "-", "evoked", "[", "(", "3)H]overflow", "from", "hippocampal", "slices", "preloaded", "with", "[", "(", "3)H]norepinephrine", "(", "[", "(", "3)H]NE", ")", ".", "The", "mechanism", "of", "inhibition", "was", "evaluated", "using", "Schild", "analysis", ".", "To", "eliminate", "the", "interaction", "of", "bupropion", "with", "DAT", "or", "NET", ",", "nomifensine", "or", "desipramine", ",", "respectively", ",", "was", "included", "in", "the", "superfusion", "buffer", ".", "A", "high", "bupropion", "concentration", "(", "100", "microM", ")", "elicited", "intrinsic", "activity", "in", "the", "[", "(", "3)H]DA", "release", "assay", ".", "However", ",", "none", "of", "the", "concentrations", "(", "1", "nM-100", "microM", ")", "examined", "evoked", "[", "(", "3)H]NE", "overflow", "and", ",", "thus", ",", "were", "without", "intrinsic", "activity", "in", "this", "assay", ".", "Moreover", ",", "bupropion", "inhibited", "both", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", "(", "IC(50", ")", "=", "1.27", "microM", ")", "and", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", "(", "IC(50", ")", "=", "323", "nM", ")", "at", "bupropion", "concentrations", "well", "below", "those", "eliciting", "intrinsic", "activity", ".", "Results", "from", "Schild", "analyses", "suggest", "that", "bupropion", "competitively", "inhibits", "nicotine", "-", "evoked", "[", "(", "3)H]DA", "overflow", ",", "whereas", "evidence", "for", "receptor", "reserve", "was", "obtained", "upon", "assessment", "of", "bupropion", "inhibition", "of", "nicotine", "-", "evoked", "[", "(", "3)H]NE", "overflow", ".", "Thus", ",", "bupropion", "acts", "as", "an", "antagonist", "at", "alpha3beta2", "*", "and", "alpha3beta4", "*", "nAChRs", "in", "rat", "striatum", "and", "hippocampus", ",", "respectively", ",", "across", "the", "same", "concentration", "range", "that", "inhibits", "DAT", "and", "NET", "function", ".", "The", "combination", "of", "nAChR", "and", "transporter", "inhibition", "produced", "by", "bupropion", "may", "contribute", "to", "its", "clinical", "efficacy", "as", "a", "smoking", "cessation", "agent", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

methimazole is a CHEMICAL, propylthiouracil is a CHEMICAL

23154533_task0

Sentence: The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant.

[ "The", "onset", "of", "antineutrophil", "cytoplasmic", "antibody", "-", "associated", "vasculitis", "immediately", "after", "methimazole", "was", "switched", "to", "propylthiouracil", "in", "a", "woman", "with", "Graves", "'", "disease", "who", "wished", "to", "become", "pregnant", "." ]

[ "CHEMICAL", "GENE-Y" ]

methimazole is a CHEMICAL, propylthiouracil is a CHEMICAL

23154533_task1

Sentence: The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. Instructions: please typing these entity words according to sentence: methimazole, propylthiouracil Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant.

[ "The", "onset", "of", "antineutrophil", "cytoplasmic", "antibody", "-", "associated", "vasculitis", "immediately", "after", "methimazole", "was", "switched", "to", "propylthiouracil", "in", "a", "woman", "with", "Graves", "'", "disease", "who", "wished", "to", "become", "pregnant", "." ]

[ "CHEMICAL", "GENE-Y" ]

methimazole, propylthiouracil

23154533_task2

Sentence: The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant.

[ "The", "onset", "of", "antineutrophil", "cytoplasmic", "antibody", "-", "associated", "vasculitis", "immediately", "after", "methimazole", "was", "switched", "to", "propylthiouracil", "in", "a", "woman", "with", "Graves", "'", "disease", "who", "wished", "to", "become", "pregnant", "." ]

[ "CHEMICAL", "GENE-Y" ]

RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, PCNA is a Protein, RAD18 is a Protein, 53BP1 is a Protein, NBS1 is a Protein, ATM is a Protein, BRCA1 is a Protein, H2AX is a Protein, RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, lysine 1268 is a Entity, 53BP1 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, 53BP1 is a Protein

375_task0

Sentence: RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O" ]

RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1.

[ "RAD18", "promotes", "DNA", "double", "-", "strand", "break", "repair", "during", "G1", "phase", "through", "chromatin", "retention", "of", "53BP1", ".", "\n", "Recruitment", "of", "RAD18", "to", "stalled", "replication", "forks", "facilitates", "monoubiquitination", "of", "PCNA", "during", "S", "-", "phase", ",", "promoting", "translesion", "synthesis", "at", "sites", "of", "UV", "irradiation", "-", "induced", "DNA", "damage", ".", "In", "this", "study", ",", "we", "show", "that", "RAD18", "is", "also", "recruited", "to", "ionizing", "radiation", "(", "IR)-induced", "sites", "of", "DNA", "double", "-", "strand", "breaks", "(", "DSBs", ")", "forming", "foci", "which", "are", "co", "-", "localized", "with", "53BP1", ",", "NBS1", ",", "phosphorylated", "ATM", ",", "BRCA1", "and", "gamma", "-", "H2AX", ".", "RAD18", "associates", "with", "53BP1", "and", "is", "recruited", "to", "DSB", "sites", "in", "a", "53BP1-dependent", "manner", "specifically", "during", "G1-phase", ",", "RAD18", "monoubiquitinates", "KBD", "domain", "of", "53BP1", "at", "lysine", "1268", "in", "vitro", ".", "A", "monoubiquitination", "-", "resistant", "53BP1", "mutant", "harboring", "a", "substitution", "at", "lysine", "1268", "is", "not", "retained", "efficiently", "at", "the", "chromatin", "in", "the", "vicinity", "of", "DSBs", ".", "In", "Rad18-null", "cells", ",", "retention", "of", "53BP1", "foci", ",", "efficiency", "of", "DSB", "repair", "and", "post", "-", "irradiation", "viability", "are", "impaired", "compared", "with", "wild", "-", "type", "cells", ".", "Taken", "together", ",", "these", "results", "suggest", "that", "RAD18", "promotes", "53BP1-directed", "DSB", "repair", "by", "enhancing", "retention", "of", "53BP1", ",", "possibly", "through", "an", "interaction", "between", "RAD18", "and", "53BP1", "and", "the", "modification", "of", "53BP1", ".", "\n" ]

[ "Entity", "Protein" ]

RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, PCNA is a Protein, RAD18 is a Protein, 53BP1 is a Protein, NBS1 is a Protein, ATM is a Protein, BRCA1 is a Protein, H2AX is a Protein, RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, lysine 1268 is a Entity, 53BP1 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, RAD18 is a Protein, 53BP1 is a Protein, 53BP1 is a Protein

375_task1

Sentence: RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1. Instructions: please typing these entity words according to sentence: RAD18, 53BP1, RAD18, PCNA, RAD18, 53BP1, NBS1, ATM, BRCA1, H2AX, RAD18, 53BP1, RAD18, 53BP1, lysine 1268, 53BP1, 53BP1, RAD18, 53BP1, RAD18, 53BP1, 53BP1 Options: Entity, Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O" ]

RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1.

[ "RAD18", "promotes", "DNA", "double", "-", "strand", "break", "repair", "during", "G1", "phase", "through", "chromatin", "retention", "of", "53BP1", ".", "\n", "Recruitment", "of", "RAD18", "to", "stalled", "replication", "forks", "facilitates", "monoubiquitination", "of", "PCNA", "during", "S", "-", "phase", ",", "promoting", "translesion", "synthesis", "at", "sites", "of", "UV", "irradiation", "-", "induced", "DNA", "damage", ".", "In", "this", "study", ",", "we", "show", "that", "RAD18", "is", "also", "recruited", "to", "ionizing", "radiation", "(", "IR)-induced", "sites", "of", "DNA", "double", "-", "strand", "breaks", "(", "DSBs", ")", "forming", "foci", "which", "are", "co", "-", "localized", "with", "53BP1", ",", "NBS1", ",", "phosphorylated", "ATM", ",", "BRCA1", "and", "gamma", "-", "H2AX", ".", "RAD18", "associates", "with", "53BP1", "and", "is", "recruited", "to", "DSB", "sites", "in", "a", "53BP1-dependent", "manner", "specifically", "during", "G1-phase", ",", "RAD18", "monoubiquitinates", "KBD", "domain", "of", "53BP1", "at", "lysine", "1268", "in", "vitro", ".", "A", "monoubiquitination", "-", "resistant", "53BP1", "mutant", "harboring", "a", "substitution", "at", "lysine", "1268", "is", "not", "retained", "efficiently", "at", "the", "chromatin", "in", "the", "vicinity", "of", "DSBs", ".", "In", "Rad18-null", "cells", ",", "retention", "of", "53BP1", "foci", ",", "efficiency", "of", "DSB", "repair", "and", "post", "-", "irradiation", "viability", "are", "impaired", "compared", "with", "wild", "-", "type", "cells", ".", "Taken", "together", ",", "these", "results", "suggest", "that", "RAD18", "promotes", "53BP1-directed", "DSB", "repair", "by", "enhancing", "retention", "of", "53BP1", ",", "possibly", "through", "an", "interaction", "between", "RAD18", "and", "53BP1", "and", "the", "modification", "of", "53BP1", ".", "\n" ]

[ "Entity", "Protein" ]

RAD18, 53BP1, RAD18, PCNA, RAD18, 53BP1, NBS1, ATM, BRCA1, H2AX, RAD18, 53BP1, RAD18, 53BP1, lysine 1268, 53BP1, 53BP1, RAD18, 53BP1, RAD18, 53BP1, 53BP1

375_task2

Sentence: RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1. Instructions: please extract entity words from the input sentence

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O" ]

RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Recruitment of RAD18 to stalled replication forks facilitates monoubiquitination of PCNA during S-phase, promoting translesion synthesis at sites of UV irradiation-induced DNA damage. In this study, we show that RAD18 is also recruited to ionizing radiation (IR)-induced sites of DNA double-strand breaks (DSBs) forming foci which are co-localized with 53BP1, NBS1, phosphorylated ATM, BRCA1 and gamma-H2AX. RAD18 associates with 53BP1 and is recruited to DSB sites in a 53BP1-dependent manner specifically during G1-phase, RAD18 monoubiquitinates KBD domain of 53BP1 at lysine 1268 in vitro. A monoubiquitination-resistant 53BP1 mutant harboring a substitution at lysine 1268 is not retained efficiently at the chromatin in the vicinity of DSBs. In Rad18-null cells, retention of 53BP1 foci, efficiency of DSB repair and post-irradiation viability are impaired compared with wild-type cells. Taken together, these results suggest that RAD18 promotes 53BP1-directed DSB repair by enhancing retention of 53BP1, possibly through an interaction between RAD18 and 53BP1 and the modification of 53BP1.

[ "RAD18", "promotes", "DNA", "double", "-", "strand", "break", "repair", "during", "G1", "phase", "through", "chromatin", "retention", "of", "53BP1", ".", "\n", "Recruitment", "of", "RAD18", "to", "stalled", "replication", "forks", "facilitates", "monoubiquitination", "of", "PCNA", "during", "S", "-", "phase", ",", "promoting", "translesion", "synthesis", "at", "sites", "of", "UV", "irradiation", "-", "induced", "DNA", "damage", ".", "In", "this", "study", ",", "we", "show", "that", "RAD18", "is", "also", "recruited", "to", "ionizing", "radiation", "(", "IR)-induced", "sites", "of", "DNA", "double", "-", "strand", "breaks", "(", "DSBs", ")", "forming", "foci", "which", "are", "co", "-", "localized", "with", "53BP1", ",", "NBS1", ",", "phosphorylated", "ATM", ",", "BRCA1", "and", "gamma", "-", "H2AX", ".", "RAD18", "associates", "with", "53BP1", "and", "is", "recruited", "to", "DSB", "sites", "in", "a", "53BP1-dependent", "manner", "specifically", "during", "G1-phase", ",", "RAD18", "monoubiquitinates", "KBD", "domain", "of", "53BP1", "at", "lysine", "1268", "in", "vitro", ".", "A", "monoubiquitination", "-", "resistant", "53BP1", "mutant", "harboring", "a", "substitution", "at", "lysine", "1268", "is", "not", "retained", "efficiently", "at", "the", "chromatin", "in", "the", "vicinity", "of", "DSBs", ".", "In", "Rad18-null", "cells", ",", "retention", "of", "53BP1", "foci", ",", "efficiency", "of", "DSB", "repair", "and", "post", "-", "irradiation", "viability", "are", "impaired", "compared", "with", "wild", "-", "type", "cells", ".", "Taken", "together", ",", "these", "results", "suggest", "that", "RAD18", "promotes", "53BP1-directed", "DSB", "repair", "by", "enhancing", "retention", "of", "53BP1", ",", "possibly", "through", "an", "interaction", "between", "RAD18", "and", "53BP1", "and", "the", "modification", "of", "53BP1", ".", "\n" ]

[ "Entity", "Protein" ]

complication is an umlsterm, intramuscular injections is an umlsterm, necrosis is an umlsterm, skin is an umlsterm, para - arterial is an umlsterm, injections is an umlsterm, vessels is an umlsterm, occurrence is an umlsterm, intra - articular injections is an umlsterm, knee is an umlsterm

DerHautarzt.90500214.eng.abstr_task0

Sentence: Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]

Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee .

[ "Embolia", "cutis", "medicamentosa", "(", "Nicolau", "Syndrom", ")", "is", "a", "very", "rare", "complication", "of", "intramuscular", "injections", "which", "presents", "with", "extensive", "necrosis", "of", "the", "injected", "skin", "area", ".", "Intra", "-", "arterial", "and", "/", "or", "para", "-", "arterial", "injections", "after", "prior", "perforation", "of", "certain", "vessels", "are", "discussed", "as", "possible", "pathogenetic", "mechanisms", ".", "We", "describe", "the", "occurrence", "of", "embolia", "cutis", "medicamentosa", "after", "intra", "-", "articular", "injections", "into", "the", "knee", "." ]

[ "umlsterm" ]

complication is an umlsterm, intramuscular injections is an umlsterm, necrosis is an umlsterm, skin is an umlsterm, para - arterial is an umlsterm, injections is an umlsterm, vessels is an umlsterm, occurrence is an umlsterm, intra - articular injections is an umlsterm, knee is an umlsterm

DerHautarzt.90500214.eng.abstr_task1

Sentence: Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee . Instructions: please typing these entity words according to sentence: complication, intramuscular injections, necrosis, skin, para - arterial, injections, vessels, occurrence, intra - articular injections, knee Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]

Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee .

[ "Embolia", "cutis", "medicamentosa", "(", "Nicolau", "Syndrom", ")", "is", "a", "very", "rare", "complication", "of", "intramuscular", "injections", "which", "presents", "with", "extensive", "necrosis", "of", "the", "injected", "skin", "area", ".", "Intra", "-", "arterial", "and", "/", "or", "para", "-", "arterial", "injections", "after", "prior", "perforation", "of", "certain", "vessels", "are", "discussed", "as", "possible", "pathogenetic", "mechanisms", ".", "We", "describe", "the", "occurrence", "of", "embolia", "cutis", "medicamentosa", "after", "intra", "-", "articular", "injections", "into", "the", "knee", "." ]

[ "umlsterm" ]

complication, intramuscular injections, necrosis, skin, para - arterial, injections, vessels, occurrence, intra - articular injections, knee

DerHautarzt.90500214.eng.abstr_task2

Sentence: Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]

Embolia cutis medicamentosa ( Nicolau Syndrom ) is a very rare complication of intramuscular injections which presents with extensive necrosis of the injected skin area . Intra-arterial and/or para-arterial injections after prior perforation of certain vessels are discussed as possible pathogenetic mechanisms . We describe the occurrence of embolia cutis medicamentosa after intra-articular injections into the knee .

[ "Embolia", "cutis", "medicamentosa", "(", "Nicolau", "Syndrom", ")", "is", "a", "very", "rare", "complication", "of", "intramuscular", "injections", "which", "presents", "with", "extensive", "necrosis", "of", "the", "injected", "skin", "area", ".", "Intra", "-", "arterial", "and", "/", "or", "para", "-", "arterial", "injections", "after", "prior", "perforation", "of", "certain", "vessels", "are", "discussed", "as", "possible", "pathogenetic", "mechanisms", ".", "We", "describe", "the", "occurrence", "of", "embolia", "cutis", "medicamentosa", "after", "intra", "-", "articular", "injections", "into", "the", "knee", "." ]

[ "umlsterm" ]

Esophageal is an umlsterm, disease is an umlsterm, etiology is an umlsterm, male is an umlsterm, patients is an umlsterm, disease is an umlsterm, dilatation is an umlsterm, esophageal is an umlsterm, Stenosis is an umlsterm, esophagitis is an umlsterm, patients is an umlsterm, All is an umlsterm, patients is an umlsterm, dysphagia is an umlsterm, esophageal is an umlsterm

DerChirurg.80690471.eng.abstr_task0

Sentence: Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth .

[ "Esophageal", "intramural", "pseudodiverticulosis", "is", "a", "very", "rare", "disease", "with", "unknown", "etiology", ",", "which", "especially", "affects", "male", "patients", "between", "45", "and", "65", "years", ".", "This", "disease", "is", "characterized", "by", "dilatation", "of", "the", "esophageal", "submucosal", "glands", "and", "their", "outlets", ".", "Stenosis", "caused", "by", "esophagitis", "due", "to", "intramural", "pseudodiverticulosis", "is", "found", "in", "most", "of", "the", "known", "patients", ".", "All", "patients", "presented", "with", "dysphagia", ",", "usually", "of", "long", "duration", ".", "The", "characteristic", "radiographic", "appearance", "is", "numerous", "intramural", "esophageal", "contrast", "-", "filled", "diverticulosis", "-", "like", "pouches", "-", "4", "mm", "in", "depth", "." ]

[ "umlsterm" ]

Esophageal is an umlsterm, disease is an umlsterm, etiology is an umlsterm, male is an umlsterm, patients is an umlsterm, disease is an umlsterm, dilatation is an umlsterm, esophageal is an umlsterm, Stenosis is an umlsterm, esophagitis is an umlsterm, patients is an umlsterm, All is an umlsterm, patients is an umlsterm, dysphagia is an umlsterm, esophageal is an umlsterm

DerChirurg.80690471.eng.abstr_task1

Sentence: Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth . Instructions: please typing these entity words according to sentence: Esophageal, disease, etiology, male, patients, disease, dilatation, esophageal, Stenosis, esophagitis, patients, All, patients, dysphagia, esophageal Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth .

[ "Esophageal", "intramural", "pseudodiverticulosis", "is", "a", "very", "rare", "disease", "with", "unknown", "etiology", ",", "which", "especially", "affects", "male", "patients", "between", "45", "and", "65", "years", ".", "This", "disease", "is", "characterized", "by", "dilatation", "of", "the", "esophageal", "submucosal", "glands", "and", "their", "outlets", ".", "Stenosis", "caused", "by", "esophagitis", "due", "to", "intramural", "pseudodiverticulosis", "is", "found", "in", "most", "of", "the", "known", "patients", ".", "All", "patients", "presented", "with", "dysphagia", ",", "usually", "of", "long", "duration", ".", "The", "characteristic", "radiographic", "appearance", "is", "numerous", "intramural", "esophageal", "contrast", "-", "filled", "diverticulosis", "-", "like", "pouches", "-", "4", "mm", "in", "depth", "." ]

[ "umlsterm" ]

Esophageal, disease, etiology, male, patients, disease, dilatation, esophageal, Stenosis, esophagitis, patients, All, patients, dysphagia, esophageal

DerChirurg.80690471.eng.abstr_task2

Sentence: Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Esophageal intramural pseudodiverticulosis is a very rare disease with unknown etiology , which especially affects male patients between 45 and 65 years . This disease is characterized by dilatation of the esophageal submucosal glands and their outlets . Stenosis caused by esophagitis due to intramural pseudodiverticulosis is found in most of the known patients . All patients presented with dysphagia , usually of long duration . The characteristic radiographic appearance is numerous intramural esophageal contrast-filled diverticulosis-like pouches - 4 mm in depth .

[ "Esophageal", "intramural", "pseudodiverticulosis", "is", "a", "very", "rare", "disease", "with", "unknown", "etiology", ",", "which", "especially", "affects", "male", "patients", "between", "45", "and", "65", "years", ".", "This", "disease", "is", "characterized", "by", "dilatation", "of", "the", "esophageal", "submucosal", "glands", "and", "their", "outlets", ".", "Stenosis", "caused", "by", "esophagitis", "due", "to", "intramural", "pseudodiverticulosis", "is", "found", "in", "most", "of", "the", "known", "patients", ".", "All", "patients", "presented", "with", "dysphagia", ",", "usually", "of", "long", "duration", ".", "The", "characteristic", "radiographic", "appearance", "is", "numerous", "intramural", "esophageal", "contrast", "-", "filled", "diverticulosis", "-", "like", "pouches", "-", "4", "mm", "in", "depth", "." ]

[ "umlsterm" ]

Web - based weight management programs is a Intervention_Educational, . is a Intervention_Other, efficacy is a Outcome_Other, Web - based tailored behavioral weight management program is a Intervention_Educational, 2862 is a Participant_Sample-size, overweight and obese ( BMI = 27 to 40 kg / m2 ) is a Participant_Condition, tailored expert system is a Intervention_Educational, information - only Web - based weight management materials is a Intervention_Educational, Weight change is a Outcome_Physical, program satisfaction is a Outcome_Other, weight loss is a Outcome_Physical, baseline weight is a Outcome_Physical, personally relevant , helpful , and easy to understand . is a Outcome_Other, Web - based tailored expert system for weight management is a Intervention_Educational, Web - based information - only weight management program is a Intervention_Educational

25784_task0

Sentence: Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O" ]

Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program .

[ "Web", "-", "based", "weight", "management", "programs", "in", "an", "integrated", "health", "care", "setting", ":", "a", "randomized", ",", "controlled", "trial", ".", "OBJECTIVE", "To", "assess", "the", "efficacy", "of", "a", "Web", "-", "based", "tailored", "behavioral", "weight", "management", "program", "compared", "with", "Web", "-", "based", "information", "-", "only", "weight", "management", "materials", ".", "RESEARCH", "METHODS", "AND", "PROCEDURES", "Participants", ",", "2862", "eligible", "overweight", "and", "obese", "(", "BMI", "=", "27", "to", "40", "kg", "/", "m2", ")", "members", "from", "four", "regions", "of", "Kaiser", "Permanente", "'", "s", "integrated", "health", "care", "delivery", "system", ",", "were", "randomized", "to", "receive", "either", "a", "tailored", "expert", "system", "or", "information", "-", "only", "Web", "-", "based", "weight", "management", "materials", ".", "Weight", "change", "and", "program", "satisfaction", "were", "assessed", "by", "self", "-", "report", "through", "an", "Internet", "-", "based", "survey", "at", "3-", "and", "6-month", "follow", "-", "up", "periods", ".", "RESULTS", "Significantly", "greater", "weight", "loss", "at", "follow", "-", "up", "was", "found", "among", "participants", "assigned", "to", "the", "tailored", "expert", "system", "than", "among", "those", "assigned", "to", "the", "information", "-", "only", "condition", ".", "Subjects", "in", "the", "tailored", "expert", "system", "lost", "a", "mean", "of", "3", "+", "/-", "0.3", "%", "of", "their", "baseline", "weight", ",", "whereas", "subjects", "in", "the", "information", "-", "only", "condition", "lost", "a", "mean", "of", "1.2", "+", "/-", "0.4", "%", "(", "p", "<", "0.0004", ")", ".", "Participants", "were", "also", "more", "likely", "to", "report", "that", "the", "tailored", "expert", "system", "was", "personally", "relevant", ",", "helpful", ",", "and", "easy", "to", "understand", ".", "Notably", ",", "36", "%", "of", "enrollees", "were", "African", "-", "American", ",", "with", "enrollment", "rates", "higher", "than", "the", "general", "proportion", "of", "African", "Americans", "in", "any", "of", "the", "study", "regions", ".", "DISCUSSION", "The", "results", "of", "this", "large", ",", "randomized", "control", "trial", "show", "the", "potential", "benefit", "of", "the", "Web", "-", "based", "tailored", "expert", "system", "for", "weight", "management", "compared", "with", "a", "Web", "-", "based", "information", "-", "only", "weight", "management", "program", "." ]

[ "Outcome_Other", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Sample-size", "Intervention_Other" ]

Web - based weight management programs is a Intervention_Educational, . is a Intervention_Other, efficacy is a Outcome_Other, Web - based tailored behavioral weight management program is a Intervention_Educational, 2862 is a Participant_Sample-size, overweight and obese ( BMI = 27 to 40 kg / m2 ) is a Participant_Condition, tailored expert system is a Intervention_Educational, information - only Web - based weight management materials is a Intervention_Educational, Weight change is a Outcome_Physical, program satisfaction is a Outcome_Other, weight loss is a Outcome_Physical, baseline weight is a Outcome_Physical, personally relevant , helpful , and easy to understand . is a Outcome_Other, Web - based tailored expert system for weight management is a Intervention_Educational, Web - based information - only weight management program is a Intervention_Educational

25784_task1

Sentence: Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program . Instructions: please typing these entity words according to sentence: Web - based weight management programs, ., efficacy, Web - based tailored behavioral weight management program, 2862, overweight and obese ( BMI = 27 to 40 kg / m2 ), tailored expert system, information - only Web - based weight management materials, Weight change, program satisfaction, weight loss, baseline weight, personally relevant , helpful , and easy to understand ., Web - based tailored expert system for weight management, Web - based information - only weight management program Options: Participant_Condition, Intervention_Educational, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O" ]

Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program .

[ "Web", "-", "based", "weight", "management", "programs", "in", "an", "integrated", "health", "care", "setting", ":", "a", "randomized", ",", "controlled", "trial", ".", "OBJECTIVE", "To", "assess", "the", "efficacy", "of", "a", "Web", "-", "based", "tailored", "behavioral", "weight", "management", "program", "compared", "with", "Web", "-", "based", "information", "-", "only", "weight", "management", "materials", ".", "RESEARCH", "METHODS", "AND", "PROCEDURES", "Participants", ",", "2862", "eligible", "overweight", "and", "obese", "(", "BMI", "=", "27", "to", "40", "kg", "/", "m2", ")", "members", "from", "four", "regions", "of", "Kaiser", "Permanente", "'", "s", "integrated", "health", "care", "delivery", "system", ",", "were", "randomized", "to", "receive", "either", "a", "tailored", "expert", "system", "or", "information", "-", "only", "Web", "-", "based", "weight", "management", "materials", ".", "Weight", "change", "and", "program", "satisfaction", "were", "assessed", "by", "self", "-", "report", "through", "an", "Internet", "-", "based", "survey", "at", "3-", "and", "6-month", "follow", "-", "up", "periods", ".", "RESULTS", "Significantly", "greater", "weight", "loss", "at", "follow", "-", "up", "was", "found", "among", "participants", "assigned", "to", "the", "tailored", "expert", "system", "than", "among", "those", "assigned", "to", "the", "information", "-", "only", "condition", ".", "Subjects", "in", "the", "tailored", "expert", "system", "lost", "a", "mean", "of", "3", "+", "/-", "0.3", "%", "of", "their", "baseline", "weight", ",", "whereas", "subjects", "in", "the", "information", "-", "only", "condition", "lost", "a", "mean", "of", "1.2", "+", "/-", "0.4", "%", "(", "p", "<", "0.0004", ")", ".", "Participants", "were", "also", "more", "likely", "to", "report", "that", "the", "tailored", "expert", "system", "was", "personally", "relevant", ",", "helpful", ",", "and", "easy", "to", "understand", ".", "Notably", ",", "36", "%", "of", "enrollees", "were", "African", "-", "American", ",", "with", "enrollment", "rates", "higher", "than", "the", "general", "proportion", "of", "African", "Americans", "in", "any", "of", "the", "study", "regions", ".", "DISCUSSION", "The", "results", "of", "this", "large", ",", "randomized", "control", "trial", "show", "the", "potential", "benefit", "of", "the", "Web", "-", "based", "tailored", "expert", "system", "for", "weight", "management", "compared", "with", "a", "Web", "-", "based", "information", "-", "only", "weight", "management", "program", "." ]

[ "Outcome_Other", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Sample-size", "Intervention_Other" ]

Web - based weight management programs, ., efficacy, Web - based tailored behavioral weight management program, 2862, overweight and obese ( BMI = 27 to 40 kg / m2 ), tailored expert system, information - only Web - based weight management materials, Weight change, program satisfaction, weight loss, baseline weight, personally relevant , helpful , and easy to understand ., Web - based tailored expert system for weight management, Web - based information - only weight management program

25784_task2

Sentence: Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O" ]

Web-based weight management programs in an integrated health care setting : a randomized , controlled trial . OBJECTIVE To assess the efficacy of a Web-based tailored behavioral weight management program compared with Web-based information-only weight management materials . RESEARCH METHODS AND PROCEDURES Participants , 2862 eligible overweight and obese ( BMI = 27 to 40 kg/m2 ) members from four regions of Kaiser Permanente 's integrated health care delivery system , were randomized to receive either a tailored expert system or information-only Web-based weight management materials . Weight change and program satisfaction were assessed by self-report through an Internet-based survey at 3- and 6-month follow-up periods . RESULTS Significantly greater weight loss at follow-up was found among participants assigned to the tailored expert system than among those assigned to the information-only condition . Subjects in the tailored expert system lost a mean of 3 +/- 0.3 % of their baseline weight , whereas subjects in the information-only condition lost a mean of 1.2 +/- 0.4 % ( p < 0.0004 ) . Participants were also more likely to report that the tailored expert system was personally relevant , helpful , and easy to understand . Notably , 36 % of enrollees were African-American , with enrollment rates higher than the general proportion of African Americans in any of the study regions . DISCUSSION The results of this large , randomized control trial show the potential benefit of the Web-based tailored expert system for weight management compared with a Web-based information-only weight management program .

[ "Web", "-", "based", "weight", "management", "programs", "in", "an", "integrated", "health", "care", "setting", ":", "a", "randomized", ",", "controlled", "trial", ".", "OBJECTIVE", "To", "assess", "the", "efficacy", "of", "a", "Web", "-", "based", "tailored", "behavioral", "weight", "management", "program", "compared", "with", "Web", "-", "based", "information", "-", "only", "weight", "management", "materials", ".", "RESEARCH", "METHODS", "AND", "PROCEDURES", "Participants", ",", "2862", "eligible", "overweight", "and", "obese", "(", "BMI", "=", "27", "to", "40", "kg", "/", "m2", ")", "members", "from", "four", "regions", "of", "Kaiser", "Permanente", "'", "s", "integrated", "health", "care", "delivery", "system", ",", "were", "randomized", "to", "receive", "either", "a", "tailored", "expert", "system", "or", "information", "-", "only", "Web", "-", "based", "weight", "management", "materials", ".", "Weight", "change", "and", "program", "satisfaction", "were", "assessed", "by", "self", "-", "report", "through", "an", "Internet", "-", "based", "survey", "at", "3-", "and", "6-month", "follow", "-", "up", "periods", ".", "RESULTS", "Significantly", "greater", "weight", "loss", "at", "follow", "-", "up", "was", "found", "among", "participants", "assigned", "to", "the", "tailored", "expert", "system", "than", "among", "those", "assigned", "to", "the", "information", "-", "only", "condition", ".", "Subjects", "in", "the", "tailored", "expert", "system", "lost", "a", "mean", "of", "3", "+", "/-", "0.3", "%", "of", "their", "baseline", "weight", ",", "whereas", "subjects", "in", "the", "information", "-", "only", "condition", "lost", "a", "mean", "of", "1.2", "+", "/-", "0.4", "%", "(", "p", "<", "0.0004", ")", ".", "Participants", "were", "also", "more", "likely", "to", "report", "that", "the", "tailored", "expert", "system", "was", "personally", "relevant", ",", "helpful", ",", "and", "easy", "to", "understand", ".", "Notably", ",", "36", "%", "of", "enrollees", "were", "African", "-", "American", ",", "with", "enrollment", "rates", "higher", "than", "the", "general", "proportion", "of", "African", "Americans", "in", "any", "of", "the", "study", "regions", ".", "DISCUSSION", "The", "results", "of", "this", "large", ",", "randomized", "control", "trial", "show", "the", "potential", "benefit", "of", "the", "Web", "-", "based", "tailored", "expert", "system", "for", "weight", "management", "compared", "with", "a", "Web", "-", "based", "information", "-", "only", "weight", "management", "program", "." ]

[ "Outcome_Other", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Sample-size", "Intervention_Other" ]

R124C is a ProteinMutation

842_task0

Sentence: Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ProteinMutation

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.

[ "Anticipation", "in", "familial", "lattice", "corneal", "dystrophy", "type", "I", "with", "R124C", "mutation", "in", "the", "TGFBI", "(", "BIGH3", ")", "gene", "." ]

[ "ProteinMutation", "DNAMutation" ]

R124C is a ProteinMutation

842_task1

Sentence: Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene. Instructions: please typing these entity words according to sentence: R124C Options: ProteinMutation

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.

[ "Anticipation", "in", "familial", "lattice", "corneal", "dystrophy", "type", "I", "with", "R124C", "mutation", "in", "the", "TGFBI", "(", "BIGH3", ")", "gene", "." ]

[ "ProteinMutation", "DNAMutation" ]

R124C

842_task2

Sentence: Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.

[ "Anticipation", "in", "familial", "lattice", "corneal", "dystrophy", "type", "I", "with", "R124C", "mutation", "in", "the", "TGFBI", "(", "BIGH3", ")", "gene", "." ]

[ "ProteinMutation", "DNAMutation" ]

Adenosine deaminase is a protein, ADA is a protein, adenosine is a compound, inosine is a compound, ammonia is a compound

DS.d469_task0

Sentence: Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "B-compound", "O" ]

Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia.

[ "Adenosine", "deaminase", "(", "ADA", ")", ",", "an", "enzyme", "involved", "in", "purine", "metabolism", ",", "catalyzes", "the", "hydrolytic", "breakdown", "of", "adenosine", "into", "inosine", "and", "free", "ammonia", "." ]

[ "protein", "compound" ]

Adenosine deaminase is a protein, ADA is a protein, adenosine is a compound, inosine is a compound, ammonia is a compound

DS.d469_task1

Sentence: Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia. Instructions: please typing these entity words according to sentence: Adenosine deaminase, ADA, adenosine, inosine, ammonia Options: compound, protein

[ "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "B-compound", "O" ]

Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia.

[ "Adenosine", "deaminase", "(", "ADA", ")", ",", "an", "enzyme", "involved", "in", "purine", "metabolism", ",", "catalyzes", "the", "hydrolytic", "breakdown", "of", "adenosine", "into", "inosine", "and", "free", "ammonia", "." ]

[ "protein", "compound" ]

Adenosine deaminase, ADA, adenosine, inosine, ammonia

DS.d469_task2

Sentence: Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia. Instructions: please extract entity words from the input sentence

[ "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "B-compound", "O" ]

Adenosine deaminase (ADA), an enzyme involved in purine metabolism, catalyzes the hydrolytic breakdown of adenosine into inosine and free ammonia.

[ "Adenosine", "deaminase", "(", "ADA", ")", ",", "an", "enzyme", "involved", "in", "purine", "metabolism", ",", "catalyzes", "the", "hydrolytic", "breakdown", "of", "adenosine", "into", "inosine", "and", "free", "ammonia", "." ]

[ "protein", "compound" ]

protease is a GENE-Y

17635930_task0

Sentence: Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]

Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

[ "Potent", "inhibition", "of", "HIV-1", "replication", "by", "novel", "non", "-", "peptidyl", "small", "molecule", "inhibitors", "of", "protease", "dimerization", "." ]

[ "GENE-Y" ]

protease is a GENE-Y

17635930_task1

Sentence: Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. Instructions: please typing these entity words according to sentence: protease Options: GENE-Y

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]

Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

[ "Potent", "inhibition", "of", "HIV-1", "replication", "by", "novel", "non", "-", "peptidyl", "small", "molecule", "inhibitors", "of", "protease", "dimerization", "." ]

[ "GENE-Y" ]

protease

17635930_task2

Sentence: Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]

Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

[ "Potent", "inhibition", "of", "HIV-1", "replication", "by", "novel", "non", "-", "peptidyl", "small", "molecule", "inhibitors", "of", "protease", "dimerization", "." ]

[ "GENE-Y" ]

Augenfolgebewegungen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Pathologie is an umlsterm, Augefolgebewegungen is an umlsterm, Augenfolgebewegungen is an umlsterm

HNO.70450385.ger.abstr_task0

Sentence: Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung .

[ "Die", "Pruefung", "der", "willkuerlichen", "langsamen", "Augenfolgebewegungen", "liefert", "wichtige", "Hinweise", "zur", "Aufdeckung", "zentral", "vestibulaerer", "Stoerungen", ".", "Ziel", "war", "es", "zu", "klaeren", ",", "ob", "neben", "der", "komplett", "gestoerten", "auch", "einer", "partiell", "gestoerten", "Blickfolgebewegung", "ein", "Krankheitswert", "zukommt", ".", "Retrospektiv", "wurde", "bei", "100", "Patienten", "die", "Blickfolgepruefung", "analysiert", ".", "Die", "einzelnen", "Kurvenverlaeufe", "wurden", "den", "3", "Gruppen", "der", "regelrechten", ",", "der", "partiell", "gestoerten", "und", "der", "komplett", "gestoerten", "Blickfolge", "zugeordnet", "und", "anschliessend", "der", "Uebereinstimmungsquotient", "errechnet", ";", "16", "Patienten", "zeigten", "qualitativ", "eine", "komplett", "gestoerte", "Blickfolge", ",", "und", "bei", "9", "von", "ihnen", "(", "56", "3", "%", ")", ",", "liess", "sich", "ein", "morphologisches", "Korrelat", "im", "Sinne", "einer", "zentralen", "Erkrankung", "finden", ".", "Bei", "29", "Patienten", "ergab", "sich", "eine", "partiell", "gestoerte", "Blickfolge", ",", "und", "nur", "bei", "2", "von", "ihnen", "(", "6,9", "%", ")", "fand", "sich", "eine", "zentrale", "Pathologie", ".", "Durchschnittlich", "fand", "sich", "der", "hoechste", "beidaeugig", "gemessene", "Uebereinstimmungsquotient", "mit", "1,44", "in", "der", "Gruppe", "mit", "komplett", "gestoerter", "Blickfolge", ".", "In", "der", "Gruppe", "mit", "partiell", "gestoerten", "Augefolgebewegungen", "lag", "er", "bei", "1,24", "und", "in", "der", "mit", "regelrechter", "Blickfolge", "bei", "1,17", ".", "Nur", "eine", "komplett", "gestoerte", "Blickfolge", "korreliert", "in", "den", "meisten", "Faellen", "mit", "einer", "zentralen", "Erkrankung", ".", "Partiell", "gestoerte", "Augenfolgebewegungen", "haben", "in", "der", "Regel", "keine", "pathologische", "Bedeutung", "." ]

[ "umlsterm" ]

Augenfolgebewegungen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Pathologie is an umlsterm, Augefolgebewegungen is an umlsterm, Augenfolgebewegungen is an umlsterm

HNO.70450385.ger.abstr_task1

Sentence: Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung . Instructions: please typing these entity words according to sentence: Augenfolgebewegungen, Patienten, Patienten, Patienten, Pathologie, Augefolgebewegungen, Augenfolgebewegungen Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung .

[ "Die", "Pruefung", "der", "willkuerlichen", "langsamen", "Augenfolgebewegungen", "liefert", "wichtige", "Hinweise", "zur", "Aufdeckung", "zentral", "vestibulaerer", "Stoerungen", ".", "Ziel", "war", "es", "zu", "klaeren", ",", "ob", "neben", "der", "komplett", "gestoerten", "auch", "einer", "partiell", "gestoerten", "Blickfolgebewegung", "ein", "Krankheitswert", "zukommt", ".", "Retrospektiv", "wurde", "bei", "100", "Patienten", "die", "Blickfolgepruefung", "analysiert", ".", "Die", "einzelnen", "Kurvenverlaeufe", "wurden", "den", "3", "Gruppen", "der", "regelrechten", ",", "der", "partiell", "gestoerten", "und", "der", "komplett", "gestoerten", "Blickfolge", "zugeordnet", "und", "anschliessend", "der", "Uebereinstimmungsquotient", "errechnet", ";", "16", "Patienten", "zeigten", "qualitativ", "eine", "komplett", "gestoerte", "Blickfolge", ",", "und", "bei", "9", "von", "ihnen", "(", "56", "3", "%", ")", ",", "liess", "sich", "ein", "morphologisches", "Korrelat", "im", "Sinne", "einer", "zentralen", "Erkrankung", "finden", ".", "Bei", "29", "Patienten", "ergab", "sich", "eine", "partiell", "gestoerte", "Blickfolge", ",", "und", "nur", "bei", "2", "von", "ihnen", "(", "6,9", "%", ")", "fand", "sich", "eine", "zentrale", "Pathologie", ".", "Durchschnittlich", "fand", "sich", "der", "hoechste", "beidaeugig", "gemessene", "Uebereinstimmungsquotient", "mit", "1,44", "in", "der", "Gruppe", "mit", "komplett", "gestoerter", "Blickfolge", ".", "In", "der", "Gruppe", "mit", "partiell", "gestoerten", "Augefolgebewegungen", "lag", "er", "bei", "1,24", "und", "in", "der", "mit", "regelrechter", "Blickfolge", "bei", "1,17", ".", "Nur", "eine", "komplett", "gestoerte", "Blickfolge", "korreliert", "in", "den", "meisten", "Faellen", "mit", "einer", "zentralen", "Erkrankung", ".", "Partiell", "gestoerte", "Augenfolgebewegungen", "haben", "in", "der", "Regel", "keine", "pathologische", "Bedeutung", "." ]

[ "umlsterm" ]

Augenfolgebewegungen, Patienten, Patienten, Patienten, Pathologie, Augefolgebewegungen, Augenfolgebewegungen

HNO.70450385.ger.abstr_task2

Sentence: Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Pruefung der willkuerlichen langsamen Augenfolgebewegungen liefert wichtige Hinweise zur Aufdeckung zentral vestibulaerer Stoerungen . Ziel war es zu klaeren , ob neben der komplett gestoerten auch einer partiell gestoerten Blickfolgebewegung ein Krankheitswert zukommt . Retrospektiv wurde bei 100 Patienten die Blickfolgepruefung analysiert . Die einzelnen Kurvenverlaeufe wurden den 3 Gruppen der regelrechten , der partiell gestoerten und der komplett gestoerten Blickfolge zugeordnet und anschliessend der Uebereinstimmungsquotient errechnet ; 16 Patienten zeigten qualitativ eine komplett gestoerte Blickfolge , und bei 9 von ihnen ( 56 3% ) , liess sich ein morphologisches Korrelat im Sinne einer zentralen Erkrankung finden . Bei 29 Patienten ergab sich eine partiell gestoerte Blickfolge , und nur bei 2 von ihnen ( 6,9% ) fand sich eine zentrale Pathologie . Durchschnittlich fand sich der hoechste beidaeugig gemessene Uebereinstimmungsquotient mit 1,44 in der Gruppe mit komplett gestoerter Blickfolge . In der Gruppe mit partiell gestoerten Augefolgebewegungen lag er bei 1,24 und in der mit regelrechter Blickfolge bei 1,17 . Nur eine komplett gestoerte Blickfolge korreliert in den meisten Faellen mit einer zentralen Erkrankung . Partiell gestoerte Augenfolgebewegungen haben in der Regel keine pathologische Bedeutung .

[ "Die", "Pruefung", "der", "willkuerlichen", "langsamen", "Augenfolgebewegungen", "liefert", "wichtige", "Hinweise", "zur", "Aufdeckung", "zentral", "vestibulaerer", "Stoerungen", ".", "Ziel", "war", "es", "zu", "klaeren", ",", "ob", "neben", "der", "komplett", "gestoerten", "auch", "einer", "partiell", "gestoerten", "Blickfolgebewegung", "ein", "Krankheitswert", "zukommt", ".", "Retrospektiv", "wurde", "bei", "100", "Patienten", "die", "Blickfolgepruefung", "analysiert", ".", "Die", "einzelnen", "Kurvenverlaeufe", "wurden", "den", "3", "Gruppen", "der", "regelrechten", ",", "der", "partiell", "gestoerten", "und", "der", "komplett", "gestoerten", "Blickfolge", "zugeordnet", "und", "anschliessend", "der", "Uebereinstimmungsquotient", "errechnet", ";", "16", "Patienten", "zeigten", "qualitativ", "eine", "komplett", "gestoerte", "Blickfolge", ",", "und", "bei", "9", "von", "ihnen", "(", "56", "3", "%", ")", ",", "liess", "sich", "ein", "morphologisches", "Korrelat", "im", "Sinne", "einer", "zentralen", "Erkrankung", "finden", ".", "Bei", "29", "Patienten", "ergab", "sich", "eine", "partiell", "gestoerte", "Blickfolge", ",", "und", "nur", "bei", "2", "von", "ihnen", "(", "6,9", "%", ")", "fand", "sich", "eine", "zentrale", "Pathologie", ".", "Durchschnittlich", "fand", "sich", "der", "hoechste", "beidaeugig", "gemessene", "Uebereinstimmungsquotient", "mit", "1,44", "in", "der", "Gruppe", "mit", "komplett", "gestoerter", "Blickfolge", ".", "In", "der", "Gruppe", "mit", "partiell", "gestoerten", "Augefolgebewegungen", "lag", "er", "bei", "1,24", "und", "in", "der", "mit", "regelrechter", "Blickfolge", "bei", "1,17", ".", "Nur", "eine", "komplett", "gestoerte", "Blickfolge", "korreliert", "in", "den", "meisten", "Faellen", "mit", "einer", "zentralen", "Erkrankung", ".", "Partiell", "gestoerte", "Augenfolgebewegungen", "haben", "in", "der", "Regel", "keine", "pathologische", "Bedeutung", "." ]

[ "umlsterm" ]

DNA polymerase kappa is a Protein, DNA polymerase kappa is a Protein, polkappa is a Protein, POLK is a Protein, stimulating protein-1 is a Protein, SP1 is a Protein, SP1 is a Protein, SP1 is a Protein, SP1 is a Protein, POLK is a Protein, SP1 is a Protein

217_task0

Sentence: Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours.

[ "Characterization", "of", "promoter", "regulatory", "elements", "involved", "in", "downexpression", "of", "the", "DNA", "polymerase", "kappa", "in", "colorectal", "cancer", ".", "\n", "The", "low", "-", "fidelity", "DNA", "polymerases", "thought", "to", "be", "specialized", "in", "DNA", "damage", "processing", "are", "frequently", "misregulated", "in", "cancers", ".", "We", "show", "here", "that", "DNA", "polymerase", "kappa", "(", "polkappa", ")", ",", "prone", "to", "replicate", "across", "oxidative", "and", "aromatic", "adducts", "and", "known", "to", "function", "in", "nucleotide", "excision", "repair", "(", "NER", ")", ",", "is", "downregulated", "in", "colorectal", "tumour", "biopsies", ".", "Contrary", "to", "the", "replicative", "poldelta", "and", "polalpha", ",", "for", "which", "only", "activating", "domains", "were", "described", ",", "we", "identified", "an", "upstream", "465-bp", "-", "long", "repressor", "region", "in", "the", "promoter", "of", "POLK", ".", "We", "also", "found", "an", "activating", "237-bp", "region", "that", "includes", "stimulating", "protein-1", "(", "SP1", ")", "and", "cyclic", "AMP", "-", "responsive", "element", "(", "CRE)-binding", "sites", ".", "Mutations", "at", "one", "CRE", "-", "binding", "site", "led", "to", "a", "dramatic", "80", "%", "decrease", "in", "promoter", "activity", ".", "Alterations", "of", "the", "SP1-binding", "site", "also", "affected", ",", "to", "a", "lesser", "extent", ",", "the", "transcription", ".", "Gel", "shift", "assays", "confirmed", "the", "role", "played", "by", "CRE", "/", "SP1", "recognition", "sequences", ".", "Moreover", ",", "ectopic", "expression", "of", "SP1", "or", "CRE", "-", "binding", "protein", "(", "CREB", ")", "protein", "favoured", "polkappa", "transcription", ".", "Finally", ",", "we", "found", "that", "polkappa", "downexpression", "in", "colorectal", "biopsies", "correlated", "with", "a", "decreased", "level", "of", "CREB", "and", "SP1", "transcripts", ".", "This", "work", "shows", "that", "the", "promoter", "of", "POLK", "is", "cis", "-", "controlled", "and", "suggests", "that", "silencing", "of", "CREB", "and", "SP1", "proteins", "could", "contribute", "to", "downregulation", "of", "this", "repair", "polymerase", "in", "colorectal", "tumours", ".", "\n" ]

[ "Protein" ]

DNA polymerase kappa is a Protein, DNA polymerase kappa is a Protein, polkappa is a Protein, POLK is a Protein, stimulating protein-1 is a Protein, SP1 is a Protein, SP1 is a Protein, SP1 is a Protein, SP1 is a Protein, POLK is a Protein, SP1 is a Protein

217_task1

Sentence: Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours. Instructions: please typing these entity words according to sentence: DNA polymerase kappa, DNA polymerase kappa, polkappa, POLK, stimulating protein-1, SP1, SP1, SP1, SP1, POLK, SP1 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours.

[ "Characterization", "of", "promoter", "regulatory", "elements", "involved", "in", "downexpression", "of", "the", "DNA", "polymerase", "kappa", "in", "colorectal", "cancer", ".", "\n", "The", "low", "-", "fidelity", "DNA", "polymerases", "thought", "to", "be", "specialized", "in", "DNA", "damage", "processing", "are", "frequently", "misregulated", "in", "cancers", ".", "We", "show", "here", "that", "DNA", "polymerase", "kappa", "(", "polkappa", ")", ",", "prone", "to", "replicate", "across", "oxidative", "and", "aromatic", "adducts", "and", "known", "to", "function", "in", "nucleotide", "excision", "repair", "(", "NER", ")", ",", "is", "downregulated", "in", "colorectal", "tumour", "biopsies", ".", "Contrary", "to", "the", "replicative", "poldelta", "and", "polalpha", ",", "for", "which", "only", "activating", "domains", "were", "described", ",", "we", "identified", "an", "upstream", "465-bp", "-", "long", "repressor", "region", "in", "the", "promoter", "of", "POLK", ".", "We", "also", "found", "an", "activating", "237-bp", "region", "that", "includes", "stimulating", "protein-1", "(", "SP1", ")", "and", "cyclic", "AMP", "-", "responsive", "element", "(", "CRE)-binding", "sites", ".", "Mutations", "at", "one", "CRE", "-", "binding", "site", "led", "to", "a", "dramatic", "80", "%", "decrease", "in", "promoter", "activity", ".", "Alterations", "of", "the", "SP1-binding", "site", "also", "affected", ",", "to", "a", "lesser", "extent", ",", "the", "transcription", ".", "Gel", "shift", "assays", "confirmed", "the", "role", "played", "by", "CRE", "/", "SP1", "recognition", "sequences", ".", "Moreover", ",", "ectopic", "expression", "of", "SP1", "or", "CRE", "-", "binding", "protein", "(", "CREB", ")", "protein", "favoured", "polkappa", "transcription", ".", "Finally", ",", "we", "found", "that", "polkappa", "downexpression", "in", "colorectal", "biopsies", "correlated", "with", "a", "decreased", "level", "of", "CREB", "and", "SP1", "transcripts", ".", "This", "work", "shows", "that", "the", "promoter", "of", "POLK", "is", "cis", "-", "controlled", "and", "suggests", "that", "silencing", "of", "CREB", "and", "SP1", "proteins", "could", "contribute", "to", "downregulation", "of", "this", "repair", "polymerase", "in", "colorectal", "tumours", ".", "\n" ]

[ "Protein" ]

DNA polymerase kappa, DNA polymerase kappa, polkappa, POLK, stimulating protein-1, SP1, SP1, SP1, SP1, POLK, SP1

217_task2

Sentence: Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (polkappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative poldelta and polalpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured polkappa transcription. Finally, we found that polkappa downexpression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours.

[ "Characterization", "of", "promoter", "regulatory", "elements", "involved", "in", "downexpression", "of", "the", "DNA", "polymerase", "kappa", "in", "colorectal", "cancer", ".", "\n", "The", "low", "-", "fidelity", "DNA", "polymerases", "thought", "to", "be", "specialized", "in", "DNA", "damage", "processing", "are", "frequently", "misregulated", "in", "cancers", ".", "We", "show", "here", "that", "DNA", "polymerase", "kappa", "(", "polkappa", ")", ",", "prone", "to", "replicate", "across", "oxidative", "and", "aromatic", "adducts", "and", "known", "to", "function", "in", "nucleotide", "excision", "repair", "(", "NER", ")", ",", "is", "downregulated", "in", "colorectal", "tumour", "biopsies", ".", "Contrary", "to", "the", "replicative", "poldelta", "and", "polalpha", ",", "for", "which", "only", "activating", "domains", "were", "described", ",", "we", "identified", "an", "upstream", "465-bp", "-", "long", "repressor", "region", "in", "the", "promoter", "of", "POLK", ".", "We", "also", "found", "an", "activating", "237-bp", "region", "that", "includes", "stimulating", "protein-1", "(", "SP1", ")", "and", "cyclic", "AMP", "-", "responsive", "element", "(", "CRE)-binding", "sites", ".", "Mutations", "at", "one", "CRE", "-", "binding", "site", "led", "to", "a", "dramatic", "80", "%", "decrease", "in", "promoter", "activity", ".", "Alterations", "of", "the", "SP1-binding", "site", "also", "affected", ",", "to", "a", "lesser", "extent", ",", "the", "transcription", ".", "Gel", "shift", "assays", "confirmed", "the", "role", "played", "by", "CRE", "/", "SP1", "recognition", "sequences", ".", "Moreover", ",", "ectopic", "expression", "of", "SP1", "or", "CRE", "-", "binding", "protein", "(", "CREB", ")", "protein", "favoured", "polkappa", "transcription", ".", "Finally", ",", "we", "found", "that", "polkappa", "downexpression", "in", "colorectal", "biopsies", "correlated", "with", "a", "decreased", "level", "of", "CREB", "and", "SP1", "transcripts", ".", "This", "work", "shows", "that", "the", "promoter", "of", "POLK", "is", "cis", "-", "controlled", "and", "suggests", "that", "silencing", "of", "CREB", "and", "SP1", "proteins", "could", "contribute", "to", "downregulation", "of", "this", "repair", "polymerase", "in", "colorectal", "tumours", ".", "\n" ]

[ "Protein" ]

Krebsfrueherkennung is an umlsterm, Mammae is an umlsterm, Haut is an umlsterm, Rektum is an umlsterm, Kolon is an umlsterm, Methoden is an umlsterm, gezielte is an umlsterm, koerperliche Untersuchung is an umlsterm, Selbstuntersuchung is an umlsterm, Mammae is an umlsterm, Zervixabstrich is an umlsterm, Blut is an umlsterm, Stuhl is an umlsterm, Mammographie is an umlsterm, Brustveraenderungen is an umlsterm

DerGynaekologe.00330474.ger.abstr_task0

Sentence: Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen .

[ "Die", "Durchfuehrung", "der", "Krebsfrueherkennung", "orientiert", "sich", "an", "den", "1971", "festgelegten", "Richtlinien", "des", "gesetzlichen", "Krebsfrueherkennungsprogramms", "(", "GKFP", ")", ".", "Untersuchte", "Organe", "sind", "das", "aeussere", "und", "innere", "Genitale", ",", "die", "Mammae", ",", "die", "Haut", "sowie", "das", "Rektum", "und", "das", "Kolon", ".", "Die", "Methoden", "umfassen", "die", "gezielte", "Anamnese", ",", "die", "koerperliche", "Untersuchung", ",", "die", "Anleitung", "zur", "Selbstuntersuchung", "der", "Mammae", ",", "den", "zytologischen", "Zervixabstrich", "und", "die", "Testung", "auf", "Blut", "im", "Stuhl", ".", "Die", "Durchfuehrung", "der", "Mammographie", "ist", "beschraenkt", "auf", "Indikationen", "wie", "Zugehoerigkeit", "zu", "anamnestischen", "Risikogruppen", "und", "manifesten", "Brustveraenderungen", "." ]

[ "umlsterm" ]

Krebsfrueherkennung is an umlsterm, Mammae is an umlsterm, Haut is an umlsterm, Rektum is an umlsterm, Kolon is an umlsterm, Methoden is an umlsterm, gezielte is an umlsterm, koerperliche Untersuchung is an umlsterm, Selbstuntersuchung is an umlsterm, Mammae is an umlsterm, Zervixabstrich is an umlsterm, Blut is an umlsterm, Stuhl is an umlsterm, Mammographie is an umlsterm, Brustveraenderungen is an umlsterm

DerGynaekologe.00330474.ger.abstr_task1

Sentence: Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen . Instructions: please typing these entity words according to sentence: Krebsfrueherkennung, Mammae, Haut, Rektum, Kolon, Methoden, gezielte, koerperliche Untersuchung, Selbstuntersuchung, Mammae, Zervixabstrich, Blut, Stuhl, Mammographie, Brustveraenderungen Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen .

[ "Die", "Durchfuehrung", "der", "Krebsfrueherkennung", "orientiert", "sich", "an", "den", "1971", "festgelegten", "Richtlinien", "des", "gesetzlichen", "Krebsfrueherkennungsprogramms", "(", "GKFP", ")", ".", "Untersuchte", "Organe", "sind", "das", "aeussere", "und", "innere", "Genitale", ",", "die", "Mammae", ",", "die", "Haut", "sowie", "das", "Rektum", "und", "das", "Kolon", ".", "Die", "Methoden", "umfassen", "die", "gezielte", "Anamnese", ",", "die", "koerperliche", "Untersuchung", ",", "die", "Anleitung", "zur", "Selbstuntersuchung", "der", "Mammae", ",", "den", "zytologischen", "Zervixabstrich", "und", "die", "Testung", "auf", "Blut", "im", "Stuhl", ".", "Die", "Durchfuehrung", "der", "Mammographie", "ist", "beschraenkt", "auf", "Indikationen", "wie", "Zugehoerigkeit", "zu", "anamnestischen", "Risikogruppen", "und", "manifesten", "Brustveraenderungen", "." ]

[ "umlsterm" ]

Krebsfrueherkennung, Mammae, Haut, Rektum, Kolon, Methoden, gezielte, koerperliche Untersuchung, Selbstuntersuchung, Mammae, Zervixabstrich, Blut, Stuhl, Mammographie, Brustveraenderungen

DerGynaekologe.00330474.ger.abstr_task2

Sentence: Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Die Durchfuehrung der Krebsfrueherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfrueherkennungsprogramms ( GKFP ) . Untersuchte Organe sind das aeussere und innere Genitale , die Mammae , die Haut sowie das Rektum und das Kolon . Die Methoden umfassen die gezielte Anamnese , die koerperliche Untersuchung , die Anleitung zur Selbstuntersuchung der Mammae , den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl . Die Durchfuehrung der Mammographie ist beschraenkt auf Indikationen wie Zugehoerigkeit zu anamnestischen Risikogruppen und manifesten Brustveraenderungen .

[ "Die", "Durchfuehrung", "der", "Krebsfrueherkennung", "orientiert", "sich", "an", "den", "1971", "festgelegten", "Richtlinien", "des", "gesetzlichen", "Krebsfrueherkennungsprogramms", "(", "GKFP", ")", ".", "Untersuchte", "Organe", "sind", "das", "aeussere", "und", "innere", "Genitale", ",", "die", "Mammae", ",", "die", "Haut", "sowie", "das", "Rektum", "und", "das", "Kolon", ".", "Die", "Methoden", "umfassen", "die", "gezielte", "Anamnese", ",", "die", "koerperliche", "Untersuchung", ",", "die", "Anleitung", "zur", "Selbstuntersuchung", "der", "Mammae", ",", "den", "zytologischen", "Zervixabstrich", "und", "die", "Testung", "auf", "Blut", "im", "Stuhl", ".", "Die", "Durchfuehrung", "der", "Mammographie", "ist", "beschraenkt", "auf", "Indikationen", "wie", "Zugehoerigkeit", "zu", "anamnestischen", "Risikogruppen", "und", "manifesten", "Brustveraenderungen", "." ]

[ "umlsterm" ]

Adhaesionen is an umlsterm, Ischaemie is an umlsterm, Fremdkoerper is an umlsterm, weiblicher Infertilitaet is an umlsterm, Lebenserwartung is an umlsterm, Komplikationen is an umlsterm, Adhaesionen is an umlsterm, Belastungen is an umlsterm, Forschung is an umlsterm, Blutgerinnung is an umlsterm, Wundheilung is an umlsterm

DerChirurg.00710510.ger.abstr_task0

Sentence: Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert .

[ "Zusammenfassung", ".", "Seit", "ueber", "einhundert", "Jahren", "sind", "peritoneale", "Adhaesionen", "als", "haeufige", "Folge", "abdomineller", "Eingriffe", "bekannt", ".", "Intraoperative", "Laesionen", "des", "Mesothels", "durch", "Abrasion", ",", "Ischaemie", ",", "Austrocknung", "und", "Fremdkoerper", "fuehren", "zu", "Beschwerden", ",", "Passagestoerungen", ",", "weiblicher", "Infertilitaet", "und", "Problemen", "bei", "Reeingriffen", ".", "Weltweit", "fuehren", "eine", "Steigerung", "von", "Lebenserwartung", "und", "Operationszahlen", "zu", "einer", "Zunahme", "der", "Komplikationen", "durch", "Adhaesionen", "und", "den", "damit", "verbundenen", ",", "sozio", "-", "oekonomischen", "Belastungen", ".", "Bis", "heute", "steht", "keine", "sichere", "und", "zuverlaessige", "Prophylaxe", "zur", "Verfuegung", ".", "Zielsetzung", "der", "Forschung", "sollte", "eine", "fluessige", "Substanz", "sein", ",", "die", "nach", "einmaliger", ",", "intraabdomineller", "Applikation", "ohne", "negativen", "Einfluss", "auf", "Blutgerinnung", "und", "Wundheilung", "das", "Auftreten", "postoperativer", "Verwachsungen", "mit", "vertretbaren", "Kosten", "signifikant", "reduziert", "." ]

[ "umlsterm" ]

Adhaesionen is an umlsterm, Ischaemie is an umlsterm, Fremdkoerper is an umlsterm, weiblicher Infertilitaet is an umlsterm, Lebenserwartung is an umlsterm, Komplikationen is an umlsterm, Adhaesionen is an umlsterm, Belastungen is an umlsterm, Forschung is an umlsterm, Blutgerinnung is an umlsterm, Wundheilung is an umlsterm

DerChirurg.00710510.ger.abstr_task1

Sentence: Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert . Instructions: please typing these entity words according to sentence: Adhaesionen, Ischaemie, Fremdkoerper, weiblicher Infertilitaet, Lebenserwartung, Komplikationen, Adhaesionen, Belastungen, Forschung, Blutgerinnung, Wundheilung Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert .

[ "Zusammenfassung", ".", "Seit", "ueber", "einhundert", "Jahren", "sind", "peritoneale", "Adhaesionen", "als", "haeufige", "Folge", "abdomineller", "Eingriffe", "bekannt", ".", "Intraoperative", "Laesionen", "des", "Mesothels", "durch", "Abrasion", ",", "Ischaemie", ",", "Austrocknung", "und", "Fremdkoerper", "fuehren", "zu", "Beschwerden", ",", "Passagestoerungen", ",", "weiblicher", "Infertilitaet", "und", "Problemen", "bei", "Reeingriffen", ".", "Weltweit", "fuehren", "eine", "Steigerung", "von", "Lebenserwartung", "und", "Operationszahlen", "zu", "einer", "Zunahme", "der", "Komplikationen", "durch", "Adhaesionen", "und", "den", "damit", "verbundenen", ",", "sozio", "-", "oekonomischen", "Belastungen", ".", "Bis", "heute", "steht", "keine", "sichere", "und", "zuverlaessige", "Prophylaxe", "zur", "Verfuegung", ".", "Zielsetzung", "der", "Forschung", "sollte", "eine", "fluessige", "Substanz", "sein", ",", "die", "nach", "einmaliger", ",", "intraabdomineller", "Applikation", "ohne", "negativen", "Einfluss", "auf", "Blutgerinnung", "und", "Wundheilung", "das", "Auftreten", "postoperativer", "Verwachsungen", "mit", "vertretbaren", "Kosten", "signifikant", "reduziert", "." ]

[ "umlsterm" ]

Adhaesionen, Ischaemie, Fremdkoerper, weiblicher Infertilitaet, Lebenserwartung, Komplikationen, Adhaesionen, Belastungen, Forschung, Blutgerinnung, Wundheilung

DerChirurg.00710510.ger.abstr_task2

Sentence: Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Seit ueber einhundert Jahren sind peritoneale Adhaesionen als haeufige Folge abdomineller Eingriffe bekannt . Intraoperative Laesionen des Mesothels durch Abrasion , Ischaemie , Austrocknung und Fremdkoerper fuehren zu Beschwerden , Passagestoerungen , weiblicher Infertilitaet und Problemen bei Reeingriffen . Weltweit fuehren eine Steigerung von Lebenserwartung und Operationszahlen zu einer Zunahme der Komplikationen durch Adhaesionen und den damit verbundenen , sozio-oekonomischen Belastungen . Bis heute steht keine sichere und zuverlaessige Prophylaxe zur Verfuegung . Zielsetzung der Forschung sollte eine fluessige Substanz sein , die nach einmaliger , intraabdomineller Applikation ohne negativen Einfluss auf Blutgerinnung und Wundheilung das Auftreten postoperativer Verwachsungen mit vertretbaren Kosten signifikant reduziert .

[ "Zusammenfassung", ".", "Seit", "ueber", "einhundert", "Jahren", "sind", "peritoneale", "Adhaesionen", "als", "haeufige", "Folge", "abdomineller", "Eingriffe", "bekannt", ".", "Intraoperative", "Laesionen", "des", "Mesothels", "durch", "Abrasion", ",", "Ischaemie", ",", "Austrocknung", "und", "Fremdkoerper", "fuehren", "zu", "Beschwerden", ",", "Passagestoerungen", ",", "weiblicher", "Infertilitaet", "und", "Problemen", "bei", "Reeingriffen", ".", "Weltweit", "fuehren", "eine", "Steigerung", "von", "Lebenserwartung", "und", "Operationszahlen", "zu", "einer", "Zunahme", "der", "Komplikationen", "durch", "Adhaesionen", "und", "den", "damit", "verbundenen", ",", "sozio", "-", "oekonomischen", "Belastungen", ".", "Bis", "heute", "steht", "keine", "sichere", "und", "zuverlaessige", "Prophylaxe", "zur", "Verfuegung", ".", "Zielsetzung", "der", "Forschung", "sollte", "eine", "fluessige", "Substanz", "sein", ",", "die", "nach", "einmaliger", ",", "intraabdomineller", "Applikation", "ohne", "negativen", "Einfluss", "auf", "Blutgerinnung", "und", "Wundheilung", "das", "Auftreten", "postoperativer", "Verwachsungen", "mit", "vertretbaren", "Kosten", "signifikant", "reduziert", "." ]

[ "umlsterm" ]

use is an umlsterm, epidural analgesia is an umlsterm, obstetrics is an umlsterm, use is an umlsterm, side effects is an umlsterm, labor is an umlsterm, stress is an umlsterm, release is an umlsterm, epinephrine is an umlsterm, norepinephrine is an umlsterm, vasoconstriction is an umlsterm, arteries is an umlsterm, fetal asphyxia is an umlsterm, fetus is an umlsterm, asphyxia is an umlsterm, epidural analgesia is an umlsterm, stress is an umlsterm, hypotension is an umlsterm, Ringer 's is an umlsterm, solution is an umlsterm, colloids is an umlsterm, concentration is an umlsterm, local anaesthetics is an umlsterm, opioids is an umlsterm, deliveries is an umlsterm, use is an umlsterm, epidural analgesia is an umlsterm, local anaesthetics is an umlsterm

DerAnaesthesist.7046s159.eng.abstr_task0

Sentence: Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]

Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced .

[ "Until", "today", ",", "the", "use", "of", "epidural", "analgesia", "in", "obstetrics", "still", "remains", "controversial", ".", "In", "the", "opinion", "of", "many", "obstetricians", "the", "use", "of", "an", "epidural", "for", "a", "healthy", "laboring", "parturient", "is", "not", "necessary", "and", "can", "lead", "to", "potentially", "harmful", "side", "effects", ".", "However", ",", "painful", "labor", "leads", "to", "a", "maternal", "stress", "reaction", "with", "the", "release", "of", "epinephrine", "and", "norepinephrine", ".", "The", "resulting", "vasoconstriction", "of", "uterine", "arteries", "can", "induce", "fetal", "asphyxia", "in", "an", "otherwise", "healthy", "fetus", "or", "can", "aggravate", "asphyxia", "in", "already", "compromised", "fetusses", ".", "Several", "studies", "show", "that", "epidural", "analgesia", "can", "attenuate", "the", "maternal", "stress", "reaction", "and", "thereby", "improve", "maternal", "and", "fetal", "well", "-", "being", ",", "as", "long", "as", "precautions", "are", "taken", ".", "The", "avoidance", "of", "maternal", "hypotension", "with", "sufficient", "volume", "preload", "with", "lactated", "Ringer", "'s", "solution", "or", "colloids", ",", "and", "decreasing", "the", "concentration", "of", "local", "anaesthetics", "by", "adding", "opioids", "will", "prevent", "an", "increase", "in", "instrumental", "deliveries", ".", "With", "the", "use", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", "the", "amount", "of", "local", "anaesthetics", "can", "even", "further", "be", "reduced", "." ]

[ "umlsterm" ]

use is an umlsterm, epidural analgesia is an umlsterm, obstetrics is an umlsterm, use is an umlsterm, side effects is an umlsterm, labor is an umlsterm, stress is an umlsterm, release is an umlsterm, epinephrine is an umlsterm, norepinephrine is an umlsterm, vasoconstriction is an umlsterm, arteries is an umlsterm, fetal asphyxia is an umlsterm, fetus is an umlsterm, asphyxia is an umlsterm, epidural analgesia is an umlsterm, stress is an umlsterm, hypotension is an umlsterm, Ringer 's is an umlsterm, solution is an umlsterm, colloids is an umlsterm, concentration is an umlsterm, local anaesthetics is an umlsterm, opioids is an umlsterm, deliveries is an umlsterm, use is an umlsterm, epidural analgesia is an umlsterm, local anaesthetics is an umlsterm

DerAnaesthesist.7046s159.eng.abstr_task1

Sentence: Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced . Instructions: please typing these entity words according to sentence: use, epidural analgesia, obstetrics, use, side effects, labor, stress, release, epinephrine, norepinephrine, vasoconstriction, arteries, fetal asphyxia, fetus, asphyxia, epidural analgesia, stress, hypotension, Ringer 's, solution, colloids, concentration, local anaesthetics, opioids, deliveries, use, epidural analgesia, local anaesthetics Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]

Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced .

[ "Until", "today", ",", "the", "use", "of", "epidural", "analgesia", "in", "obstetrics", "still", "remains", "controversial", ".", "In", "the", "opinion", "of", "many", "obstetricians", "the", "use", "of", "an", "epidural", "for", "a", "healthy", "laboring", "parturient", "is", "not", "necessary", "and", "can", "lead", "to", "potentially", "harmful", "side", "effects", ".", "However", ",", "painful", "labor", "leads", "to", "a", "maternal", "stress", "reaction", "with", "the", "release", "of", "epinephrine", "and", "norepinephrine", ".", "The", "resulting", "vasoconstriction", "of", "uterine", "arteries", "can", "induce", "fetal", "asphyxia", "in", "an", "otherwise", "healthy", "fetus", "or", "can", "aggravate", "asphyxia", "in", "already", "compromised", "fetusses", ".", "Several", "studies", "show", "that", "epidural", "analgesia", "can", "attenuate", "the", "maternal", "stress", "reaction", "and", "thereby", "improve", "maternal", "and", "fetal", "well", "-", "being", ",", "as", "long", "as", "precautions", "are", "taken", ".", "The", "avoidance", "of", "maternal", "hypotension", "with", "sufficient", "volume", "preload", "with", "lactated", "Ringer", "'s", "solution", "or", "colloids", ",", "and", "decreasing", "the", "concentration", "of", "local", "anaesthetics", "by", "adding", "opioids", "will", "prevent", "an", "increase", "in", "instrumental", "deliveries", ".", "With", "the", "use", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", "the", "amount", "of", "local", "anaesthetics", "can", "even", "further", "be", "reduced", "." ]

[ "umlsterm" ]

use, epidural analgesia, obstetrics, use, side effects, labor, stress, release, epinephrine, norepinephrine, vasoconstriction, arteries, fetal asphyxia, fetus, asphyxia, epidural analgesia, stress, hypotension, Ringer 's, solution, colloids, concentration, local anaesthetics, opioids, deliveries, use, epidural analgesia, local anaesthetics

DerAnaesthesist.7046s159.eng.abstr_task2

Sentence: Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]

Until today , the use of epidural analgesia in obstetrics still remains controversial . In the opinion of many obstetricians the use of an epidural for a healthy laboring parturient is not necessary and can lead to potentially harmful side effects . However , painful labor leads to a maternal stress reaction with the release of epinephrine and norepinephrine . The resulting vasoconstriction of uterine arteries can induce fetal asphyxia in an otherwise healthy fetus or can aggravate asphyxia in already compromised fetusses . Several studies show that epidural analgesia can attenuate the maternal stress reaction and thereby improve maternal and fetal well-being , as long as precautions are taken . The avoidance of maternal hypotension with sufficient volume preload with lactated Ringer's solution or colloids , and decreasing the concentration of local anaesthetics by adding opioids will prevent an increase in instrumental deliveries . With the use of patient-controlled epidural analgesia ( PCEA ) the amount of local anaesthetics can even further be reduced .

[ "Until", "today", ",", "the", "use", "of", "epidural", "analgesia", "in", "obstetrics", "still", "remains", "controversial", ".", "In", "the", "opinion", "of", "many", "obstetricians", "the", "use", "of", "an", "epidural", "for", "a", "healthy", "laboring", "parturient", "is", "not", "necessary", "and", "can", "lead", "to", "potentially", "harmful", "side", "effects", ".", "However", ",", "painful", "labor", "leads", "to", "a", "maternal", "stress", "reaction", "with", "the", "release", "of", "epinephrine", "and", "norepinephrine", ".", "The", "resulting", "vasoconstriction", "of", "uterine", "arteries", "can", "induce", "fetal", "asphyxia", "in", "an", "otherwise", "healthy", "fetus", "or", "can", "aggravate", "asphyxia", "in", "already", "compromised", "fetusses", ".", "Several", "studies", "show", "that", "epidural", "analgesia", "can", "attenuate", "the", "maternal", "stress", "reaction", "and", "thereby", "improve", "maternal", "and", "fetal", "well", "-", "being", ",", "as", "long", "as", "precautions", "are", "taken", ".", "The", "avoidance", "of", "maternal", "hypotension", "with", "sufficient", "volume", "preload", "with", "lactated", "Ringer", "'s", "solution", "or", "colloids", ",", "and", "decreasing", "the", "concentration", "of", "local", "anaesthetics", "by", "adding", "opioids", "will", "prevent", "an", "increase", "in", "instrumental", "deliveries", ".", "With", "the", "use", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", "the", "amount", "of", "local", "anaesthetics", "can", "even", "further", "be", "reduced", "." ]

[ "umlsterm" ]

subdural hematomas is an umlsterm, acceleration is an umlsterm, injuries is an umlsterm, traffic accidents is an umlsterm, vein is an umlsterm, ruptures is an umlsterm, causes is an umlsterm, Ruptures is an umlsterm, vessels is an umlsterm, literature is an umlsterm, institute is an umlsterm, systematic is an umlsterm, analysis is an umlsterm, veins is an umlsterm, blunt head injury is an umlsterm, morphological is an umlsterm, vessels is an umlsterm, imaging is an umlsterm, contrast is an umlsterm, car is an umlsterm, age is an umlsterm, head injury is an umlsterm, fractures is an umlsterm, injuries is an umlsterm, skull is an umlsterm, skull fracture is an umlsterm, focal brain injury is an umlsterm, signs is an umlsterm, diffuse brain injury is an umlsterm, direct is an umlsterm, head is an umlsterm, car is an umlsterm, ruptures is an umlsterm, veins is an umlsterm, survival is an umlsterm, minor is an umlsterm, ruptures is an umlsterm, thrombosis is an umlsterm, ruptures is an umlsterm, thrombosis is an umlsterm, knowledge is an umlsterm, vein is an umlsterm, ruptures is an umlsterm, frequency is an umlsterm, vein is an umlsterm, head injuries is an umlsterm, literature is an umlsterm, intracranial pressure is an umlsterm, accident is an umlsterm, cerebral circulation is an umlsterm

DerUnfallchirurg.01030552.eng.abstr_task0

Sentence: Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases .

[ "Experimental", "data", "and", "clinical", "as", "well", "as", "postmortem", "experiences", "have", "indicated", "that", "subdural", "hematomas", "are", "less", "frequent", "in", "acceleration", "injuries", "in", "traffic", "accidents", "compared", "to", "falls", "or", "assaults", ".", "The", "present", "report", "demonstrates", "that", "this", "does", "not", "hold", "true", "in", "the", "same", "way", "for", "bridging", "vein", "ruptures", "(", "one", "of", "the", "predominant", "causes", "for", "subdural", "bleedings", ")", ".", "Ruptures", "of", "these", "vessels", "without", "subdural", "bleeding", "(", "SDB", ")", "are", "only", "seldom", "mentioned", "in", "the", "literature", ".", "However", ",", "if", "no", "SDB", "is", "present", ",", "no", "one", "will", "look", "for", "these", "structures", ".", "In", "our", "institute", "a", "systematic", "analysis", "of", "the", "bridging", "veins", "in", "all", "cases", "of", "lethal", "blunt", "head", "injury", "is", "made", ":", "prior", "to", "the", "careful", "morphological", "preparation", "we", "investigate", "these", "vessels", "by", "radiographic", "imaging", "after", "filling", "with", "contrast", "medium", ".", "6", "car", "passengers", "(", "age", "between", "4", "and", "31", "years", ")", "which", "suffered", "a", "lethal", "head", "injury", "were", "examined", "in", "the", "last", "year", ".", "2", "victims", "had", "impressed", "fractures", "with", "cerebral", "compression", "injuries", ".", "In", "1", "case", "the", "base", "of", "the", "skull", "was", "broken", "and", "in", "3", "cases", "no", "skull", "fracture", "was", "present", ";", "no", "serious", "focal", "brain", "injury", "had", "occured", "in", "these", "4", "cases", ",", "but", "3", "victims", "had", "signs", "of", "diffuse", "brain", "injury", ".", "In", "5", "cases", "a", "direct", "impact", "of", "the", "head", "against", "the", "interior", "of", "the", "car", "was", "obvious", ".", "In", "5", "cases", "ruptures", "of", "serveral", "bridging", "veins", "could", "be", "demonstrated", ".", "In", "one", "case", "(", "survival", "for", "3", "days", ")", "a", "minor", "SDB", "(", "20", "ml", ")", "was", "present", "and", "the", "ruptures", "had", "been", "closed", "by", "thrombosis", ";", "another", "victim", "died", "at", "the", "scene", ".", "The", "other", "3", "victims", "survived", "between", "4", "and", "15", "hours", "without", "developing", "SDB", "and", "without", "closing", "of", "the", "ruptures", "by", "thrombosis", ".", "This", "combination", "is", "surprising", "and", "shows", "that", "our", "knowledge", "concerning", "the", "relationship", "between", "bridging", "vein", "ruptures", "and", "SDB", "is", "restrictred", ".", "The", "frequency", "of", "bridging", "vein", "lesions", "in", "severe", "head", "injuries", "is", "likely", "underestimated", "in", "the", "clinical", "as", "well", "as", "in", "the", "postmortem", "literature", ".", "A", "rapid", "increase", "of", "intracranial", "pressure", "after", "the", "accident", "resulting", "in", "a", "collapse", "of", "the", "cerebral", "circulation", "is", "probably", "responsible", "for", "the", "absence", "of", "the", "SDB", "in", "the", "presented", "cases", "." ]

[ "umlsterm" ]

subdural hematomas is an umlsterm, acceleration is an umlsterm, injuries is an umlsterm, traffic accidents is an umlsterm, vein is an umlsterm, ruptures is an umlsterm, causes is an umlsterm, Ruptures is an umlsterm, vessels is an umlsterm, literature is an umlsterm, institute is an umlsterm, systematic is an umlsterm, analysis is an umlsterm, veins is an umlsterm, blunt head injury is an umlsterm, morphological is an umlsterm, vessels is an umlsterm, imaging is an umlsterm, contrast is an umlsterm, car is an umlsterm, age is an umlsterm, head injury is an umlsterm, fractures is an umlsterm, injuries is an umlsterm, skull is an umlsterm, skull fracture is an umlsterm, focal brain injury is an umlsterm, signs is an umlsterm, diffuse brain injury is an umlsterm, direct is an umlsterm, head is an umlsterm, car is an umlsterm, ruptures is an umlsterm, veins is an umlsterm, survival is an umlsterm, minor is an umlsterm, ruptures is an umlsterm, thrombosis is an umlsterm, ruptures is an umlsterm, thrombosis is an umlsterm, knowledge is an umlsterm, vein is an umlsterm, ruptures is an umlsterm, frequency is an umlsterm, vein is an umlsterm, head injuries is an umlsterm, literature is an umlsterm, intracranial pressure is an umlsterm, accident is an umlsterm, cerebral circulation is an umlsterm

DerUnfallchirurg.01030552.eng.abstr_task1

Sentence: Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases . Instructions: please typing these entity words according to sentence: subdural hematomas, acceleration, injuries, traffic accidents, vein, ruptures, causes, Ruptures, vessels, literature, institute, systematic, analysis, veins, blunt head injury, morphological, vessels, imaging, contrast, car, age, head injury, fractures, injuries, skull, skull fracture, focal brain injury, signs, diffuse brain injury, direct, head, car, ruptures, veins, survival, minor, ruptures, thrombosis, ruptures, thrombosis, knowledge, vein, ruptures, frequency, vein, head injuries, literature, intracranial pressure, accident, cerebral circulation Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases .

[ "Experimental", "data", "and", "clinical", "as", "well", "as", "postmortem", "experiences", "have", "indicated", "that", "subdural", "hematomas", "are", "less", "frequent", "in", "acceleration", "injuries", "in", "traffic", "accidents", "compared", "to", "falls", "or", "assaults", ".", "The", "present", "report", "demonstrates", "that", "this", "does", "not", "hold", "true", "in", "the", "same", "way", "for", "bridging", "vein", "ruptures", "(", "one", "of", "the", "predominant", "causes", "for", "subdural", "bleedings", ")", ".", "Ruptures", "of", "these", "vessels", "without", "subdural", "bleeding", "(", "SDB", ")", "are", "only", "seldom", "mentioned", "in", "the", "literature", ".", "However", ",", "if", "no", "SDB", "is", "present", ",", "no", "one", "will", "look", "for", "these", "structures", ".", "In", "our", "institute", "a", "systematic", "analysis", "of", "the", "bridging", "veins", "in", "all", "cases", "of", "lethal", "blunt", "head", "injury", "is", "made", ":", "prior", "to", "the", "careful", "morphological", "preparation", "we", "investigate", "these", "vessels", "by", "radiographic", "imaging", "after", "filling", "with", "contrast", "medium", ".", "6", "car", "passengers", "(", "age", "between", "4", "and", "31", "years", ")", "which", "suffered", "a", "lethal", "head", "injury", "were", "examined", "in", "the", "last", "year", ".", "2", "victims", "had", "impressed", "fractures", "with", "cerebral", "compression", "injuries", ".", "In", "1", "case", "the", "base", "of", "the", "skull", "was", "broken", "and", "in", "3", "cases", "no", "skull", "fracture", "was", "present", ";", "no", "serious", "focal", "brain", "injury", "had", "occured", "in", "these", "4", "cases", ",", "but", "3", "victims", "had", "signs", "of", "diffuse", "brain", "injury", ".", "In", "5", "cases", "a", "direct", "impact", "of", "the", "head", "against", "the", "interior", "of", "the", "car", "was", "obvious", ".", "In", "5", "cases", "ruptures", "of", "serveral", "bridging", "veins", "could", "be", "demonstrated", ".", "In", "one", "case", "(", "survival", "for", "3", "days", ")", "a", "minor", "SDB", "(", "20", "ml", ")", "was", "present", "and", "the", "ruptures", "had", "been", "closed", "by", "thrombosis", ";", "another", "victim", "died", "at", "the", "scene", ".", "The", "other", "3", "victims", "survived", "between", "4", "and", "15", "hours", "without", "developing", "SDB", "and", "without", "closing", "of", "the", "ruptures", "by", "thrombosis", ".", "This", "combination", "is", "surprising", "and", "shows", "that", "our", "knowledge", "concerning", "the", "relationship", "between", "bridging", "vein", "ruptures", "and", "SDB", "is", "restrictred", ".", "The", "frequency", "of", "bridging", "vein", "lesions", "in", "severe", "head", "injuries", "is", "likely", "underestimated", "in", "the", "clinical", "as", "well", "as", "in", "the", "postmortem", "literature", ".", "A", "rapid", "increase", "of", "intracranial", "pressure", "after", "the", "accident", "resulting", "in", "a", "collapse", "of", "the", "cerebral", "circulation", "is", "probably", "responsible", "for", "the", "absence", "of", "the", "SDB", "in", "the", "presented", "cases", "." ]

[ "umlsterm" ]

subdural hematomas, acceleration, injuries, traffic accidents, vein, ruptures, causes, Ruptures, vessels, literature, institute, systematic, analysis, veins, blunt head injury, morphological, vessels, imaging, contrast, car, age, head injury, fractures, injuries, skull, skull fracture, focal brain injury, signs, diffuse brain injury, direct, head, car, ruptures, veins, survival, minor, ruptures, thrombosis, ruptures, thrombosis, knowledge, vein, ruptures, frequency, vein, head injuries, literature, intracranial pressure, accident, cerebral circulation

DerUnfallchirurg.01030552.eng.abstr_task2

Sentence: Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Experimental data and clinical as well as postmortem experiences have indicated that subdural hematomas are less frequent in acceleration injuries in traffic accidents compared to falls or assaults . The present report demonstrates that this does not hold true in the same way for bridging vein ruptures ( one of the predominant causes for subdural bleedings ) . Ruptures of these vessels without subdural bleeding ( SDB ) are only seldom mentioned in the literature . However , if no SDB is present , no one will look for these structures . In our institute a systematic analysis of the bridging veins in all cases of lethal blunt head injury is made : prior to the careful morphological preparation we investigate these vessels by radiographic imaging after filling with contrast medium . 6 car passengers ( age between 4 and 31 years ) which suffered a lethal head injury were examined in the last year . 2 victims had impressed fractures with cerebral compression injuries . In 1 case the base of the skull was broken and in 3 cases no skull fracture was present ; no serious focal brain injury had occured in these 4 cases , but 3 victims had signs of diffuse brain injury . In 5 cases a direct impact of the head against the interior of the car was obvious . In 5 cases ruptures of serveral bridging veins could be demonstrated . In one case ( survival for 3 days ) a minor SDB ( 20 ml ) was present and the ruptures had been closed by thrombosis ; another victim died at the scene . The other 3 victims survived between 4 and 15 hours without developing SDB and without closing of the ruptures by thrombosis . This combination is surprising and shows that our knowledge concerning the relationship between bridging vein ruptures and SDB is restrictred . The frequency of bridging vein lesions in severe head injuries is likely underestimated in the clinical as well as in the postmortem literature . A rapid increase of intracranial pressure after the accident resulting in a collapse of the cerebral circulation is probably responsible for the absence of the SDB in the presented cases .

[ "Experimental", "data", "and", "clinical", "as", "well", "as", "postmortem", "experiences", "have", "indicated", "that", "subdural", "hematomas", "are", "less", "frequent", "in", "acceleration", "injuries", "in", "traffic", "accidents", "compared", "to", "falls", "or", "assaults", ".", "The", "present", "report", "demonstrates", "that", "this", "does", "not", "hold", "true", "in", "the", "same", "way", "for", "bridging", "vein", "ruptures", "(", "one", "of", "the", "predominant", "causes", "for", "subdural", "bleedings", ")", ".", "Ruptures", "of", "these", "vessels", "without", "subdural", "bleeding", "(", "SDB", ")", "are", "only", "seldom", "mentioned", "in", "the", "literature", ".", "However", ",", "if", "no", "SDB", "is", "present", ",", "no", "one", "will", "look", "for", "these", "structures", ".", "In", "our", "institute", "a", "systematic", "analysis", "of", "the", "bridging", "veins", "in", "all", "cases", "of", "lethal", "blunt", "head", "injury", "is", "made", ":", "prior", "to", "the", "careful", "morphological", "preparation", "we", "investigate", "these", "vessels", "by", "radiographic", "imaging", "after", "filling", "with", "contrast", "medium", ".", "6", "car", "passengers", "(", "age", "between", "4", "and", "31", "years", ")", "which", "suffered", "a", "lethal", "head", "injury", "were", "examined", "in", "the", "last", "year", ".", "2", "victims", "had", "impressed", "fractures", "with", "cerebral", "compression", "injuries", ".", "In", "1", "case", "the", "base", "of", "the", "skull", "was", "broken", "and", "in", "3", "cases", "no", "skull", "fracture", "was", "present", ";", "no", "serious", "focal", "brain", "injury", "had", "occured", "in", "these", "4", "cases", ",", "but", "3", "victims", "had", "signs", "of", "diffuse", "brain", "injury", ".", "In", "5", "cases", "a", "direct", "impact", "of", "the", "head", "against", "the", "interior", "of", "the", "car", "was", "obvious", ".", "In", "5", "cases", "ruptures", "of", "serveral", "bridging", "veins", "could", "be", "demonstrated", ".", "In", "one", "case", "(", "survival", "for", "3", "days", ")", "a", "minor", "SDB", "(", "20", "ml", ")", "was", "present", "and", "the", "ruptures", "had", "been", "closed", "by", "thrombosis", ";", "another", "victim", "died", "at", "the", "scene", ".", "The", "other", "3", "victims", "survived", "between", "4", "and", "15", "hours", "without", "developing", "SDB", "and", "without", "closing", "of", "the", "ruptures", "by", "thrombosis", ".", "This", "combination", "is", "surprising", "and", "shows", "that", "our", "knowledge", "concerning", "the", "relationship", "between", "bridging", "vein", "ruptures", "and", "SDB", "is", "restrictred", ".", "The", "frequency", "of", "bridging", "vein", "lesions", "in", "severe", "head", "injuries", "is", "likely", "underestimated", "in", "the", "clinical", "as", "well", "as", "in", "the", "postmortem", "literature", ".", "A", "rapid", "increase", "of", "intracranial", "pressure", "after", "the", "accident", "resulting", "in", "a", "collapse", "of", "the", "cerebral", "circulation", "is", "probably", "responsible", "for", "the", "absence", "of", "the", "SDB", "in", "the", "presented", "cases", "." ]

[ "umlsterm" ]

Biobrane is a NO_NORMALIZABLES, clorhexidina is a NORMALIZABLES, Imipenem is a NORMALIZABLES, Cilastatina is a NORMALIZABLES

261_task0

Sentence: Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, NO_NORMALIZABLES

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio.

[ "Varón", "de", "75", "años", "de", "edad", "con", "antecedentes", "de", "hipertensión", "arterial", ",", "diabetes", "mellitus", "tipo", "2", ",", "accidente", "isquémico", "transitorio", ",", "hipotiroidismo", "autoinmune", "y", "deterioro", "cognitivo", "leve", ".", "Sufrió", "una", "quemadura", "por", "contacto", "con", "llama", "por", "inflamación", "de", "la", "ropa", "al", "avivar", "una", "llama", "con", "gasóleo", ",", "a", "consecuencia", "de", "la", "cual", "presentaba", "lesiones", "dérmicas", "profundas", "y", "subdérmicas", "en", "ambas", "extremidades", "inferiores", ",", "con", "una", "superficie", "corporal", "total", "quemada", "del", "20", "%", ".", "Las", "quemaduras", "eran", "dérmicas", "profundas", "en", "la", "superficie", "posterior", "de", "ambos", "muslos", "y", "circunferenciales", "en", "ambas", "piernas", ",", "con", "una", "placa", "de", "afectación", "subdérmica", "en", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ",", "así", "como", "quemaduras", "dérmicas", "superficiales", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "la", "cara", ".", "\n", "La", "reanimación", "en", "las", "primeras", "horas", "tras", "el", "accidente", "se", "realizó", "en", "un", "hospital", "de", "otra", "región", ",", "desde", "el", "que", "se", "derivó", "a", "la", "Unidad", "de", "Cuidados", "Intensivos", "de", "nuestro", "hospital", "para", "continuar", "con", "el", "tratamiento", "de", "las", "lesiones", ".", "\n", "El", "día", "del", "ingreso", "hospitalario", "realizamos", "escarotomías", "de", "urgencia", "en", "ambas", "piernas", "y", "completamos", "la", "reanimación", "inicial", ".", "Durante", "las", "primeras", "3", "semanas", "de", "ingreso", "realizamos", "4", "sesiones", "de", "desbridamiento", "seriado", "de", "las", "zonas", "quemadas", "y", "cobertura", "con", "autoinjerto", "de", "piel", "parcial", "mallado", "de", "la", "superficie", "anterior", "de", "los", "muslos", "en", "los", "defectos", "provocados", "por", "la", "exéresis", "de", "las", "quemaduras", "más", "profundas", ",", "piernas", "y", "muslos", "posteriores", ",", "y", "con", "sustitutivos", "dérmicos", "(", "Biobrane", "®", ")", "en", "las", "zonas", "desbridadas", "de", "quemaduras", "superficiales", ",", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "áreas", "parcheadas", "de", "las", "piernas", "A", "la", "semana", "de", "postoperatorio", "objetivamos", "la", "pérdida", "del", "injerto", "de", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ".", "\n\n", "En", "una", "nueva", "sesión", "quirúrgica", "realizamos", "desbridamiento", "de", "la", "zona", "pretibial", "izquierda", ",", "con", "persistencia", "bajo", "el", "injerto", "de", "quemadura", "que", "no", "había", "sido", "eliminada", "durante", "las", "cirugías", "previas", ".", "Tras", "la", "adecuada", "eliminación", "de", "esta", "escara", "objetivamos", "un", "defecto", "pretibial", "de", "20", "cm", "de", "longitud", ",", "con", "exposición", "de", "la", "tibia", ".", "Realizamos", "escoplado", "de", "la", "totalidad", "del", "periostio", "expuesto", "e", "inicio", "de", "terapia", "de", "vacío", "sobre", "el", "defecto", "resultante", ".", "Aplicamos", "la", "terapia", "de", "vacío", "mediante", "dispositivo", "VAC", "®", "(", "KCI", "Clinic", "Spain", "SL", ")", ",", "en", "modo", "continuo", ",", "a", "125", "mmHg", ".", "Las", "curas", "se", "realizaron", "cada", "72", "horas", "con", "jabón", "de", "clorhexidina", ".", "No", "fueron", "necesarios", "nuevos", "procesos", "de", "desbridamiento", "en", "quirófano", ".", "Tras", "45", "días", "de", "terapia", "de", "vacío", "comprobamos", "la", "cobertura", "completa", "del", "hueso", "por", "tejido", "de", "granulación", "y", "realizamos", "tratamiento", "definitivo", "con", "autoinjertos", "de", "piel", "parcial", "tomados", "de", "los", "glúteos", ",", "tras", "lo", "cual", "conseguimos", "el", "cierre", "completo", "de", "las", "heridas", ".", "\n\n", "Durante", "el", "periodo", "de", "aplicación", "de", "la", "terapia", "los", "cultivos", "microbiológicos", "del", "tejido", "de", "granulación", "subyacente", "fueron", "positivos", "para", "Pseudomonas", "aeruginosa", "multirresistente", ",", "que", "previamente", "el", "paciente", "había", "presentado", "también", "en", "orina", ".", "Instauramos", "tratamiento", "sistémico", "con", "Imipenem", "y", "Cilastatina", ",", "y", "practicamos", "desbridamiento", "parcial", "del", "tejido", "de", "granulación", "más", "superficial", "e", "hipertrófico", "durante", "los", "cambios", "de", "cura", "en", "la", "habitación", ".", "Una", "vez", "completada", "la", "terapia", "de", "vacío", "e", "injertado", "el", "defecto", ",", "el", "paciente", "no", "volvió", "a", "presentar", "signos", "de", "infección", "de", "los", "injertos", ".", "A", "los", "100", "días", "de", "ingreso", "fue", "dado", "de", "alta", "hospitalaria", ",", "con", "dificultad", "para", "la", "deambulación", "y", "con", "tratamiento", "rehabilitador", "en", "régimen", "ambulatorio", ".", "\n" ]

[ "NORMALIZABLES", "NO_NORMALIZABLES" ]

Biobrane is a NO_NORMALIZABLES, clorhexidina is a NORMALIZABLES, Imipenem is a NORMALIZABLES, Cilastatina is a NORMALIZABLES

261_task1

Sentence: Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio. Instructions: please typing these entity words according to sentence: Biobrane, clorhexidina, Imipenem, Cilastatina Options: NORMALIZABLES, NO_NORMALIZABLES

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio.

[ "Varón", "de", "75", "años", "de", "edad", "con", "antecedentes", "de", "hipertensión", "arterial", ",", "diabetes", "mellitus", "tipo", "2", ",", "accidente", "isquémico", "transitorio", ",", "hipotiroidismo", "autoinmune", "y", "deterioro", "cognitivo", "leve", ".", "Sufrió", "una", "quemadura", "por", "contacto", "con", "llama", "por", "inflamación", "de", "la", "ropa", "al", "avivar", "una", "llama", "con", "gasóleo", ",", "a", "consecuencia", "de", "la", "cual", "presentaba", "lesiones", "dérmicas", "profundas", "y", "subdérmicas", "en", "ambas", "extremidades", "inferiores", ",", "con", "una", "superficie", "corporal", "total", "quemada", "del", "20", "%", ".", "Las", "quemaduras", "eran", "dérmicas", "profundas", "en", "la", "superficie", "posterior", "de", "ambos", "muslos", "y", "circunferenciales", "en", "ambas", "piernas", ",", "con", "una", "placa", "de", "afectación", "subdérmica", "en", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ",", "así", "como", "quemaduras", "dérmicas", "superficiales", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "la", "cara", ".", "\n", "La", "reanimación", "en", "las", "primeras", "horas", "tras", "el", "accidente", "se", "realizó", "en", "un", "hospital", "de", "otra", "región", ",", "desde", "el", "que", "se", "derivó", "a", "la", "Unidad", "de", "Cuidados", "Intensivos", "de", "nuestro", "hospital", "para", "continuar", "con", "el", "tratamiento", "de", "las", "lesiones", ".", "\n", "El", "día", "del", "ingreso", "hospitalario", "realizamos", "escarotomías", "de", "urgencia", "en", "ambas", "piernas", "y", "completamos", "la", "reanimación", "inicial", ".", "Durante", "las", "primeras", "3", "semanas", "de", "ingreso", "realizamos", "4", "sesiones", "de", "desbridamiento", "seriado", "de", "las", "zonas", "quemadas", "y", "cobertura", "con", "autoinjerto", "de", "piel", "parcial", "mallado", "de", "la", "superficie", "anterior", "de", "los", "muslos", "en", "los", "defectos", "provocados", "por", "la", "exéresis", "de", "las", "quemaduras", "más", "profundas", ",", "piernas", "y", "muslos", "posteriores", ",", "y", "con", "sustitutivos", "dérmicos", "(", "Biobrane", "®", ")", "en", "las", "zonas", "desbridadas", "de", "quemaduras", "superficiales", ",", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "áreas", "parcheadas", "de", "las", "piernas", "A", "la", "semana", "de", "postoperatorio", "objetivamos", "la", "pérdida", "del", "injerto", "de", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ".", "\n\n", "En", "una", "nueva", "sesión", "quirúrgica", "realizamos", "desbridamiento", "de", "la", "zona", "pretibial", "izquierda", ",", "con", "persistencia", "bajo", "el", "injerto", "de", "quemadura", "que", "no", "había", "sido", "eliminada", "durante", "las", "cirugías", "previas", ".", "Tras", "la", "adecuada", "eliminación", "de", "esta", "escara", "objetivamos", "un", "defecto", "pretibial", "de", "20", "cm", "de", "longitud", ",", "con", "exposición", "de", "la", "tibia", ".", "Realizamos", "escoplado", "de", "la", "totalidad", "del", "periostio", "expuesto", "e", "inicio", "de", "terapia", "de", "vacío", "sobre", "el", "defecto", "resultante", ".", "Aplicamos", "la", "terapia", "de", "vacío", "mediante", "dispositivo", "VAC", "®", "(", "KCI", "Clinic", "Spain", "SL", ")", ",", "en", "modo", "continuo", ",", "a", "125", "mmHg", ".", "Las", "curas", "se", "realizaron", "cada", "72", "horas", "con", "jabón", "de", "clorhexidina", ".", "No", "fueron", "necesarios", "nuevos", "procesos", "de", "desbridamiento", "en", "quirófano", ".", "Tras", "45", "días", "de", "terapia", "de", "vacío", "comprobamos", "la", "cobertura", "completa", "del", "hueso", "por", "tejido", "de", "granulación", "y", "realizamos", "tratamiento", "definitivo", "con", "autoinjertos", "de", "piel", "parcial", "tomados", "de", "los", "glúteos", ",", "tras", "lo", "cual", "conseguimos", "el", "cierre", "completo", "de", "las", "heridas", ".", "\n\n", "Durante", "el", "periodo", "de", "aplicación", "de", "la", "terapia", "los", "cultivos", "microbiológicos", "del", "tejido", "de", "granulación", "subyacente", "fueron", "positivos", "para", "Pseudomonas", "aeruginosa", "multirresistente", ",", "que", "previamente", "el", "paciente", "había", "presentado", "también", "en", "orina", ".", "Instauramos", "tratamiento", "sistémico", "con", "Imipenem", "y", "Cilastatina", ",", "y", "practicamos", "desbridamiento", "parcial", "del", "tejido", "de", "granulación", "más", "superficial", "e", "hipertrófico", "durante", "los", "cambios", "de", "cura", "en", "la", "habitación", ".", "Una", "vez", "completada", "la", "terapia", "de", "vacío", "e", "injertado", "el", "defecto", ",", "el", "paciente", "no", "volvió", "a", "presentar", "signos", "de", "infección", "de", "los", "injertos", ".", "A", "los", "100", "días", "de", "ingreso", "fue", "dado", "de", "alta", "hospitalaria", ",", "con", "dificultad", "para", "la", "deambulación", "y", "con", "tratamiento", "rehabilitador", "en", "régimen", "ambulatorio", ".", "\n" ]

[ "NORMALIZABLES", "NO_NORMALIZABLES" ]

Biobrane, clorhexidina, Imipenem, Cilastatina

261_task2

Sentence: Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 75 años de edad con antecedentes de hipertensión arterial, diabetes mellitus tipo 2, accidente isquémico transitorio, hipotiroidismo autoinmune y deterioro cognitivo leve. Sufrió una quemadura por contacto con llama por inflamación de la ropa al avivar una llama con gasóleo, a consecuencia de la cual presentaba lesiones dérmicas profundas y subdérmicas en ambas extremidades inferiores, con una superficie corporal total quemada del 20%. Las quemaduras eran dérmicas profundas en la superficie posterior de ambos muslos y circunferenciales en ambas piernas, con una placa de afectación subdérmica en la superficie anterior de la pierna izquierda, así como quemaduras dérmicas superficiales en el lateral de los muslos y en la cara. La reanimación en las primeras horas tras el accidente se realizó en un hospital de otra región, desde el que se derivó a la Unidad de Cuidados Intensivos de nuestro hospital para continuar con el tratamiento de las lesiones. El día del ingreso hospitalario realizamos escarotomías de urgencia en ambas piernas y completamos la reanimación inicial. Durante las primeras 3 semanas de ingreso realizamos 4 sesiones de desbridamiento seriado de las zonas quemadas y cobertura con autoinjerto de piel parcial mallado de la superficie anterior de los muslos en los defectos provocados por la exéresis de las quemaduras más profundas, piernas y muslos posteriores, y con sustitutivos dérmicos (Biobrane®) en las zonas desbridadas de quemaduras superficiales, en el lateral de los muslos y en áreas parcheadas de las piernas A la semana de postoperatorio objetivamos la pérdida del injerto de la superficie anterior de la pierna izquierda. En una nueva sesión quirúrgica realizamos desbridamiento de la zona pretibial izquierda, con persistencia bajo el injerto de quemadura que no había sido eliminada durante las cirugías previas. Tras la adecuada eliminación de esta escara objetivamos un defecto pretibial de 20 cm de longitud, con exposición de la tibia. Realizamos escoplado de la totalidad del periostio expuesto e inicio de terapia de vacío sobre el defecto resultante. Aplicamos la terapia de vacío mediante dispositivo VAC® (KCI Clinic Spain SL), en modo continuo, a 125 mmHg. Las curas se realizaron cada 72 horas con jabón de clorhexidina. No fueron necesarios nuevos procesos de desbridamiento en quirófano. Tras 45 días de terapia de vacío comprobamos la cobertura completa del hueso por tejido de granulación y realizamos tratamiento definitivo con autoinjertos de piel parcial tomados de los glúteos, tras lo cual conseguimos el cierre completo de las heridas. Durante el periodo de aplicación de la terapia los cultivos microbiológicos del tejido de granulación subyacente fueron positivos para Pseudomonas aeruginosa multirresistente, que previamente el paciente había presentado también en orina. Instauramos tratamiento sistémico con Imipenem y Cilastatina, y practicamos desbridamiento parcial del tejido de granulación más superficial e hipertrófico durante los cambios de cura en la habitación. Una vez completada la terapia de vacío e injertado el defecto, el paciente no volvió a presentar signos de infección de los injertos. A los 100 días de ingreso fue dado de alta hospitalaria, con dificultad para la deambulación y con tratamiento rehabilitador en régimen ambulatorio.

[ "Varón", "de", "75", "años", "de", "edad", "con", "antecedentes", "de", "hipertensión", "arterial", ",", "diabetes", "mellitus", "tipo", "2", ",", "accidente", "isquémico", "transitorio", ",", "hipotiroidismo", "autoinmune", "y", "deterioro", "cognitivo", "leve", ".", "Sufrió", "una", "quemadura", "por", "contacto", "con", "llama", "por", "inflamación", "de", "la", "ropa", "al", "avivar", "una", "llama", "con", "gasóleo", ",", "a", "consecuencia", "de", "la", "cual", "presentaba", "lesiones", "dérmicas", "profundas", "y", "subdérmicas", "en", "ambas", "extremidades", "inferiores", ",", "con", "una", "superficie", "corporal", "total", "quemada", "del", "20", "%", ".", "Las", "quemaduras", "eran", "dérmicas", "profundas", "en", "la", "superficie", "posterior", "de", "ambos", "muslos", "y", "circunferenciales", "en", "ambas", "piernas", ",", "con", "una", "placa", "de", "afectación", "subdérmica", "en", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ",", "así", "como", "quemaduras", "dérmicas", "superficiales", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "la", "cara", ".", "\n", "La", "reanimación", "en", "las", "primeras", "horas", "tras", "el", "accidente", "se", "realizó", "en", "un", "hospital", "de", "otra", "región", ",", "desde", "el", "que", "se", "derivó", "a", "la", "Unidad", "de", "Cuidados", "Intensivos", "de", "nuestro", "hospital", "para", "continuar", "con", "el", "tratamiento", "de", "las", "lesiones", ".", "\n", "El", "día", "del", "ingreso", "hospitalario", "realizamos", "escarotomías", "de", "urgencia", "en", "ambas", "piernas", "y", "completamos", "la", "reanimación", "inicial", ".", "Durante", "las", "primeras", "3", "semanas", "de", "ingreso", "realizamos", "4", "sesiones", "de", "desbridamiento", "seriado", "de", "las", "zonas", "quemadas", "y", "cobertura", "con", "autoinjerto", "de", "piel", "parcial", "mallado", "de", "la", "superficie", "anterior", "de", "los", "muslos", "en", "los", "defectos", "provocados", "por", "la", "exéresis", "de", "las", "quemaduras", "más", "profundas", ",", "piernas", "y", "muslos", "posteriores", ",", "y", "con", "sustitutivos", "dérmicos", "(", "Biobrane", "®", ")", "en", "las", "zonas", "desbridadas", "de", "quemaduras", "superficiales", ",", "en", "el", "lateral", "de", "los", "muslos", "y", "en", "áreas", "parcheadas", "de", "las", "piernas", "A", "la", "semana", "de", "postoperatorio", "objetivamos", "la", "pérdida", "del", "injerto", "de", "la", "superficie", "anterior", "de", "la", "pierna", "izquierda", ".", "\n\n", "En", "una", "nueva", "sesión", "quirúrgica", "realizamos", "desbridamiento", "de", "la", "zona", "pretibial", "izquierda", ",", "con", "persistencia", "bajo", "el", "injerto", "de", "quemadura", "que", "no", "había", "sido", "eliminada", "durante", "las", "cirugías", "previas", ".", "Tras", "la", "adecuada", "eliminación", "de", "esta", "escara", "objetivamos", "un", "defecto", "pretibial", "de", "20", "cm", "de", "longitud", ",", "con", "exposición", "de", "la", "tibia", ".", "Realizamos", "escoplado", "de", "la", "totalidad", "del", "periostio", "expuesto", "e", "inicio", "de", "terapia", "de", "vacío", "sobre", "el", "defecto", "resultante", ".", "Aplicamos", "la", "terapia", "de", "vacío", "mediante", "dispositivo", "VAC", "®", "(", "KCI", "Clinic", "Spain", "SL", ")", ",", "en", "modo", "continuo", ",", "a", "125", "mmHg", ".", "Las", "curas", "se", "realizaron", "cada", "72", "horas", "con", "jabón", "de", "clorhexidina", ".", "No", "fueron", "necesarios", "nuevos", "procesos", "de", "desbridamiento", "en", "quirófano", ".", "Tras", "45", "días", "de", "terapia", "de", "vacío", "comprobamos", "la", "cobertura", "completa", "del", "hueso", "por", "tejido", "de", "granulación", "y", "realizamos", "tratamiento", "definitivo", "con", "autoinjertos", "de", "piel", "parcial", "tomados", "de", "los", "glúteos", ",", "tras", "lo", "cual", "conseguimos", "el", "cierre", "completo", "de", "las", "heridas", ".", "\n\n", "Durante", "el", "periodo", "de", "aplicación", "de", "la", "terapia", "los", "cultivos", "microbiológicos", "del", "tejido", "de", "granulación", "subyacente", "fueron", "positivos", "para", "Pseudomonas", "aeruginosa", "multirresistente", ",", "que", "previamente", "el", "paciente", "había", "presentado", "también", "en", "orina", ".", "Instauramos", "tratamiento", "sistémico", "con", "Imipenem", "y", "Cilastatina", ",", "y", "practicamos", "desbridamiento", "parcial", "del", "tejido", "de", "granulación", "más", "superficial", "e", "hipertrófico", "durante", "los", "cambios", "de", "cura", "en", "la", "habitación", ".", "Una", "vez", "completada", "la", "terapia", "de", "vacío", "e", "injertado", "el", "defecto", ",", "el", "paciente", "no", "volvió", "a", "presentar", "signos", "de", "infección", "de", "los", "injertos", ".", "A", "los", "100", "días", "de", "ingreso", "fue", "dado", "de", "alta", "hospitalaria", ",", "con", "dificultad", "para", "la", "deambulación", "y", "con", "tratamiento", "rehabilitador", "en", "régimen", "ambulatorio", ".", "\n" ]

[ "NORMALIZABLES", "NO_NORMALIZABLES" ]

Pediatric is a Person, under 18 years is a Value, Pregnancy is a Condition, unresponsive is a Observation, at baseline is a Temporal, neurologic deficits is a Condition, at baseline is a Temporal, allergic is a Condition, dexmedetomidine is a Drug

NCT02245256_exc_task0

Sentence: Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Value, Person, Observation, Drug

[ "B-Person", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "B-Observation", "B-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "O", "B-Drug", "O" ]

Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine

[ "Pediatric", "patients", "(", "under", "18", "years", ")", "Pregnancy", "Patients", "who", "are", "unresponsive", "at", "baseline", ",", "who", "have", "neurologic", "deficits", "at", "baseline", ",", "or", "who", "are", "allergic", "to", "dexmedetomidine", "\n" ]

[ "Condition", "Drug", "Value", "Scope", "Observation", "Temporal", "Person" ]

Pediatric is a Person, under 18 years is a Value, Pregnancy is a Condition, unresponsive is a Observation, at baseline is a Temporal, neurologic deficits is a Condition, at baseline is a Temporal, allergic is a Condition, dexmedetomidine is a Drug

NCT02245256_exc_task1

Sentence: Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine Instructions: please typing these entity words according to sentence: Pediatric, under 18 years, Pregnancy, unresponsive, at baseline, neurologic deficits, at baseline, allergic, dexmedetomidine Options: Temporal, Condition, Value, Person, Observation, Drug

[ "B-Person", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "B-Observation", "B-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "O", "B-Drug", "O" ]

Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine

[ "Pediatric", "patients", "(", "under", "18", "years", ")", "Pregnancy", "Patients", "who", "are", "unresponsive", "at", "baseline", ",", "who", "have", "neurologic", "deficits", "at", "baseline", ",", "or", "who", "are", "allergic", "to", "dexmedetomidine", "\n" ]

[ "Condition", "Drug", "Value", "Scope", "Observation", "Temporal", "Person" ]

Pediatric, under 18 years, Pregnancy, unresponsive, at baseline, neurologic deficits, at baseline, allergic, dexmedetomidine

NCT02245256_exc_task2

Sentence: Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine Instructions: please extract entity words from the input sentence

[ "B-Person", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "B-Observation", "B-Temporal", "I-Temporal", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Condition", "O", "B-Drug", "O" ]

Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine

[ "Pediatric", "patients", "(", "under", "18", "years", ")", "Pregnancy", "Patients", "who", "are", "unresponsive", "at", "baseline", ",", "who", "have", "neurologic", "deficits", "at", "baseline", ",", "or", "who", "are", "allergic", "to", "dexmedetomidine", "\n" ]

[ "Condition", "Drug", "Value", "Scope", "Observation", "Temporal", "Person" ]

cellular is a Cell, CRP is a Gene_or_gene_product, breast cancer is a Cancer, patients is a Organism, endocrine is a Anatomical_system, patients is a Organism, endocrine is a Anatomical_system, breast cancer is a Cancer, breast cancer is a Cancer, patients is a Organism, endocrine is a Anatomical_system, beta - interferon is a Gene_or_gene_product, interleukin-2 is a Gene_or_gene_product, cellular is a Cell, CRP is a Gene_or_gene_product, Interleukin-2 is a Gene_or_gene_product, lymphocytes is a Cell, CD4 + , CD8 + , CD16 + 56 + ( NK ) cells is a Cell, IL-6 is a Gene_or_gene_product, IL-12 is a Gene_or_gene_product, CRP is a Gene_or_gene_product, IL-10 is a Gene_or_gene_product, TGFbeta1 is a Gene_or_gene_product, IL-10 is a Gene_or_gene_product, TGFbeta1 is a Gene_or_gene_product, cellular is a Cell, IL-2 is a Gene_or_gene_product, CRP is a Gene_or_gene_product

137_task0

Sentence: Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Anatomical_system, Organism, Cancer, Gene_or_gene_product, Cell

[ "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Anatomical_system", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively.

[ "Relationship", "of", "cellular", "immunity", ",", "cytokines", "and", "CRP", "with", "clinical", "course", "in", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "immunotherapy", ".", "\n", "We", "have", "reported", "important", "benefits", "and", "survival", "with", "an", "immunotherapy", "schedule", "in", "patients", "with", "endocrine", "-", "dependent", "breast", "cancer", "and", "distant", "metastases", ".", "Here", "clinical", "outcome", "is", "updated", "and", "its", "correlation", "with", "new", "immunological", "data", "is", "shown", ".", "In", "32", "evaluated", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "a", "new", "immunotherapy", "schedule", "(", "cyclic", "administration", "of", "beta", "-", "interferon", "and", "interleukin-2", ")", ",", "cellular", "immunity", ",", "cytokines", "and", "CRP", "were", "related", "to", "the", "clinical", "course", ".", "Estimated", "and", "true", "5", "-", "10", "year", "overall", "survival", "rates", "from", "first", "line", "antiestrogen", "and", "distant", "metastases", "were", "higher", "than", "previously", "reported", "in", "a", "similar", "population", ".", "Interleukin-2", "administration", "was", "followed", "by", "a", "significant", "increase", "in", "total", "lymphocytes", ",", "CD4", "+", ",", "CD8", "+", ",", "CD16", "+", "56", "+", "(", "NK", ")", "cells", ",", "IL-6", ",", "IL-12", ",", "and", "CRP", "(", "from", "P<0.04", "to", "P<0.000", ")", "but", "no", "change", "in", "IL-10", "and", "TGFbeta1", "during", "clinical", "benefit", ".", "During", "progressive", "disease", "no", "change", "was", "observed", "in", "the", "former", "parameters", ",", "concomitant", "with", "a", "significant", "increase", "in", "IL-10", "(", "P=0.020", ")", "and", "a", "significant", "decrease", "in", "TGFbeta1", "(", "P=0.023", ")", ".", "These", "findings", "confirm", "that", "cellular", "immunity", "is", "significantly", "stimulated", "by", "IL-2", "only", "during", "clinical", "benefit", ".", "Furthermore", ",", "these", "results", "demonstrate", "that", "different", "changes", "of", "proinflammatory", "cytokines", ",", "CRP", "and", "inhibiting", "factors", "are", "consistent", "with", "associated", "clinical", "benefit", "or", "with", "disease", "progression", ",", "respectively", ".", "\n" ]

[ "Cell", "Gene_or_gene_product", "Cancer", "Anatomical_system", "Organism" ]

cellular is a Cell, CRP is a Gene_or_gene_product, breast cancer is a Cancer, patients is a Organism, endocrine is a Anatomical_system, patients is a Organism, endocrine is a Anatomical_system, breast cancer is a Cancer, breast cancer is a Cancer, patients is a Organism, endocrine is a Anatomical_system, beta - interferon is a Gene_or_gene_product, interleukin-2 is a Gene_or_gene_product, cellular is a Cell, CRP is a Gene_or_gene_product, Interleukin-2 is a Gene_or_gene_product, lymphocytes is a Cell, CD4 + , CD8 + , CD16 + 56 + ( NK ) cells is a Cell, IL-6 is a Gene_or_gene_product, IL-12 is a Gene_or_gene_product, CRP is a Gene_or_gene_product, IL-10 is a Gene_or_gene_product, TGFbeta1 is a Gene_or_gene_product, IL-10 is a Gene_or_gene_product, TGFbeta1 is a Gene_or_gene_product, cellular is a Cell, IL-2 is a Gene_or_gene_product, CRP is a Gene_or_gene_product

137_task1

Sentence: Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively. Instructions: please typing these entity words according to sentence: cellular, CRP, breast cancer, patients, endocrine, patients, endocrine, breast cancer, breast cancer, patients, endocrine, beta - interferon, interleukin-2, cellular, CRP, Interleukin-2, lymphocytes, CD4 + , CD8 + , CD16 + 56 + ( NK ) cells, IL-6, IL-12, CRP, IL-10, TGFbeta1, IL-10, TGFbeta1, cellular, IL-2, CRP Options: Anatomical_system, Organism, Cancer, Gene_or_gene_product, Cell

[ "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Anatomical_system", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively.

[ "Relationship", "of", "cellular", "immunity", ",", "cytokines", "and", "CRP", "with", "clinical", "course", "in", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "immunotherapy", ".", "\n", "We", "have", "reported", "important", "benefits", "and", "survival", "with", "an", "immunotherapy", "schedule", "in", "patients", "with", "endocrine", "-", "dependent", "breast", "cancer", "and", "distant", "metastases", ".", "Here", "clinical", "outcome", "is", "updated", "and", "its", "correlation", "with", "new", "immunological", "data", "is", "shown", ".", "In", "32", "evaluated", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "a", "new", "immunotherapy", "schedule", "(", "cyclic", "administration", "of", "beta", "-", "interferon", "and", "interleukin-2", ")", ",", "cellular", "immunity", ",", "cytokines", "and", "CRP", "were", "related", "to", "the", "clinical", "course", ".", "Estimated", "and", "true", "5", "-", "10", "year", "overall", "survival", "rates", "from", "first", "line", "antiestrogen", "and", "distant", "metastases", "were", "higher", "than", "previously", "reported", "in", "a", "similar", "population", ".", "Interleukin-2", "administration", "was", "followed", "by", "a", "significant", "increase", "in", "total", "lymphocytes", ",", "CD4", "+", ",", "CD8", "+", ",", "CD16", "+", "56", "+", "(", "NK", ")", "cells", ",", "IL-6", ",", "IL-12", ",", "and", "CRP", "(", "from", "P<0.04", "to", "P<0.000", ")", "but", "no", "change", "in", "IL-10", "and", "TGFbeta1", "during", "clinical", "benefit", ".", "During", "progressive", "disease", "no", "change", "was", "observed", "in", "the", "former", "parameters", ",", "concomitant", "with", "a", "significant", "increase", "in", "IL-10", "(", "P=0.020", ")", "and", "a", "significant", "decrease", "in", "TGFbeta1", "(", "P=0.023", ")", ".", "These", "findings", "confirm", "that", "cellular", "immunity", "is", "significantly", "stimulated", "by", "IL-2", "only", "during", "clinical", "benefit", ".", "Furthermore", ",", "these", "results", "demonstrate", "that", "different", "changes", "of", "proinflammatory", "cytokines", ",", "CRP", "and", "inhibiting", "factors", "are", "consistent", "with", "associated", "clinical", "benefit", "or", "with", "disease", "progression", ",", "respectively", ".", "\n" ]

[ "Cell", "Gene_or_gene_product", "Cancer", "Anatomical_system", "Organism" ]

cellular, CRP, breast cancer, patients, endocrine, patients, endocrine, breast cancer, breast cancer, patients, endocrine, beta - interferon, interleukin-2, cellular, CRP, Interleukin-2, lymphocytes, CD4 + , CD8 + , CD16 + 56 + ( NK ) cells, IL-6, IL-12, CRP, IL-10, TGFbeta1, IL-10, TGFbeta1, cellular, IL-2, CRP

137_task2

Sentence: Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Anatomical_system", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course. Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. Interleukin-2 administration was followed by a significant increase in total lymphocytes, CD4+, CD8+, CD16+56+ (NK) cells, IL-6, IL-12, and CRP (from P<0.04 to P<0.000) but no change in IL-10 and TGFbeta1 during clinical benefit. During progressive disease no change was observed in the former parameters, concomitant with a significant increase in IL-10 (P=0.020) and a significant decrease in TGFbeta1 (P=0.023). These findings confirm that cellular immunity is significantly stimulated by IL-2 only during clinical benefit. Furthermore, these results demonstrate that different changes of proinflammatory cytokines, CRP and inhibiting factors are consistent with associated clinical benefit or with disease progression, respectively.

[ "Relationship", "of", "cellular", "immunity", ",", "cytokines", "and", "CRP", "with", "clinical", "course", "in", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "immunotherapy", ".", "\n", "We", "have", "reported", "important", "benefits", "and", "survival", "with", "an", "immunotherapy", "schedule", "in", "patients", "with", "endocrine", "-", "dependent", "breast", "cancer", "and", "distant", "metastases", ".", "Here", "clinical", "outcome", "is", "updated", "and", "its", "correlation", "with", "new", "immunological", "data", "is", "shown", ".", "In", "32", "evaluated", "breast", "cancer", "patients", "with", "endocrine", "-", "dependent", "distant", "metastases", "treated", "with", "a", "new", "immunotherapy", "schedule", "(", "cyclic", "administration", "of", "beta", "-", "interferon", "and", "interleukin-2", ")", ",", "cellular", "immunity", ",", "cytokines", "and", "CRP", "were", "related", "to", "the", "clinical", "course", ".", "Estimated", "and", "true", "5", "-", "10", "year", "overall", "survival", "rates", "from", "first", "line", "antiestrogen", "and", "distant", "metastases", "were", "higher", "than", "previously", "reported", "in", "a", "similar", "population", ".", "Interleukin-2", "administration", "was", "followed", "by", "a", "significant", "increase", "in", "total", "lymphocytes", ",", "CD4", "+", ",", "CD8", "+", ",", "CD16", "+", "56", "+", "(", "NK", ")", "cells", ",", "IL-6", ",", "IL-12", ",", "and", "CRP", "(", "from", "P<0.04", "to", "P<0.000", ")", "but", "no", "change", "in", "IL-10", "and", "TGFbeta1", "during", "clinical", "benefit", ".", "During", "progressive", "disease", "no", "change", "was", "observed", "in", "the", "former", "parameters", ",", "concomitant", "with", "a", "significant", "increase", "in", "IL-10", "(", "P=0.020", ")", "and", "a", "significant", "decrease", "in", "TGFbeta1", "(", "P=0.023", ")", ".", "These", "findings", "confirm", "that", "cellular", "immunity", "is", "significantly", "stimulated", "by", "IL-2", "only", "during", "clinical", "benefit", ".", "Furthermore", ",", "these", "results", "demonstrate", "that", "different", "changes", "of", "proinflammatory", "cytokines", ",", "CRP", "and", "inhibiting", "factors", "are", "consistent", "with", "associated", "clinical", "benefit", "or", "with", "disease", "progression", ",", "respectively", ".", "\n" ]

[ "Cell", "Gene_or_gene_product", "Cancer", "Anatomical_system", "Organism" ]

TNF - alpha is a Protein, TNF - alpha is a Protein, IkappaB alpha is a Protein, TNF - alpha is a Protein, IkappaB alpha is a Protein

842_task0

Sentence: Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly.

[ "Nuclear", "factor", "-", "kappaB", "induction", "in", "CD45RO+", "and", "CD45RA+", "T", "cell", "subsets", "during", "aging", ".", "\n", "An", "increase", "in", "the", "ratio", "of", "memory", "to", "naive", "T", "cells", "has", "been", "postulated", "to", "underlie", "immune", "hyporesponsiveness", "accompanying", "aging", ".", "Our", "analyses", "of", "the", "induction", "of", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "in", "activated", "memory", "(", "CD45RO+", ")", "and", "naive", "(", "CD45RA+", ")", "T", "cell", "subsets", "from", "young", "and", "elderly", "donors", "has", "demonstrated", "that", ",", "regardless", "of", "donor", "age", ",", "memory", "T", "cells", "are", "not", "significantly", "altered", "in", "their", "responsiveness", "to", "TNF", "-", "alpha", "-", "mediated", "induction", "of", "NFkappaB.", "Although", "treatment", "with", "TNF", "-", "alpha", "induced", "nuclear", "localization", "of", "NFkappaB", "in", "both", "memory", "and", "naive", "T", "cell", "subsets", ",", "irrespective", "of", "the", "age", "of", "the", "donor", ",", "the", "levels", "of", "induced", "NFkappaB", "were", "significantly", "lower", "in", "both", "subsets", "of", "T", "cells", "obtained", "from", "the", "elderly", ",", "when", "compared", "to", "those", "in", "young", ".", "Examination", "of", "IkappaB", "alpha", "regulation", "revealed", "that", "TNF", "-", "alpha", "-", "mediated", "degradation", "of", "IkappaB", "alpha", "in", "both", "memory", "and", "naive", "T", "cells", "from", "the", "elderly", "was", "severely", "impaired", ",", "thus", "contributing", "to", "the", "lowered", "induction", "of", "the", "observed", "NFkappaB.", "In", "addition", ",", "this", "age", "-", "related", "decrease", "in", "induction", "of", "nuclear", "NFkappaB", "correlated", "with", "decrease", "in", "intracellular", "IL-2", "receptor", "expression", "and", "anti", "-", "CD3-induced", "proliferation", "of", "both", "memory", "and", "naive", "T", "cells", "subsets", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "the", "age", "-", "related", "hyporesponsiveness", "cannot", "be", "attributed", "to", "a", "skewing", "of", "the", "T", "cell", "population", "towards", "a", "memory", "phenotype", "in", "the", "elderly", "." ]

[ "Protein" ]

TNF - alpha is a Protein, TNF - alpha is a Protein, IkappaB alpha is a Protein, TNF - alpha is a Protein, IkappaB alpha is a Protein

842_task1

Sentence: Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly. Instructions: please typing these entity words according to sentence: TNF - alpha, TNF - alpha, IkappaB alpha, TNF - alpha, IkappaB alpha Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly.

[ "Nuclear", "factor", "-", "kappaB", "induction", "in", "CD45RO+", "and", "CD45RA+", "T", "cell", "subsets", "during", "aging", ".", "\n", "An", "increase", "in", "the", "ratio", "of", "memory", "to", "naive", "T", "cells", "has", "been", "postulated", "to", "underlie", "immune", "hyporesponsiveness", "accompanying", "aging", ".", "Our", "analyses", "of", "the", "induction", "of", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "in", "activated", "memory", "(", "CD45RO+", ")", "and", "naive", "(", "CD45RA+", ")", "T", "cell", "subsets", "from", "young", "and", "elderly", "donors", "has", "demonstrated", "that", ",", "regardless", "of", "donor", "age", ",", "memory", "T", "cells", "are", "not", "significantly", "altered", "in", "their", "responsiveness", "to", "TNF", "-", "alpha", "-", "mediated", "induction", "of", "NFkappaB.", "Although", "treatment", "with", "TNF", "-", "alpha", "induced", "nuclear", "localization", "of", "NFkappaB", "in", "both", "memory", "and", "naive", "T", "cell", "subsets", ",", "irrespective", "of", "the", "age", "of", "the", "donor", ",", "the", "levels", "of", "induced", "NFkappaB", "were", "significantly", "lower", "in", "both", "subsets", "of", "T", "cells", "obtained", "from", "the", "elderly", ",", "when", "compared", "to", "those", "in", "young", ".", "Examination", "of", "IkappaB", "alpha", "regulation", "revealed", "that", "TNF", "-", "alpha", "-", "mediated", "degradation", "of", "IkappaB", "alpha", "in", "both", "memory", "and", "naive", "T", "cells", "from", "the", "elderly", "was", "severely", "impaired", ",", "thus", "contributing", "to", "the", "lowered", "induction", "of", "the", "observed", "NFkappaB.", "In", "addition", ",", "this", "age", "-", "related", "decrease", "in", "induction", "of", "nuclear", "NFkappaB", "correlated", "with", "decrease", "in", "intracellular", "IL-2", "receptor", "expression", "and", "anti", "-", "CD3-induced", "proliferation", "of", "both", "memory", "and", "naive", "T", "cells", "subsets", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "the", "age", "-", "related", "hyporesponsiveness", "cannot", "be", "attributed", "to", "a", "skewing", "of", "the", "T", "cell", "population", "towards", "a", "memory", "phenotype", "in", "the", "elderly", "." ]

[ "Protein" ]

TNF - alpha, TNF - alpha, IkappaB alpha, TNF - alpha, IkappaB alpha

842_task2

Sentence: Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nuclear factor-kappaB induction in CD45RO+ and CD45RA+ T cell subsets during aging. An increase in the ratio of memory to naive T cells has been postulated to underlie immune hyporesponsiveness accompanying aging. Our analyses of the induction of nuclear factor-kappaB (NFkappaB) in activated memory (CD45RO+) and naive (CD45RA+) T cell subsets from young and elderly donors has demonstrated that, regardless of donor age, memory T cells are not significantly altered in their responsiveness to TNF-alpha-mediated induction of NFkappaB. Although treatment with TNF-alpha induced nuclear localization of NFkappaB in both memory and naive T cell subsets, irrespective of the age of the donor, the levels of induced NFkappaB were significantly lower in both subsets of T cells obtained from the elderly, when compared to those in young. Examination of IkappaB alpha regulation revealed that TNF-alpha-mediated degradation of IkappaB alpha in both memory and naive T cells from the elderly was severely impaired, thus contributing to the lowered induction of the observed NFkappaB. In addition, this age-related decrease in induction of nuclear NFkappaB correlated with decrease in intracellular IL-2 receptor expression and anti-CD3-induced proliferation of both memory and naive T cells subsets. Taken together, our results suggest that the age-related hyporesponsiveness cannot be attributed to a skewing of the T cell population towards a memory phenotype in the elderly.

[ "Nuclear", "factor", "-", "kappaB", "induction", "in", "CD45RO+", "and", "CD45RA+", "T", "cell", "subsets", "during", "aging", ".", "\n", "An", "increase", "in", "the", "ratio", "of", "memory", "to", "naive", "T", "cells", "has", "been", "postulated", "to", "underlie", "immune", "hyporesponsiveness", "accompanying", "aging", ".", "Our", "analyses", "of", "the", "induction", "of", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "in", "activated", "memory", "(", "CD45RO+", ")", "and", "naive", "(", "CD45RA+", ")", "T", "cell", "subsets", "from", "young", "and", "elderly", "donors", "has", "demonstrated", "that", ",", "regardless", "of", "donor", "age", ",", "memory", "T", "cells", "are", "not", "significantly", "altered", "in", "their", "responsiveness", "to", "TNF", "-", "alpha", "-", "mediated", "induction", "of", "NFkappaB.", "Although", "treatment", "with", "TNF", "-", "alpha", "induced", "nuclear", "localization", "of", "NFkappaB", "in", "both", "memory", "and", "naive", "T", "cell", "subsets", ",", "irrespective", "of", "the", "age", "of", "the", "donor", ",", "the", "levels", "of", "induced", "NFkappaB", "were", "significantly", "lower", "in", "both", "subsets", "of", "T", "cells", "obtained", "from", "the", "elderly", ",", "when", "compared", "to", "those", "in", "young", ".", "Examination", "of", "IkappaB", "alpha", "regulation", "revealed", "that", "TNF", "-", "alpha", "-", "mediated", "degradation", "of", "IkappaB", "alpha", "in", "both", "memory", "and", "naive", "T", "cells", "from", "the", "elderly", "was", "severely", "impaired", ",", "thus", "contributing", "to", "the", "lowered", "induction", "of", "the", "observed", "NFkappaB.", "In", "addition", ",", "this", "age", "-", "related", "decrease", "in", "induction", "of", "nuclear", "NFkappaB", "correlated", "with", "decrease", "in", "intracellular", "IL-2", "receptor", "expression", "and", "anti", "-", "CD3-induced", "proliferation", "of", "both", "memory", "and", "naive", "T", "cells", "subsets", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "the", "age", "-", "related", "hyporesponsiveness", "cannot", "be", "attributed", "to", "a", "skewing", "of", "the", "T", "cell", "population", "towards", "a", "memory", "phenotype", "in", "the", "elderly", "." ]

[ "Protein" ]

ATM is a Genes & Molecular Sequences, ATR is a Genes & Molecular Sequences

1635_task0

Sentence: ATM and ATR: components of an integrated circuit. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Genes & Molecular Sequences

[ "B-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O" ]

ATM and ATR: components of an integrated circuit.

[ "ATM", "and", "ATR", ":", "components", "of", "an", "integrated", "circuit", "." ]

[ "Genes & Molecular Sequences", "Diseases & Disorders", "" ]

ATM is a Genes & Molecular Sequences, ATR is a Genes & Molecular Sequences

1635_task1

Sentence: ATM and ATR: components of an integrated circuit. Instructions: please typing these entity words according to sentence: ATM, ATR Options: Genes & Molecular Sequences

[ "B-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O" ]

ATM and ATR: components of an integrated circuit.

[ "ATM", "and", "ATR", ":", "components", "of", "an", "integrated", "circuit", "." ]

[ "Genes & Molecular Sequences", "Diseases & Disorders", "" ]

ATM, ATR

1635_task2

Sentence: ATM and ATR: components of an integrated circuit. Instructions: please extract entity words from the input sentence

[ "B-Genes & Molecular Sequences", "O", "B-Genes & Molecular Sequences", "O", "O", "O", "O", "O", "O", "O" ]

ATM and ATR: components of an integrated circuit.

[ "ATM", "and", "ATR", ":", "components", "of", "an", "integrated", "circuit", "." ]

[ "Genes & Molecular Sequences", "Diseases & Disorders", "" ]

radiologische is an umlsterm, Haende is an umlsterm, Kniegelenke is an umlsterm, Haende is an umlsterm, Haende is an umlsterm, Arthrosemuster is an umlsterm, Arthrosen is an umlsterm, Gelenke is an umlsterm, radiologischen is an umlsterm, Arthrose is an umlsterm, Haenden is an umlsterm, Hypertrophie is an umlsterm, Belastung is an umlsterm, Kraftgriff is an umlsterm, Coxarthrose is an umlsterm

ZfuerRheumatologie.90580345.ger.abstr_task0

Sentence: Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf .

[ "Bei", "25", "pensionierten", "landwirtschaftlichen", "Arbeitern", ",", "welche", "durchschnittlich", "51", "Jahre", "eine", "Schwerarbeit", "als", "Knechte", "\"", "\"", "verrichtet", "hatten", ",", "erfolgte", "eine", "eingehende", "klinische", "und", "radiologische", "Untersuchung", "der", "Haende", ",", "Hueft-", "und", "Kniegelenke", ",", "wobei", "das", "Schwergewicht", "im", "Bereich", "der", "Haende", "lag", ".", "Das", "im", "Bereich", "der", "Haende", "gefundene", "Arthrosemuster", "zeigte", "eine", "auffaellige", "Verteilung", "mit", "einem", "ueberproportionalen", "Befall", "der", "Metacarpophalangealgelenke", "und", "weniger", "ausgepraegt", "der", "Intercarpalgelenke", ".", "Die", "Arthrosen", "der", "Metacarpophalangealgelenke", "betrafen", "gehaeuft", "Strahl", "I", "-", "III", ",", "diejenigen", "der", "Intercarpalgelenke", "gehaeuft", "die", "peritrapezialen", "Gelenke", ".", "Insbesondere", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", "bestaetigte", "sich", "eine", "Diskrepanz", "zwischen", "den", "klinisch", "z.", "T.", "eindruecklichen", "hypertrophen", "Veraenderungen", "(", "welche", "durchaus", "den", "Eindruck", "von", "Bouchardarthrosen", "erwecken", "konnten", ")", "und", "den", "selten", "vorkommenden", ",", "leichten", "radiologischen", "Zeichen", "der", "Arthrose", ".", "Die", "Ergebnisse", "betonen", "die", "Bedeutung", "des", "Belastungsmusters", "fuer", "die", "Entwicklung", "arthrotischer", "Veraenderungen", "an", "den", "Haenden", ".", "Die", "Untersuchung", "zeigt", "zudem", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", ",", "dass", "eine", "Hypertrophie", "der", "periartikulaeren", "Strukturen", "als", "Anpassung", "an", "die", "jahrzehntelange", "manuelle", "Belastung", "im", "Kraftgriff", "auftreten", "kann", ".", "Mit", "einer", "Ausnahme", "wiesen", "zudem", "saemtliche", "Teilnehmer", "mindestens", "eine", "unilaterale", "Coxarthrose", "auf", "." ]

[ "umlsterm" ]

radiologische is an umlsterm, Haende is an umlsterm, Kniegelenke is an umlsterm, Haende is an umlsterm, Haende is an umlsterm, Arthrosemuster is an umlsterm, Arthrosen is an umlsterm, Gelenke is an umlsterm, radiologischen is an umlsterm, Arthrose is an umlsterm, Haenden is an umlsterm, Hypertrophie is an umlsterm, Belastung is an umlsterm, Kraftgriff is an umlsterm, Coxarthrose is an umlsterm

ZfuerRheumatologie.90580345.ger.abstr_task1

Sentence: Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf . Instructions: please typing these entity words according to sentence: radiologische, Haende, Kniegelenke, Haende, Haende, Arthrosemuster, Arthrosen, Gelenke, radiologischen, Arthrose, Haenden, Hypertrophie, Belastung, Kraftgriff, Coxarthrose Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf .

[ "Bei", "25", "pensionierten", "landwirtschaftlichen", "Arbeitern", ",", "welche", "durchschnittlich", "51", "Jahre", "eine", "Schwerarbeit", "als", "Knechte", "\"", "\"", "verrichtet", "hatten", ",", "erfolgte", "eine", "eingehende", "klinische", "und", "radiologische", "Untersuchung", "der", "Haende", ",", "Hueft-", "und", "Kniegelenke", ",", "wobei", "das", "Schwergewicht", "im", "Bereich", "der", "Haende", "lag", ".", "Das", "im", "Bereich", "der", "Haende", "gefundene", "Arthrosemuster", "zeigte", "eine", "auffaellige", "Verteilung", "mit", "einem", "ueberproportionalen", "Befall", "der", "Metacarpophalangealgelenke", "und", "weniger", "ausgepraegt", "der", "Intercarpalgelenke", ".", "Die", "Arthrosen", "der", "Metacarpophalangealgelenke", "betrafen", "gehaeuft", "Strahl", "I", "-", "III", ",", "diejenigen", "der", "Intercarpalgelenke", "gehaeuft", "die", "peritrapezialen", "Gelenke", ".", "Insbesondere", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", "bestaetigte", "sich", "eine", "Diskrepanz", "zwischen", "den", "klinisch", "z.", "T.", "eindruecklichen", "hypertrophen", "Veraenderungen", "(", "welche", "durchaus", "den", "Eindruck", "von", "Bouchardarthrosen", "erwecken", "konnten", ")", "und", "den", "selten", "vorkommenden", ",", "leichten", "radiologischen", "Zeichen", "der", "Arthrose", ".", "Die", "Ergebnisse", "betonen", "die", "Bedeutung", "des", "Belastungsmusters", "fuer", "die", "Entwicklung", "arthrotischer", "Veraenderungen", "an", "den", "Haenden", ".", "Die", "Untersuchung", "zeigt", "zudem", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", ",", "dass", "eine", "Hypertrophie", "der", "periartikulaeren", "Strukturen", "als", "Anpassung", "an", "die", "jahrzehntelange", "manuelle", "Belastung", "im", "Kraftgriff", "auftreten", "kann", ".", "Mit", "einer", "Ausnahme", "wiesen", "zudem", "saemtliche", "Teilnehmer", "mindestens", "eine", "unilaterale", "Coxarthrose", "auf", "." ]

[ "umlsterm" ]

radiologische, Haende, Kniegelenke, Haende, Haende, Arthrosemuster, Arthrosen, Gelenke, radiologischen, Arthrose, Haenden, Hypertrophie, Belastung, Kraftgriff, Coxarthrose

ZfuerRheumatologie.90580345.ger.abstr_task2

Sentence: Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Bei 25 pensionierten landwirtschaftlichen Arbeitern , welche durchschnittlich 51 Jahre eine Schwerarbeit als Knechte " " verrichtet hatten , erfolgte eine eingehende klinische und radiologische Untersuchung der Haende , Hueft- und Kniegelenke , wobei das Schwergewicht im Bereich der Haende lag . Das im Bereich der Haende gefundene Arthrosemuster zeigte eine auffaellige Verteilung mit einem ueberproportionalen Befall der Metacarpophalangealgelenke und weniger ausgepraegt der Intercarpalgelenke . Die Arthrosen der Metacarpophalangealgelenke betrafen gehaeuft Strahl I-III , diejenigen der Intercarpalgelenke gehaeuft die peritrapezialen Gelenke . Insbesondere im Bereich der proximalen Interphalangealgelenke bestaetigte sich eine Diskrepanz zwischen den klinisch z.T. eindruecklichen hypertrophen Veraenderungen ( welche durchaus den Eindruck von Bouchardarthrosen erwecken konnten ) und den selten vorkommenden , leichten radiologischen Zeichen der Arthrose . Die Ergebnisse betonen die Bedeutung des Belastungsmusters fuer die Entwicklung arthrotischer Veraenderungen an den Haenden . Die Untersuchung zeigt zudem im Bereich der proximalen Interphalangealgelenke , dass eine Hypertrophie der periartikulaeren Strukturen als Anpassung an die jahrzehntelange manuelle Belastung im Kraftgriff auftreten kann . Mit einer Ausnahme wiesen zudem saemtliche Teilnehmer mindestens eine unilaterale Coxarthrose auf .

[ "Bei", "25", "pensionierten", "landwirtschaftlichen", "Arbeitern", ",", "welche", "durchschnittlich", "51", "Jahre", "eine", "Schwerarbeit", "als", "Knechte", "\"", "\"", "verrichtet", "hatten", ",", "erfolgte", "eine", "eingehende", "klinische", "und", "radiologische", "Untersuchung", "der", "Haende", ",", "Hueft-", "und", "Kniegelenke", ",", "wobei", "das", "Schwergewicht", "im", "Bereich", "der", "Haende", "lag", ".", "Das", "im", "Bereich", "der", "Haende", "gefundene", "Arthrosemuster", "zeigte", "eine", "auffaellige", "Verteilung", "mit", "einem", "ueberproportionalen", "Befall", "der", "Metacarpophalangealgelenke", "und", "weniger", "ausgepraegt", "der", "Intercarpalgelenke", ".", "Die", "Arthrosen", "der", "Metacarpophalangealgelenke", "betrafen", "gehaeuft", "Strahl", "I", "-", "III", ",", "diejenigen", "der", "Intercarpalgelenke", "gehaeuft", "die", "peritrapezialen", "Gelenke", ".", "Insbesondere", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", "bestaetigte", "sich", "eine", "Diskrepanz", "zwischen", "den", "klinisch", "z.", "T.", "eindruecklichen", "hypertrophen", "Veraenderungen", "(", "welche", "durchaus", "den", "Eindruck", "von", "Bouchardarthrosen", "erwecken", "konnten", ")", "und", "den", "selten", "vorkommenden", ",", "leichten", "radiologischen", "Zeichen", "der", "Arthrose", ".", "Die", "Ergebnisse", "betonen", "die", "Bedeutung", "des", "Belastungsmusters", "fuer", "die", "Entwicklung", "arthrotischer", "Veraenderungen", "an", "den", "Haenden", ".", "Die", "Untersuchung", "zeigt", "zudem", "im", "Bereich", "der", "proximalen", "Interphalangealgelenke", ",", "dass", "eine", "Hypertrophie", "der", "periartikulaeren", "Strukturen", "als", "Anpassung", "an", "die", "jahrzehntelange", "manuelle", "Belastung", "im", "Kraftgriff", "auftreten", "kann", ".", "Mit", "einer", "Ausnahme", "wiesen", "zudem", "saemtliche", "Teilnehmer", "mindestens", "eine", "unilaterale", "Coxarthrose", "auf", "." ]

[ "umlsterm" ]